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Abstract 
Background: Nutrition support is essential for patients with head and neck cancer. Poor 
nutritional status and weight loss are associated with reduced quality of life, treatment 
interruptions and an increased risk of unplanned hospital admissions which also contribute 
to increased healthcare costs. There are a number of patient, clinical and treatment 
characteristics which have been found to increase the risk of swallowing and nutrition 
difficulties during treatment. This information has been used to identify which groups of 
patients may therefore benefit from placement of a proactive gastrostomy prior to 
commencement of treatment. A local protocol for this purpose is in place at the Royal 
Brisbane and Women’s Hospital. Historically this approach of nutrition support was shown 
to be effective in improving nutrition outcomes and reducing admissions for patients 
receiving radiotherapy, however more recently in studies of patients receiving concurrent 
chemoradiotherapy this no longer appears to be an adequate intervention to achieve 
maintenance of weight or nutritional status. In addition, with the advent of advancing 
radiotherapy techniques and emerging human papillomavirus-related tumours, there are 
questions as to whether proactive gastrostomy placement is still warranted.  
Objectives: The objectives of the research in this thesis were firstly to determine the impact 
of new radiotherapy techniques on nutrition outcomes; how this may influence the protocol 
for predicting proactive gastrostomy placement; and the impact of human papillomavirus 
status on nutrition outcomes. As adherence to the protocol had been declining in light of the 
advancing radiotherapy techniques, the second objective was to compare the nutrition 
outcomes of patients treated according to the local protocol to those that weren’t. Finally the 
third main objective was to investigate a novel pre-treatment nutrition intervention strategy 
to determine if this would improve nutrition outcomes compared to standard care with 
proactive gastrostomy placement. 
Methods: The first objectives were addressed through retrospective cohort studies and 
included patients treated for head and neck cancer over a one year period following 
commencement of helical intensity-modulated radiotherapy. The second objective was 
addressed through a prospective comparative cohort study. Patients were recruited over a 
two year period and observed throughout standard care during treatment and for one month 
post-treatment. Nutrition outcomes (weight loss and incidence of tube feeding) and clinical 
outcomes (unplanned admissions) were collected and compared between the protocol 
adherent group (proactive gastrostomy placement) and non-adherent group (no proactive 
gastrostomy placement; managed with oral diet and tube feeding as required).  
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The final objective was addressed through a prospective randomised controlled trial. 
Patients were recruited over three years if they were planned for proactive gastrostomy 
insertion prior to treatment. They were randomised to either standard care or to the early 
nutrition intervention whereby prophylactic enteral nutrition was prescribed before treatment. 
Primary outcome of weight loss was collected at three months post-treatment, as well as 
nutritional status, body composition, quality of life and treatment outcomes. 
Results: In summary the results from this research have found that patients still have 
significant weight loss and a high requirement for tube feeding despite the advancing 
radiotherapy techniques. The protocol for proactive gastrostomy insertion remains valid for 
use and there is a potential that human papillomavirus status may be an additional 
parameter that could help to further select appropriate patients for tube feeding. Adherence 
to the protocol did show improved nutritional outcomes and less unplanned admissions. The 
early nutrition intervention however was not found to be effective at improving patient 
outcomes, but this finding was limited following poor adherence to the intervention. 
Discussion: Overall this research has contributed significantly to the field with five published 
manuscripts (Chapters 4-7) and three under review (Chapter 8). This research provides the 
first study to report on the nutrition outcomes following helical intensity-modulated 
radiotherapy. Whilst the protocol for proactive gastrostomy insertion remains valid with this 
type of treatment, the research has shown that additional adjustments could be made to 
improve the predictive ability even further. The method of tube feeding remains controversial 
in the literature. Randomised controlled trials are particularly challenging due to strong 
patient preferences for the mode of tube feeding thus limiting consent for randomisation. 
The comparative cohort study within this thesis is in favour of the proactive approach and 
provides a contribution to the body of literature on this topic to assist clinicians in making an 
informed decision. Finally although the early nutrition intervention was not found to be 
effective at improving outcomes as hypothesised, the findings from the study did highlight 
the number of barriers that patients face in achieving nutrition prescriptions throughout the 
course of treatment including; clinical symptoms, environmental factors and various 
psychosocial issues. These will be important to investigate in future research to enable the 
design of effective multidisciplinary models of care to overcome and address these barriers 
to allow patients to achieve nutrition goals and optimal outcomes. 
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1.1 Background 
1.1.1 Head and neck cancer 
Head and neck cancer (HNC) is the seventh most common cancer worldwide (Bossola, 
2015). The incidence is higher in males and in the African American population (Marur & 
Forastiere, 2008). The term HNC encompasses a range of tumour sites including the upper 
aero digestive tract (oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx), as well 
as the paranasal sinuses and the salivary glands (Mehanna, Paleri, West, & Nutting, 2010a). 
Presenting clinical symptoms can include hoarseness, stridor, dysphagia, otalgia, neck 
lump, mouth ulcers, and cranial nerve palsy (Mehanna, et al., 2010a). 
Diagnosis is confirmed from physical examinations, including endoscopy and biopsy, with 
the extent of local and regional disease determined through various imaging techniques, 
such as MRI, CT and PET (Marur & Forastiere, 2008). The TNM staging system is used to 
classify cancer staging; with T stage accounting for tumour size, N stage accounting for 
degree of nodal spread, and M stage accounting for metastatic spread (Deschler & Day, 
2008). 
Treatment options are usually multimodality and can include surgery, radiotherapy, 
chemotherapy and/or biological therapy. It is important to consider optimal survival 
outcomes as well as the impact on functional outcomes and patient quality of life, and thus 
the role of the multidisciplinary team is essential for treatment planning (Mehanna, West, 
Nutting, & Paleri, 2010b) 
Most HNCs are of squamous cell histology arising in the upper aero digestive mucosa 
(Argiris, Karamouzis, Raben, & Ferris, 2008). Established causative or risk factors include 
extensive use of tobacco and high consumption of alcohol, accounting for up to 80% of all 
cases (Stenson, 2010). However a sub group of HNC, particularly in the oropharynx, are 
caused by the human papillomavirus (Leemans, Braakhuis, & Brakenhoff, 2011). 
Some dietary factors have also been associated with an increased risk of HNC, including 
low intakes of carotenoids and other protective micronutrients from fruits and vegetables 
(Stenson, 2010). As studies have shown that smokers eat less fruit and vegetables and 
micronutrients than non-smokers (Birkett, 1999; Dyer et al., 2003), these patients are often 
nutritionally compromised from the onset.  
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1.1.2 Overview of malnutrition in head and neck cancer 
Accepted definitions of malnutrition from the International Statistical Classification of 
Diseases and Related Health Problems Tenth Revision, Australian Modification (ICD-10-
AM) are; severe malnutrition if body mass index (BMI) <18.5 kg/m2 or unintentional loss of 
weight (>10%) with evidence of suboptimal intake resulting in severe loss of subcutaneous 
fat and/or severe muscle wasting, and mild-moderate malnutrition if BMI <18.5 kg/m2 or 
unintentional loss of weight (5-9%) with evidence of suboptimal intake resulting in 
mild/moderate loss of subcutaneous fat and/or mild/moderate muscle wasting (National 
Centre for Classification in Health, 2010). Similarly the Academy of Nutrition and Dietetics 
and the American Society for Parental and Enteral Nutrition recently published their 
consensus statement for the diagnosis of malnutrition which requires at least two of the 
following six markers to be present: unintended weight loss; loss of muscle or subcutaneous 
fat; fluid accumulation; insufficient energy intake; and diminished functional status using 
handgrip strength (White, Guenter, Jensen, Malone, & Schofield, 2012). This definition has 
been compared to the assessment of nutritional status using the established Patient-
Generated Subjective Global Assessment tool (Ottery, 2005) and was found to be in good 
agreement with 94% sensitivity (Mulasi et al., 2016). 
Malnutrition rates at diagnosis have been reported at 30-50% (van Bokhorst-de van der 
Schueren et al., 1999). The prevalence of malnutrition may be changing with an increasing 
incidence of oropharyngeal HNC caused by the human papillomavirus (HPV) (Ramqvist & 
Dalianis, 2010). These patients typically are well-nourished, non-smokers, with low levels of 
alcohol intake, and overall have a better prognosis (Mallen-St Clair, Alani, Wang, & 
Srivatsan, 2016). Despite this, a recent cross-sectional study in cancer patients (n=366 with 
HNC) reported pre-treatment malnutrition prevalence at 49% (Hebuterne et al., 2014), and 
a smaller prospective longitudinal study (n=19) reported prevalence rates of 68% (Mulasi et 
al., 2016). Both of these rates are still high but neither of these studies provided details of 
HPV status.  
1.1.3 Causes of malnutrition in head and neck cancer 
The causes of malnutrition in patients with HNC are multifactorial (Figure 1-1). As well as 
the pre-treatment lifestyle factors described above, other psychosocial factors can play a 
role with pre-treatment depression associated with pre-treatment malnutrition (Britton et al., 
2012; Kim et al., 2016), and also predictive of malnutrition during and post-treatment (Britton 
et al., 2012). 
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Tumour burden has physical effects from the tumour location itself, resulting in dysphagia 
or odynophagia, which can lead to a reduced or altered food intake prior to diagnosis, 
contributing to weight loss (Alshadwi et al., 2013). Tumour burden can also have 
consequences on loss of appetite and body composition through the complex metabolic 
effects and mediators of cancer cachexia (Couch et al., 2015). 
Once treatment commences, side effects from surgery, radiotherapy and/or chemotherapy, 
such as worsening dysphagia/odynophagia, xerostomia, dysgeusia, mucositis, oral thrush, 
nausea/vomiting, fibrosis, trismus and poor appetite (Alshadwi et al., 2013), can increase 
the risk of worsening or developing malnutrition during the treatment trajectory (Mulasi et 
al., 2016). Physical symptoms can also persist into the post-treatment/rehabilitation phase 
and impact on the patients’ psychological well-being (Turner et al., 2014), which has been 
shown to affect the patients’ nutritional self-care behaviours (Britton et al., 2012). 
1.1.4 Consequences of malnutrition 
Malnutrition is well known to be associated with adverse clinical outcomes and costs across 
a range of clinical settings (Watterson et al., 2009). Nutritional status has long been 
recognised as the second most important factor in predicting long-term prognosis in HNC 
(Brookes, 1985).
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Figure 1-1: Causes of malnutrition in head and neck cancer 
Source: Developed by author with adaptations from Talwar & Findlay, 2012 
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The consequences of malnutrition in HNC patients have been widely studied and include:  
- reduced immune function, increased risk of infection, and impaired wound 
healing (Linn, Robinson, & Klimas, 1988a; Matthews, Lampe, & Dragosz, 1995; van 
Bokhorst-de van der Schueren et al., 1998)  
- increased admissions, complications, treatment interruptions and length of stay 
(Capuano et al., 2008; Goodwin & Torres, 1984; Guo, Ma, & Zhang, 1994; Guo, Ma, 
Zhang, & Hu, 2007; Guo, Zhang, Ma, Zhang, & Huang, 1996; Linn & Robinson, 1988b; 
Linn et al., 1988a; Matthews et al., 1995; Ravasco, Monteiro-Grillo, Vidal, & Camilo, 
2004; Shirodkar & Mohandas, 2005; van Bokhorst-de van der Schueren et al., 1997) 
- reduced quality of life (QOL), functioning and increased fatigue (Capuano et al., 
2010; Jager-Wittenaar et al., 2011a; Langius et al., 2013a; Ravasco et al., 2004; van 
den Berg, Rasmussen-Conrad, van Nispen, van Binsbergen, & Merkx, 2008) 
- increased risk of recurrence and reduced survival (Brookes, 1985; Capuano et al., 
2008; Goodwin & Torres, 1984; Kubrak et al., 2010; Mick, Vokes, Weichselbaum, & 
Panje, 1991; Platek et al., 2010; van Bokhorst-de van der Schueren et al., 2000) 
Only two studies found that malnutrition at baseline had no impact on survival outcomes 
(Matthews et al., 1995; van Bokhorst-de van der Schueren, 1999). More recent studies have 
demonstrated the detrimental impact of weight loss on survival outcomes. In a large study 
with mixed cancer diagnoses (n=8160), it was reported that decreasing BMI and increasing 
percentage weight loss were both independent predictors of survival (Martin et al., 2015). 
Two randomised controlled trials (RCT) in HNC and colorectal cancer patients demonstrated 
individualised dietary counselling improved nutritional status/intake and QOL (Ravasco, 
Monteiro-Grillo, Marques Vidal, & Camilo, 2005a; Ravasco, Monteiro-Grillo, Vidal, & Camilo, 
2005b). In a long-term follow-up study of their colorectal cohort – the patients with dietary 
counselling had better QOL and survival; with depleted nutritional intake/status predictive of 
shorter survival and late toxicity (Ravasco, Monteiro-Grillo, & Camilo, 2012). Meanwhile a 
study of HNC patients (n=1340), found weight loss was also a major prognostic indicator for 
survival (Langius et al., 2013b). The study reported >10% weight loss pre-treatment was 
associated with worse overall survival and disease-specific survival. In addition critical 
weight loss during radiotherapy (defined as >5% during or >7.5% by three months post-
treatment) was significantly associated with worse disease-specific survival. Overall the 
body of evidence supports that malnutrition and weight loss have adverse consequences in 
this patient population and thus nutrition care plays a crucial role in optimising patient 
outcomes. 
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1.2 Theoretical model 
In 2011, an Australian Dietitian Steering Committee published online “Evidence-based 
practice guidelines for the nutritional management of adult patients with head and neck 
cancer” (Head & Neck Guideline Steering Committee, 2011), which have been endorsed 
internationally by the Dietitians Association of Australia, Dietitians New Zealand, British 
Dietetic Association and are connected to another on-line resource “Practice-based 
Evidence through Nutrition” from the Dietitians of Canada. The use of wiki platform 
technology has meant the guidelines can continually be updated and revised as new 
evidence is published (Brown et al., 2013a). These guidelines used a framework adapted 
from recognised Nutrition Care Models (Hakel-Smith & Lewis, 2004; Lacey & Pritchett, 2003; 
Splett & Myers, 2001) which consist of three phases: 
- Appropriate access to nutrition care (nutrition screening and assessment) 
- Quality nutrition care (nutrition diagnosis and intervention - including goals, 
prescription and implementation) 
- Nutrition monitoring and evaluation (measuring and evaluating outcomes) 
Outcomes assessed during the monitoring and evaluation phase have been established as 
a cascade of events following quality nutrition care. Initially resulting in improved 
intermediate outcomes (i.e. nutritional outcome measures), which flow on to an improvement 
in clinical, cost and patient outcomes (Figure 1-2) (Splett, 1996). The research questions 
addressed in this thesis will therefore be applied in the context of this theoretical nutrition 
care model and the results will be used to provide any relevant updates to the online 
evidence-based guidelines (Head & Neck Guideline Steering Committee, 2011). 
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Figure 1-2: Theoretical Model – Nutrition Care Model 
Source: Splett, 1996. Abbreviations: MNT = Medical Nutrition Therapy 
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2.1 Literature review methodology 
The Cochrane Database of Systematic Reviews, CENTRAL, PubMed, MEDLINE, EMBASE, 
CINAHL and AMED databases were searched in January 2012 and repeated in January 
2017. Search terms included: “head and neck cancer” AND “radiotherapy OR radiation OR 
chemoradiotherapy OR chemoradiation” AND “enteral nutrition OR enteral feeding OR tube 
feeding OR gastrostomy OR PEG”. The outcomes were not specified in the search strategy 
thus allowing for a range of outcome measures to be considered including weight, nutritional 
status, quality of life and other clinical outcomes. Inclusion criteria for the review were a 
diagnosis of mucosal head and neck cancer, curative intent treatment, radiotherapy as part 
of the treatment plan, and the study of a nutrition intervention and associated outcome. 
Exclusions were applied for thyroid and oesophageal cancers, primary treatment with 
surgery and those where nutrition parameters were not the primary outcomes of the study. 
The search was limited to articles in English only and included all adult human studies from 
1980 onwards. The strength of the evidence was assessed using the National Health and 
Medical Research Council “NHMRC Levels of Evidence and Grades for Developers of 
Guidelines” (NHMRC, 2009) and rated between levels I (highest) to level IV (lowest). The 
quality of the studies were assessed using the Academy of Nutrition and Dietetics “Evidence 
Analysis Manual: Steps in the Academy Evidence Analysis Process” whereby an overall 
rating of positive, neutral or negative quality was assigned (Academy of Nutrition and 
Dietetics, 2016). As part of this quality assessment tool the data from each individual study 
was reviewed to account for any author bias in their own conclusions. 
2.2 Access to appropriate nutrition care : Identification of future nutritional risk  
It is widely acknowledged that the dietitian should be part of the multidisciplinary team for 
treating patients with HNC (Head & Neck Guideline Steering Committee, 2011). Patients 
should be screened for malnutrition risk at diagnosis (Isenring et al., 2013; Watterson et al., 
2009), as pre-treatment weight loss and malnutrition have been associated with reduced 
survival outcomes (Kubrak et al., 2010; Platek et al., 2010). Many studies frequently classify 
severity of weight loss outcomes using the accepted definition of clinically significant weight 
loss >10% (National Centre for Classification in Health, 2010), however poorer survival 
outcomes have been shown with weight loss <10% (Langius et al., 2013b; Martin et al., 
2015). Therefore it is also important to recognise patients who may be well-nourished at 
diagnosis but are at future risk of nutritional deterioration, and provide appropriate timely 
intervention and education (Talwar, Donnelly, Skelly, & Donaldson, 2016).  
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The literature has identified a range of tumour, treatment and patient characteristics 
available to clinicians at diagnosis that are associated with future weight loss and/or need 
for tube feeding as discussed below. 
2.2.1 Predictors of weight loss 
There have been fourteen studies which have investigated predictors of weight loss 
following treatment for HNC. The type of treatment varies between studies, including single, 
double and triple modality, which means care needs to be taken in the interpretation. The 
results of all the studies are summarised in Table 2-1.There was only one level I positive 
quality study (Trotti et al., 2003) which was a systematic review on mucositis and impact on 
outcomes. Although this was a pooled cohort of 6181 patients from 33 RCT’s, only 10 
studies reported on the outcome of weight loss. A significant association between grade 3-
4 mucositis and weight loss was reported (r=0.83, p=0.001), with a mean weight loss of 6-
12%. 
This likely explains why other treatment-related factors such as higher radiotherapy dose, 
larger radiotherapy fields and hyperfractionated/accelerated regimens are also associated 
with weight loss, (Larsson, Hedelin, Johansson, & Athlin, 2005; Mallick et al., 2013; Munshi 
et al., 2003) as higher rates of mucositis would also be expected. The most common 
treatment factor associated with weight loss, was the addition of chemotherapy, supported 
by two level III studies (Mallick et al., 2013; Walsh et al., 2011) and three level IV studies 
(Beaver, Matheny, Roberts, & Myers, 2001; Munshi et al., 2003; Nugent, Parker, & McIntyre, 
2010a). A post-treatment neck dissection in a patient population predominantly treated with 
chemoradiotherapy (CRT) was also found to be associated with an increased risk of weight 
loss (O'Shea, Byrne, Tuckett, O'Leary, & Sheahan, 2015).  
The oropharynx was the most common tumour characteristic associated with weight loss, 
and was supported by one level II study (positive quality) (Ottosson, Zackrisson, Kjellen, 
Nilsson, & Laurell, 2013), one level III-3 study (positive quality) (Lonbro, Petersen, 
Andersen, & Johansen, 2016), and three level IV studies (one positive and two neutral 
quality) (Beaver et al., 2001; Nourissat et al., 2010; Nugent et al., 2010a). There is also 
some evidence (level III-IV) that a more advanced stage is associated with increased risk of 
weight loss (Ehrsson, Langius-Eklof, & Laurell, 2012; Lonbro et al., 2016; Nourissat et al., 
2010), however all of these studies were undertaken in patient populations receiving 
definitive or adjuvant radiotherapy alone. 
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The most common patient factor predictive of weight loss was a higher baseline weight or 
BMI, supported by three recent large positive quality studies (level II-IV) (Lonbro et al., 2016; 
Nourissat et al., 2010; Ottosson et al., 2013). Pre-treatment patient factors such as the 
presence of nutrition impact symptoms or dysphagia or poor performance status were all 
associated with weight loss (Kubrak et al., 2010; Munshi et al., 2003; Nourissat et al., 2010). 
The impact of age on weight loss is conflicting with two level III-3 positive quality studies 
reporting different outcomes. One study found that patients older than 60.9 years receiving 
definitive or adjuvant radiotherapy had less than half the odds (OR=0.46, p=0.005) of 10% 
or more weight loss compared to younger patients (Lonbro et al., 2016). Meanwhile another 
study found that patients over 65 years receiving CRT were more likely to experience weight 
loss (Chang et al., 2015). 
In summary, the highest level of evidence and most consistent body of evidence supports 
that patients at greatest risk of weight loss are those with: oropharyngeal tumours; more 
advanced stage disease; higher weight/BMI at baseline; and treatment regimens which 
increases the risk of grade 3-4 mucositis, including the addition of chemotherapy.  
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Table 2-1: Summary of studies investigating predictors of weight loss in patients with 
head and neck cancer 
Risk Factor Total 
Studies 
Level I Level II Level III Level IV 
Patient Factors 
Pre-treatment weight 
loss 
1    Beaver 2001 (Ø) 
Higher baseline 
weight or BMI 
3  Ottosson 
2013 (+) 
Lonbro 2016 (+) Nourissat 2010 (+) 
Pre-treatment 
dysphagia 
2    Nourissat 2010 (+) 
Kubrak 2010 (Ø) 
Nutrition impact 
symptoms or opioid 
use pre-treatment 
2    Nourissat 2010 (+) 
Kubrak 2010 (Ø) 
Poor baseline 
performance status 
2    Nourissat 2010 (+) 
Munshi 2003 (Ø) 
Older age 1   Chang 2015 (+)  
Younger age 1   Lonbro 2016 (+)  
Tumour Factors 
Oral cavity 2   Lonbro 2016 (+) Nourissat 2010 (+) 
Oropharynx 5  Ottosson 
2013 (+) 
Lonbro 2016 (+) Nourissat 2010 (+) 
Nugent 2010a (Ø) 
Beaver 2001 (Ø) 
Nasopharynx 1    Beaver 2001 (Ø) 
Hypopharynx 1    Nourissat 2010 (+) 
Larynx 1   Lonbro 2016 (+)  
Higher N stage 1    O'Shea 2015 (+) 
Higher TNM stage 3   Lonbro 2016 (+) Nourissat 2010 (+) 
Ehrsson 2012 (Ø) 
Treatment Factors 
Chemotherapy 5   Mallick 2013 (Ø) 
Walsh 2011 (Ø) 
Nugent 2010a (Ø) 
Munshi 2003 (Ø) 
Beaver 2001 (Ø) 
Multimodality 
treatments 
1    O'Shea 2015 (+) 
Nutrition impact 
symptoms or opioid 
use pre-treatment 
1 Trotti 
2003 (+) 
   
Higher RT doses 1    Munshi 2003 (Ø) 
Larger RT fields/oral 
mucosa 
1   Mallick 2013 (Ø)  
Accelerated or  
hyperfractionated 
RT 
1    Larsson 2005 (Ø) 
Abbreviations: BMI=Body Mass Index; TNM=Tumour, Nodal, Metastases Staging; RT=Radiotherapy. Quality 
rating: (+) = positive; (Ø) = neutral; (-) = negative. 
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2.2.2 Predictors of tube feeding 
A number of prognosis studies have looked at which patient groups are more likely to require 
a gastrostomy or feeding tube. In this body of literature, as well as variations in inclusion 
criteria for tumour sites and treatment, there are also differences in tube type, placement 
timing, outcome measures and follow-up time points. The summary of factors associated 
with tube feeding requirement are in Table 2-2.  
Two level II positive quality studies (Lango et al., 2016; Ottosson et al., 2013) provide the 
highest level of evidence to support the following patient risk factors: low BMI, pre-treatment 
dysphagia, pre-treatment nutrition impact symptoms, heavy smoker, poor performance 
status, and older age. Although the study by Ottosson et al. (2013) has a large sample size 
(n=712), the findings are limited to patients receiving radiotherapy. The study by Lango et 
al. (2016) was completed in patients receiving (chemo) radiotherapy but had a small sample 
in comparison (n=84). Pre-treatment weight loss was the only other patient factor supported 
by a number of level III and IV studies (Beaver et al., 2001; Gardine et al., 1988; Mangar, 
Slevin, Mais, & Sykes, 2006; Mays, Moustafa, Worley, Waltonen & D'Agostino, 2014; 
Orphanidou et al., 2011). 
In total there are four level II studies (three positive and one neutral quality) which also 
identify tumour sites, tumour staging and treatment to be important predictive factors. The 
highest level of evidence identifies: tumours of the oropharynx (Barnhart et al., 2017), 
followed by the hypopharynx and oral cavity (Ottosson et al., 2013); higher T stage (Brown 
et al., 2016a); higher overall TNM stage (Lango et al., 2016; Ottosson et al., 2013); and 
chemotherapy (Barnhart et al., 2017; Brown et al., 2016a; Lango et al., 2016). All of these 
factors were supported by a large number of level III-IV studies as well. Other key treatment 
factors were accelerated or hyperfractionated radiotherapy (Ottosson et al., 2013) and 
bilateral neck treatment (Barnhart et al., 2017). The level I systematic review also found 
grade 3-4 mucositis to be associated with feeding tube requirement (r=0.88, p=0.004) which 
was based on five RCT’s, n=819 (Trotti et al., 2003).  
In summary, the highest level of evidence and most consistent body of evidence supports 
that patients at greatest risk of requiring tube feeding are those with; oropharyngeal tumours, 
more advanced stage disease, receiving chemotherapy as part of treatment and of older 
age. This aligns quite closely to the risk factors identified for weight loss during treatment. 
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Table 2-2: Summary of studies investigating predictive factors of tube feeding 
requirement 
Risk Factor Total Level I Level II Level III Level IV 
Patient Factors 
Pre-treatment 
weight loss 
 
5   Mays 2014 (Ø) 
Orphanidou 2011 (Ø) 
Gardine 1988 (Ø) 
Mangar 2006 (Ø) 
Beaver 2001 (Ø) 
Low BMI 
 
5  Ottosson 
2013 (+) 
Orphanidou 2011 (Ø) 
Strom 2013 (Ø) 
Wermker 2012 (Ø) 
Mangar 2006 (Ø) 
 
Low albumin 
 
1    Mangar 2006 (Ø) 
Pre-treatment 
dysphagia 
6  Lango 
2016 (+) 
Ottosson 
2013 (+) 
Mays 2014 (Ø) 
Orphanidou 2011 (Ø) 
Larsson 2005 (Ø) 
Nutrition 
symptoms or 
opioid use pre-
treatment 
5  Lango 
2016 (+) 
Ottosson 
2013 (+) 
Orphanidou 2011 (Ø) 
 
Larsson 2005 (Ø) 
Jeffery 2012 (-) 
High alcohol 
 
1    Schweinfurth 2001 (Ø) 
High smoking 2  Lango 
2016 (+) 
 Mangar 2006 (Ø) 
Poor baseline 
performance 
status 
 
6  Lango 
2016 (+) 
Ottosson 
2013 (+) 
 Yang 2016 (Ø) 
Poulsen 2008 (Ø) 
Mangar 2006 (Ø) 
Matuschek 2016 (-) 
Older age 
 
8  Ottosson 
2013 (+) 
Chang 2015 (+) Beadle 2017 (Ø) 
Sachdev 2015 (Ø) 
Mangar 2006 (Ø) 
Al-Othman 2003 (Ø) 
Jeffery 2012 (-) 
Cheng 2006 (-) 
Female gender 
 
1    Mekhail 2001 (Ø) 
Single 
 
1   Locher 2013 (Ø)  
Tumour Factors 
Oral cavity 
 
5  Ottosson 
2013 (+) 
Ahmed 2005 (Ø) 
Wermker 2012 (Ø) 
Chen 2017 (+) 
Beaver 2001 (Ø) 
Oropharynx 
 
17  Barnhart 
2017 (+) 
Ahmed 2005 (Ø) 
Chepeha 2004 (Ø) 
Locher 2013 (Ø) 
Wermker 2012 (Ø) 
Gardine 1988 (Ø) 
Chen 2017 (+) 
Beadle 2017 (Ø) 
Zauls 2013 (Ø) 
Ishiki 2012 (Ø) 
Nugent 2010a (Ø) 
Larsson 2005 (Ø) 
Beaver 2001 (Ø) 
Schweinfurth 2001 (Ø) 
Ringstrom 1999 (Ø) 
Matuschek 2016 (-) 
Cheng 2006 (-) 
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Risk Factor Total Level I Level II Level III Level IV 
Tumour Factors cont. 
Nasopharynx 
 
1    Larsson 2005 (Ø) 
Hypopharynx 
 
7  Ottosson 
2013 (+) 
Ahmed 2005 (Ø) 
 
Beadle 2017 (Ø) 
Ishiki 2012 (Ø) 
Larsson 2005 (Ø) 
Mekhail 2001 (Ø) 
Cheng 2006 (-) 
Larynx 
 
2   Locher 2013 (Ø) Chen 2017 (+) 
Higher T stage 10  Brown 
2016a (Ø) 
Ahmed 2005 (Ø) 
Mays 2014 (Ø) 
Strom 2013 (Ø) 
Wermker 2012 (Ø) 
Beaver 2001 (Ø) 
Schweinfurth 2001 (Ø) 
Mekhail 2001 (Ø) 
Ringstrom 1999 (Ø) 
Jack 2012 (-) 
Higher N stage 
 
5   Mays 2014 (Ø) 
Locher 2013 (Ø) 
Wermker 2012 (Ø) 
Beadle 2017 (Ø) 
Al-Othman 2003 (Ø) 
 
Higher TNM 
stage 
8  Lango 
2016 (+) 
Ottosson 
2013 (+) 
Chepeha 2004 (+) 
Gardine 1988 (Ø) 
Poulsen 2008 (Ø) 
Mangar 2006 (Ø) 
Cheng 2006 (-) 
Riera 2002 (-) 
Moderate to 
poor histology  
  
1    Schweinfurth 2001 (Ø) 
Treatment Factors 
Chemotherapy 16  Barnhart 
2017 (+) 
Lango 
2016 (+) 
Brown 
2016a (Ø) 
Mallick 2013 (Ø) 
Locher 2013 (Ø) 
Strom 2013 (Ø) 
Walsh 2011 (Ø) 
Bhayani 2013b (+) 
Beadle 2017 (Ø) 
Ishimaru 2016 (Ø) 
Yang 2016 (Ø) 
Nugent 2010a (Ø) 
Al-Othman 2003 (Ø) 
Mekhail 2001 (Ø) 
Matuschek 2016 (-) 
Cheng 2006 (-) 
Multimodality 
treatments 
 
7   Chepeha 2004 (+) 
Mays 2014 (Ø) 
Gardine 1988 (Ø) 
Chen 2017 (+) 
Beaver 2001 (Ø) 
Schweinfurth 2001 (Ø) 
Jack 2012 (-) 
Accelerated or 
hyper-
fractionated 
RT 
 
3  Ottosson 
2013 (+) 
Strom 2013 (Ø) Poulsen 2008 (Ø) 
Larger RT 
fields/oral 
mucosa 
 
3   Mallick 2013 (Ø) 
Sanguineti 2011 (Ø) 
Poulsen 2008 (Ø) 
Higher RT 
dose >60gy/ 
Definitive RT 
 
2   Locher 2013 (Ø) Al-Othman 2003 (Ø) 
Bilateral neck 
RT 
2  Barnhart 
2017 (+) 
Wermker 2012 (Ø)  
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Risk Factor Total Level I Level II Level III Level IV 
Surgical Factors 
Surgery to oral 
cavity  
 
2    Chen 2017 (+) 
Schweinfurth 2001 (Ø) 
Surgery to 
base of tongue 
or pharynx 
 
4   Chepeha 2004 (+) 
Wermker 2012 (Ø) 
Chen 2017 (+) 
Schweinfurth 2001 (Ø) 
Surgery to 
larynx  
 
2   Mays 2014 (Ø) Chen 2017 (+) 
Flap 
reconstruction 
5   Chepeha 2004 (+) 
Mays 2014 (Ø) 
Chen 2017 (+) 
Schweinfurth 2001 (Ø) 
Cheng 2006 (-) 
Other factors 
 
Nutrition 
symptoms or 
opioid use pre-
treatment  
3 Trotti 
2003 (+) 
Ottosson 
2013 (+) 
 Riera 2002 (Ø) 
No 
prophylactic 
pain control 
(gabapentin) 
 
1    Yang 2016 (Ø) 
Non-adherent 
to swallow 
exercises 
 
1    Bhayani 2013b (+) 
Tracheostomy 
 
2   Mays 2014 (Ø) Cheng 2006 (-) 
Fistula 
 
1    Riera 2002 (-) 
Abbreviations: BMI=Body Mass Index; TNM=Tumour, Nodal, Metastases Staging; RT=Radiotherapy. Quality 
rating: (+) = positive; (Ø) = neutral; (-) = negative.
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2.2.3 Guidelines for high risk patients 
Using evidence to predict patients at future risk of weight loss or tube feeding would help to 
select patients who may benefit from a prophylactic gastrostomy (proPEG). Pre-treatment 
insertion avoids the difficulties of undergoing the procedure when cytotoxic or once acute 
toxicities have developed e.g. mucositis, oesophagitis and neutropenia, and helps minimise 
the risk of complications (Garsed, Armstrong, & Scott, 2007).  
There are currently three sets of guidelines published from the UK and Australia that identify 
high risk patients undergoing radiotherapy treatment. Two recommend high risk patients 
receive a proPEG (Brown et al., 2013b; Wood, 2005). The third classifies patients as high 
or low nutritional risk, but favours a reactive approach to tube placement (Kiss et al., 2012). 
All three sets of guidelines demonstrated significant clinical benefits following 
implementation such as less weight loss, fewer hospital admissions, reduced length of stay, 
fewer unplanned nasogastric tube (NGT) insertions, improved transition to oral diet post-
treatment and reduced oncologist review at two weeks post-treatment (Brown, Ross, Jones, 
Hughes, & Banks, 2014a; Hughes et al., 2013; Kiss et al., 2012; Wood, 2005). The 
Australian protocol for proPEG insertion is the only validated version and following further 
review was subsequently revised (Brown et al., 2016a).  
Guidelines for gastrostomy selection in the surgical population have also been developed in 
the UK (Jack, Dawson, Reilly, & Shoaib, 2012), and more recently a predictive model has 
been developed and validated in the USA (Mays et al., 2014). Despite the accuracy of this 
predictive model, it is quite complex and will be challenging to transfer into a clinical setting. 
A summary of each of the published guidelines/models described above are in Table 2-3.  
This body of evidence has been considered in the internationally endorsed guidelines to 
provide evidence-based practical recommendations as follows:  
“Prophylactic enteral feeding should be considered to improve nutritional status, cost and 
patient outcomes for patients who have: T4 tumours undergoing concurrent 
chemoradiotherapy; hypopharyngeal tumours undergoing concurrent chemoradiotherapy; 
Other patient groups should be considered by the multidisciplinary team on an individual 
basis dependent on other clinical factors such as tumour site, staging, effect of multi-
modality treatments, radiotherapy treatment fields and dose, type of surgical procedure, 
nutritional status and dysphagia.” (Head & Neck Guideline Steering Committee, 2011). 
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However the recommendation is currently only weakly supported (Grade C), and so it is not 
surprising that practices remain varied worldwide, with discrepancies reported in Australia 
(Brown & Findlay, 2011), UK (Moor, Patterson, Kelly, & Paleri, 2010) America (Koyfman & 
Adelstein, 2012), Canada (Orphanidou et al., 2011) and Italy (Trignani et al., 2015).   
The validated revised Australian protocol describing the risk factors which inform the high 
risk criteria for consideration of proPEG insertion (Brown et al., 2016b) was selected to be 
used for the studies included in this thesis.
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Table 2-3: Summary of existing guidelines for gastrostomy selection 
Citation Country Criteria for Gastrostomy 
 
Wood 
2005 
UK o Radical radiotherapy/chemoradiation: Oral cavity, Nasopharynx, 
Oropharynx, Hypopharynx 
o Palliative radiotherapy/chemoradiation (radical length): Oral cavity, 
Nasopharynx, Oropharynx, Hypopharynx 
o Patients (including carcinomas of the larynx) with: 
o Advanced disease 
o >10% weight loss within 6 months 
o BMI < 20 
o Over 70 years of age 
o Undergoing combined treatment 
o Patients with a small treatment field or reduced dose – Consider 
on an individual basis and discuss with the oncology dietitian and 
the ENT speech and language therapist 
 
Kiss  
2012 
Australia o T3/T4 oral cavity 
o T3/T4 and/or N2/N3 oropharynx/hypopharynx/larynx/nasopharynx 
o Adjuvant chemoradiation 
o Infield boost 
o Severe malnutrition (PG-SGA C) 
o Moderate malnutrition (PG-SGA B) in the presence of dysphagia 
 
Jack  
2012 
UK o Oral cavity, T3/T4, texture modified diet, surgery alone 
o Oral cavity, T3/T4, full diet, surgery and radiotherapy 
o Oral cavity, T1/T2, texture modified diet, surgery alone 
o Oral cavity, T1/T2, full diet, surgery and chemoradiotherapy 
o Mandible tumours, any stage or treatment 
o Oropharynx, T2/T3, fluid diet, surgery and radiotherapy 
 
Brown 
2013b 
Australia o Oral cavity with bilateral chemoradiotherapy 
o Midline oropharyngeal with chemoradiotherapy 
o Hypopharyngeal or nasopharyngeal with chemoradiotherapy 
o Dysphagia at presentation or prior to 
radiotherapy/chemoradiotherapy 
o Severe malnutrition at presentation: 
o Unintentional weight loss >10% in 6 months 
o BMI <18.5 
o BMI <20 with unintentional weight loss 5-10% in 6 months 
o Dietitian assessment SGA C 
o Poor oral intake (minimal intake >5days and/or unlikely to 
improve for >5 days) 
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Mays 
2014 
USA Predictive probability = X/(1 + X) 
X= e [5.8517 − (0.6874 × A) − (0.8847 × B) − (0.4541 × C) − (1.4086 × 
D) − (0.6947 × E) − (0.9533 × F) − (0.6588 × G) − (3.7531 × H) − 
(0.5632 × I)] 
where  
A = Preoperative weight loss (No = 1, Yes = 0) 
B = Clinical node stage (N0 = 1,N1 = 0,N2 = 0) 
C = Clinical node stage (N1 = 1,N0 = 0,N2 = 0) 
D = Preoperative irradiation (No = 1, Yes = 0) 
E = Dysphagia (No = 1, Yes = 0) 
F = Tracheostomy (No = 1, Yes = 0) 
G = Reconstruction type; (primary closure or SSG = 1, microvascular 
free flap or pedicled rotation flap = 0) 
H = Supra-cricoid laryngectomy (No = 1, Yes = 0) 
I = T stage (T1 or T2=1, T3 or T4=0) 
 
Brown 
2016a 
Australia o Oral/oropharyngeal with bilateral chemoradiotherapy 
o Hypopharyngeal or nasopharyngeal or unknown primary with 
chemoradiotherapy 
o Severe malnutrition at presentation: 
o Unintentional weight loss >10% in 6 months 
o BMI <20 with unintentional weight loss 5-10% in 6 months 
o Dietitian assessment SGA C 
 
Abbreviations: BMI=Body Mass Index; ENT=Ear Nose Throat; TNM=Tumour, Nodal, Metastases Staging; PG-
SGA=Patient-Generated Subjective Global Assessment; SGA=Subjective Global Assessment; SSG=Split 
Skin Graft.
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2.3 Nutrition goals and prescription 
Following nutrition screening, assessment and diagnosis, the first step of nutrition 
intervention is goal setting and nutrition prescription. In patients who have been identified at 
risk of malnutrition or malnourished, the aim is to maintain/prevent a decline/improve 
nutritional status (Watterson et al., 2009). Whilst this is the ideal goal for all patients 
commencing treatment, studies have shown that weight loss occurs despite nutrition 
intervention (Jager-Wittenaar et al., 2011b; Paccagnella et al., 2010; van den Berg et al., 
2010), and thus the consensus goal for patients receiving CRT is to minimise a decline in 
nutritional status/weight (Head & Neck Guideline Steering Committee, 2011). 
The number of studies investigating nutrition requirements in patients with HNC is very low. 
Only one study (level III-2 neutral quality) has measured resting energy expenditure with 
indirect calorimetry in patients undergoing CRT (n=18) and found that requirements were 
approximately 90-100kJ/kg/day throughout treatment, but were slightly more elevated at two 
weeks post-treatment at 105kJ/kg/day (Garcia-Peris et al., 2005).  
Other studies have determined requirements based on energy/protein intakes from food 
records and assessed outcomes to determine adequacy. One level IV (positive quality) 
study found that patients with sufficient intakes (defined as >145kJ/kg/day and >1.5g 
protein/kg/day) lost less body weight/lean mass during treatment than those with insufficient 
intakes; and only those with sufficient intakes were able to achieve weight gain post-
treatment (Jager-Wittenaar et al., 2011b). One level IV (neutral quality) study monitored 
energy intakes for a group of HNC patients (n=47) and found they were at 135kJ/kg/day 
pre/during treatment and increased to 160kJ/kg/day at six months post-treatment (van den 
Berg et al., 2006). However, patients who received CRT (n=3) intakes were only 80kJ/kg/day 
at the end of treatment resulting in the largest weight loss; which continued post-treatment 
despite increases in energy intake up to 155kJ/kg/day. A recent level IV neutral quality study 
in a larger sample (n=116) with approximately 60% receiving CRT had similar findings – 
with energy and protein intakes respectively at 115kJ/kg/day and 1.1g/kg/day at baseline, 
reducing to 95kJ/kg/day and 1.0g/kg/day at the end of treatment, and improving to 
135kJ/kg/day and 1.3g/kg/day at two to three months post-treatment, however nutrition 
outcomes were not reported (Alvarez-Camacho et al., 2016).
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One level IV (neutral quality) study (n=39) has investigated energy requirements at one year 
post-treatment based on how optimal BMI was achieved through long-term enteral feeding 
(Schattner et al., 2005). The authors concluded the following energy prescriptions were 
required for each goal; 145kJ/kg/day for weight maintenance, 185kJ/kg/day for weight gain 
and 115kJ/kg/day for weight loss. 
Overall the evidence is limited and inconsistent, and there is a lack of longitudinal studies 
with sufficient sample size. Therefore the current consensus recommendation for the 
nutrition prescription in any cancer patient is to provide 105-125kJ/kg/day (low level of 
evidence) and 1.5g protein/kg/day (moderate level of evidence) (Arends et al., 2017). 
2.4 Nutrition implementation 
The second step of nutrition intervention is selection of the nutrition implementation method 
to meet these goals and prescription. The evidence for the following methods of 
implementation are described below and include dietary counselling, oral nutrition 
supplements and tube feeding. 
2.4.1 Dietary counseling and oral nutrition supplements 
There is level I evidence for the role of nutrition support for patients receiving radiotherapy 
from two positive quality systematic reviews (Garg, Yoo, & Winquist, 2010; Langius et al., 
2013c). Garg et al. (2010) identified three RCT’s in relation to dietary counselling (Isenring, 
Bauer, & Capra, 2007; Isenring, Capra, & Bauer, 2004; Ravasco et al., 2005a) and two 
RCT’s in relation to oral nutrition supplements (Arnold & Richter, 1989; Nayel, el-Ghoneimy, 
& el-Haddad, 1992). The systematic review by Langius et al. (2013c) identified two additional 
RCT’s for dietary counselling (Macia et al., 1991; van den Berg et al., 2010) and they also 
included Ravasco et al. (2005a) in the analysis of oral nutrition supplements as this study 
had a third arm of oral supplements alone for comparison. Both reviews concluded beneficial 
effects of dietary counselling in relation to improving nutritional status and QOL compared 
to usual care (ad lib diet / nurse education and nutrition booklet). Whilst the patient numbers 
in individual studies were small (less than 50 randomised per arm), they were well-designed 
and of high quality. The role of oral nutrition supplements was deemed to be inconsistent, 
however they have been shown to be a cost effective intervention in malnourished patients 
in both the acute and community settings (Elia, Normand, Laviano, & Norman, 2016a; Elia, 
Normand, Norman, & Laviano, 2016b). 
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Since the systematic reviews were completed, a prospective level IV (neutral quality) study 
has evaluated the effect of nutrition counselling and oral nutrition supplements on toxicity 
outcomes from CRT, and found a relatively low rate of grade three mucositis at 33%, 
however interpretation was limited due to a lack of control group (Valentini et al., 2012). 
There has also been a quasi RCT (level III-1 neutral quality) that compared a daily oral 
nutrition supplement versus no supplement and reported improvements on QOL and less 
need for feeding tube placement (Trachootham et al., 2015). The supplement used was 
described as a novel type of oral supplement (Nutrijelly – semi solid texture) which was 
acceptable to the Thai population. It provides 230-260kcal and 10-11g protein per serve and 
thus is similar to other commercial liquid oral supplements. However, this study was severely 
limited by the lack of any nutritional outcome measures or details of nutrition interventions 
other than provision of a daily supplement. Finally a small cross-sectional study (n=32) in a 
post CRT treatment population with median follow-up of 44 months (range 14-68 months) is 
the first study to report on longer term nutritional needs of patients (van den Berg et al., 
2014). The authors reported malnutrition risk and weight loss is still a concern, especially in 
females and patients with high BMI pre-treatment, and that a high degree of food 
modifications, and use of nutritional supplements and tube feeding are still required. It was 
also found that food group recommendations and alcohol intake were not meeting 
guidelines, and that dietary advice for survivorship management is also important. 
2.4.2 Timing of intervention 
It is now widely accepted, based on the findings above, that patients receiving radiotherapy 
for HNC should be automatically referred to the dietitian for individualised dietary counselling 
(with or without oral nutrition supplements as required), with a minimum of weekly review 
during treatment and for at least six weeks post-treatment (Head & Neck Guideline Steering 
Committee, 2011). The limitations from these systematic review findings are that the majority 
of studies were undertaken in patients receiving radiotherapy alone, compared to current 
standard of care which is concurrent CRT, and the requirement or benefit of longer term 
nutrition intervention beyond six weeks post-treatment is not known. Nutrition support has 
been widely investigated for the role of preoperative nutrition support (Bertrand, Piquet, 
Bordier, Monnier, & Roulet, 2002; Flynn & Leightty, 1987; Weimann et al., 2006) particularly 
in regards to the role of immunonutrition (Stableforth, Thomas, & Lewis, 2009), but there 
have been limited studies investigating the timing of nutrition support prior to oncological or 
radiotherapy treatment. Positive outcomes have recently been reported following pre-
treatment nutrition intervention in lung cancer patients undergoing CRT (Kiss et al., 2016).  
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Two studies have reported the success of an early nutrition intervention in HNC patients 
undergoing (chemo) radiotherapy, with less weight loss, fewer treatment interruptions, less 
unplanned admissions and higher completion of chemotherapy (Paccagnella et al., 2010; 
Wang, Wang, Pang, & Yeh, 2012). The intervention groups both had a dietetic review pre-
treatment, but also received regular contact throughout treatment. Paccagnella et al. (2010) 
also had regular dietitian review post-treatment and Wang et al. (2012) also had mandatory 
hospitalisation and NGT placement throughout treatment to supplement oral intake. Both 
were in comparison to usual care in which patients received a nutrition booklet and were 
only referred to a dietitian in severe cases of symptoms or weight loss. Given the increase 
in dietetic intervention as a whole, it is unlikely the positive outcomes were due to the pre-
treatment counselling alone. 
A post-hoc analysis of an RCT (Rabinovitch et al., 2006), found that patients who received 
pre-treatment nutrition support had less weight loss and less mucositis, however were also 
more likely to have reduced locoregional control and survival. However, patients who 
received this support had more severe weight loss/dysphagia and advanced disease, and 
were therefore more likely to have poorer clinical outcomes. A recent study also looked at 
the impact of feeding tube timing in a population of patients with HPV-related oropharyngeal 
cancer undergoing adjuvant (chemo) radiotherapy. They did not use proPEG tubes, but 
found that patients who had their feeding tube placed prior to treatment, for therapeutic 
reasons, had a reduced survival (Verma et al., 2015). Again this group of patients had poorer 
nutritional status pre-treatment with 10.1% weight loss compared to 1.2% weight loss in 
patients who had feeding tubes placed later. Thus the presence of the feeding tube prior to 
treatment is really a surrogate marker for poor nutritional status and this is more likely the 
reason for reduced survival (Martin et al., 2015). 
2.4.3 Tube feeding: Optimal type and timing 
As many patients are unable to maintain adequate oral intake during treatment tube feeding 
is often recommended (Arends et al., 2006). The selection of tube type (gastrostomy versus 
NGT) and the timing of placement (prophylactic versus reactive) are areas that are highly 
debated. A gastrostomy tube is preferred if anticipated duration of nutrition support is likely 
to be greater than four weeks (Arends et al., 2006). Historically, many centres favoured the 
proPEG method, however there has been a trend in recent times to move away from this 
approach and favour reactive management with an NGT (Clavel et al., 2011; Lawson et al., 
2009; Madhoun, Blankenship, Blankenship, Krempl, & Tierney, 2011).  
 Chapter 2 Literature Review 
 26 
This section discusses the key evidence in the field with a detailed overview of the individual 
studies in the Appendices (Appendix A and Appendix B). For prophylactic tubes versus oral 
intake there were two level II neutral studies and five level III-2 studies (one positive, one 
neutral, three negative); for prophylactic tubes versus reactive tubes there were seven level 
III-2 studies (two positive, five neutral); for prophylactic tubes versus reactive management 
(oral intake +/- tube feeding as required) there were three level II studies (one positive, two 
neutral), twenty-five level III-2 studies (five positive, twenty neutral) and three level III-3 
studies (two positive, one neutral). For reactive tubes versus oral intake there were four level 
III-2 studies (three neutral, one negative); and for comparison of reactive tubes there were 
two level II studies (one neutral, one negative) and four level III-2 studies (three neutral, one 
negative).  
In 2014, the Canadian Agency for Drugs and Technologies in Health completed a review of 
systematic reviews and guidelines to determine the clinical effectiveness of NGT versus 
gastrostomy for patients with HNC. They identified four systematic reviews (Langius et al., 
2013c; Nugent, Lewis, & O'Sullivan, 2013; Orphanidou et al., 2011; Wang, Liu, Liu, Ye, & 
Huang, 2014a) and four sets of clinical practice guidelines (Canada 2009, UK 2011, 
Australia 2014 and America 2014) and provided detailed critical appraisal of the evidence. 
In summary, due to the lack of high level and high quality evidence to support one method 
over the other, no clear recommendations could be made from this review which was 
reflected in the other clinical guidelines available. Since this review, the UK guidelines have 
been updated although again no clear recommendations are made regarding feeding tube 
choice, other than consideration of gastrostomy if tube feeding is anticipated for greater than 
four weeks and that prophylactic feeding can be offered as part of locally agreed guidelines 
(Talwar et al., 2016). 
Of the systematic reviews included above, the highest quality review (Level I positive) was 
based on four RCTs with heterogenic study designs (Langius et al., 2013c). The first was a 
prophylactic NGT intervention trial versus oral intake undertaken in the 1980’s and published 
in two papers (Daly et al., 1984; Hearne et al., 1985). This intervention achieved higher 
energy and protein intakes and less weight loss, with no differences in toxicities, treatment 
response or survival. The individual study provides level II evidence (neutral quality) that 
tube feeding has superior outcomes to oral intake alone, however applicability to 
contemporary practices thirty years later is limited. 
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The second RCT (neutral quality) compared reactive nutrition support with either 
gastrostomy or NGT (Corry et al., 2008). The gastrostomy group had less weight loss at six 
weeks post-treatment but this difference was not maintained six months later, and they had 
longer duration of tube use, although dysphagia outcomes were no different at six months. 
Overall QOL was no different between groups, but differences were seen for certain 
domains. This individual study provides level II evidence (neutral quality) that both 
gastrostomy and NGT provide similar outcomes when placed reactively, and thus tube 
selection should consider the acceptability to the patient in terms of the different impacts on 
QOL.  
The final two RCT’s were both comparisons of proPEG versus reactive management (oral 
+/- tube feeding as required). One study (positive quality) reported on QOL outcomes and 
BMI (Salas et al., 2009). There were no differences in BMI at six months, but the proPEG 
group had a higher QOL for some domains at some time points. The second study (neutral 
quality) had no difference in weight loss outcomes, treatment delays, unplanned admissions 
or survival between groups, but the proPEG group had better QOL at six months for a 
number of domains, and less swallow problems at one year (Silander et al., 2012). These 
two studies both provide level II evidence that the prophylactic approach does not improve 
clinical or nutrition outcomes (although weight change was only monitored from six months 
post-treatment) but can improve some aspects of QOL compared to the reactive approach, 
with no impact on long-term swallow. Due to the overall variations in study design and 
sources of bias, the conclusion of the systematic review was that the effect of tube feeding 
interventions was inconsistent. 
Two additional systematic reviews have been completed since the Canadian Agency for 
Drugs and Technologies in Health review (Shaw et al., 2015; Zhang, Zhu, Ling, Zhang, & 
Wan, 2016). As no new RCT’s have been published since those included in the reviews by 
Langius et al. (2013c) and Wang et al. (2014a), the new systematic reviews broadened their 
inclusion criteria to include prospective and retrospective comparative studies, and so have 
been graded as level III-I (both were considered high quality). Due to differences in inclusion 
criteria with respect to the intervention and outcomes, different papers were included for 
each review. A summary of all systematic reviews to date has been compiled (Table 2-4). 
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Zhang et al. (2016) concluded that proPEG may be the optimal tube feeding method in 
reducing the rate of treatment interruptions and unplanned hospital admissions, with no 
difference in terms of tube complications. Both proPEG and NGT were found to be superior 
to reactive gastrostomy in terms of minimising weight loss. However, it was acknowledged 
that this was based on limited high level evidence (two RCTs and 11 cohort studies all with 
risk of bias) and that further research is required to confirm these findings. The review also 
did not consider other relevant outcomes such as tube dependency, QOL and cost. 
Tube dependency however was covered by Shaw et al. (2015). Five studies examined 
prevalence of tube use post-treatment (two were in favour of the reactive group, one found 
no difference, and two did not find any differences beyond three months). Seven studies 
examined duration of tube use (three studies were in favour of the reactive group, and four 
studies had no difference). Due to inconsistencies in results, no firm conclusions could be 
made. 
Another RCT comparing NGT (n=50) and gastrostomy (n=50) has been completed in India 
(Sadasivan, Faizal, & Kumar, 2012) however was not identified for inclusion in any of the 
systematic reviews. Whilst nutritional and QOL outcomes were better in the gastrostomy 
group the trial was deemed to be of negative quality. The methodology was very unclear 
with respect to the timing of the tube placement and thus it was difficult to ascertain if tubes 
were placed before surgery or radiotherapy and prophylactically or reactively. 
A well-designed RCT is currently underway in the UK (Paleri et al., 2016) which will hopefully 
start to address some of the uncertainty regarding optimal tube selection. This research 
group is comparing the proPEG approach to reactive management (oral nutrition with NGT 
as required) with outcomes of swallowing, QOL, nutritional parameters (BMI, weight and 
intake of enteral nutrition during treatment), admissions, dilatations, survival, and tube 
complications, with follow-up until 12 months post-treatment. 
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Table 2-4: Summary of systematic reviews on tube feeding interventions in head and neck cancer 
Citation Level & 
Quality  
Study design Interventions & Outcomes Results Comments/Limitations 
Langius 
2013c 
I + Systematic review of 
RCTs 
 
N=10 
 
N=536 participants 
 
HNC with RT/CRT 
6 RCT’s (7 papers) of diet/ONS 
interventions 
- Dietary counselling (n=4) 
- Dietary counselling/ONS (n=1) 
- ONS (n=2) 
 
4 RCT’s (5 papers) of tube 
interventions 
- NGT vs oral (n=2) 
- NGT vs gastrostomy (n=1) 
- proPEG vs reactive (n=2) 
 
Outcomes: 
- Nutrition 
- QOL 
- Dysphagia 
Dietary counselling 
beneficial on nutrition 
intake/status & QOL 
 
ONS/tube feeding effects 
inconsistent 
 
NGT beneficial on nutrition 
intake/wt vs oral intake  
 
Gastrostomy short-term 
benefit on wt loss vs NGT  
 
proPEG no difference for wt 
at 6mths, some benefit on 
short-term QOL (some 
domains), less dysphagia at 
1 year vs reactive 
 
All studies high risk of bias 
 
Small number of studies on 
ONS and tube feeding  
 
 
Garg 2010 I + Systematic review of 
RCT’s 
 
N=10 
 
N=585 participants 
 
HNC with RT/CRT 
10 RCT/papers of: 
- Dietary counselling/ONS (n=5) 
- Drug interventions (n=4) 
- Prophylactic tube feeding (n=1) 
 
Outcomes: 
- Nutrition 
Nutritional status appeared 
to be maintained or 
improved with dietary 
counselling, megesterol 
acetate and prophylactic 
tube feeding 
 
 
Limited RCTs addressing 
clinical question of interest  
 
>95% of patients had RT 
alone vs usual CRT 
 
Tube feeding conclusion 
based on one study 
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Citation Level & 
Quality  
Study design Interventions & Outcomes Results Comments/Limitations 
Nugent 2013 I Ø Systematic review of 
RCT’s 
  
N=1  
 
N=33 participants 
 
HNC with RT/CRT 
. 
 
Compared tube feeding 
methods. 
 
Gastrostomy (n=15) vs NGT 
(n=18) – both reactive tube 
feeding. 
 
Outcomes: 
- Nutritional status 
- Tube complications  
- Timing tube placed 
- QOL/ Patient satisfaction 
- Health economics 
- RT delays 
- Duration tube feeding 
- Reason for ceasing 
 
No conclusive evidence on 
which to base 
recommendations for the 
optimal method of enteral  
feeding during treatment 
and in the post-treatment 
period  
 
 
Systematic review well 
written but overall neutral 
rating as only based on one 
article of low quality 
 
Zhang 2016 III-I + Systematic review 
and network meta-
analysis of level II to 
III-2 papers 
 
N=13 (2 RCT) 
 
N=1631 participants 
 
HNC with RT/CRT 
 
 
Compared one or more tube 
feeding method (proPEG vs 
reactive gastrostomy vs NGT vs 
oral) 
 
Outcomes: 
- Wt 
- Treatment delays 
- Admissions 
- Tube complications 
 
 
proPEG and NGT had less 
wt loss vs reactive 
gastrostomy 
 
proPEG had less treatment 
delays and admissions vs 
others 
 
No differences in tube 
complications 
Risk of bias appraised using 
Cochrane handbook (RCTs) 
and Newcastle-Ottawa scale 
(others) 
 
Did not include other 
outcomes such as cost, QOL 
and tube dependency 
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Citation Level & 
Quality  
Study design Interventions & Outcomes Results Comments/Limitations 
Shaw 2015 III-I + Systematic review of 
level II to III-2 
papers 
 
N=20 (2 RCT) 
 
N=3168 participants 
 
HNC with 
RT/CRT/POCRT 
 
Compared proPEG with other 
nutrition interventions 
 
Outcomes: 
- Swallow  
- Wt 
 
Inconclusive due to poor 
study quality, high risk of 
bias, wide variation in 
treatment, RT type and 
patient population and 
inconsistent methods to 
assess dysphagia 
 
Wt loss outcomes 
inconsistent: 6/15 had 
significant differences in 
favour of proPEG, 7/15 had 
no differences and 2/15 
unclear 
 
Included 5 conference 
abstracts 
 
Used Cochrane review 
procedures 
 
Focus on swallow outcomes 
which has not identified all 
studies with nutrition 
outcomes 
Wang 2014a  III-1 Ø Systematic review of 
level II to III-2 
papers 
 
N=8 (1 RCT) 
 
N=818 participants 
 
HNC with RT/CRT 
(+/- surgery) 
 
 
Compared tube feeding 
methods (NGT and 
gastrostomy) 
 
Outcomes: 
- Nutrition status  
- Complications  
- Survival 
- Duration tube feeding  
- Delays/admissions 
- QOL 
No differences for nutrition 
status, infection, survival, 
RT delays 
 
NGT has higher 
dislodgements, admissions, 
length of stay 
 
Gastrostomy has higher 
dysphagia and duration 
tube feeding 
 
QOL benefits in both groups 
for different domains  
 
Combination of reactive and 
proPEG studies  
 
Quality assessment tool 
graded all as good quality 
 
Different outcomes assessed 
in different studies 
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Citation Level & 
Quality  
Study design Interventions & Outcomes Results Comments/Limitations 
Orphanidou 
2011 
III-3 Ø Systematic review of 
level III/IV papers 
 
N=7 
 
N=435 participants 
 
HNC with CRT 
 
Compared proPEG with other 
nutrition interventions 
 
- proPEG vs reactive (n=2) 
- proPEG with no control (n=5) 
 
Outcomes: 
- Adverse effects 
Lack of high level evidence, 
no conclusions drawn 
 
Used to develop local 
guidelines in Canada 
Due to small numbers, 
broadened search to include 
stage I/II and RT alone (n=13 
extra papers) 
 
Lack of information on search 
strategy, quality assessment 
methods, what the outcomes 
were. 
 
 
Abbreviations: RCT=Randomised Controlled Trial; HNC=Head and Neck Cancer; RT=Radiotherapy; CRT=Chemoradiotherapy; ONS=Oral Nutrition Supplements; 
NGT=Nasogastric Tube; proPEG=Prophylactic Gastrostomy; QOL=Quality of Life; Wt=Weight; POCRT=Post-operative Chemoradiotherapy. Quality rating: (+) = 
positive; (Ø) = neutral; (-) = negative. 
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2.5 Other considerations for nutrition interventions 
2.5.1 Patient adherence, motivation and preferences 
Patient motivation can also impact the effectiveness of nutrition care process (Splett & 
Myers, 2001), however adherence to dietary advice/recommendations is rarely captured. 
One of the key RCT’s comparing dietary counselling and supplements to usual care did 
measure adherence with dietary recommendations on a weekly basis through a daily 
supplement consumption record maintained by the patient and verified by a carer/relative. 
It found that even at three months follow-up the nutrition intervention group had remained 
adherent with dietary recommendations, and this translated into positive patient outcomes 
(Ravasco et al., 2005a).  
There has been only one other study (level IV neutral quality) that reported on clinical 
outcomes according to adherence and non-adherence with dietary recommendations 
(Capuano et al., 2008). Forty seven percent of patients were deemed non-adherent – 
defined as either not accepting nutritional counselling or refusing NGT or gastrostomy tubes 
during treatment (although reasons for refusal were not stated). Ninety percent of adherent 
patients maintained their weight and all of the non-adherent patients continued to lose 
weight during treatment (mean weight change 0% vs -11% respectively), and this trend 
continued in the 30-day follow-up period post-treatment. However, while this study 
accounted for adherence to the tube feeding recommendation or referral to a dietitian, it did 
not account for adherence to the recommendations given in the consultation.  
It is known that treatment preferences can also affect patient participation and adherence to 
interventions in RCTs (King et al., 2005). A previous RCT comparing different feeding tubes 
found patients had a strong preference for feeding tube type and thus did not want to be 
randomised (Corry et al., 2008). Therefore feasibility testing of this type of trial is important 
for future studies and is currently being considered in the pilot study comparing proPEG to 
the reactive approach (Paleri et al., 2016). The patient experience with feeding tubes may 
also account for factors relating to patient adherence and four recent qualitative studies have 
investigated this. Merrick & Farrell (2012) reported three main themes emerged from their 
study on gastrostomy tube experience; positive adaptation to acceptance of tube feeding 
(n=9); ambivalence between acceptance and rejection of the tube (n=4); and anxiety and 
fear of the tube (n=2) (Merrick & Farrell, 2012). The positive cognitive approach towards the 
tube in the first group may have been a contributing factor to less weight loss (6.5% vs 10-
15%).  
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Two studies reporting on patient experiences with gastrostomy tubes have been completed 
in the UK (Mayre-Chilton, Talwar, & Goff, 2011) and Canada (Osborne, Collin, Posluns, 
Stokes, & Vandenbussche, 2012). Both indicated primarily positive or neutral experiences 
with the tube with perceived benefits in preventing weight loss, however the impact of the 
tube on social and daily activities and intimacy were raised. A recent study in Sweden 
compared experiences of NGT and gastrostomy feeding, and whilst positive and negative 
experiences were reported, there were no clear preferences for tube type highlighting the 
importance of individual care (Ehrsson, Sundberg, Laurell, & Langius-Eklof, 2015). Cultural 
acceptance of tube feeding is also an important consideration, with low acceptance in 
Thailand (Pramyothin, Manyanont, Trakarnsanga, Petsuksiri, & Ithimakin, 2016) and long-
term NGT feeding reported to be preferable to gastrostomy tubes in many Asian nations 
(Jaafar, Mahadeva, Morgan, & Tan, 2016). 
2.5.2 Complications with gastrostomy placement 
Patients also need to be informed of the potential complications of treatment 
recommendations so that they can make informed decisions regarding their healthcare. 
Gastrostomy insertion may be a common method of intervention, however it is a medical 
procedure which entails risks. There has been one systematic review and meta-analysis 
which has reported on complications following percutaneous endoscopic gastrostomy 
(PEG) or radiologically inserted gastrostomy (RIG) tube insertions in patients with HNC 
(Grant et al., 2009). They included 27 studies of retrospective case series or cohorts 
(n=2379) and found similar mortality rates (PEG 2.2% vs RIG 1.8%) but higher major 
complications (8.9% vs 7.4%) and minor complications (22.1% vs 19.5%) with RIG tubes. 
The results from this study found that in comparison to a meta-analysis on mixed or non-
cancer patients (n=5752) (Wollman, D'Agostino, Walus-Wigle, Easter, & Beale, 1995), 
patients with HNC have similar PEG major complication rates but RIG procedure-related 
mortality and major complications are higher. However as the results are based on low levels 
of evidence with high risk of bias the authors are unable to firmly conclude or recommend 
the optimal method of gastrostomy tube placement.  
Neoplastic seeding is also a concern following gastrostomy placement, and although the 
incidence is rare, with a large series (n=208) reporting a rate of 0.92% (Cruz, Mamel, Brady, 
& Cass-Garcia, 2005), the outcomes are poor; with overall mortality of 87% and one year 
survival of 35% (Huang et al., 2013).  
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A literature review of cases of neoplastic seeding from HNC identified 38 cases of 
metastases at the gastrostomy site and 13 cases of tracheostomy site seeding (Nisa, 
Khanfir, & Giger, 2013). A subsequent review identified an additional four patients with 
gastrostomy site metastasis (total accumulative cases n=42) (Huang et al., 2013). This 
updated review of gastrostomy site seeding reported that in 97% of cases the pull technique 
was used and that 89% occurred when the tube was placed prior to treatment A recent 
retrospective cohort study in Taiwan also reports an increased oesophageal cancer risk 
(HR=2.31, p=0.02) in their patients with a gastrostomy (n=1851) compared to a matched 
control group of patients without a gastrostomy (n=3702) (Lin, Lin, Lee, Huang, & Chang, 
2016). Theories have been proposed on the possible mechanism by which seeding occurs 
such as swallowing of tumour cells or lymphatic spread, but it has also been suggested that 
direct implantation may occur with the pull technique from the endoscope, and thus debate 
on the optimal method continues. 
Since the systematic review by Grant et al. (2009), a retrospective comparative cohort study 
(level III-2 neutral quality) was completed comparing PEG and RIG tubes. Although no 
statistical differences in major or minor complications were found, it was acknowledged there 
was a high number of tube dislodgements in the RIG group (McAllister et al., 2013). A 
second retrospective comparative cohort study (level III-2 neutral quality) was completed 
comparing pull PEG with push PEG, and whilst a higher incidence of complications (tube 
blockage and dislodgement) was reported with the push method, the findings were limited 
as the study was completed in a mixed patient population with a tube selection bias as all 
HNC patients had the push PEG (Kohler et al., 2015).  
The first RCT in this area (level II positive quality) has examined outcomes following two 
methods of radiological insertion – traditional percutaneous placement (n=29) and per-oral 
placement (n=27), with no differences in pain scores, time and success of procedure, 
complications and QOL (Bernstein et al., 2015). There was only one major complication, 
overall infection rates were 8% and overall minor complications were 31-41%. Follow-up 
was limited to six months post insertion, and this may not have been long enough to observe 
cases of seeding, as previously reported to occur on average at eight months post insertion 
(Huang et al., 2013). Therefore the evidence remains unclear as to the optimal method of 
placement with the choice often dependent upon the institution and the skill of the staff 
available.  
 Chapter 2 Literature Review 
36 
One study has suggested the “overtube-assisted PEG placement” technique could be an 
alternative method to reduce the risk of tumour seeding (Musumba et al., 2015). Other 
methods of tube feeding have also been reported in the literature such as cervical 
oesophagostomy (Wang et al., 2014b), but this was a small case series of nasopharyngeal 
cancer patients with severe dysphagia post-treatment in China and the advantage of this 
method over gastrostomy feeding is unclear. Due to the risks involved with any procedure, 
it is important to inform and select patients appropriately to minimise exposure to any 
unnecessary risks. 
2.5.3 Predictors of prolonged tube feeding 
Some patients may require prolonged or long-term tube feeding following treatment. It has 
been shown that the requirement for tube feeding for acute toxicity is not associated with 
the long-term need for tube feeding (Al-Othman, Amdur, Morris, Hinerman, & Mendenhall, 
2003). There is still no accepted definition of the term “tube dependency”, however study 
designs have become more specific when investigating this phenomenon with clearer time 
points for outcome measures and definitions of tube use to classify true dependent cases. 
For the purposes of this literature review, prolonged tube feeding has been defined as 
requiring tube feeding beyond three months post-treatment. A summary of evidence from 
all studies is available in Table 2-5. 
There have been two level II neutral quality studies (Wopken et al., 2014a; Wopken et al., 
2014b) that provide the highest level of evidence to date for a number of predictive factors 
of prolonged tube feeding at six months post-treatment. These factors include: pre-treatment 
weight loss; higher T stage; higher N stage; chemotherapy; accelerated or hyperfractionated 
radiotherapy; bilateral neck radiation; and higher radiation doses to the pharyngeal 
constrictor muscles or larynx. This information was then used to develop a predictive model 
to determine the probability of tube dependency in patients. The factors with the largest body 
of additional evidence (level III/IV studies) to support their role in prolonged tube feeding 
duration include: higher T stage (n=8); higher N stage (n=6); the hypopharynx (n=6); older 
age (n=6); chemotherapy (n=4); and the dose to swallowing structures (n=5). Whilst some 
of these factors are similar to the predictors of tube feeding during treatment (i.e. increased 
stage, increased age and chemotherapy), the tumour site effects are noticeably different.
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The oropharynx is more important in the acute phase due to the radiotherapy dose to the 
oral mucosa, resulting in mucositis (Sanguineti, Rao, Gunn, Ricchetti, & Fiorino, 2013). The 
hypopharynx is more important in the chronic phase due to the radiotherapy dose to the 
swallowing structures being in closer proximity, resulting in dysphagia (Bhayani et al., 
2013a). Emerging research is also suggesting that it may be more important to identify 
tumour subsites as risk factors, such as the posterior wall in the hypopharynx (Bhayani et 
al., 2013a; Homma et al., 2016; Murono et al., 2015). Other social factors are also beginning 
to be identified such as smoking (Bhayani et al., 2013a; O'Shea et al., 2015), social supports 
(Jang et al., 2013; Magnuson et al., 2013) and the impact of patient adherence to swallowing 
exercises (Bhayani et al., 2013a; Bhayani et al., 2013b). Finally, in addition to pre-treatment 
weight loss identified in two studies by Wopken et al. (2014a, 2014b), low BMI at baseline 
(McRackan et al., 2008; Miyamoto et al., 2012) and greater than 10% weight loss during 
treatment (Bhayani et al., 2013b) have also been associated with prolonged tube feeding. 
This illustrates that patients with the greatest nutritional deficits are using their tubes for 
longer, which is an anticipated outcome of appropriate tube use to improve nutritional status. 
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Table 2-5: Summary of studies investigating predictive of tube feeding dependency 
(>3months post treatment).  
Risk Factor Total Level II Level III Level IV 
Patient Factors 
 
Pre-treatment weight 
loss 
 
3 Wopken 
2014a (Ø) 
Wopken 
2014b (Ø)  
Jang 2013 (+) 
Low BMI 
 
2  Miyamoto 2012 (Ø) 
McRackan 2008 (Ø) 
 
Pre-treatment dysphagia 
 
1  
 
Amin 2012 (Ø) 
Nutrition symptoms or 
opioid use pre-treatment 
 
2   Jang 2013 (+) 
Sanguineti 2013 (Ø) 
High smoking 4   O’Shea 2015 (+) 
Bhayani 2013a (+) 
Setton 2015 (Ø) 
Amin 2012 (Ø) 
Non smoking 
 
1   Homma 2016 (Ø) 
Poor baseline 
performance status 
 
2   Homma 2016 (Ø) 
Pohar 2015 (Ø) 
Older age 
 
6  Machtay 2008 (Ø) 
Miyamoto 2012 (Ø) 
Shinozaki 2014 (Ø) 
Setton 2015 (Ø) 
Kornguth 2005 (Ø) 
Lawson 2009 (Ø) 
Female gender 
 
3   Homma 2016 (Ø) 
Sanguineti 2013 (Ø) 
Al-Othman 2003 (Ø) 
Single 
 
2  Magnuson 2013 (Ø) Jang 2013 (+) 
Tumour Factors 
 
Hypopharynx 
 
6  Machtay 2008 (Ø) 
 
Bhayani 2013a (Ø) 
Homma 2016 (Ø) 
Murono 2015 (Ø) 
Ishiki 2012 (Ø) 
Al-Othman 2003 (Ø) 
 
Larynx 
 
2  Machtay 2008 (Ø) Hurst 2016 (Ø) 
Multiple synchronous 
primary 
 
1   Al-Othman 2003 (Ø) 
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Risk Factor Total Level II Level III Level IV 
Tumour Factors cont. 
Higher TNM stage 3   Akst (+) 
Homma 2016 (Ø) 
Lohia 2014 (Ø) 
Higher T stage 10 Wopken 
2014a (Ø) 
Wopken 
2014b (Ø) 
Machtay 2008 (Ø) 
Gokhale 2010 (Ø) 
Lavo 2017 (Ø) 
Pohar 2015 (Ø) 
Amin 2012 (Ø) 
Lawson 2009 (Ø) 
Avery 2008 (Ø) 
Kornguth 2005 (Ø) 
Higher N stage 
 
7 Wopken 
2014b (Ø) 
 Hurst 2016 (Ø) 
Lavo 2017 (Ø) 
Setton 2015 (Ø) 
Lawson 2009 (Ø) 
Avery 2008 (Ø) 
Kornguth 2005 (Ø) 
Treatment Factors 
 
Chemotherapy 6 Wopken 
2014a (Ø) 
Wopken 
2014b (Ø) 
 Lavo 2017 (Ø) 
Setton 2015 (Ø) 
Sanguineti 2013 (Ø) 
Kornguth 2005 (Ø) 
Multimodality treatments 
 
4  Machtay 2008 (Ø) 
Magnuson 2013 (Ø) 
Miyamoto 2012 (Ø) 
Avery 2008 (Ø) 
Accelerated or  
hyperfractionated RT 
 
2 Wopken 
2014a (Ø) 
Wopken 
2014b (Ø) 
  
Larger RT fields/oral 
mucosa 
 
3  Sanguineti 2011 (Ø) 
 
Gensheimer 2016 (Ø) 
Sanguineti 2013 (Ø) 
3D conformal RT 3   Bhayani 2013b (+) 
Beadle 2017 (Ø) 
Lohia 2014 (Ø) 
Higher RT dose >60Gy/ 
Definitive RT 
 
1   Al-Othman 2003 (Ø) 
Bilateral neck RT 3 Wopken 
2014b (Ø) 
 Chen 2017 (+) 
Higher dose to 
pharyngeal constrictor 
muscles or larynx 
6 Wopken 
2014a (Ø) 
 
Gokhale 2010 (Ø) Vlacich 2014 (Ø) 
Sanguineti 2013 (Ø) 
Amin 2012 (Ø) 
Li 2009 (Ø) 
Pre-treatment CT Scan 
Gross Tumour Volume 
 
 
1   Hurst 2016 (Ø) 
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Risk Factor Total Level II Level III Level IV 
Surgical Factors 
 
Glossectomy or 
Maxillectomy 
 
1   Avery 2008 (Ø) 
Flap reconstruction 
 
1   Chen 2017 (+) 
Other factors 
 
Tracheostomy 
 
1  Magnuson 2013 (Ø)  
>10% weight loss during 
treatment 
 
1   Bhayani 2013b (+) 
Non-adherence to 
swallow exercises 
 
1   Bhayani 2013a (+) 
Bhayani 2013b (+) 
Vocal cord paralysis 
 
1   Lavo 2017 (Ø) 
Laryngeal oedema 
 
1   Lavo 2017 (Ø) 
Abbreviations: BMI=Body Mass Index; TNM=Tumour, Nodal, Metastases Staging; RT=Radiotherapy. Quality 
rating: (+) = positive; (Ø) = neutral; (-) = negative.
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2.5.4 Impact on quality of life  
There are a number of patient and treatment factors that affect QOL outcomes including: 
type of treatment (Metreau, Louvel, Godey, Le Clech, & Jegoux, 2014; Payakachat, 
Ounpraseuth, & Suen, 2013); persistent smoking (Egestad & Emaus, 2014); higher baseline 
BMI (Egestad & Nieder, 2015); type of radiotherapy treatment (Vainshtein et al., 2015); 
socioeconomic factors and comorbidities (Wells et al., 2016). Tube feeding, with an NGT or 
gastrostomy, has been shown to cause psychosocial distress; although short-term 
significant improvements in QOL are seen indicating a degree of adaptation (Roberge et al., 
2000). It is well known that a prolonged feeding tube is associated with reduced QOL 
(Rogers, Thomson, O'Toole, & Lowe, 2007; Terrell et al., 2004) as well as depression (Chen 
et al., 2013). A recent large cross-sectional study (n=280) in survivors up to five years post-
treatment confirmed that presence of a feeding tube was an independent predictor of poorer 
cancer-specific QOL (Wells et al., 2016). Of note, as the feeding tube is most likely in-situ 
to improve a patient’s nutritional status, malnutrition may actually be a confounding factor of 
reduced QOL (Ravasco et al., 2004). However, patients are generally keen to have their 
tube removed as soon as possible, with a recent qualitative study suggesting that patients 
appear to equate tube removal with a positive transitional stage in the recovery process 
towards cure from their cancer (Merrick & Farrell, 2012). Thus it is important for patients 
(and carers) to understand the potential impacts of tube feeding upon QOL and be provided 
with appropriate supports and counselling to develop coping strategies to adapt to the 
impact of tube feeding upon their personal lives (Brotherton, Abbott, & Aggett, 2006). 
Prevention of long-term tube dependence is also important and adherence to swallowing 
exercises has been shown to be beneficial (Hutcheson et al., 2013) as well as the evolution 
of treatment regimens (discussed in the next section). 
2.5.5 Effect of evolving treatment regimens and p16/HPV status 
Radiotherapy techniques have evolved from 3D conformal techniques to intensity-
modulated radiotherapy (IMRT), which means the dose to surrounding tissues and/or organs 
at risk, such as the salivary glands, can be spared. This has resulted in a reduction in long-
term dysphagia and xerostomia (Kam et al., 2007; Nutting et al., 2011; Pow et al., 2006), 
Consequently, it is anticipated that a patient’s nutritional intake would improve, however the 
studies are yet to measure this as a specific primary outcome to demonstrate this theoretical 
benefit, and high rates of weight loss and tube feeding during and post-treatment have still 
been reported (Caudell et al., 2010; Gunn, Endres, Parker, Sormani, & Sanguineti, 2010; 
Studer et al., 2010). Therefore recommendations for nutrition intervention have not changed. 
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More recently helical-IMRT has been introduced, which is more targeted than IMRT, and 
raises the question as to whether the anticipated reduction in toxicities would reduce the 
need for intensive nutrition intervention. There are currently no studies that have specifically 
investigated the impact of helical-IMRT on nutrition outcomes. Level IV studies have 
reported weight or tube feeding as secondary outcomes, and significant weight loss still 
appears to be an issue (Capelle et al., 2012; Chao, Low, Perez, & Purdy, 2000; You et al., 
2012). Details of tube feeding are minimal with one small case series (n=5) reporting that all 
patients had a proPEG placed (Loo et al., 2011); and one study (n=17) reported no–one 
required a gastrostomy (Chao et al., 2000); however use of tubes was not described and 
weight loss was prevalent.  
Similarly, it has also been noted that proton therapy is another form of radiotherapy 
technique with reported reduced toxicity and improved efficacy (McKeever et al., 2016). 
Early reports published in the last year are indicating a reduction in the need for tube feeding 
(Blanchard et al., 2016; Gunn et al., 2016; McDonald, Liu, Moore, & Johnstone, 2016; Phan 
et al., 2016), although grade three mucositis was still reported at 58% (Gunn et al., 2016) 
and weight loss outcomes have not been studied. 
Other new developing treatments include progress with targeted systemic agents such as 
anti-Epidermal Growth Factor Receptor therapies including monoclonal antibodies (e.g. 
Cetuximab). Early trials indicated that Cetuximab did not increase the toxicity of treatment 
compared to radiotherapy alone (Bonner et al., 2006), and a follow-up sub-analysis of the 
data according to p16 status (as a marker of HPV) found that this also had no effect on 
mucositis, dysphagia or feeding tube use (Bonner et al., 2016). At the time of 
commencement of this thesis there had only been two studies reporting a comparison of 
Cetuximab with Cisplatin, which showed higher rates of toxicity, weight loss and feeding 
tube use with Cetuximab (Walsh et al., 2011) and no significant differences with feeding 
tube dependence at nine months (Koutcher et al., 2011). Since then the studies have had 
mixed results with: one showing no difference in weight loss or feeding tube use (Ye, Hay, 
Laskin, Wu, & Ho, 2013); one showing higher rate of tube placement with Cisplatin (Levy et 
al., 2014); one showing higher need for nutrition support with Cetuximab (Magrini et al., 
2015); and a small case series of patients receiving Cetuximab with a high use of feeding 
tubes (11/14 patients) and high rates of mucositis (Yokota et al., 2015). The most recent 
study (n=500) found use of nutrition support was higher in the Cisplatin group at 30 days 
post commencement of treatment, but no different on completion of treatment (Ishimaru et 
al., 2016).  
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Other studies comparing outcomes with weekly versus high dose Cisplatin also show no 
differences in weight loss, tube use during treatment or tube dependency at six months 
(Jagdis et al., 2014; Oosting et al., 2016). The role of induction or neoadjuvant 
chemotherapy is also an area of interest but a large number of variables within studies make 
interpretation of the data challenging (e.g. different lengths of treatment times, cycles, 
chemotherapy agents and control groups) (Dobrosotskaya et al., 2014; Jensen et al., 2011). 
Immunotherapy is also an emerging area of research that will need to be considered in the 
future (Ferris, 2015). 
As patients with HPV-related disease have been found to have improved survival outcomes 
(Benson, Li, Eisele, & Fakhry, 2013), research has expanded to investigate whether current 
recommended treatments remain suitable for this sub-set of patients, with a greater focus 
on survivorship and long-term QOL (Rischin, Ferris, & Le, 2015). There is an increasing 
number of radiation and chemotherapy de-intensification trials, such as reducing radiation 
dose and avoiding or reducing Cisplatin, with the aim to reduce toxicity and long-term side 
effects (Bhatia & Burtness, 2015). There is also a renewed interest in surgical management 
with the advent of trans-oral robotic surgical techniques for early stage oropharyngeal 
cancers, which reduces long-term speech and swallowing dysfunction (Holsinger & Ferris, 
2015). A recent systematic review reports reactive feeding tube placement rates of 18-39% 
following this surgical technique with long-term dependence of 0-7% (mean follow-up of 11-
26 months) (Hutcheson, Holsinger, Kupferman, & Lewin, 2015). Although a recent 
Australian study has reported tube feeding outcomes acutely postoperatively with long-term 
data on tube dependency; nutritional status and weight outcomes remain unknown 
(Hirshoren et al., 2016). 
In summary it can be seen that healthcare treatments and techniques continue to evolve for 
patients with HNC and it is important to re-assess the appropriateness of nutrition 
interventions and recommendations for practice accordingly. 
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3.1 Thesis aims and objectives 
Malnutrition and weight loss remain a significant issue in patients with HNC, despite 
aggressive nutrition interventions with intensive dietetic counselling and insertion of proPEG 
tubes. Causes of malnutrition and weight loss from tumour burden and treatment side effects 
are well established (Figure 1-1). A number of additional causes have been generated from 
the literature and observations from clinical practice that require consideration (Figure 3-1). 
Figure 3-1: Additional causes of significant weight loss in head and neck cancer  
Source: Developed by author Abbreviations: HPV=Human Papillomavirus 
The overarching aim of the research from this thesis is to minimise this weight loss and 
improve nutrition outcomes, which will subsequently improve other clinical, cost and patient 
outcomes. This will be addressed by the following objectives: 1) to optimise the identification 
of patients for access to appropriate nutrition care; 2) to optimise the nutrition interventions 
that are implemented as part of the nutrition care process. Several novel areas of research 
will be considered across different aspects of the nutrition care model as outlined in Figure 
3-2 and the remainder of this chapter.
Significant 
weight loss
Nutritional
• increased 
requirements with 
chemoradiotherapy
• increased 
requirements with 
HPV-related tumours
Feed intolerance
• nausea/vomiting
• diarrhoea
• constipation
• bloating
• reflux
Psychosocial
• fatigue
• lack of time
• finances
• lack of support
Psychological
• motivation
• need to persuade 
patient to use tube
• perceived view of 
failure by patient if 
need to use tube
• period of adaptation 
and adjustment to 
tube is required
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Figure 3-2: Outline of research in this thesis in the context of the nutrition care model 
Abbreviations: IMRT=Intensity-Modulated Radiotherapy; proPEG=Prophylactic Gastrostomy; RCT= 
Randomised Controlled Trial 
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3.2 Appropriate access to nutrition care 
3.2.1 The impact of evolving treatments on nutrition care 
The first step in receiving quality nutrition care is to determine appropriate access through 
screening or assessment. Current clinical practice guidelines recommend routine referral to 
the dietitian for all patients receiving radiotherapy for HNC. The literature review identified 
that there is a lack of information regarding the impact of helical-IMRT on nutrition outcomes.  
Therefore, this thesis (Chapter 4) will provide novel research to compare the nutrition 
outcomes between cohorts of patients receiving 3D conformal radiotherapy compared to 
helical-IMRT to understand the impact of advancing treatment on nutritional outcomes and 
nutrition interventions required. The findings will directly inform recommendations for clinical 
practice and determine whether referral procedures for appropriate access to nutrition care 
need to change. 
3.2.2 The identification of patients for proactive gastrostomy 
The protocol for proPEG at the Royal Brisbane and Women’s Hospital is another method of 
identifying high risk patients for appropriate nutrition care. This protocol was previously 
validated in a patient cohort receiving 3D conformal radiotherapy (Brown et al., 2013b). 
Therefore, this thesis will provide novel research to validate this protocol in a new cohort 
receiving helical-IMRT.  
As well as changes to radiotherapy techniques the literature review identified that there was 
a lack of information on whether new systemic therapies, such as Cetuximab, or a diagnosis 
of a HPV-related cancer can influence nutrition outcomes. Therefore this thesis will provide 
further novel research in these areas to determine the impact of these new factors on the 
requirement for proPEG.  
Together these findings (Chapter 5) will provide a unique insight into the nutritional needs 
of patients in the evolving epidemiology of HNC and current treatment regimens and provide 
information on the optimal identification of patients for proPEG. 
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3.3 Quality nutrition care and outcomes 
3.3.1 Optimising nutrition interventions during treatment 
Once patients have obtained access to nutrition care, the quality nutrition care process can 
commence. Despite a significant body of literature on tube interventions during treatment, 
there is still a lack of consensus on the optimal method due to a lack of high quality RCT’s. 
Only two studies have compared proPEG versus the reactive approach of tube feeding if 
and when required (Salas et al., 2009; Silander et al., 2012; Silander, Jacobsson, Berteus-
Forslund, & Hammerlid, 2013) and this is the most applicable study design to informing 
current practice. Since work on this thesis commenced, a pilot RCT comparing these two 
methods of nutrition support is now underway (Paleri et al., 2016).  
Meanwhile, this thesis (Chapter 6) reports on prospective clinical outcomes (weight) and 
cost outcomes (admissions) of high risk patients who receive a proPEG versus those who 
are managed reactively. This research will therefore provide additional evidence to add to 
the body of literature to help inform decision-making in clinical practice regarding timing of 
feeding tube placement until further high level evidence becomes available. 
3.3.2 Early nutrition intervention pre-treatment 
As prior research identified that patients continue to lose weight, despite proPEG and weekly 
dietetic counselling (Brown et al., 2014a), the final main study from this thesis (Chapters 7 
and 8) investigates a novel early nutrition intervention that is commenced prior to treatment 
via the proPEG. There have been no studies in the literature to date that have investigated 
additional pre-treatment nutrition interventions in comparison to standard best practice care 
models of regular dietitian care during and post-treatment. Current studies which use 
proPEG tubes and report on the timing of commencement of nutrition support, do so when 
clinically indicated in response to deterioration in swallowing or nutritional status (Beer, 
Krause, Zuercher, & Stanga, 2005; Marcy et al., 2000; Nguyen et al., 2006; Nugent et al., 
2010a; Raykher et al., 2009; Scolapio, Spangler, Romano, McLaughlin, & Salassa, 2001; 
Wiggenraad et al., 2007). A range of outcomes following the theoretical model will be 
assessed from this intervention study: clinical outcomes (weight, body composition, 
nutritional status, and treatment tolerance); cost outcomes (unplanned admissions); and 
patient outcomes (survival and QOL). The results of this research will directly inform future 
clinical practice and will provide more evidence on the role of pre-treatment nutrition support 
in this patient population.
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4.1 Chapter overview 
The findings in this chapter have been published in the European Journal of Clinical Nutrition 
(Journal Impact Factor 2.935; Ranked 31/80 Nutrition & Dietetics category; Quartile 2). 
Section 4.2 and 4.3 are presented in their accepted format prior to publication.  
The aim of this chapter was to investigate how the emerging technology in radiotherapy 
techniques has translated into clinical practice, specifically the impact on nutritional 
outcomes. As targeted radiotherapy techniques have been developed to minimise toxicity 
to normal tissues it was expected to see a reduction in treatment-related toxicities which in 
turn was expected to result in a reduction in nutrition impact symptoms and thus reduce 
weight loss and the decline in nutritional status. However there are very few studies which 
have investigated this hypothesis in relation to nutrition outcomes. Therefore the nutrition 
outcomes of patients receiving the new technique (helical-IMRT) were compared to patients 
who received the previous technique (3D conformal radiotherapy) via a retrospective clinical 
audit. 
Results of this study were presented at the following international and national conferences: 
6th European Congress on Head and Neck Oncology, Liverpool UK, 2014 (Appendix C -
11.3.2) and the Dietitians Association of Australia 31st National Conference, Brisbane, 
Australia, 2014 (Appendix C – 11.3.3). 
Date submitted: 20/04/2015 
Date accepted: 21/07/2015 
Citation: Brown, T., Banks, M., Hughes, B., Lin, C., Kenny, L., Bauer, J. (2015). New 
radiotherapy techniques do not reduce the need for nutrition intervention in patients with 
head and neck cancer. Eur J Clin Nutr, 69(10), 1119-24. doi:10.1038/ejcn.2015.141 
.
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4.2 Abstract 
Background/Objectives: Since 2007 our institution has used validated guidelines for the 
insertion of proactive gastrostomy feeding tubes in patients with head and neck cancer. 
Helical Intensity-Modulated Radiotherapy (H-IMRT) delivered by Tomotherapy™, is an 
advanced radiotherapy technique introduced at our centre in 2010. This form of therapy 
reduces long-term treatment-related toxicity to normal tissues. The aim of this study is to 
compare weight change and need for tube feeding following H-IMRT (n=53) with patients 
that would have previously been treated with 3D conformal radiotherapy (n=134). 
Subjects/Methods: Patients with head and neck cancer assessed as high nutritional risk with 
recommendation for proactive gastrostomy were identified from cohorts from 2007-08 and 
2010-11. Retrospective data were collected on clinical factors, weight change from baseline 
to completion of treatment, incidence of severe weight loss (>10%) and tube feeding. 
Statistical analyses to compare outcomes between the two treatments included Chi Square, 
Fishers Exact and Two Sample Wilcoxon tests (p<0.05). 
Results: The H-IMRT cohort had higher proportions of patients with definitive 
chemoradiotherapy (p=0.032) and more advanced N stage (p<0.001). Nutrition outcomes 
were not significantly different between H-IMRT and conformal radiotherapy respectively: 
need for proactive gastrostomy (n=49, 92% versus n=115, 86%, p=0.213); median 
percentage weight change (-7.2% versus -7.3%, p=0.573); severe weight loss incidence 
(28% versus 27%, p=0.843).  
Conclusions: Both groups had median weight loss >5% and high incidences of tube feeding 
and severe weight loss. Nutrition intervention remains critical in this patient population, 
despite advances in radiotherapy techniques, and no changes to current management are 
recommended.
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4.3 Manuscript 
INTRODUCTION  
Patients with mucosal squamous cell carcinoma cancer of the head and neck have a high 
incidence of malnutrition and frequently require enteral tube feeding. Since 2007 our 
institution has used validated local hospital guidelines: The RBWH Swallowing and Nutrition 
Management Guidelines for Patients with Head and Neck Cancer (S&N Guidelines), for a 
proactive approach to the insertion of enteral feeding tubes (Brown et al., 2013b). 
Implementation of the S&N Guidelines has reduced unplanned hospital admissions and 
length of stay (Hughes et al., 2013) and adherence to the S&N Guidelines has improved 
nutrition outcomes (Brown et al., 2014a). There is no international consensus for the optimal 
method of tube feeding (Nugent et al., 2013), and centres have adapted either a proactive 
or reactive approach. The majority of studies supporting prophylactic gastrostomy insertion 
have been undertaken in patients receiving treatment with conformal radiotherapy or 
radiotherapy alone (Lee et al., 1998; Senft, Fietkau, Iro, Sailer, & Sauer, 1993; Tyldesley et 
al., 1996). As radiotherapy techniques and treatment regimens evolve, nutrition support 
recommendations also require ongoing review.  
Intensity-Modulated Radiotherapy (IMRT) is a targeted form of radiotherapy. When 
compared to three-dimensional (3D) conformal radiotherapy, IMRT allows better 
preservation of organs and tissue in close proximity to the cancer being treated (e.g. parotid 
glands), and so reduces late side effects such as xerostomia and thereby improves quality 
of life (Vergeer et al., 2009). Although, some authors have postulated this may lead to a 
reduced need for a gastrostomy (Sanguineti et al., 2011), there are studies that continue to 
support the role of a prophylactic gastrostomy with IMRT, particularly with concurrent 
treatment (Romesser et al., 2012). There have been concerns that prophylactic gastrostomy 
insertion increases the risk of gastrostomy dependency, with longer duration of tube usage 
and increased dysphagia post-treatment (Corry et al., 2008; Kramer, Newcomb, Hessler, & 
Siddiqui, 2014; Mekhail et al., 2001), although some studies with IMRT have not found this 
to be of concern (Amin et al., 2012; de Arruda et al., 2006; Rusthoven et al., 2008).  
Since 2010 the majority of patients with squamous cell carcinoma of the head and neck in 
our centre have been treated with Helical-IMRT (H-IMRT) using Tomotherapy™. Several 
studies have suggested H-IMRT can achieve superior dose sparing to organs at risk versus 
other forms of IMRT (Fiorino et al., 2006; Lee et al., 2008a; Ruchala, Olivera, Schloesser, & 
Mackie, 1999; Sheng, Molloy, & Read, 2006).  
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This has strengthened the hypothesis that intensive nutrition support with a feeding tube 
may no longer be warranted. However the extent of nutrition outcomes and requirement for 
tube feeding following H-IMRT has not been widely reported. Therefore the aim of this study 
was to investigate weight change and the requirement for tube feeding in a cohort of high 
risk patients receiving H-IMRT compared to a high risk cohort receiving standard conformal 
radiotherapy to see if any change to nutrition management is warranted. 
SUBJECTS AND METHODS 
Study design and data collection 
This was a retrospective comparative cohort study. Data collection was via retrospective 
chart audit and the use of existing clinical databases in the patient administration systems 
of the hospital. Independent variables included: gender; age; clinical factors (tumour site, 
tumour stage, and treatment); and adherence to the S&N Guidelines recommendations for 
proactive gastrostomy insertion. Dependent variables included: percentage weight change 
from diagnosis to the end of radiotherapy treatment, the incidence and use of proactively 
placed gastrostomy tubes and the incidence, type and duration of use of reactive feeding 
tubes.  
Study Population 
Patients attending the multidisciplinary Combined Head & Neck Clinic for cancer treatment 
over two time periods at a large metropolitan tertiary referral hospital were screened for 
inclusion in the study. The first cohort (January 2007 to December 2008) was treated with 
3D conformal radiotherapy and the second cohort (July 2010 to June 2011) received either 
3D conformal radiotherapy or H-IMRT. Patients were excluded if they had: benign disease; 
a non-head and neck tumour; palliative intent treatment; refused treatment; treatment at 
another hospital; incomplete/missing data; or no access to the medical chart. The remaining 
eligible patients were classified as high risk or non-high risk according to the S&N Guidelines 
(Figure 4-1). For the purposes of this study, only high risk patients receiving definitive or 
adjuvant radiotherapy as part of their treatment were included to provide a final comparative 
sample of patients who received either H-IMRT or 3D conformal radiotherapy (Figure 4-2). 
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Figure 4-1: Royal Brisbane and Women’s Hospital Swallowing and nutrition 
management guidelines for patients with head and neck cancer – revised version 
2010 
Original Source: Brown et al., 2016a  
These guidelines have minor alterations to the high risk definition compared with the original version used from 
2007 to 2009. They previously included the diagnosis of dysphagia at baseline. This has now been removed 
and unknown primary tumours added. 
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Figure 4-2: Cohort inclusion and exclusion criteria
2 year cohort 
(2007-2008) 
n=1009 
1 year cohort 
(2010-2011) 
n=551 
Treated at tertiary centre with 
blanket referral to dietitian 
n=1028 
Excluded (missing data, no chart) 
n=100 
Total eligible 
n=871 
Total eligible (full dataset) 
n=771 
Total eligible (high risk) 
n=209 
Final sample 
n=187 
Excluded (palliative, benign, non-head 
and neck, or declined treatment) 
n=157 
Excluded (surgery alone) 
n=22 
Excluded (non-high risk) 
n=562 
Helical-IMRT 
n=53 
3D conformal 
n=134 
Total cohort 
n=1560 
Patients attending Combined Head and Neck Clinic 
n=1560 
Excluded (not treated at the tertiary 
centre, private or short stay surgical) 
n=532 
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Nutrition Intervention 
High risk patients were recommended for gastrostomy placement prior to treatment 
(proactive gastrostomy tube placement). This guideline recommendation encompasses 
those who would benefit from immediate nutrition support due to poor nutritional status or 
significant dysphagia at diagnosis (a therapeutic gastrostomy) as well as those who would 
benefit from future nutrition support due to predicted treatment side effects (a prophylactic 
gastrostomy). All other patients who may require tube feeding during treatment have either 
a nasogastric or gastrostomy tube placed depending on predicted duration of need (reactive 
tube placement). 
All patients were screened at baseline by the dietitian using the validated Malnutrition 
Screening Tool (Ferguson et al., 1999a). Patients who were identified at risk of malnutrition 
(score 2-5) were provided with dietary advice or referred to their local dietitian service pre-
treatment. Patients were referred routinely to the surgical dietitian and/or radiotherapy 
dietitian respectively according to their treatment plan. Outpatients were seen on a weekly 
basis during treatment and inpatients were seen daily to weekly as clinically indicated as 
part of standard care.  
Weight was recorded at diagnosis and at the end of radiotherapy treatment and percentage 
weight change calculated. Nutrition requirements were calculated by the dietitian using the 
ratio method (Isenring et al., 2013). Energy requirements (125kJ/kg/day or 30kcal/kg/day) 
and protein requirements (1.2g/kg/day) were based on actual body weight, unless the 
patient was overweight (body mass index >25kg/m2), and then adjusted body weight was 
used. Adjusted body weight was calculated using the following equation (IBW+ [(actual body 
weight-IBW)*25%]), whereby ideal body weight (IBW) was the weight at body mass index 
25kg/m2. At each dietetic review, weight was monitored, and energy and protein intakes 
were estimated using a 24 hour recall method. The dietitian estimated actual intake against 
standard portion sizes and revised nutrition requirements and prescriptions as clinically 
indicated.  
Initiation of tube feeding for all patients was recommended if oral intake fell to <60% of 
estimated energy requirements and was not anticipated to improve in the next 10 days. 
Patients continued on tube feeding until they were able to establish a minimum of 60% of 
their nutrition requirements orally and maintain their weight. All patients were referred to 
their local dietitian service on completion of treatment. 
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Outcomes 
Percentage weight change was chosen as the primary nutrition outcome for this study as it 
has been widely used and accepted in the literature. Unintentional weight loss of >10% 
within the previous six months signifies a substantial nutritional deficit (Rivadeneira, Evoy, 
Fahey, Lieberman, & Daly, 1998). It has been associated with moderate-severe malnutrition 
and therefore is considered a simple valuable measure to use for this purpose (Attar et al., 
2012). Significant weight loss has also been shown to negatively impact on patient and 
clinical outcomes, such as quality of life (Langius et al., 2013a) and survival (Langius et al., 
2013b; Martin et al., 2015), and thus is a clinically significant measure readily available from 
retrospective data collection. 
The nutrition outcome data were used to retrospectively determine the validity of the S&N 
Guideline recommendation for proactive gastrostomy. For each patient the outcome of 
whether they were deemed to “need or not need a proactive gastrostomy” was calculated. 
A patient was deemed to truly “need a proactive gastrostomy” if the following clinical 
outcomes occurred: 
- Patient had a proactive gastrostomy placed as per the S&N Guidelines and it was 
used for nutrition support 
- Patient had a reactive feeding tube placed and it was used for >4 weeks 
- Patient had an unused proactive gastrostomy, or a reactive feeding tube for <4 
weeks, or no feeding tube, AND lost ≥10% body weight  
These outcome definitions are described fully elsewhere when they were used to originally 
validate the S&N Guidelines (Brown et al., 2013b), and are deemed to confirm the prediction 
that the patient required a proactive gastrostomy as per the S&N Guidelines. 
Statistical Analysis 
Based on the sample size from the two cohorts there was an approximate ratio of 1:2.5 
patients in each treatment group. In a previous study the response within each group had a 
standard deviation of 5. If the true difference in the treatment groups’ mean weight loss is 
2.3%, we will be able to reject the null hypothesis that the population means treatment 
groups are equal with probability (power) 0.804. The Type I error probability associated with 
this test of this null hypothesis is 0.05. 
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Statistical analysis was performed to determine any baseline differences between the 
treatment groups. Categorical variables were collapsed when necessary for the Chi-square 
test as per details in Table 4-1. Continuous variables were assessed for normal distribution 
using the Shapiro-Wilk test and non-parametric tests were used when the data were not 
normally distributed. To compare outcomes the Two Sample Wilcoxon test was used for 
continuous variables and the Chi-square test or Fishers exact test for the categorical 
variables. Statistical significance was set at p<0.05 for all analyses. Data were analysed 
using R Commander Version 1.8-3 and R version 2.14.2 (2012-02-29). 
Ethics 
The study was deemed a quality improvement study and exempt from full ethical review by 
the Human Research Ethical Committee at the Hospital. Patients received standard 
nutritional care during their treatment and were not subject to any experimental intervention. 
All data used is routinely collected for ongoing quality assurance and available in the patient 
administration systems of the hospital. 
RESULTS 
Sample population  
There were 187 high risk patients eligible for the study after applying inclusion and exclusion 
criteria (Figure 4-2). Reasons for high risk rating were as follows: oral cavity cancer and 
bilateral chemoradiotherapy (n=42); oropharyngeal cancer and bilateral chemoradiotherapy 
(n=108); nasopharyngeal cancer and chemoradiotherapy (n=6); hypopharyngeal cancer 
and chemoradiotherapy (n=13); unknown primary and chemoradiotherapy (n=6); severe 
malnutrition at presentation (n=12); severe dysphagia at presentation (n=0). 
Of those presenting with severe malnutrition (defined as either unintentional weight loss 
>10% in six months, body mass index <20 kg/m2 with unintentional weight loss 5-10% in six 
months, or Subjective Global Assessment C); four patients had postoperative radiotherapy 
for oral cavity (n=1) or laryngeal (n=3) tumours; five patients had radiotherapy for 
oropharyngeal (n=3), hypopharyngeal (n=1) or laryngeal (n=1) tumours; and the remaining 
three patients had chemoradiotherapy for a laryngeal tumour. High risk patients who 
received H-IMRT (n=53) were compared to high risk patients who received 3D conformal 
radiotherapy (n=134) (Table 4-1). None of the patients had metastatic disease and all 
received curative intent treatment. 
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Whilst there were no statistically significant differences for age, gender, site or T stage; the 
H-IMRT cohort had more advanced nodal disease (N2 or N3 stage), 85% versus 57% 
(p<0.001), as well as a higher proportion treated with definitive chemoradiotherapy, 94% 
versus 78% (p=0.017). 
S&N Guideline adherence and method of tube feeding 
Overall adherence with the S&N Guidelines high risk category recommendations was high 
with 157/187 patients (84%) receiving a proactive gastrostomy. Two patients in the H-IMRT 
group had a reactive tube placed versus 14 patients in the 3D conformal group. The overall 
method of tube feeding was no different between the two groups (p=0.172) (Table 4-2). 
Nutrition Outcomes - weight 
The mean weight at baseline was not significantly different between the two groups 
(p=0.272). There were no significant differences between the two types of treatment with 
regards to the outcome of weight change from diagnosis to the end of radiotherapy treatment 
(Table 4-2). Median percentage weight change was -7.2% (range: -19.1, 8.5) in the H-IMRT 
group versus -7.3% (range: -20.1, 22.9) in the conformal group (p=0.573). Incidence of 
severe weight loss (≥10%) was 28% in the H-IMRT group versus 27% in the conformal group 
(p=0.843).
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Table 4-1: Patient characteristics: Demographics and clinical data 
 Helical-IMRT  
(n=53) 
3D conformal  
(n=134) 
P values 
 N (%)  
Age (years) a   0.324 
Median (range) 59 (32,85) 61 (26,86)  
Gender b   0.756 
Male 43 (81) 106 (79)  
Female 10 (19) 28 (21)  
Site b   0.132 
Oral cavity 7 (13) 36 (27)  
Oropharynx 36 (68) 75 (56)  
Nasopharynx 4 (7) 2 (1)  
Hypopharynx 3 (6) 11 (8)  
Larynx 1 (2) 6 (5)  
Unknown primary 2 (4) 4 (3)  
T Classification b    0.103 
T1 11 (21) 12 (9)  
T2 14 (26) 34 (25)  
T3 14 (26) 32 (24)  
T4 12 (23) 52 (39)  
Tx 2 (4) 4 (3)  
N Classification b   <0.001 c 
N0 3 (6) 30 (22)  
N1 5 (9) 28 (21)  
N2 44 (83) 68 (51)  
N3 1 (2) 8 (6)  
Treatment b    0.032 c 
RT 0 (0) 5 (4)  
ChemoRT 50 (94) 105 (78)  
Surgery + RT 1 (2) 3 (2)  
Surgery & ChemoRT 2 (4) 21 (16)  
Abbreviations: IMRT=Intensity-Modulated Radiotherapy; 3D=Three-Dimensional; RT=Radiotherapy; 
ChemoRT=Chemoradiotherapy. a Two sample Wilcoxon test. b Chi Square test (site: oral vs oropharyngeal vs 
all others; T stage: T1/T2 vs T3/T4/Tx; N stage: N0/N1 vs N2/N3; treatment: definitive RT +/- chemo vs adjuvant 
RT +/- chemo). c Statistical significance p<0.05.
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Table 4-2: Comparison of nutrition outcomes for helical-IMRT and 3D conformal 
radiotherapy treatments 
 Helical-IMRT  
(n=53) 
3D conformal 
(n=134) 
P values 
Median (range) 
Weight a 
Baseline (kg) 78 (46,126) 74 (42,150) 0.276 
End of radiotherapy (kg) 76 (44,116) 69 (37, 137) 0.277 
Weight change (kg) -4.8 (-18.0, 4.1) -5.35 (-21.3, 10.3) 0.873 
Weight Loss a 
Weight loss (%) -7.2 (-19.1, 8.5) -7.3 (-20.1, 22.9) 0.573 
 N (%)  
>10% weight loss b   0.843 
Yes 15 (28) 36 (27)  
No 38 (72) 98 (73)  
Tube outcomes c   0.172 
Proactive tube 49 (92) 108 (81)  
Reactive tube  2 (4) 14 (10)  
Nil tube  2 (4) 12 (9)  
Met criteria d “needed a proactive gastrostomy” b 0.213 
Yes 49 (92) 115 (86)  
No  4 (8) 19 (14)  
Abbreviations: IMRT=Intensity-Modulated Radiotherapy; 3D=Three dimensional. Statistical significance 
p<0.05. a Two Sample Wilcoxon Test. b Chi Square test. c Fishers exact test. d Definition of criteria for “needed 
a proactive gastrostomy” according to Brown et al., 2013b 
 
Nutrition outcomes – “need a proactive gastrostomy” 
Both groups had a high proportion of patients who met the positive prediction “need a 
proactive gastrostomy” based on their actual clinical outcomes; with 92% in the H-IMRT 
group (n=49) versus 86% in the 3D group (n=115) (p=0.213) (Table 4-2). There were nine 
unused proactive tubes overall, of which three patients had severe weight loss (≥10%); and 
14 patients that did not receive any form of tube feeding, however six of these also had 
severe weight loss (≥10%) (Table 4-3). 
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Table 4-3: Description of tube feeding and nutrition outcomes to determine the need 
for proactive gastrostomy tube following helical-IMRT and 3D conformal radiotherapy 
treatments 
Positive prediction a 
“needed a proactive gastrostomy” 
 
Helical-IMRT 
(n=53) 
3D conformal 
(n=134) 
Met criteria 
 
49 (92%) 115 (86%) 
Proactive PEG used 46 102 
Reactive NGT and PEG 1 2 
Reactive PEG 1 1 
Reactive NGT > 4 weeks 0 1 
Reactive NGT < 4 weeks + >10% wt loss 0 1 
Unused proactive PEG + >10% wt loss 1 2 
Nil tube + >10% wt loss 
 
0 6 
Did not meet criteria 
 
4 (8%) 19 (14%) 
Reactive NGT < 4 weeks + <10% wt loss 0 9 
Unused proactive PEG + <10% wt loss 2 4 
Nil tube + <10% wt loss 
 
2 6 
Abbreviations: IMRT=Intensity-Modulated Radiotherapy; 3D=Three dimensional. PEG=gastrostomy tube; 
NGT=nasogastric tube. a Definition of criteria for “needed a proactive gastrostomy” according to Brown et al., 
2013b. 
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DISCUSSION  
The results from this study demonstrate that despite advances in radiotherapy techniques 
which reduce long-term toxicity and side effects (Vergeer et al., 2009), this has not translated 
into improved early nutritional outcomes. We have found no statistical difference in the mean 
weight loss during treatment and in the need for tube feeding, with a large proportion of 
patients still meeting the positive prediction for proactive gastrostomy placement. Whilst 
acknowledging there were differences in clinical characteristics between the two groups 
(higher rates of advanced N stage disease and more patients receiving definitive 
chemoradiotherapy in the H-IMRT group) which could possibly be attributed to the 
increasing incidence of human papillomavirus-related oropharyngeal cancers (Hocking et 
al., 2011); ultimately there was still a high incidence of weight loss and requirement for tube 
feeding in both groups.  
Research relating to impact of H-IMRT on nutrition outcomes and tube feeding requirements 
is sparse (Chatterjee et al., 2011), although there are some studies reporting on outcomes 
following linear accelerator based IMRT (Caudell et al., 2010; Gunn et al., 2010; Studer et 
al., 2010). The current evidence indicates that weight loss is a recurring problem, despite 
advancing radiotherapy techniques, which supports the ongoing essential need for nutrition 
intervention. Maintaining and improving nutritional status has been shown to improve quality 
of life (Langius et al., 2013a; van den Berg et al., 2008) and other clinical outcomes 
(Capuano et al., 2008). Capelle et al. (2012) reported a median loss of 6% of pre 
radiotherapy weight (with a maximum weight loss of 13.6%) in a small case series (n=20) of 
patients receiving definitive or adjuvant chemoradiotherapy (Capelle et al., 2012). You et al. 
(2012) reported 23% of their patients (7/31) lost >5% of their body weight and these weight 
changes and anatomical contour changes impacted on severity of side effects such as 
xerostomia (You et al., 2012). Duma et al. (2012) were investigating the dosimetric effect of 
adaptive radiotherapy and they reported re-planning usually occurred by the end of the third 
week of treatment, at which point there was a median weight loss of 2.3kg (0 to -10.7kg), 
however overall weight change was not reported (Duma, Kampfer, Schuster, Winkler, & 
Geinitz, 2012). There is even less data in the literature on the usage of feeding tubes with 
H-IMRT. In one small study (n=5), all patients had a proactive gastrostomy tube placed 
however nutritional outcomes or tube use were not reported (Loo et al., 2011). Another small 
study (n=17) reported that no patients in their case series received a gastrostomy (although 
the use of nasogastric tubes was not reported), however 29% (n=5) had severe weight loss 
≥10% (Chao et al., 2000). 
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Multidisciplinary team adherence to the S&N Guideline recommendations for high risk 
patients improved over time, with adherence of 80% (2007-08) increasing to 89% (2010-
11). Despite a high rate of tube feeding and therefore nutrition intervention in this patient 
group, the weight loss outcomes remain sub optimal. Both groups had median weight loss 
≥5% and a high incidence of severe weight loss (≥10%) which is consistent with the literature 
(Capelle et al., 2012; Chao et al., 2000; Silander et al., 2013).  
Further research is required to investigate why patients continue to lose significant weight, 
despite intensive nutrition interventions, and investigate strategies to overcome this weight 
loss (Brown et al., 2014b). The aetiology of patients’ weight loss is likely multi-factorial, and 
not simply related to the radiotherapy dosimetry. Patients receiving concurrent 
chemoradiotherapy often experience additional chemotherapy induced side effects such as 
nausea, vomiting, taste changes, loss of appetite and fatigue. Silander et al. (2013) 
demonstrated patients were not able to meet their recommended energy and protein intakes 
despite prophylactic gastrostomy, hypothesising treatment side effects as the main barrier 
(Silander et al., 2013).  
Patient adherence to recommendations is also an important consideration, as we have 
shown in this study that despite proactive gastrostomy insertion, there were three patients 
that chose not to use their tube when it was recommended to do so, resulting in clinically 
significant weight loss. Capuano et al. (2008) reported 47% of patients were deemed non-
adherent – either not accepting nutritional counselling or refusing nasogastric or 
gastrostomy tubes during treatment, and this had a significant impact on their outcomes 
(Capuano et al., 2008). Further research to develop our understanding of factors which 
impact upon weight loss and adherence is required to enable the development of effective 
strategies to ultimately improve nutrition outcomes. 
A retrospective study design results in limitations such as patient exclusions due to 
difficulties accessing charts and missing data. It also limits the ability to measure other 
clinical outcomes which are not part of routine practice such as quality of life, blood results, 
body composition and toxicity profiles. Whilst reduced late toxicity has been demonstrated 
with IMRT (Vergeer et al., 2009), the research with H-IMRT remains limited with studies only 
reporting the reduction in doses to organs at risk compared to IMRT (Fiorino et al., 2006; 
Lee et al., 2008a; Ruchala et al., 1999; Sheng et al., 2006). A prospective observational 
study is currently in progress to determine acute and late toxicity profiles following H-IMRT 
and will be reported on separately. 
Chapter 4 The impact of evolving treatments on nutrition care 
 65 
The duration of gastrostomy use should be more carefully considered in future studies. If 
duration of gastrostomy use is <4 weeks, a nasogastric tube may be more appropriate 
(Arends et al., 2006), as long as there is no compromise to the ultimate nutrition outcome 
and degree of weight loss. Whilst the high risk definition for the S&N Guidelines actually 
changed slightly over the period of data collection for the two cohorts (Brown et al., 2016a), 
this had a negligible impact on results due to small numbers in the categories affected by 
change, (no patients classified as high risk due to dysphagia alone and only six patients with 
an unknown primary treated with chemoradiotherapy).  
Additional outcome measures such as nutritional status using validated tools (Bauer, Capra, 
& Ferguson, 2002) or a combination of standardised characteristics to diagnose malnutrition 
(White et al., 2012) would have been useful to include in this study, however the detail 
required for these types of assessment were usually only routinely recorded at baseline. 
Therefore percentage weight loss was used as the primary nutrition outcome as this was a 
convenient measure available through retrospective chart audit. Given >10% weight loss 
has been shown to impact on patient and clinical outcomes (Langius et al., 2013b; Langius 
et al., 2013a; Martin et al., 2015), this was considered a suitable nutrition outcome measure 
for this study design.  
The strength of this study is it is the largest cohort to date with adequate statistical power to 
report on nutrition outcomes following H-IMRT. We were fortunate to able to compare 
patients receiving the two types of treatment over a similar period of time at one centre with 
no other contemporaneous changes in practice at our institution that may have confounded 
these results. Concurrent comparative cohort studies will become increasingly difficult to 
perform as centres migrate to the use of advanced techniques as their new standard of care. 
Our study also benefits from minimal selection bias with the use of validated guidelines to 
clearly identify high risk patients for proactive tube feeding, with a high rate of adherence by 
the multi-disciplinary team. 
In conclusion, although H-IMRT has been shown to deliver reduced doses to normal tissue, 
there are no significant differences in incidence of tube feeding or weight loss during 
treatment when compared to conformal 3D radiotherapy techniques. Therefore the 
placement of a proactive gastrostomy tube is still warranted in high risk patients and nutrition 
intervention remains critical.
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4.4 Chapter summary 
This is the first study of its kind to report fully on nutrition outcomes following treatment with 
helical-IMRT in a large sample size (n=187). The results of this study have demonstrated 
that despite advances in radiotherapy techniques, nutrition intervention remains critical in 
this patient population. There were no clinical or statistical differences between the two 
treatment groups in regards to any of the nutrition outcome measures. Both groups lost a 
median of 7% weight loss during treatment, and approximately a quarter to a third of patients 
in each group had a severe weight loss of 10% or greater. This implies that radiotherapy 
dosimetry and the improved target precision with these advancing techniques are not the 
only factors that influence nutrition outcomes in this population. The majority of all patients 
in the study also met the criteria for proPEG placement. The rate was slightly higher in the 
helical-IMRT group at 92% vs 86%, which may have been due to the higher rates of 
chemoradiotherapy and advanced N stage disease in this group. These clinical 
characteristics are likely to have influenced decision-making in the selection of patients to 
receive helical-IMRT and created some sample bias. However, overall the findings from this 
study have demonstrated that weight loss and tube feeding remain significant issues in this 
patient population. 
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5.1 Chapter overview 
As the previous chapter demonstrated a need for ongoing nutrition intervention in patients 
receiving helical-IMRT, placement of proPEG is still an important consideration. The protocol 
used to identify patients at the Royal Brisbane and Women’s Hospital (RBWH) was originally 
validated in a cohort of patients who received three-dimensional conformal radiotherapy 
(Brown et al., 2013b). The aim of the first study in this chapter was to review the protocol to 
ensure it remained valid in a new cohort of patients receiving helical-IMRT.  
The first study is presented in section 5.2 as the accepted format prior to publication in the 
European Journal of Clinical Nutrition (Journal Impact Factor 2.935; Ranked 31/80 Nutrition 
& Dietetics category; Quartile 2). Preliminary results were presented at the 15th Australia 
and New Zealand Head and Neck Cancer Society Annual Scientific Meeting, Melbourne, 
Australia, 2013 (Appendix C – 11.3.4). 
Date submitted: 26/04/2015 
Date accepted: 19/12/2015 
Citation: Brown, T., Getliffe, V., Banks, M., Hughes, B., Lin, C., Kenny, L., Bauer, J. (2016). 
Validation of an updated evidence-based protocol for proactive gastrostomy tube insertion 
in patients with head and neck cancer. Eur J Clin Nutr, 70(5), 574-81. 
doi:10.1038/ejcn.2015.230. 
Meanwhile other clinical factors not previously taken into account had also emerged 
including: p16 status (an immunohistological marker for HPV-related tumours); type of 
systemic therapy (Cetuximab was a newly approved monoclonal antibody); and albumin and 
C-reactive protein (CRP) (biomarkers of pre-cachexia). The aim of the second study in this 
chapter was to explore whether these additional clinical factors should be considered and 
incorporated into the protocol.  
 Chapter 5 The identification of patients for proactive gastrostomy  
 70 
The second study is presented in section 5.3 as the accepted format prior to publication in 
Head and Neck (Journal Impact Factor 2.760; Ranked 3/43 Otorhinolaryngology category; 
Quartile 1). This study was presented at the Multinational Association of Supportive Care in 
Cancer Annual Meeting, Adelaide, Australia, 2016 (Appendix C – 11.3.5). 
Date submitted: 23/03/2016 
Date accepted: 07/10/2016 
Citation: Brown, T., Wittholz, K., Way, M., Banks, M., Hughes, B., Lin, C., Kenny, L., Bauer, 
J. (2017). Investigation of p16 status, chemotherapy regimen and other nutrition markers for 
predicting gastrostomy in patients with head and neck cancer. Head Neck, 39(5), 868-875. 
doi:10.1002/hed.24630 
Section 5.4 provides an overall summary of the findings from these two studies. 
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5.2 Validation of protocol 
5.2.1 Abstract 
Background/Objectives: Evidence-based practice guidelines are available to assist in the 
decision-making for nutrition interventions in patients with head and neck cancer. Re-
assessment of guideline recommendations is important with changing demographics, new 
treatment regimens, advancing radiotherapy techniques, such as helical intensity-
modulated radiotherapy, and the emergence of new literature. The aim of this study was to 
validate the updated high risk category definition in our local hospital protocol for the 
swallowing and nutrition management of patients with head and neck cancer to determine 
the ongoing predictive ability for identifying proactive gastrostomy requirement in a new 
cohort. 
Subjects/Methods: Patients attending a major tertiary hospital for head and neck cancer 
treatment from 2010 – 2011 were included (n=270). Data were collected on; patient 
demographics (age, gender), clinical factors (tumour site, staging and treatment), nutrition 
outcome measures (weight, enteral feeding), and protocol adherence. Sensitivity and 
specificity were calculated and compared to the original validation study. 
Results: Proactive gastrostomy tubes were inserted in 86 patients. Overall protocol 
adherence was 93%. Sensitivity improved to 72% (increase of 18%) and specificity improved 
to 96% (increase of 3%) compared to the original validation study where patients received 
three-dimensional (3-D) conformal radiotherapy.  
Conclusion: The results of this study confirm the updated high risk category in the protocol 
for the swallowing and nutrition management of patients with head and neck cancer remains 
valid to predict proactive gastrostomy in a mixed population receiving helical intensity-
modulated radiotherapy and 3-D conformal radiotherapy. The protocol has an improved 
sensitivity and specificity and hence remains just as relevant for advanced techniques of 
radiation treatment delivery.  
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5.2.2 Manuscript 
INTRODUCTION  
Patients with squamous cell carcinoma of the head and neck frequently experience 
dysphagia as a result of cancer treatment or the tumour itself, which often results in a need 
for tube feeding to provide adequate nutritional intake. The optimal form of tube feeding 
remains controversial in the literature, with inadequate high level evidence to enable any 
firm recommendations (Langius et al., 2013c; Nugent et al., 2013; Wang et al., 2014a). Risks 
of gastrostomy placement in the selection of feeding tube need to be considered (Grant et 
al., 2009). Some studies have shown benefits with prophylactic gastrostomy placement 
compared to a reactive approach to nutrition support including reduced weight loss/improved 
nutritional status (Chang et al., 2009; Lewis, Brody, Touger-Decker, Parrott, & Epstein, 
2014; Rutter et al., 2011; Silander et al., 2012), improved quality of life (Salas et al., 2009), 
and reduced admissions and healthcare costs (Baschnagel et al., 2014; Hughes et al., 
2013). Other studies have shown no difference in outcomes with feeding tube selection and 
suggest a reactive approach may be more favourable to reduce duration of feeding tube use 
(Kramer et al., 2014; Sheth, Sharp, & Walters, 2013). Whilst there are concerns that 
gastrostomy placement may result in gastrostomy dependency and increased dysphagia 
post-treatment (Corry et al., 2008; Ward et al., 2016), other studies have not supported this 
finding (Crombie et al., 2015; Prestwich et al., 2014). 
A hospital protocol for the swallowing and nutrition management of patients with head and 
neck cancer was developed at our institution in order to help clinicians identify high risk 
patient groups who would benefit from proactive gastrostomy placement. The risk categories 
in the protocol have been validated for their ability to predict the need for proactive 
gastrostomy placement in a patient population receiving three-dimensional (3-D) conformal 
radiotherapy (Brown et al., 2013b). Implementation of the protocol has been shown to 
reduce unplanned hospital admissions and length of stay (Hughes et al., 2013) and 
adherence to the protocol has been demonstrated to improve nutrition outcomes (Brown et 
al., 2014a). The protocol was subsequently modified following availability of new evidence 
(Isenring et al., 2008) and further internal evaluation to improve their accuracy and validity 
(Brown et al., 2016a) which resulted in some changes to the high risk category definition 
(Figure 5-1). 
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Figure 5-1: Comparison of the high risk category of the Royal Brisbane and Women’s 
Hospital protocol for the swallowing and nutrition management of patients with head 
and neck cancer for each cohort 
Abbreviations: chemoRT=chemoradiotherapy; BMI=body mass index; SGA=subjective global assessment. 
Adapted from Brown et al., 2013b. 
HIGH RISK PATIENTS – ORIGINAL (2007-2008 COHORT)) 
Oral + bilateral chemoRT  OR 
Midline Oropharyngeal + chemoRT  OR 
Nasopharyngeal/hypopharyngeal + chemoRT  OR 
Dysphagia at presentation or prior to radiotherapy/chemoRT  OR 
Severe malnutrition at presentation:  
- Unintentional weight loss >10% in 6 months 
- BMI <18.5 or BMI <20 with unintentional weight loss 5-10% in 6 months 
HIGH RISK PATIENTS – NEW (2010-2011 COHORT) 
Oral/oropharyngeal + bilateral chemoRT  OR 
Nasopharyngeal/hypopharyngeal/unknown primary + chemoRT  OR 
Severe malnutrition at presentation:  
- Unintentional weight loss >10%  in 6 months 
- BMI <20 with unintentional weight loss 5-10% in 6 months 
- Dietitian assessment SGA C 
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Evolving radiotherapy techniques, such as conformal radiotherapy or linear accelerator-
based intensity-modulated radiation therapy (IMRT), have been used in recent years with 
the aim of limiting the radiation dose to healthy tissues and organs to minimise unwanted 
side effects. Around the same time of implementation of the updated protocol, a new 
radiotherapy technique Helical-IMRT (H-IMRT) was also introduced at our hospital. This is 
a relatively new type of IMRT delivery system using a Tomotherapy™ machine. It further 
limits radiation damage to normal tissue compared to IMRT and thereby results in less long-
term side effects of radiation (Capelle et al., 2012; van Vulpen et al., 2005). To date the 
majority of studies investigating nutrition outcomes and tube feeding requirements have 
been undertaken in patients receiving 3-D conformal radiotherapy or IMRT, and therefore 
the nutritional needs of patients following H-IMRT are largely unknown.  
Additionally in recent years there has been an increasing incidence of human papillomavirus 
(HPV)-related head and neck tumours (Jemal et al., 2013). These patients present with 
distinct carcinogenesis, risk factors, clinical presentation and prognosis compared to HPV-
negative patients (Benson et al., 2013; Bonilla-Velez, Mroz, Hammon, & Rocco, 2013; 
Evans et al., 2013; Gillison et al., 2008; Petrelli, Sarti, & Barni, 2014; Ramqvist & Dalianis, 
2010) resulting in a change of clinical and demographical profile of the population. Patients 
with HPV-positive tumours show better response to treatment, overall survival, and 
progression-free survival (Benson et al., 2013), and therefore research into alternative 
treatment protocols to reduce toxicities without compromising oncological outcomes are 
underway (Rischin & Corry, 2013). 
As treatment methods evolve through technology and further research to optimise patient 
outcomes, it is important to continue to re-evaluate the evidence for supportive cares such 
as the nutrition management of this patient population. Therefore the main aim of this study 
was to validate the updated high risk category definition in the protocol for the swallowing 
and nutrition management of patients with head and neck cancer to determine the ongoing 
predictive ability for identifying proactive gastrostomy requirement in a new cohort to account 
for any changes in treatment and population characteristics that are likely to have occurred 
over the recent years. The second aim was to determine if there was any impact specifically 
from the use of H-IMRT treatment on the applicability of the protocol.
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SUBJECTS AND METHODS 
Study Setting 
This is a single institution study where all patients with head and neck cancer attend a 
multidisciplinary clinic at a tertiary hospital for diagnosis, staging and planning of treatment. 
All patients are assessed by: surgical and medical specialists (Ear, Nose and Throat 
Surgeons; Plastic and Reconstructive Surgeons; Oral and Maxillofacial Surgeons; Radiation 
Oncologists and Medical Oncologists); a dentist; speech pathologist; dietitian; and nursing 
staff. The protocol for the swallowing and nutrition management of patients with head and 
neck cancer is applied to each patient to assist in the planning of their nutrition management 
as part of their treatment. 
Study population 
Patients were eligible for the study if they attended our hospital for assessment and 
treatment between July 2010 and June 2011. Inclusion criterion was a referral to a dietitian 
at our hospital, which occurs as part of standard care during curative intent surgical and/or 
oncological treatment for head and neck cancer. Patients were therefore ineligible if they 
had: benign disease; a non-head and neck tumour; treatment of palliative intent; treatment 
privately or at another facility or on the short stay surgical unit. Patients were excluded if 
there was: incomplete data (i.e. weight was not recorded or the patient did not complete 
treatment); or no access to the medical chart (i.e. patients did not consent for chart to be 
used for audit/research purposes or the medical chart was destroyed) The study was 
deemed a quality improvement study and exempt from full ethical review by the Human 
Research Ethical Committee at the Hospital. 
Study design and data collection 
Data collection was via retrospective chart audit and the use of existing clinical databases. 
Independent variables included: gender, age, clinical factors (tumour site, tumour stage, and 
treatment location), patient risk rating from the protocol (high or low), and adherence to the 
protocol risk category recommendations. Dependent variables included: nutrition outcome 
measures (percentage weight loss from baseline at diagnosis to the end of cancer 
treatment); incidence of proactive tube placement and use of this tube; and the incidence of 
reactive tube placement, including type of tube and duration of use.  
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Use of the tube was recorded by the dietitian in the medical notes as part of standard 
assessment on each review during and after treatment. Data on gastrostomy complications 
rates were also collected for the 30-day period post insertion. Major complications were 
defined as those requiring surgical intervention, blood transfusion or IV antibiotics. 
Admissions or prolonged admissions relating to gastrostomy complications were noted.  
Outcomes 
The dependent variables were used to assess the primary outcome of whether each patient 
was deemed to require or not require a proactive gastrostomy. Patients were confirmed as 
high risk, and therefore requiring a proactive gastrostomy, if significant weight loss (≥10% 
baseline body weight) had occurred by the end of the acute-phase cancer treatment, or a 
proactive tube was placed and used or a reactive tube was placed and used for more than 
four weeks. These outcome definitions are described fully elsewhere (Brown et al., 2013b), 
and were previously used to confirm the need for intensive early nutrition support 
intervention, and thus placement of a proactive gastrostomy. A contingency table was used 
to compare these patient outcomes with the protocol risk category and determine sensitivity, 
specificity, positive predictive value and negative predictive value. The results were 
compared to data from the original validation study. 
Statistical Analysis 
Statistical analysis was performed between the current cohort and the historical cohort (used 
to previously validate the protocol) to determine if there were any differences between the 
cohorts’ categorical variables and continuous variables, using the Chi-square test and the 
Independent Samples T-test respectively. Categories were collapsed to enable statistical 
comparison as follows: Treatment Site (oropharynx and nasopharynx), T Classification (T0 
and Tx; recurrent and other), N Classification (other and unknown), and Treatment Type 
(radiotherapy alone and chemotherapy alone). Age was a continuous variable (years) and 
presented as mean + sd. Levene’s test was applied to check assumption of equal population 
variance prior to the Independent Samples T-test. Statistical significance was set at p<0.05. 
Data were analysed using R Commander Version 1.8-3 and R version 2.14.2 (2012-02-29).
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RESULTS 
Patient Characteristics 
There were 551 patients who attended the hospital for assessment during the one year study 
period. After inclusion and exclusion criteria were applied this gave a final sample size of 
n=270 for analysis (Figure 5-2). Patients had a median age of 63 years (range 15-90 years) 
and were mainly men (77%). The most frequent squamous cell carcinoma of the head and 
neck sub sites were oral cavity (30%) and oropharynx (24%). Tumour classification was 
distributed evenly, and 14% of patients presented with recurrent disease. Seventy five 
percent of all patients received multimodality treatment. There were 75 patients who 
received H-IMRT, accounting for 33% of all patients receiving radiotherapy (n=230), with the 
remainder receiving 3-D conformal radiotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2: CONSORT diagram to illustrate eligible patient sample with inclusion and 
exclusion criteria
Total patients = 551 
Attended clinic during study period 
 
Total patients ineligible = 227 
 
 Treatment elsewhere n=187 
 Palliative    n=30 
 Benign                 n=5 
 Non head and neck n=5 
o Thyroid (n=1) 
o Oesophageal (n=4) 
 
 
 Total patients eligible = 324 
Referred to hospital dietitian during curative 
intent cancer treatment  
 
Total patients excluded = 54 
 
 Incomplete data  n=30 
 No chart access  n=24 
 
 
Final sample = 270 
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The patient demographics and clinical characteristics are summarised (Table 5-1), and 
compared to the cohort from the original validation study (n=501). There were no significant 
differences between the two cohorts with respect to gender, or age, however there were a 
number of statistically significant differences with respect to tumour site, staging and 
treatment. In the current cohort there was a lower proportion of patients with laryngeal 
cancer, fewer patients with recurrent disease, more patients with N2 disease and fewer 
patients that received radiotherapy alone. 
Assessment using the protocol identified 88 patients as high risk accounting for 33% of the 
cohort. Reasons for high risk rating are shown (Figure 5-3). Of those presenting with severe 
malnutrition; one patient had radiotherapy for laryngeal cancer, another had radiotherapy 
for oral cavity cancer, and the third had salvage surgery for recurrent disease.  
Overall a gastrostomy tube or nasogastric tube was inserted in 37% (n=100) of patients at 
some stage during cancer treatment (Table 5-2). This was very similar to the cohort from 
the original validation study where it was required in 34% of patients (n=173), (p=0.488). 
Gastrostomy Complications 
Gastrostomy data complications were available for 79/92 patients (12 patients had their 
tubes placed privately, and one patient had an existing tube in-situ). The rate of major 
complications from gastrostomy insertion was 3.8% (n=3); one patient required surgical 
intervention for a laparoscopy and bowel drain; one patient require IV antibiotics for 
suspected bowel perforation; one patient developed an ileus. An additional three patients 
had a prolonged admission post insertion managed conservatively and a further six patients 
required an admission for IV antibiotics for a site infection.  
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Table 5-1: Comparison of patient demographics and clinical characteristics 
Patient 
Characteristics 
Previous 2 year cohort 
(2007-2008) N=501 
New 1 year cohort  
(2010-2011) N=270 
P Value 
n  % n % 
Age years (Mean ± SD)  63.51 + 12.40 63.15 + 12.91  P=0.708 
Gender      P=0.948 
Male 387 77% 208 77%  
Female 114 23% 62 23%  
Site a     P=0.004 
Oral cavity 139 28% 81 30%  
Oropharynx 101 20% 65 24%  
Nasopharynx 5 1% 4 2%  
Hypopharynx 16 3% 14 5%  
Larynx 78 16% 18 7%  
Unknown primary 28 6% 9 3%  
Other 134 27% 79 29%  
T Classification b     P=0.080 
T0 0 0% 13 5%  
T1 93 19% 45 17%  
T2 102 20% 69 26%  
T3 71 14% 34 13%  
T4 87 17% 60 22%  
Tx 37 7% 9 3%  
Recurrent 110 22% 38 14%  
Other 1 0% 2 1%  
N Classification c     P<0.001 
N0 176 35% 93 34%  
N1 79 16% 45 17%  
N2 100 20% 88 33%  
N3 14 3% 4 1%  
Recurrent 110 22% 38 14%  
Other 1 0% 2 1%  
Unknown 21 4% 0 0%  
Treatment d     P=0.023 
Surgery 73 15% 40 15%  
Radiotherapy 85 17% 28 10%  
ChemoRT 143 29% 91 34%  
Surgery + RT 153 31% 96 36%  
Surgery & ChemoRT 46 9% 15 6%  
Chemotherapy 1 0% 0 0%  
Additional Treatment Details  
Tomotherapy 0 0% 75 28% P<0.001 
Cetuximab 34 7% 16 6% P=0.538 
Abbreviations: RT=radiotherapy. Statistical methods: continuous variables analysed using independent 
samples t-test; categorical variables analysed using chi-squared test; p<0.05 significant. a Owing to small cell 
size; combined oropharynx and nasopharynx. b Owing to small cell size; combined T0 and Tx; combined 
recurrent and other. c Owing to small cell size; combined other and unknown. d Owing to small cell size; 
combined radiotherapy alone and chemotherapy alone. Adapted from Brown et al., 2013b. 
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Reason for high risk rating 
 
Oral + bilateral chemoRT     n=17 
Oropharyngeal + bilateral chemoRT    n=54 
Nasopharyngeal + chemoRT     n=4 
Hypopharyngeal + chemoRT     n=4 
Unknown primary + chemoRT    n=6 
Severe malnutrition at presentation    n=3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3: Adherence to the Royal Brisbane and Women’s Hospital protocol for the swallowing and nutrition management of 
patients with head and neck cancer and associated outcomes 
Abbreviations: chemoRT=chemoradiotherapy; PEG=proactive gastrostomy. 
Total patients = 270 
Attended clinic during study period 
 
Non High Risk n=182 
 
Adherence to Protocol 
(had proactive gastrostomy) 
n=78 
High Risk n=88 
Non Adherence to Protocol 
(no proactive gastrostomy) 
n=10 
Adherence to Protocol 
(no proactive gastrostomy) 
n=174 
Non Adherence to Protocol 
(had proactive gastrostomy) 
n=8 
“Needed 
PEG” 
n=6 
“Did not 
need PEG”  
n=4 
“Needed 
PEG” 
n=75 
“Did not 
need PEG”  
n=3 
“Needed 
PEG” 
n=25 
“Did not 
need PEG”  
n=149 
“Needed 
PEG” 
n=7 
“Did not 
need PEG”  
n=1 
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Table 5-2: Method of nutrition support utilised during treatment in the 2010-2011 
patient cohort 
Type of Nutrition Support 
 
n % 
Nil tube feeding 
 
170 63 
Proactive gastrostomy tube a 
 
Used 
Unused 
 
86 
 
80 
6 
32 
 
93 
7 
Reactive tube 
 
NGT < 4 weeks 
NGT > 4weeks 
NGT & PEG 
PEG 
 
14 
 
5 
3 
3 
3 
5 
 
36 
21 
21 
21 
Abbreviations: PEG=gastrostomy tube; NGT=nasogastric tube. a Proactive gastrostomy tube indicates 
therapeutic or prophylactic gastrostomy placed prior or within first 2 weeks of treatment. 
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Adherence to the protocol 
Overall adherence with the protocol risk category recommendations by the treating medical 
team was high (93% compared to 87% in the original cohort for validation). Of the 88 high 
risk patients, 89% (n=78) received a proactive gastrostomy as per the protocol 
recommendation (Figure 5-3). Only three of these patients ended up not meeting the final 
criteria for proactive gastrostomy, as they did not use their tube and had less than 10% 
weight loss. Two patients did not use their tube against recommendations and thus lost more 
than 10% weight. All other patients used their tube. A proactive gastrostomy was not placed 
in the remaining 10 high risk patients because the procedure was medically contraindicated 
(n=1), was refused by the patient or treating Consultant (n=2), or other reasons such as 
scheduling difficulties (n=7). Six of these patients did end up meeting the final outcome 
criteria for proactive gastrostomy insertion based on their individual outcomes (Figure 5-3). 
Of the 182 non high risk patients, eight did have a proactive gastrostomy tube inserted, 
despite no recommendation in the protocol. Seven of these patients did use their tube (one 
patient had >10% weight loss despite tube use) and therefore selection for placement was 
deemed appropriate. Only one patient did not use the tube as predicted by the risk rating 
and was able to minimise weight loss to <10%. Of the remaining 174 low risk patients without 
a tube, three patients had a gastrostomy placed during treatment, three patients had a 
nasogastric tube for more than four weeks, and 19 patients had more than 10% weight loss. 
Therefore in total 25 patients did end up meeting the final outcome criteria for proactive 
gastrostomy insertion based on their individual outcomes. 
Validation of the protocol 
Of the 270 patients, 113 (42%) met the predefined positive prediction “did need a proactive 
gastrostomy” based on patient outcomes. Of these, 32 patients (28%) failed to be identified 
as high risk using the protocol. An exploration of this group was undertaken to see if any 
common factors could be identified. Overall seven patients had surgery alone and all others 
had unilateral radiotherapy (either adjuvant or definitive +/- chemotherapy). There were 
seven patients the Consultants identified for proactive gastrostomy which were mainly T3, 
T4 or N2 staging (n=5) and oral cavity tumours (n=5). There were seven patients who 
required a reactive feeding tube, four of which had surgery alone, but otherwise there were 
no other common factors with site or staging. The remaining 18 patients who all lost >10% 
body weight had no other common sites but the majority had T3, T4 or N2 staging (n=10/18). 
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Of the 270 patients, the remaining 157 patients, all of whom lost <10% body weight, met the 
predefined alternative patient outcome “did not need a proactive gastrostomy”. Of these, 
seven (4%) patients were identified as false positives (i.e. a result that indicates the patient 
is high risk when they are not). Therefore, sensitivity of the protocol risk categories to predict 
patients’ need for a proactive gastrostomy was 72%, specificity was 96%, positive predictive 
value was 92%, and negative predictive value was 82% (Table 5-3).  
Table 5-3: Sensitivity and specificity of the risk categories in the Royal Brisbane and 
Women’s Hospital protocol for the swallowing and nutrition management of patients 
with head and neck cancer to predict requirement for proactive gastrostomy insertion 
in a mixed cohort of patients receiving 3-D conformal radiotherapy and helical-IMRT 
 
Prediction for proactive 
gastrostomy a  
(defined from patient outcomes at end 
of acute cancer treatment) 
 
Positive and negative 
predictive values 
 
Positive: 
Did need a 
proactive 
gastrostomy b (n) 
 
Negative: 
Did not need a 
proactive 
gastrostomy c (n) 
Determined 
from protocol 
risk criteria 
High risk d 
 
81 (TP) 7 (FP) 
 
PPV=TP/(TP+FP) 
92% 
 
All other 
patients e 
32 (FN) 150 (TN) 
 
NPV=TN/(FN+TN) 
82% 
 
 
Sensitivity and specificity 
Sensitivity 
=TP/(TP+FN) 
72% 
 
Specificity 
=TN/(FP+TN) 
96% 
 
 
Abbreviations: FN=false negative; FP=false positive; IMRT=intensity-modulated radiotherapy; NPV=negative 
predictive value; PPV=positive predictive value; TN=true negative; TP=true positive. a Proactive gastrostomy 
indicates therapeutic or prophylactic gastrostomy placed prior or within first 2 weeks of treatment. b Positive 
prediction = met the predefined primary patient outcome. “A patient did not have an active gastrostomy or long-
term NGT and had >10% weight loss or patient had an active gastrostomy or long-term NGT”. c Negative 
prediction = met the predefined alternative patient outcome. “A patient did not have an active gastrostomy or 
long-term NGT and had <10% weight loss”. d Recommended for proactive gastrostomy insertion. e No 
recommendation for proactive gastrostomy insertion. 
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DISCUSSION 
This study aimed to validate the updated protocol for the swallowing and nutrition 
management of patients with head and neck cancer in relation to the new high risk category 
definition for proactive gastrostomy insertion. The study was undertaken in a new cohort, 
with patients receiving standard 3-D conformal radiotherapy and H-IMRT. Compared to data 
collected in the validation of the original protocol where patients only received 3-D conformal 
radiotherapy (Brown et al., 2013b), this study found both the sensitivity and specificity 
improved and that indication for proactive gastrostomy using the updated high risk category 
definition was appropriate.  
The increased sensitivity of 72% (compared to previous results of 54%) meant that there 
were a lower percentage of false negatives and more patients were likely to be correctly 
identified for a gastrostomy when required. When the characteristics of the false negatives 
were investigated to see if any improvements could be made to the guidelines; advanced 
staging (such as T3 and T4) appeared to be an important factor to consider, which is also 
widely supported in the literature (Chang et al., 2009; Jack et al., 2012; Strom et al., 2013). 
A number of patients also received surgery alone or postoperative radiotherapy, and so 
more consideration should perhaps be given the surgical procedure. Other guidelines have 
since been developed specifically for this (Jack et al., 2012) and they could be used to further 
inform decision-making in this population.  
The specificity remained high at 96% (compared to previous results of 93%) indicating a 
lower percentage of false positives and fewer patients were likely to receive a gastrostomy 
unnecessarily. The improvement in the sensitivity and specificity compared to the previous 
study is attributed to the minor changes to the criteria used to identify high risk patients in 
the protocol (Figure 5-1) and the clinical and treatment differences noted between the 
cohorts which may possibly be explained by the increasing incidence of HPV oropharyngeal 
tumours (Jemal et al., 2013).  
In regards to the advances in treatment techniques over time, research relating specifically 
to H-IMRT and its’ impact on nutrition outcomes and tube feeding requirements is sparse, 
with the majority of the studies to date reporting on outcomes following linear accelerator 
based IMRT. Long-term benefits following IMRT are well documented with reduced 
xerostomia and improved quality life, due to reduced radiation dose to the parotid glands 
(Vergeer et al., 2009).  
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Due to the reduced dose-volume achieved with IMRT some authors have postulated this 
may lead to a reduced need for a gastrostomy when treated with IMRT alone (Sanguineti et 
al., 2011). However, there are studies that also continue to support the role of a proactive 
gastrostomy with IMRT, particularly with concurrent treatment (Romesser et al., 2012), and 
rates of gastrostomy dependence have not been found to be any different with IMRT 
(Rusthoven et al., 2008).  
Several studies suggest that H-IMRT can achieve superior dose sparing to organs at risk 
versus other forms of IMRT (Fiorino et al., 2006; Lee et al., 2008a; Sheng et al., 2006; van 
Vulpen et al., 2005), strengthening the rationale that intensive nutrition support with a 
feeding tube may no longer be warranted with this advanced treatment technique. However 
there is very limited data on the usage of feeding tubes with H-IMRT. In one small study 
(n=5), all patients had a proactive gastrostomy tube placed however nutritional outcomes or 
tube use were not reported (Loo et al., 2011). Another small study (n=17) reported that no 
patients in their case series received a gastrostomy however 29% (n=5) had severe weight 
loss >10% (Chao et al., 2000).  
Weight loss secondary to acute radiation toxicity is a well-recognised side effect of radical 
treatment for head and neck cancer (Chatterjee et al., 2011) and a number of studies support 
that weight loss is a recurring problem with H-IMRT(Capelle et al., 2012; Duma et al., 2012; 
You et al., 2012). Similarly we found 64% of patients experienced clinically significant weight 
loss during treatment; 46% (123/270) lost >5% and 18% (49/270) lost >10% of their body 
weight. Of the patients that received H-IMRT (n=75), 25% lost >5% and 23% lost >10%. 
Weight loss remains prevalent, despite advances in treatment techniques (Brown et al., 
2015), and therefore nutrition support is essential to assist with maintaining nutritional status 
which has been shown to improve quality of life (Langius et al., 2013a; van den Berg et al., 
2008) and other clinical outcomes (Capuano et al., 2008). The protocol for proactive 
gastrostomy placement hence remains just as relevant for advanced techniques of radiation 
treatment delivery.  
There are limitations in the interpretation of these results due to the study being undertaken 
at a single site and therefore limiting the applicability to other centres not using the protocol. 
The retrospective study design also results in a number of patients being excluded due to 
access issues to the medical chart and missing outcome weight data. 
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There was a smaller sample size compared to the previous cohort used (one year versus 
two years data collection), and the study only had a small subset of radiotherapy patients 
that actually received H-IMRT (75/230). This introduced some selection bias as patients 
were generally prioritised for H-IMRT if they had extensive fields, high risk tumour sites such 
as the base of tongue or required bilateral irradiation rather than ipsilateral irradiation.  
The strength of this study is the favourable sample size compared to other published studies 
to date which have reported on nutrition outcomes and tube feeding requirements with H-
IMRT, which therefore helps to develop our knowledge in this field. Studies with IMRT have 
shown median gastrostomy use of three months (de Arruda et al., 2006) and benefits in 
expediting gastrostomy removal with the dose constraints formulated during planning (Amin 
et al., 2012), however we do not fully understand the impact of H-IMRT on the duration of 
gastrostomy use. According to the evidence-based European Society of Clinical Nutrition 
and Metabolism non-surgical oncology guidelines (Arends et al., 2006) a nasogastric tube 
is recommended for nutrition support that is required for <4 weeks and therefore this may 
be a more appropriate method of tube feeding if indeed the duration of gastrostomy use is 
<4 weeks. Therefore determining the duration of gastrostomy use will be an important 
consideration in future studies with H-IMRT.  
In summary the results of this study confirm the protocol’s updated high risk category is valid 
to predict proactive gastrostomy placement with a higher sensitivity and specificity. The 
revised version is therefore preferable for clinical use and has been shown to be appropriate 
for a mixed patient cohort receiving both 3-D conformal radiotherapy and H-IMRT. 
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5.3 Investigation of other factors. 
5.3.1 Abstract 
Background: The study aim was to determine if p16 status, chemotherapy regimen or other 
nutrition markers could improve protocol accuracy in predicting proactive gastrostomy in 
patients with head and neck cancer. 
Methods: Patients who received curative treatment from July 2010 to June 2011 were 
included (n=269). Associations between dependent variables (age, gender, tumour site, 
staging, treatment, p16 status, albumin, Malnutrition Screening Tool (MST) score), the 
protocol risk rating and requirement for proactive gastrostomy were examined.  
Results: Current protocol correctly identified 81/88 (92%) high risk patients for gastrostomy, 
but incorrectly classified 32/181 (18%) low risk patients. Analysis of low risk patients with 
oral or oropharyngeal cancers, found p16-positive disease had 4.4 times greater odds 
(p=0.049), and those at risk of malnutrition had 4.5 times greater odds (p=0.019), of requiring 
gastrostomy. 
Conclusions: Malnutrition risk and p16 status could be used to identify further patients who 
may benefit from proactive gastrostomy. 
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5.3.2 Manuscript 
INTRODUCTION 
Malnutrition and swallowing dysfunction are common among patients with head and neck 
cancer. This is linked to the aggressive nature and location of the disease and treatment 
side effects which include odynophagia, nausea and vomiting, xerostomia, poor appetite 
and dysphagia which in turn leads to weight loss and dehydration (Head & Neck Guideline 
Steering Committee, 2011; Kramer et al., 2014; Nicolini et al., 2013). Extensive research 
supports nutritional intervention, specifically enteral nutrition, to help patients meet their 
nutritional requirements and mitigate these side effects (Brown et al., 2014a; Brown et al., 
2013b; Isenring et al., 2004; Jeffery, Sherriff, & Langdon, 2012). Although the optimal form 
of nutrition support is yet to be identified (Moor et al., 2010; Nugent et al., 2013), proactive 
gastrostomy placement (insertion of a feeding gastrostomy tube prior to treatment) in 
anticipation of adverse outcomes that may lead to malnutrition, has gained popularity 
(Orphanidou et al., 2011). As previous observational studies (Locher et al., 2013; Strom et 
al., 2013) have identified, predicting the requirement for proactive gastrostomy placement is 
often complicated by confounding factors and selection bias.  
At our facility, the decision for proactive gastrostomy placement is based on a validated 
protocol (Figure 5-4) to categorise patients’ level of predicted nutritional risk as high or 
medium/low based on risk factors which have been shown in the literature to increase 
dysphagia, weight loss and the need for tube feeding during treatment (Brown et al., 2013b). 
The protocol helps guide decision-making by the multidisciplinary team to determine 
appropriate nutrition and swallowing management, including recommendations for proactive 
gastrostomy placement and tube feeding, but the final decision also considers the individual 
patient circumstances such as the extent of dysphagia at presentation, any medical 
contraindications for tube placement and patient choice. Adoption of this protocol locally has 
shown improved nutritional outcomes (Brown et al., 2014a) and decreased unplanned 
hospital admissions and length of stay (Hughes et al., 2013). However since their 
development nearly 10 years ago, additional factors have emerged in clinical practice that 
have the potential to impact on patient outcomes during treatment for head and neck cancer 
that were not previously considered.
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Figure 5-4: Royal Brisbane and Women’s Hospital Swallowing and nutrition 
management guidelines for patients with head and neck cancer – revised version 
2010 
Original Source: Brown et al., 2016a 
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Firstly, a new international definition and classification of cancer cachexia was released in 
2011, which is now defined in three stages – pre-cachexia, cachexia and refractory cachexia 
(Fearon et al., 2011). Initially, identification of cachexia was through the chief diagnostic 
criterion of non-oedematous weight loss of >5% in the last 12 months (Evans et al., 2008) 
and screening tools such as the Malnutrition Screening Tool (MST) have been previously 
recommended for use in cancer patients to detect this (Isenring et al., 2013).  
Early identification of the pre-cachexia phase (weight loss of <5%) is now deemed important 
to enable early interventions (Couch et al., 2014; Lucia, Esposito, Rossi Fanelli, & 
Muscaritoli, 2012). However it has been suggested that significant biochemical and 
molecular changes may occur before any weight loss is evident (Couch et al., 2014; Lucia 
et al., 2012) and therefore markers such as C-reactive protein (CRP) and serum albumin 
which are linked to the inflammatory process in cachexia may also be useful as an early 
diagnostic indicator of this condition (Couch et al., 2007; Gupta & Lis, 2010).  
Secondly, whilst chemoradiotherapy (CRT) has been linked with weight loss and the need 
for tube feeding (Silander et al., 2012; Strom et al., 2013), there are different types, doses 
and delivery schedules of chemotherapy used in treatment of HNC which have altered 
toxicity profiles (Espeli et al., 2012; Frenkel et al., 2013; Geeta et al., 2006; Ley et al., 2013; 
Walsh et al., 2011).  
Cetuximab, a monoclonal antibody targeting the epithelial growth factor receptor (EGFR) 
was approved for use in Australia in 2007, following the pivotal results of the combination 
demonstrating superior response rates and survival compared to radiotherapy alone 
(Bonner et al., 2006) and therefore was a suitable alternative for patients unable to have 
chemotherapy. Consequently, the planned chemotherapy agent and dose used may have 
differing effects on inhibiting patients from meeting their nutritional requirements and so may 
be appropriate for inclusion in the criteria for determining placement of proactive feeding 
tubes.  
Finally, in recent years there has been an increasing incidence of human papillomavirus 
(HPV)-associated oropharyngeal tumours (Jemal et al., 2013). These patients present with 
distinct carcinogenesis, risk factors, and clinical presentation compared to HPV-negative 
disease (Benson et al., 2013; Bonilla-Velez et al., 2013; Evans et al., 2013; Gillison et al., 
2008; Petrelli et al., 2014; Ramqvist & Dalianis, 2010). This unique disease subset 
demonstrates a better response to treatment, overall survival, and progression-free survival 
(Benson et al., 2013) compared to HPV-negative head and neck cancer.  
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As such, research into the de-intensification of treatment in order to reduce toxicities without 
compromising oncological outcomes are underway. However, the impact of HPV 
(specifically p16 status; an immunochemistry marker) on nutrition outcomes in head and 
neck cancer populations is unknown. 
Whilst our previous research has indicated that the protocol has a high sensitivity and 
specificity in predicting patients that would benefit from a proactive gastrostomy (Brown et 
al., 2016b), the aim of this study was to explore whether any of these other newly identified 
relevant clinical factors should also be considered and incorporated into the protocol to 
improve the validity even further. 
MATERIALS AND METHODS 
Study Setting 
In this single institutional cohort study, a convenience sample was used from a previous 
quality improvement project. This sample was taken from patients who attended the tertiary 
hospital for surgical or oncological curative treatment from July 2010 to June 2011. All 
patients are seen by the dietitian automatically during their surgical admissions or 
radiotherapy treatment. Patients are classified as a high or low nutrition risk according to our 
local protocol (Figure 5-4) (Brown et al., 2016b). Patients in the high risk category are those 
recommended for a proactive gastrostomy placement prior to treatment. The criteria is 
primarily based on tumour site and planned treatment, as well as the degree of weight loss 
or malnutrition at baseline. Full details are available in Figure 5-4. The risk rating was 
determined at the multidisciplinary meeting based on clinical staging for those treated 
definitively and on pathological staging based on those treated adjuvantly. This ensured 
patients were appropriately classified following upstaging or down staging after surgery. 
Exclusion criteria included non-head and neck tumours, benign disease, treatment of 
palliative intent or patients who declined treatment, and those less than 18 years old (Figure 
5-5). Those participants with missing weight data or no medical chart access were also 
excluded. All participants provided previous consent for their medical charts to be used in 
quality improvement projects. Ethics approval for this study was granted by the Royal 
Brisbane and Women’s Hospital Human Research Ethics Committee (HREC/14/QRBW/92) 
who approved this project for Low and Negligible Risk Research as set out in the National 
Health and Medical Research Statement. 
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Figure 5-5: Exclusion criteria applied to cohort
Attended the Head and 
Neck Clinic 
(n = 551)
Planned treatment at 
tertiary hospital 
(n = 364)
Exclusion criteria (n = 41)
Palliative (n = 30)
Benign disease (n = 5)
Non head and neck Tumours (n = 5)
Less than 18 years old (n = 1)
Excluded due to other factors (n = 54)
Missing data (n = 30)
No medical chart access (n = 24)
Final sample
(n = 269)
Treatment 
elsewhere 
(n=187)
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Data collection 
Information was gathered through retrospective chart audits and electronic medical data 
base review. The following variables were collected and grouped as follows: age, gender, 
tumour sites (oral = oral cavity; oropharyngeal = oropharynx, nasopharynx, hypopharynx 
and unknown primary; other = larynx and other sites), T-classification (T0 and TX; T1 and 
T2; T3 and T4; recurrent), N-classification (N0; N1, N2a and N2b; N2c and N3; recurrent), 
overall treatment which was then categorised according to surgical status (yes or no) and 
radiation status (surgery alone; radiotherapy and postoperative radiotherapy; CRT and 
postoperative CRT), intended chemotherapy treatment (high-dose cisplatin, low-dose 
weekly cisplatin or cetuximab), radiotherapy technique (helical intensity-modulated 
radiotherapy (H-IMRT) or 3D conformal) and the MST score (a malnutrition screening tool 
validated in radiation oncology patients which considers recent nutritional intake and weight 
loss (Ferguson et al., 1999a)). The following pathology tests were also reviewed: pre-
treatment serum albumin, pre-treatment CRP and the results from immunochemistry to 
determine p16 status (a surrogate marker for HPV) as either positive or negative. Blood 
results were included if they were taken within one month prior to treatment commencement. 
Tumour sites and classifications were coded using the International Classification of 
Disease-Version 10-Australian Modification, (National Centre for Classification in Health, 
2010) and the Union for International Cancer Control Tumour, Node, and Metastasis (TNM) 
staging system.  
Outcome measures 
The outcome variables in the dataset were; percentage weight loss during treatment (from 
baseline at diagnosis to the end of treatment), type of feeding tube inserted, and then where 
applicable, the use of gastrostomy (actively used for any period of time or unused), and 
duration of nasogastric tube use (short-term <4 weeks, or long-term >4 weeks). These 
variables were used to determine the primary outcome of whether each patient was deemed 
to require or not require a proactive gastrostomy according to the following criteria. Patients 
were deemed to meet the criteria ‘needed a proactive gastrostomy’ when; a) a patient had 
an actively used gastrostomy OR b) a patient had a long-term nasogastric feeding tube for 
greater than four weeks OR c) a patient did not have an actively used gastrostomy or a long-
term nasogastric feeding tube for greater than four weeks AND had ≥10% weight loss.  
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Conversely patients were deemed to meet the criteria ‘did not need a proactive gastrostomy’ 
when; a patient did not have an active gastrostomy or long-term feeding tube AND had 
<10% weight loss. Specifics of this definition have been described elsewhere (Brown et al., 
2013b). 
Statistical Analysis 
The analysis was organised into three distinct stages for this study. (1) Determine which 
baseline independent patient variables are associated with the protocol risk category rating. 
(2) Determine if any of the baseline independent patient variables not already associated 
with the protocol risk category rating are associated with the primary outcome of proactive 
gastrostomy requirement. (3) Determine if any of the baseline independent patient variables 
are useful in discriminating between those patients that were deemed low risk but would 
have benefited from a proactive gastrostomy and those that were correctly deemed low risk. 
Descriptive characteristics were determined using frequencies and percentages for 
categorical variables and means and standard deviations for continuous variables. 
Pearson’s chi-squared test, or Fisher’s Exact test when necessary, were used to test 
associations between categorical variables. Logistic regression was used to investigate the 
outcome “needed a proactive gastrostomy”, and variables were entered into the multivariate 
model if p<0.2 on univariate analysis. Overall statistical significance was set at p<0.05. Data 
was analysed using IBM SPSS database and statistical package (version 22, SPSS Inc., 
Chicago). 
RESULTS 
Of the total 269 patients in this study, the majority were males (77%) and greater than 65 
years old (42%). The tumour sites were evenly distributed with oral cavity (30%), 
oropharyngeal (34%) and other (36%). The oropharyngeal group consisted primarily of 
oropharynx (n=65), followed by hypopharynx (n=14), nasopharynx (n=4) and unknown 
primary (n=9). The other group consisted of larynx (n=18) and all other salivary and skin 
tumours (n=78).The majority of all patients received multi-modality treatment (75%), 
including 34% treated with definitive CRT, 41% surgery and adjuvant (chemo)radiotherapy 
and only 15% surgery alone. Additional patient characteristics are summarised in Table 5-
4. Given the low proportion of patients with a recorded pre-treatment CRP value (n = 6), this 
variable was excluded from further statistical analyses. 
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Table 5-4: Patient demographics and clinical characteristics including comparison 
between high and low risk groups using current protocol definitions 
Variable name Variable categories Total 
(n=269) 
High Risk 
(n=88) 
Low Risk 
(n=181) 
p-value 
  N (%)  
Gender 
 
Male 208 (77.3) 70 (79.5) 138 (76.2) 0.544 
Female 61 (22.7) 18 (20.5) 43 (23.8)  
Age (years) 
 
<50 32 (11.9) 14 (15.9) 18 (9.9) 0.069 
50-65 123 (45.7) 45 (51.1) 78 (43.1)  
>65 114 (42.4) 29 (33.0) 85 (47.0)  
Tumour Site 
Oral 81 (30.1) 18 (20.5) 63 (34.8) <0.001 
Oropharynx 92 (34.2) 68 (77.3) 24 (13.3)  
Larynx & other 96 (35.7) 2 (2.3) 94 (51.9)  
T Classification 
(n=267) 
 
T0 & TX 20 (7.5) 4 (4.5) 16 (8.9) 0.001 
T1 & T2 114 (42.7) 43 (48.9) 71 (39.7)  
T3 & T4 94 (35.2) 38 (43.2) 56 (31.3)  
Recurrent 39 (14.6) 3 (3.4) 36 (20.1)  
N Classification 
(n=267) 
 
N0 95 (35.6) 9 (10.2) 86 (48.0) <0.001 
N1, N2a, N2b 103 (38.6) 51 (58) 52 (29.1)  
N2c, N3 30 (11.2) 25 (28.4) 5 (2.8)  
Recurrent 39 (14.6) 3 (3.4) 36 (20.1)  
Radiotherapy type 
(n=229) 
H-IMRT 75 (32.8) 53 (60.9) 22 (15.5) <0.001 
3D Conformal 154 (67.2) 34 (39.1) 120 (84.5)  
MST score 
(n=184) 
0-1 135 (73.4) 52 (73.2) 83 (73.5) 0.975 
2 to 5 49 (26.6) 19 (26.8) 30 (26.5)  
Serum Albumin 
(n=193) 
>35 168 (87.0) 64 (80.0) 104 (92.0) 0.014 
<35 25 (13.0) 16 (20.0) 9 (8.0)  
Overall treatment 
 
RT 28 (10.4) 0 (0) 28 (15.5) <0.001 
CRT 91 (33.8) 77 (87.5) 14 (7.7)  
Surgery + RT 95 (35.3) 2 (2.3) 93 (51.4)  
Surgery + CRT 15 (5.6) 8 (9.1) 7 (3.9)  
Surgery 40 (14.9) 1 (1.1) 39 (21.5)  
Radiation Status 
 
Surgery alone 40 (14.9) 1 (1.1) 39 (21.5) <0.001 
Radiotherapy 123 (45.7) 2 (2.3) 121 (66.9)  
CRT 106 (39.4) 85 (96.6) 21 (11.6)  
Surgery Status 
 
No 119 (44.2) 77 (87.5) 42 (23.2) <0.001 
Yes 150 (55.8) 11 (12.5) 139 (76.8)  
Chemotherapy 
Type (n=106) 
 
Cisplatin (weekly) 40 (37.7) 29 (34.1) 11 (52.4) 0.278 
Cisplatin (high dose) 50 (47.2) 43 (50.6) 7 (33.3)  
Cetuximab 16 (15.1) 13 (15.3) 3 (14.3)  
p16 status 
(n=163) 
Positive 59 (36.1) 45 (57.7) 14 (16.5) <0.001 
Negative 104 (63.8) 33 (42.3) 71 (83.5)  
Smoking Status 
(n=145) 
Non Smoker 33 (22.8) 8 (14.8) 25 (27.5) 0.080 
Current Smoker 45 (31.0) 22 (40.7) 23 (25.3)  
Ex-smoker 67 (46.2) 24 (44.4) 43 (47.3)  
Abbreviations: H-IMRT=Helical Intensity-Modulated Radiotherapy; MST=Malnutrition Screening Tool; 
RT=Radiotherapy; CRT= Chemoradiotherapy.
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Based on the current protocol 88 patients were deemed high risk; of those 88 patients 92% 
(n=81) were correctly identified as high risk (true positives) whilst only 8% (n=7) were false 
positives. Of the 181 that were deemed low risk, 18% (n=32) were deemed to have been 
candidates for a proactive gastrostomy and 82% (n=149) were correctly identified to not 
require a proactive gastrostomy (true negatives). Thus the protocol has a high sensitivity 
and specificity and a high positive predictive value (92%) in classifying those who would 
benefit from a proactive gastrostomy (Brown et al., 2016b). Age was not found to be 
associated with the outcome “met criteria for proactive gastrostomy” (p=0.463), however 
smoking status was associated (p=0.041). Current smokers were more likely to meet the 
criteria for proactive gastrostomy (38% vs 25%) and non-smokers were less likely to meet 
the criteria (14% vs 30%). 
On exploration of the characteristics associated with protocol risk rating, it was found that 
patients classified as high risk tended to have oropharyngeal tumours (p<0.001), were 
receiving concurrent chemotherapy (p<0.001), were receiving H-IMRT (p<0.001), were not 
undergoing surgery (p<0.001), and had higher T-classification (p=0.001) and N-
classification cancers (p<0.001). They also were more likely to have p16-positive cancers 
(p<0.001), and had serum albumin levels greater than 35 (p=0.014). There was no 
association with age, gender, or MST or with the new variable of interest - chemotherapy 
type (p=0.278) (Table 5-4).  
As there is a high potential for confounding associations between all these variables, and 
as tumour site and treatment are the primary variables used for the current protocol, further 
investigation was carried out to see if these two variables were correlated with any other 
dependent variables. All variables were found to be correlated to tumour site and/or 
treatment, with the exception of MST and serum albumin (Table 5-5). However neither of 
these were subsequently found to be associated with the primary outcome “met criteria for 
proactive gastrostomy” (MST, p=0.271 and serum albumin, p=0.126), and so would not be 
beneficial in adding into the protocol high risk category definition. Overall this shows the 
current two variables used in the protocol (site and treatment) incorporate almost all other 
clinical factors and are therefore good proxies for all these other factors that may contribute 
to the predicted need for a gastrostomy. 
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On review of the low risk patients only (n=181) to determine which characteristics are 
common to those that “met criteria for proactive gastrostomy” (n=32), we found that the only 
variable associated was MST, p=0.039. Logistic regression indicates that the odds of 
requiring a proactive gastrostomy when identified at risk of malnutrition (MST = 2 – 5) are 
2.7 times greater than those not at risk of malnutrition (MST = 0 – 1) (p=0.044). This is based 
on the 113 low risk patients who had MST recorded (Table 5-6). 
To determine the role of p16 status, sub group analysis was performed on patients that were 
deemed low risk and had an oral or oropharyngeal tumours (n=87), as p16 status is not 
routinely available to those with other cancers (i.e. laryngeal, skin, salivary). In this sub 
group, 19 patients met the criteria for proactive gastrostomy, and this was again only 
significantly associated with MST (p=0.030), and moderately associated with p16 status 
(p=0.074). Therefore MST and p16 status were eligible to be entered into a logistic 
regression model. In this sub group of low risk patients with an oral or oropharyngeal 
tumours, patients with p16-positive disease had 4.4 times greater odds of requiring a 
proactive gastrostomy than those who were p16-negative (p=0.049), and those at risk of 
malnutrition (MST = 2-5) had 4.5 times greater odds of requiring a proactive gastrostomy 
than those not at risk of malnutrition (MST= 0-1) (p=0.019) (Table 5-6).
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Table 5-5: Statistical associations (p values) between all clinical variables and two of 
the variables that inform the current protocol high risk definition  
Other Variables 
 
Variables which inform current high risk definition 
Tumour site Radiation Status 
Gender <0.001 0.255 
Age  0.004 0.03 
Tumour site N/A <0.001 
T Classification <0.001 <0.001 
N Classification <0.001 <0.001 
Radiotherapy type <0.001 <0.001 
MST 0.142 0.3 
Serum Albumin 0.116 0.129 
Radiation Status <0.001 N/A 
Surgery Status <0.001 <0.001 
Chemotherapy type 0.061 N/A 
p16 status <0.001 <0.001 
Risk Rating <0.001 <0.001 
Abbreviations: N/A=not applicable; MST=Malnutrition Screening Tool. 
Table 5-6: Logistic regression models for predicting proactive gastrostomy 
Cohort  Variable B P value Exp(B) 
95% C.I. for Exp(B) 
Lower Upper 
All low risk 
patients  
(n=113) 
MST      
0-1 0 reference 1   
2-5 0.99 0.044 2.69 1.03 7.05 
Low risk patients 
with oral or 
oropharyngeal 
tumour only 
(n=67) 
p16 status      
Negative 0 reference 1   
Positive 1.48 0.049 4.41 1.01 19.31 
MST      
0-1 0 reference 1   
2-5 1.50 0.019 4.48 1.29 15.64 
Abbreviations: CI=confidence interval; MST=Malnutrition Screening Tool.
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DISCUSSION  
This study aimed to investigate potential new clinical markers on their ability to predict the 
requirement of a proactive gastrostomy for patients with head and neck cancer. This 
included; albumin as a marker of pre-cachexia, p16 as a marker of HPV status and the 
prescribed chemotherapy regimen. The current protocol primarily use tumour site and 
treatment (either oral cavity or oropharynx with bilateral CRT or nasopharynx, hypopharynx 
or unknown primary with CRT) as the current clinical factors to predict the need for proactive 
gastrostomy. Severe malnutrition is also part of the current high risk definition but is rarely 
used as a sole indicator, as it is often seen in conjunction with the tumour site and/or with 
the TNM stage which determines when CRT, rather than radiotherapy alone, is required. 
The use of tumour site and treatment to determine the risk rating also explains a number of 
the other associations seen with the high risk category. Tumours of larger size and/or in 
difficult locations where functional outcomes cannot be safely preserved are often 
recommended for definitive radiotherapy over surgery. Similarly patient selection for H-IMRT 
is based on whether the tumour site is critical to the swallowing functionality, or if extensive 
fields or bilateral neck irradiation is required. Therefore tumour site and staging has a great 
influence on overall treatment selection and helps explain the characteristics of the high risk 
population. 
Whilst we have previously shown the guidelines in their current format have a high validity 
(Brown et al., 2016b), this study has confirmed that the two key variables of tumour site and 
treatment are strongly associated to a number of other clinical variables, thus eliminating 
the need to include any additional variables which would unnecessarily add to the complexity 
of the high risk criteria definition. The significance of tumour site is expected given the role 
of the pharynx in the swallowing process. This supports findings from previous studies which 
also documented tumour site to be a significant independent predictive factor for the 
requirement of proactive tube placement (Habib et al., 2014; Wermker, Jung, Huppmeier, 
Joos, & Kleinheinz, 2012).  
Concurrent CRT has also consistently been reported in the literature to increase the need 
for nutritional support and enteral tube feeding (Locher et al., 2013) due to the enhancement 
of radiation side effects such as mucositis and dysgeusia as well as other severe toxicities 
associated with different chemotherapy agents which impact on a patients’ ability to 
consume adequate nutrition orally.
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The type of chemotherapy regimen has not been found to be a factor to assist predicting the 
need for proactive gastrostomy insertion in this study. This was also the case in the study 
by Wopken et al. (2014b) who reported that chemotherapy (regardless of the regimen) was 
a predictor of tube feeding at six months after treatment (Wopken et al., 2014b), and despite 
different toxicity profiles from different chemotherapy agents, the impact on weight loss and 
tube feeding is similar (Ye et al., 2013). Some studies suggest that the need for nutritional 
support is even greater in patients receiving Cetuximab treatment (Magrini et al., 2015; 
Walsh et al., 2011; Yokota et al., 2015). As such, it appears that CRT overall, regardless of 
dose or type, is most important for consideration.  
This study also did not find a role for baseline serum albumin levels in predicting a patients’ 
need for proactive gastrostomy, and the limitations of retrospective data collection meant 
that CRP could not be fully investigated. However the early identification of patients at risk 
of malnutrition remains an important consideration. A recent review focused on nutrition 
support in cancer patients, highlighted that malnourished patients have a poorer response 
to chemotherapy and higher risk of toxicity (Bozzetti, 2013) indicating that consideration of 
pre-treatment risk of malnutrition is important.  
The MST is an appropriate validated malnutrition screening tool and has also been 
recommended for assisting in the identification of cachexia (Bauer et al., 2006). Further 
research into the ability of the MST or other tools to identify the pre-cachexia state would be 
of interest, and provide a simpler and less invasive approach than reliance on blood samples 
for albumin or other inflammatory markers that are not routinely measured. 
This study did find that low-risk patients with an oral or oropharyngeal tumour, with p16-
positive disease had 4.4 times greater odds of requiring a proactive gastrostomy than those 
who were p16-negative. This subset of patients are likely to be those undergoing unilateral 
radiotherapy treatment and therefore not identified as a high risk patient who receives 
bilateral treatment. This finding of positive p16 status increasing the need for proactive 
gastrostomy may be explained by other studies which have reported that patients with p16-
positive disease have a higher acute toxicity than p16-negative disease (Becker-Schiebe, 
Sperling, Pinkert, & Hoffmann, 2015), and rates of dysphagia and organ toxicity are higher 
in patients with p16-positive disease (Tehrany et al., 2015).
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We also found that current smoking status had an association with the need for a proactive 
gastrostomy, which is in line with other studies (Mangar et al., 2006). However as p16-
positivity is generally associated with non-smoking (Marur, D'Souza, Westra, & Forastiere, 
2010), (although it is possible to see in current smokers), this suggests some potential 
contradiction of our finding of p16-positive disease also being associated with need for 
proactive gastrostomy. There are likely multifactorial reasons for this. Due to the different 
demographics and clinical presentation of the p16-positive and negative populations a 
difference in quality of life has been reported, with a higher baseline quality of life and a 
larger decrease in quality of life immediately post-treatment for patients with p16-positive 
disease (Maxwell et al., 2014; Sharma et al., 2012). This may be explained by the increased 
toxicity seen, or may be due to other psychosocial factors yet to be fully explored, such as 
differences in coping strategies and levels of psychological distress. These may all be other 
important variables to consider in the prediction of proactive gastrostomy requirement. 
The main limitations of this study were the retrospective study design and the large amounts 
of missing data, in particular smoking status and immunochemistry for p16 (not routinely 
requested in patients with non-mucosal tumour sites at this facility). Therefore there were 
only 67 patients included in the final model due to missing data, and only 16 of which met 
the outcome for proactive gastrostomy. As such, these results should be interpreted with 
caution due to small sample sizes in some groups resulting in large confidence intervals.  
Dysphagia at presentation was not included as a variable for investigation, although the 
consideration of tumour site and volume may also account for this as a surrogate marker 
(Colangelo, Logemann, & Rademaker, 2000). Furthermore, this study did not consider social 
status which has been reported as a significant predictor for proactive gastrostomy 
placement in a prior study (Locher et al., 2013) and may be an important variable to improve 
the predictive ability of these guidelines. Another variable to also consider for future studies 
is the radiotherapy dose to the pharyngeal constrictor muscles and mylo/geniohyoid 
complex, as it has been shown that the dose and volume to these are associated with 
dysphagia and gastrostomy tube dependence (Dale et al., 2016; Li et al., 2009). Multivariate 
analysis including these variables would then help determine any confounding relationships 
between radiotherapy dose, tumour site and p16 status, or indeed if p16 status could be 
used as a surrogate marker of the oropharynx and thus constrictor dose.
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Overall, the findings support the current high risk criteria in the swallowing and nutrition 
guidelines which currently consider treatment type, tumour site and nutritional status. These 
results suggest that the current guidelines, whilst only made up of three variables, act as 
proxies for almost all other clinical factors. The findings do not support the addition of serum 
albumin, p16 status or chemotherapy type or dose in the high risk criteria. However using 
the MST (and p16 status in oral or oropharyngeal tumours) may help identify other low risk 
patients that do actually require a proactive gastrostomy, and thus improve the guidelines’ 
sensitivity. 
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5.4 Chapter summary 
The results of this study have demonstrated that the updated protocol remains valid for 
predicting who would benefit from proPEG in a mixed cohort of patients receiving 3D 
conformal and helical-IMRT. In comparison to the original validation study, there is an 
improvement in sensitivity (from 54% to 72%) and a slight increase in specificity (from 93% 
to 96%). There were a few other clinical differences noted between the cohorts such as a 
reduction in laryngeal cancers and recurrent tumours, an increase in advanced N stage 
disease and a reduction in treatment with radiotherapy alone. It is possible that these 
changes may be attributed to reduction in smoking behaviours (Luke, Yeoh, & Roder, 2008) 
as well as the increasing incidence of HPV-related oropharyngeal tumours (Jemal et al., 
2013) which are usually treated with multimodality treatment due to more extensive nodal 
involvement (Mallen-St Clair et al., 2016).  
There was no additional benefit of adding the other factors under investigation (p16 status, 
chemotherapy type, albumin or CRP) to the high risk definition, as the two key variables 
currently used (tumour site and treatment) were found to be related to almost all other 
variables and thus were sufficient predictors on their own. This retains a simple predictive 
model which is highly effective with a positive predictive value of 92%.  
To improve the low risk definition and identify patients who would have benefited from 
proPEG (n=32, 18%) a baseline malnutrition screening tool (MST) score of two or more 
increased the odds 2.7 fold of requiring a tube. The role of p16 status in the low risk definition 
was inconclusive as whilst it potentially helped to identify the need for tube feeding in a sub-
group of patients with oral or oropharyngeal cancer (p16-positive disease had a 4.4 
increased odds compared to p16-negative disease), this was based on a limited sample size 
of patients who had a p16 test completed, and findings need to be confirmed in a larger 
sample size. 
In summary it was concluded to continue with the current protocol in its current format. This 
research illustrates the importance of quality improvement work to continually re-evaluate 
procedures and interventions to ensure they remain relevant in dynamic healthcare 
environments with changing disease profiles and evolving treatments.
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6.1 Chapter overview 
The findings in this chapter have been published in the Journal of the Academy of Nutrition 
and Dietetics (Journal Impact Factor 3.609; Ranked 19/80 Nutrition & Dietetics category; 
Quartile 1). Section 6.2 and 6.3 are presented in their accepted format prior to publication.  
Despite the evidence outlined in previous chapters to demonstrate the critical need for 
nutrition intervention and the validity of the protocol to identify patients who would benefit 
from proPEG, we observed that adherence to the protocol by the multidisciplinary team 
started to decline over time. Adherence rates to the high risk category recommendation to 
place a proPEG had fallen to just 60% in 2015 (Appendix C – 11.3.6). Therefore the aim of 
the study in this chapter was to compare the nutritional and clinical outcomes of all patients 
classified as high risk who were having treatment at the RBWH based on whether they 
received a proPEG (adherence to local protocol recommendation) or whether they were 
managed reactively (non-adherence to local protocol recommendation). 
Results of this study were presented at the following international conference: World 
Congress of Larynx Cancer, Cairns, Australia, 2015 (Appendix C – 11.3.7). 
Date submitted: 20/05/2016 
Date accepted: 14/10/2016 
Citation: Brown, T., Banks, M., Hughes, B., Lin, C., Kenny, L., Bauer, J. (2016). Comparison 
of nutritional and clinical outcomes in patients with head and neck cancer undergoing 
chemoradiotherapy utilizing prophylactic versus reactive nutrition support approaches. 
Journal of the Academy of Nutrition and Dietetics, Advance online publication. 
doi:10.1016/j.jand.2016.10.013 
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6.2 Abstract 
Background: The optimal method of tube feeding for patients with head and neck cancer 
remains unclear. A validated protocol is available which identifies high nutritional risk 
patients who would benefit from prophylactic gastrostomy tube placement. Adherence to 
this protocol is ultimately determined by clinical team discretion or patient decision. 
Objective: The study aim was to compare outcomes following adherence and non-
adherence to this validated protocol thus comparing a prophylactic and reactive approach 
to nutrition support in this patient population. 
Design: Prospective comparative cohort study. Patients were observed during routine 
clinical practice over two years. 
Participants/setting: Patients with head and neck cancer having curative intent treatment 
between August 2012 and July 2014 at a tertiary hospital in Queensland, Australia, were 
included if assessed as high nutrition risk according to the validated protocol (n=130). 
Patients were grouped according to protocol adherence as to whether they received 
prophylactic gastrostomy as per protocol recommendation (proPEG, n=69) or not (noPEG, 
n=61). 
Main outcome measures: Primary outcome was percentage weight change during 
treatment. Secondary outcomes were feeding tube use and hospital admissions. 
Statistical analysis performed: Chi-square, Fishers Exact and Two Sample T tests were 
performed to determine differences between the groups. Linear and logistic regression were 
used to examine weight loss and unplanned admissions respectively. 
Results: Patient characteristics; 88% male, median 59 years old, with predominantly stage 
IV oropharyngeal cancer receiving definitive chemoradiotherapy. Statistically significantly 
less weight loss in the proPEG group (7.0% versus 9.0%, p=0.048) and more unplanned 
admissions in the noPEG group (82% versus 75%, p=0.029). In the noPEG group 26 
patients (43%) required a feeding tube or had ≥10% weight loss. 
Conclusion: Prophylactic gastrostomy improved nutrition outcomes and reduced unplanned 
hospital admissions. Further investigation of characteristics of patients with minimal weight 
loss or feeding tube use could help refine and improve the protocol. 
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6.3 Manuscript 
INTRODUCTION  
The role of dietary counselling in improving nutrition outcomes for patients with head and 
neck cancer has been well documented (Garg et al., 2010; Langius et al., 2013c), but the 
optimal management with patients requiring enteral tube feeding remains unclear and so no 
firm recommendations can be made (Langius et al., 2013c; Nugent et al., 2013). The debate 
in the literature continues as to whether patients with head and neck cancer should have a 
nasogastric tube or gastrostomy tube (Corry et al., 2008; Wang et al., 2014a) and the optimal 
timing of gastrostomy placement (Bradley, Brown, & Paleri, 2015; Talwar & Findlay, 2012). 
Enteral feeding tubes can either be placed prior to the commencement of treatment in 
anticipation of the need for tube feeding later on (prophylactic) or they can be placed during 
treatment when deemed required (reactive).  
Studies comparing prophylactic versus reactive gastrostomy tube placement have mixed 
findings with some reporting less weight loss and fewer unplanned admissions (Lewis et al., 
2014; Romesser et al., 2012) and others reporting no difference in nutrition outcomes, 
disease control or survival (Kramer et al., 2014; Williams et al., 2012). However rates of 
weight loss despite prophylactic gastrostomy placement were still clinically significant with 
approximately 10% weight loss or more at three months post-treatment (Brown et al., 2014a; 
Romesser et al., 2012) and at six months post-treatment (Kramer et al., 2014; Williams et 
al., 2012). The detrimental impact of malnutrition is well documented in terms of increased 
complications and healthcare costs in surgical patients (Gourin, Couch, & Johnson, 
2014).The impact of poor nutrition outcomes has also recently been shown to have a 
significant prognostic effect on reducing survival outcomes for patients with head and neck 
cancer receiving radiotherapy (Langius et al., 2013b) and reducing their quality of life 
(Langius et al., 2013a), and thus is a key outcome measure to consider. 
A validated protocol has been developed in Australia (Brown et al., 2016b) to identify 
patients who would benefit from gastrostomy insertion prior to treatment (Figure 6-1) and 
form part of the local hospital’s procedure on the “Swallowing and Nutrition Management 
Guidelines for Patients with Head and Neck Cancer”. The published protocol has been 
included as part of internationally endorsed dietetic guidelines on the nutritional 
management of patients with head and neck cancer (Head & Neck Guideline Steering 
Committee, 2011).
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The true extent of protocol implementation is unknown, however the literature continues to 
report the approach to prophylactic gastrostomy selection remains varied between hospitals 
in Australia (Brown & Findlay, 2011) and worldwide (Koyfman & Adelstein, 2012; Moor et 
al., 2010; Orphanidou et al., 2011). The protocol uses clinical information at diagnosis based 
on tumour site and treatment plan and nutritional status to determine the patients’ future 
nutrition risk rating and pathway of care. Patients classified as high risk are recommended 
for prophylactic gastrostomy placement and all other patients are managed reactively as 
required. This protocol has shown a number of positive outcomes with reduced unplanned 
admissions and length of stay (Hughes et al., 2013), improved nutrition outcomes with 
protocol adherence (Brown et al., 2014a), and no detrimental impact on swallowing function 
(Crombie et al., 2015).  
Following local implementation at the tertiary hospital where the protocol was developed, 
initial adherence to the recommendation of prophylactic gastrostomy placement for high risk 
patients was 75% in 2008 (Brown et al., 2013b) which improved to 89% in 2010 (Brown et 
al., 2016b), however since then it has fallen to 60% in 2015 (unpublished data).This decline 
appeared to coincide with the introduction of helical intensity-modulated radiotherapy at this 
hospital site in 2010. The reason for the healthcare teams’ decline in adherence to this 
recommendation has been based on the premise that helical intensity-modulated 
radiotherapy has improved dose reduction for organs at risk (Sheng et al., 2006), therefore 
reducing radiotherapy toxicities and potential nutrition impact symptoms which may imply 
aggressive nutrition support via a gastrostomy may no longer be required. However recent 
studies in this limited area of research to date have not supported this hypothesis reporting 
feeding tube use and weight loss is still high (Brown et al., 2015). 
Using the validated protocol to identify a cohort of high nutrition risk patients, the aim of this 
study was to compare the nutritional and clinical outcomes of high nutrition risk patients who 
received a prophylactic gastrostomy tube (healthcare team adherence to the protocol 
recommendation) versus the outcomes of high nutrition risk patients who did not receive a 
prophylactic gastrostomy tube (healthcare team non-adherence to the protocol 
recommendation). These two groups thus enabled a comparison between a prophylactic 
and reactive approach to nutrition support in a similar group of patients within one institution. 
The hypothesis being that the prophylactic gastrostomy group would have less weight loss 
and fewer unplanned admissions than the group that did not receive a prophylactic 
gastrostomy and were managed reactively.  
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MATERIALS AND METHODS 
Study design  
This was a prospective cohort study to monitor the outcomes of high nutrition risk patients 
with head and neck cancer. On attendance at the multidisciplinary clinic for diagnostic 
staging and treatment planning, patients were assessed using the protocol (Brown et al., 
2016a) to assign a nutrition risk rating of high or low, whereby high risk patients are 
recommended for prophylactic gastrostomy insertion (Figure 6-1). Patients were grouped as 
follows: those who received a prophylactic gastrostomy prior to commencement of 
radiotherapy, as per the protocol recommendation (proPEG) and those who did not receive 
a prophylactic gastrostomy prior to radiotherapy, against the protocol recommendation 
(noPEG), either due to a patient or Consultant decision. A prophylactic tube placement was 
defined as placement of a gastrostomy prior to commencement of treatment. Any feeding 
tubes (nasogastric or gastrostomy) placed after commencement of treatment were defined 
as reactive tube placement. Key outcome variables of interest were weight change during 
treatment, requirement for enteral tube feeding and incidence of unplanned hospital 
admissions and associated length of stay. Predictor variables included patient 
demographics and clinical characteristics such as tumour site, staging and treatment. Other 
covariates considered were the treating radiation oncologist. 
Study population 
Patients attending a tertiary hospital for treatment for head and neck cancer between August 
2012 and July 2014 were assessed for inclusion in the study. The tertiary hospital provides 
specialist cancer care services for a wide geographical region of Australia. Patients were 
included in this study if they were assigned a high nutrition risk rating and received curative 
intent treatment at the tertiary hospital. The high nutrition risk group included patients with a 
diagnosis of oral or oropharyngeal cancer receiving bilateral chemoradiotherapy, patients 
with nasopharyngeal or hypopharyngeal cancers or unknown primaries receiving 
chemoradiotherapy and patients with severe malnutrition on presentation (Figure 6-1).
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Figure 6-1: Royal Brisbane and Women’s Hospital Swallowing and nutrition 
management guidelines for patients with head and neck cancer – revised 2010 
Original Source: Brown et al., 2016a 
 
Patients were excluded if they did not complete treatment or were unable to have a 
gastrostomy due to medical contraindications to the procedure. Treatment for this patient 
group consisted of helical intensity-modulated radiotherapy at a dose of 2Gy/day for five 
days/week, to total doses of 70Gy (definitive) or 60Gy (adjuvant). Chemotherapy was 
prescribed according to clinician discretion and consisted of either high dose Cisplatin, 
weekly Cisplatin or Cetuximab. The sample size was based on a convenience sample of 
eligible patients over the study time period.  
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Nutrition Management 
All patients were screened at diagnosis using the recommended validated Malnutrition 
Screening Tool (Isenring et al., 2013) and at risk patients were referred to their local dietitian 
pre-treatment. During treatment, the dietitian and speech pathologist saw all patients weekly 
and the patient was referred to their local dietetic and speech pathology service in their 
home town for ongoing review post-treatment. Nutritional requirements were calculated 
using 1.2g protein/kg/day and 30kcal/kg/day (125 kilojoules/kg/day) (Isenring et al., 2013), 
using actual body weight unless the patient had a body mass index >25kg/m2, and then 
adjusted body weight was used.  
Patients were advised on a high protein, high energy diet with or without oral nutrition 
supplements to meet these requirements. Tube feeding was initiated in either group if 
patients were unable to maintain weight on oral intake alone (continued weight loss on 
weekly reviews) or diet history indicated oral intake was <60% of nutritional requirements 
and it was anticipated there would be no improvement over the next 10 days. Tube feeding 
was usually initiated as supplementary bolus feeding using a 1.5kcal/ml polymeric fibre 
containing feed unless there were concerns with tolerance in which case pump feeding was 
used, and feeding rates/volumes were titrated to meet nutritional requirements according to 
level of oral intake. The decision relating to tube type in the noPEG group was based on the 
anticipation of duration of enteral feeding (Arends et al., 2006). Full details of the nutritional 
management pathway is illustrated in Figure 6-1.  
Outcome measures 
Data were prospectively collected from medical charts during standard clinical care for the 
following predictor variables; baseline patient demographics (age, sex), and clinical 
characteristics (tumour site, cancer staging, treatment, and p16 status as an 
immunohistological marker of human papillomavirus-related tumours).The treating radiation 
oncologist (Consultant A, B, C or other) was also recorded as a covariate to account for any 
potential individual variations in decision-making or treatment planning. Outcome variables 
were also prospectively collected as described below and included: weight change during 
treatment; feeding tube use; hospital admissions and length of stay. Weight was measured 
in kilograms on standard scales at diagnosis and weekly during treatment as part of usual 
clinical care. Weight change during treatment was the difference in weights from diagnosis 
to the last week of radiotherapy and percentage weight change was calculated.  
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Feeding tube use was a binary outcome variable (yes or no) and defined as follows: for the 
proPEG group this was determined by whether patients actually used their gastrostomy tube 
for enteral feeding during treatment or not; for the noPEG group this was determined by 
whether patients required insertion of a reactive enteral feeding tube or not. This data was 
prospectively recorded by the clinical dietitian during weekly clinical reviews in assessing 
oral and enteral intakes. These feeding tube use outcomes were then taken into 
consideration with weight loss outcomes to determine retrospectively whether the patient 
met the final outcome criteria for truly requiring a prophylactic gastrostomy. These 
predefined criteria have been described fully elsewhere (Brown et al., 2013b), but essentially 
if a patient used a gastrostomy feeding tube or had a nasogastric feeding tube for more than 
four weeks or had 10% weight loss or more, they were deemed in retrospect to have met 
the criteria and would have benefited from placement of a prophylactic gastrostomy. 
All admissions to the tertiary hospital from diagnosis to one month post-treatment were 
recorded prospectively by the dietitian during routine clinical care (this therefore excluded 
any admissions to private hospitals or those outside of the health service district). The 
dietitian was responsible for seeing patients routinely in weekly outpatient clinics and 
whenever admitted as an inpatient. The data were verified by checking the electronic 
hospital admission database systems and any missing data were collected by medical chart 
review. Admission type (planned or unplanned) and the timing of admission (pre/during 
treatment or post-treatment) were recorded. An unplanned admission was defined as an 
unexpected admission or a prolonged planned admission. Length of stay (LOS) was 
recorded in days for each admission type and any prolonged length of stays greater than 
seven days were noted. The reasons for unplanned admissions were coded as either a 
medical admission or a nutrition-related admission - sub divided into either: gastrointestinal 
disturbances (nausea, vomiting, diarrhoea, constipation); pain related to mucositis; enteral 
tube management issues (gastrostomy complications or insertion/management of a 
nasogastric tube); or other nutrition reasons (general poor intake, lack of appetite, 
dehydration, fatigue, or other social factors affecting nutritional intake/meal preparation e.g. 
temporary accommodation or social isolation from partners/family). Planned admissions 
were for administration of chemotherapy.
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Ethical statement 
The study was deemed exempt by the Human Research Ethical Committee at the Royal 
Brisbane and Women’s Hospital according to the “National Statement on Ethical Conduct in 
Human Research (2007)”. 
Statistical considerations 
Statistical analysis was performed between the proPEG and noPEG groups to determine if 
there were any baseline differences between the demographics and clinical characteristics. 
Categorical variables were summarized as counts and frequencies and compared using the 
Chi-square test. If the assumptions of the Chi-square test could not be met due to small 
expected cell counts, variables were collapsed if clinically meaningfully to do so, otherwise 
Fishers Exact test was used. Continuous variables were summarized as means and 
standard deviations and compared using the Two Sample T test (following assessment of 
normal distribution using the Shapiro-Wilk test).  
The null hypothesis stated that there was no difference in outcomes (weight loss or 
unplanned admissions) between the proPEG and noPEG groups. Multivariate analysis was 
performed to adjust for any baseline differences or confounding effects. Percentage weight 
loss (as a continuous variable) was calculated from diagnosis to last week of radiotherapy 
and was examined using linear regression. Unplanned admissions and length of stay greater 
than seven days (as categorical variables) were examined using logistic regression. 
Predictor or covariate variables with a p<0.2 on bivariable analysis were entered into the 
multivariable models. Final variable selection for each multivariable model used Akaike’s 
Information Criteria (AIC) with a backward stepwise algorithm. The final models reported 
were with the smallest objective AIC.  
Statistical significance was set at p<0.05 for all analyses. Data were analysed using R 
Commander Version 2.1-7 and R version 3.1.3 (2015-03-09) (R Foundation for Statistical 
Computing, Vienna, Austria) (R Core Team, 2014).
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Table 6-1: Summary of characteristics of patients with head and neck cancer 
receiving chemoradiotherapy – a comparison between patients with and without a 
prophylactic gastrostomy 
Patient 
Characteristics 
All Patients 
(n=130) 
proPEG a 
(n=69) 
noPEG b 
(n=61) P value c 
n (%) 
Age (years) P=0.64  
Mean ± SD  
Median (range)  
59.1 + 9.7 
59 (37-83) 
59.5 + 10.0 
60 (40-83) 
58.7 + 9.5 
59 (37-81)  
 
Sex  P=0.43  
Male 114 88% 62 90% 52 85%  
Female  16 12%  7 10%  9 15%  
Tumor Site d  P=0.006  
Oral cavity  12 9%  5 7%  7 12%  
Oropharynx 100 77% 59 86% 41 67%  
Nasopharynx  4 3%  1 1%  3 5%  
Hypopharynx  6 5%  4 6%  2 3%  
Unknown primary  8 6%  0 0%  8 13%  
Tumor Classification e P=0.003  
T0  8 6%  0 0%  8 13%  
T1 22 17%  8 12% 14 23%  
T2 45 35% 25 36% 20 33%  
T3 31 24% 20 29% 11 18%  
T4 24 18% 16 23%  8 13%  
Nodal Classification f  P=0.27  
N0  9 7%  4 6%  5 8%  
N1  7 5%  6 9%  1 2%  
N2a  8 6%  2 3%  6 10%  
N2b 65 50% 31 45% 34 56%  
N2c 35 27% 24 35% 11 18%  
N3  6 5%  2 3%  4 6%  
Overall Cancer Stage g P=0.17  
II  1 1%  0 0%  1 2%  
III  10 8%  8 12%  2 3%  
IV 119 91% 61 88% 58 95%  
Treatment  P=0.10  
ChemoRT h 115 88% 64 93% 51 84%  
Adj ChemoRT h  15 12%  5 7% 10 16%  
p16 Status i P=0.58  
Positive  96 77% 52 79% 44 75%  
Negative  29 23% 14 21% 15 25%  
Treating Radiation Oncologist P<0.001  
Consultant A 40 31% 14 20% 26 43%  
Consultant B 36 28% 15 22% 21 34%  
Consultant C 33 25% 25 36% 8 13%  
Other 21 16% 15 22% 6 10%  
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Abbreviations: a proPEG=prophylactic gastrostomy tube placed according to protocol. b noPEG=no prophylactic 
gastrostomy tube against protocol recommendation. c Continuous variables analysed using T tests and 
categorical variables analysed using Chi Square (unless stated otherwise) with statistical significance set at 
p<0.05. d Tumor site analysed with Fishers Exact test as following categories = Oropharynx/Nasopharynx vs 
Oral vs Hypopharynx vs Unknown Primary. e Tumor classification analysed as following categories = T0/T1 vs 
T2/T3 vs T4. f Nodal classification analysed as following categories = N0/N1/N2a vs N2b vs N2c/N3. g Overall 
cancer stage analysed as following categories = II/III vs IV. h ChemoRT=chemoradiotherapy. i p16= 
immunohistological marker of human papillomavirus-related tumors. 
 
RESULTS 
Patient characteristics 
Over the two years, 139 patients were identified as high risk using the protocol and of these 
130 were eligible for inclusion. The cohort characteristics were typical for a head and neck 
cancer profile and reflective of the criteria of the local protocol to determine the high risk 
rating. There were 69 patients who received a prophylactic gastrostomy according to the 
protocol recommendation (proPEG group) and 61 patients who did not receive a 
prophylactic gastrostomy (noPEG group). Protocol adherence to the high risk pathway is 
therefore 53% in this cohort. Statistically significant differences were seen between these 
two groups with respect to tumour site, tumour stage, and treating radiation oncologist 
(Table 6-1). All patients completed treatment and had follow-up data. 
 Weight outcomes 
On bivariable analysis the variables associated with the outcome of weight loss (age 
p=0.006, site p=0.033, group p=0.112) and the differences between the groups (see Table 
6-1 for variables with p<0.2) were entered into the model for multivariate analysis. Four 
variables remained significant in the final model (group, age, tumour site and treating 
Consultant) where AIC=403. The difference in weight loss between groups when adjusted 
for age, tumour site and treating Consultant was significant, with the noPEG group losing 
approximately 2% more weight than the proPEG group (ß = -1.95, 95% CI [-3.77, 1.76], 
p=0.04). Other associations with less weight loss on multivariate analysis were 
hypopharyngeal (p=0.01) or unknown primary tumours (p=0.01) compared to 
oropharyngeal/nasopharyngeal tumours, and increasing age (p=0.002). 
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Tube feeding 
Overall 91% of patients used their prophylactic gastrostomy (n=63). Of the six patients who 
did not use their gastrostomy, three were non adherent to recommendations to use it 
resulting in one patient losing more than 10% body weight and two patients losing more than 
5% weight. In the noPEG group, 13 patients required a reactive feeding tube (one patient 
had a gastrostomy and all others had a nasogastric tube) and 13 patients on oral nutrition 
support lost more than 10% of their body weight. Therefore overall 26 patients (43%) met 
the pre-determined criteria for prophylactic gastrostomy insertion on the basis of their 
outcomes (i.e. had reactive feeding tube or more than 10% weight loss) and therefore may 
have benefited from prophylactic tube feeding (Table 6-2). 
Table 6-2: Summary of tube feeding outcomes in patients with head and neck cancer 
receiving chemo-radiotherapy – a comparison between patients with and without a 
prophylactic gastrostomy 
Outcome 
proPEG a (n=69) 
 
noPEG b (n=61) 
n  
 
% n  % 
Tube use c 
 
63  91% 13 21% 
No tube use and >10% weight loss 
 
1  1% 13  21% 
No tube use and <10% weight loss 
 
5  7% 35  57% 
Met predefined outcome criteria for 
prophylactic gastrostomy d 
 
64  
 
93% 26  43% 
Did not meet predefined outcome 
criteria for prophylactic gastrostomy 
 
5 
 
7% 35  57% 
Abbreviations: a proPEG=prophylactic gastrostomy tube placed according to protocol. b noPEG=no 
prophylactic tube against protocol recommendation. c Tube use=use of prophylactic gastrostomy in the proPEG 
group or use of a reactive feeding tube in the noPEG group. d Met predefined outcome criteria for prophylactic 
gastrostomy = used a prophylactic gastrostomy feeding tube or reactive feeding tube or had >10% weight loss. 
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Sub analysis of the noPEG group to compare any differences between the patients that met 
the predefined outcome criteria for prophylactic gastrostomy (n=26) and those that didn’t 
(n=35), found no statistically significant differences with respect to age, sex, tumour site, 
stage, treatment or p16 status (Table 6-3). Exploratory analysis found patients who met the 
criteria for prophylactic gastrostomy had a higher incidence of T3 and T4 tumours and 
nasopharyngeal tumours. The patients that did not meet the predefined outcome criteria for 
prophylactic gastrostomy had more unknown primary tumours, and more adjuvant rather 
than definitive chemoradiotherapy.  
Comparison of outcomes within the proPEG group to compare any differences between the 
patients that met the predefined outcome criteria for prophylactic gastrostomy (n=64) and 
the five patients that didn’t, found definitive chemoradiotherapy compared to adjuvant 
chemoradiotherapy (p=0.04) was associated with meeting the criteria, however analysis in 
this group was limited due to a small sample size of only five patients not meeting the criteria. 
Admission outcomes 
Approximately 50% of patients in each group were affected by an unplanned admission 
(p=0.877). Weight loss was the only other variable found to be associated with unplanned 
admissions for inclusion in multivariate analysis (p=0.110) and entered into the model with 
the differences between the groups (see Table 6-1 for variables with p<0.2) to give a final 
model with AIC=187. Logistic regression found no association with group and unplanned 
admissions (odds ratio (OR) 1.12, 95% CI [0.5, 2.6], p=0.803) or indeed any other 
independent predictors in the model.  
There were 25% in each group affected by a LOS greater than seven days (p=0.995). 
Weight loss and N stage were the only other variables found to be associated with LOS for 
inclusion in multivariate analysis (p=0.050 and p=0.191 respectively) and were entered into 
the model with the baseline differences between the groups as before (see Table 6-1 for 
variables with p<0.2) to give a final AIC=154. Logistic regression found no association with 
group and LOS (OR 0.91, 95% CI [0.3, 2.6], p=0.859), however less weight loss had a 
reduced odds of a LOS greater than seven days and this was statistically significant (OR 
0.91, 95% CI [0.8-1.0], p=0.036)
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Table 6-3: Summary of characteristics of patients with head and neck cancer 
receiving chemoradiotherapy who did not receive a prophylactic gastrostomy as per 
protocol according to their final actual tube feeding and weight loss outcomes  
Patient 
Characteristics 
Met predefined outcome 
criteria for prophylactic 
gastrostomy a 
(n=26) 
Did not meet predefined 
outcome criteria for 
prophylactic gastrostomy 
(n=35) 
P value b 
n (%) 
Age (years)  
Mean ± SD 
Median (range) 
 
58.0 ± 11.2 
59 (37-81) 
 
59.2 ± 8.1 
59 (38-74) 
P=0.64  
Sex c P=1  
Male 22 85% 30 86%  
Female 4 15% 5 14%  
Tumor Site d P=0.77  
Oral cavity 4 15% 3 9%  
Oropharynx 18 69% 23 66%  
Nasopharynx 3 12% 0 0%  
Hypopharynx 0 0% 2 6%  
Unknown primary 1 4% 7 20%  
Tumor Classification e  P=0.39  
T0 1 4% 7 20%  
T1 6 23% 8 23%  
T2 9 35% 11 31%  
T3 5 19% 6 17%  
T4 5 19% 3 9%  
Nodal Classification f P=0.84  
N0 3 12% 2 6%  
N1 1 4% 0 0%  
N2a 2 8% 4 11%  
N2b 14 54% 20 57%  
N2c 5 19% 6 17%  
N3 1 4% 3 9%  
Treatment c P=0.49  
ChemoRT g 23 88% 28 80%  
Surgery & ChemoRT g 3 12% 7 20%  
p16 Status h P=0.25  
Positive 16 67% 28 80%  
Negative 8 33% 7 20%  
Abbreviations: a Met predefined outcome criteria for prophylactic gastrostomy = used a prophylactic 
gastrostomy feeding tube or reactive feeding tube or had >10% weight loss. b Continuous variables analysed 
using T tests and categorical variables analysed using Chi Square (unless stated otherwise) with statistical 
significance set at p<0.05. c Analysed using Fishers Exact test. d Tumor site analysed as following categories 
= Oropharyngeal vs all others. e Tumor classification analysed as following categories = T0/T1 vs T2 vs T3/T4. 
f Nodal classification analysed as following categories = N0/N1/N2a vs N2b vs N2c/N3. g 
ChemoRT=chemoradiotherapy. h p16 = immunohistological marker of human papillomavirus-related tumors. 
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Figure 6-2: Reasons for unplanned nutrition related admissions in patients with head 
and neck cancer receiving chemoradiotherapy – a comparison between patients with 
a prophylactic gastrostomy (proPEG) and those managed reactively (noPEG) 
Nutrition-related unplanned admissions were significantly higher in the noPEG group (91% 
vs 65%, p=0.0008). The reasons for unplanned admissions are summarized in Figure 6-2. 
While gastrostomy complications accounted for 15% of unplanned admissions, mainly due 
to prolonged admission post insertion for pain management, 9% of unplanned admissions 
in the noPEG group was for insertion and management of a nasogastric tube, and this was 
not statistically different. There was no procedure-related mortality in this cohort. The 
proportion of unplanned admissions during treatment (82% vs 74%, p=0.006) and post-
treatment (40% vs 24%, p=0.006) was significantly higher in the noPEG group. The mean 
LOS per unplanned admission event was lower in the proPEG group (4.2 + 5.1 days versus 
6.2 + 7.6 days, p=0.084). Overall the proPEG group had 106 admission events (excluding 
routine overnight admissions for insertion of gastrostomy) with total LOS of 374 days (46 
days planned and 328 days unplanned), and the noPEG group had 107 admissions with 
total LOS of 355 days (63 days planned and 292 days unplanned).  
Outcomes of patients excluded for gastrostomy placement 
Of the eight patients who were medically contraindicated for gastrostomy placement, four 
required a nasogastric tube, one had ≥10% weight loss during treatment, one had 5.5% 
weight loss, and the other two patients died during treatment. One patient did not receive a 
gastrostomy due to scheduling difficulties and lost 16.5% body weight. In total, these nine 
patients had 226 days of unplanned admissions.
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DISCUSSION 
This comparative cohort study was initiated to determine the outcomes of patients who had 
reactive nutrition management as they did not receive a prophylactic gastrostomy as per 
protocol recommendations, and compare it to those that were managed prophylactically. In 
this study, the 2.0% difference in weight loss between groups in favour of the proPEG group 
was statistically significant following multivariate analysis (p=0.04). A number of studies 
have shown similar benefits with less weight loss with a prophylactic approach (Lewis et al., 
2014; Silander et al., 2012), but others have found no difference (Kramer et al., 2014; Olson 
et al., 2013; Williams et al., 2012). Although the difference may appear small it is clinically 
significant, with a recent large prospective cohort study (n=8160) showing that even subtle 
weight loss is an independent predictor of survival (Martin et al., 2015). 
A number of studies have compared prophylactic versus reactive approaches to nutrition 
support with mixed results and outcomes, but there are limitations and variations in 
methodology. Some studies have compared prophylactic gastrostomy to reactive 
gastrostomy (Kramer et al., 2014; Olson et al., 2013), or to a reactive nasogastric tube 
(Prestwich et al., 2014) or to either type of reactive feeding tube or no feeding tube (Lewis 
et al., 2014; Silander et al., 2012; Williams et al., 2012). Many of these historical cohort 
studies are deemed to have a high degree of selection bias, as patients with most advanced 
disease or nutritional deficits are often those selected for prophylactic gastrostomy. One 
study hoped to avoid this issue by comparing approaches across two different centres, with 
one using prophylactic gastrostomy placement and the other using the reactive approach 
(Olson et al., 2013), but this also resulted in clinical differences between groups. The current 
study had hoped to avoid this problem by the use of a validated protocol for patient selection 
for gastrostomy (Brown et al., 2013b), but due to non-adherence from the healthcare team, 
a selection bias was again created with different clinical characteristics between the two 
groups. As per other authors, this study adjusted for these group differences in multivariate 
analysis, with the additional strength of also including the treating Consultant as a covariate 
to adjust for any selection bias from the medical team. Indeed this was found to be an 
important variable in the final model, although there was no impact of the treating Consultant 
per se on weight loss outcomes. As high level randomized controlled trials have been shown 
to be challenging in this population to address this question of optimal tube feeding type 
(Corry et al., 2008), this current study adds to the existing body of evidence from other 
prospective cohort trials, and therefore provides further information to assist in the decision-
making for the selection of feeding tubes for this patient population. 
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Interestingly one of the few randomized controlled trials in this field found significantly less 
weight loss at six months in the prophylactic group (11.4%) compared to the reactive group 
(13.6%), with the nadir of weight loss up to six months post-treatment (Silander et al., 2012). 
Therefore a limitation of the current study is that weight was only recorded to the end of 
treatment and so any differences beyond the end of treatment cannot be accounted for. 
Weight loss >10% during and up to 12 weeks post-treatment has been associated with 
worse quality of life outcomes (Langius et al., 2013a), and >5% weight loss during treatment 
or >7.5% weight loss up to 12 weeks post-treatment has been shown to be associated with 
worse survival outcomes (Langius et al., 2013b). In this era of chemoradiotherapy treatment 
a number of studies are reporting significant weight loss of 9-12% despite prophylactic 
gastrostomy placement (Brown et al., 2014a; Rutter et al., 2011), and so it is important to 
consider approaches to improve nutritional outcomes. A randomized controlled trial is 
currently underway to evaluate if an early nutrition intervention using the prophylactic 
gastrostomy can optimize and improve a patient’s nutrition outcome (Brown et al., 2014b).  
There are concerns that gastrostomy placement may result in feeding tube dependency and 
increased dysphagia post-treatment (Corry et al., 2008), however several studies have 
shown that prophylactic gastrostomy placement does not impact on long-term swallow 
function (Crombie et al., 2015; Prestwich et al., 2014; Silander et al., 2012). Although not 
collected specifically as part of this study, additional research is being carried out locally to 
determine swallow function and incidence of dysphagia during and post-treatment, as this 
remains an important area of research and will be reported on separately.  
In line with the findings of this study, a reduction in unplanned admissions with the 
prophylactic approach has also been reported in a number of studies (Hughes et al., 2013; 
Lewis et al., 2014; Olson et al., 2013; Rutter et al., 2011; Williams et al., 2012), although 
was not supported in the randomized controlled trial previously mentioned (Silander et al., 
2012). A strength of this study was looking at unplanned admissions for up to a month post-
treatment, however this only captured patients living in the local area (which typically 
accounts for approximately half of the patients treated at the tertiary hospital), and not those 
that may have returned home to remote, rural or regional areas, who may have had 
admissions locally. Although unplanned nutrition-related admissions were higher in the 
noPEG group it was interesting to see patients in the proPEG group were still admitted for 
a range of nutritional reasons.
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While a gastrostomy may not mitigate against an admission for additional medical 
management for nausea, vomiting or pain, it was unexpected to see admissions for poor 
appetite and intake. However patient adherence to nutrition recommendations was not 
collected as part of this study, and is likely to be a contributing factor for these type of 
admissions, as patient adherence with nutrition advice is known to have an impact on 
outcomes (Capuano et al., 2008). The higher rate of other medical admissions in the 
proPEG group was not attributable to the tube placement. These type of admissions were 
similar in each group and included medical conditions such as cellulitis, hyperglycaemia, 
chest pain, hypotension, neutropenia, non-neutropenic fevers, dyspnoea, liver failure and 
other systemic infections. 
This study has shown that a review of the current protocol to determine gastrostomy tube 
placement is required, as 57% of patients in the noPEG group, did not have significant 
weight loss or require a feeding tube as expected, and therefore it was the correct decision 
not to place a gastrostomy. Unfortunately in comparing the sub groups within this group, 
who subsequently met the criteria for prophylactic gastrostomy versus those that didn’t, no 
statistical differences were found, which is likely limited by the small sample size.  
The selection bias results from this study imply T stage and tumour site are the most 
important factors which influence decision-making. It is not known how much baseline 
nutritional status or swallowing function impacted on the team decision, or what other factors 
radiation oncologists may take into account in their decision-making e.g. radiation field size 
and dose to the pharyngeal constrictor muscles (Vlacich et al., 2014), or other social factors 
(Magnuson et al., 2013) or comorbidities (Blanchford et al., 2014). These factors will require 
further investigation to inform updates to the protocol to more accurately identify the patients 
who will benefit most from prophylactic gastrostomy placement and minimise exposure to 
unnecessary clinical risks.  
CONCLUSIONS 
This study has demonstrated improved nutritional outcomes and less unplanned nutrition-
related admissions with prophylactic gastrostomy placement in a high risk group of patients 
with head and neck cancer, compared to those who had reactive management. As 
approximately half of the high risk patients managed reactively were appropriately identified 
to not require a prophylactic gastrostomy the protocol requires further review to improve the 
specificity.  
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6.4 Chapter summary 
This chapter reported on outcomes following non-adherence to the local protocol for proPEG 
placement. A significant proportion of patients in the reactive group (protocol non-
adherence) ended up with a feeding tube or more than 10% weight loss (43%), and thus 
implied a proPEG was warranted. Conversely 57% of patients in this group actually had 
reasonably nutrition outcomes with <10% weight loss, and thus non-adherence to the 
protocol was the right decision. It is unclear whether these cases were a Consultant-initiated 
decision or a patient-initiated decision as this information could not be distinguished from 
the medical chart. Positive outcomes from a patient-led decision may have been due to 
strong motivation to maintain weight and oral intake to avoid a feeding tube. A Consultant-
led decision was likely to be based on other clinical factors beyond the current scope of the 
protocol which implies that other factors may be influencing decision-making and further 
investigation of the protocol high risk definition would be beneficial. 
In addition this chapter has provided further evidence to support that the proPEG approach 
does result in less weight loss and unplanned admissions than the reactive nutrition support 
approach. Our proPEG group had 2% less weight loss during treatment than the reactive 
group (p=0.048), and the rate of unplanned admissions overall was lower at 75% vs 82% in 
the reactive group (p=0.029). However mean weight loss during treatment is still clinically 
significant at 7-9% and further optimisation of nutrition outcomes is required.
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7.1 Chapter overview 
The findings in this chapter have been published in the BMC Nursing Open Access Journal. 
(Journal Impact Factor 0.561; Ranked 16/65 Nursing Open Access category; Quartile 1). 
Section 7.2 and 7.3 are presented in their accepted format prior to publication.  
The results from previous chapters have shown that weight loss during treatment remains 
significant despite proPEG placement. Previous research at the RBWH has also shown that 
weight loss continues post-treatment with approximately 9% weight loss by three months 
post-treatment (Brown et al., 2014a) and other studies have reported a nadir of weight loss 
at six months post-treatment at 11% (Silander et al., 2012). The aim of this chapter is to 
describe the methodology used for a novel nutrition intervention approach which aims to 
improve nutrition outcomes in patients receiving a proPEG. This study forms the main phase 
of the research for this thesis. 
This protocol has been presented at the following conference: Clinical Oncological Society 
of Australia 39th Annual Scientific Meeting, Brisbane, Australia, 2012 (Appendix C – 11.3.8). 
Date submitted: 05/05/2013 
Date accepted: 26/06/2014 
Citation: Brown, T., Banks, M., Hughes, B., Kenny, L., Lin, C., Bauer, J. (2014). Protocol 
for a randomized comparison of early prophylactic feeding via gastrostomy versus standard 
care in high risk patients with head and neck cancer. BMC Nursing, 13, 17. 
doi:10.1186/1472-6955-13-17 
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7.2  Abstract 
Background: Patients with head and neck cancer are at high risk of malnutrition and 
dysphagia. Enteral tube feeding via a gastrostomy or nasogastric tube is often required in 
response to dysphagia, odynophagia or other side effects of treatment that lead to 
dehydration and/or weight-loss during or after cancer treatment. A recent systematic review 
concluded that the optimal method of tube feeding remains unclear; however prophylactic 
placement of a gastrostomy, in anticipation of its use during and after treatment, is common 
practice. A number of benefits have been demonstrated with a prophylactic gastrostomy 
tube; however the majority of these studies have been undertaken in patients receiving 
radiotherapy alone. More recent studies in patient populations receiving concurrent 
chemoradiotherapy are showing that despite prophylactic gastrostomy placement significant 
weight loss still occurs, placing the patient at risk of the consequences of malnutrition. 
Therefore we set out to investigate innovative prophylactic nutrition support via the 
gastrostomy to optimise the nutritional outcomes of patients with head and neck cancer.  
Methods/design: Patients with head and neck cancer will be eligible for this single centre 
randomised controlled trial if they are identified for referral for a prophylactic gastrostomy 
using local guidelines. Patients will be excluded if they are: under the age of eighteen; 
pregnant; unable to give informed consent; or severely malnourished or moderately 
malnourished with significant dysphagia requiring a liquid or puree diet. All eligible patients 
who consent for the study will be allocated randomly to either the intervention or control 
group (usual care). The intervention group will commence prophylactic supplementary 
nutrition support via the gastrostomy immediately following placement compared to usual 
care where nutrition support is commenced via the gastrostomy when clinically indicated 
during treatment. Key outcome measures will be percentage weight loss, body composition, 
nutritional status and quality of life, measured at baseline and three months post-treatment.  
Discussion: To our knowledge this is the first study to evaluate the effectiveness of early 
prophylactic tube feeding compared to commencement of feeding during treatment, as per 
current standard practice, in patients undergoing prophylactic gastrostomy prior to treatment 
for head and neck cancer.  
Trial registration: Trial has been registered in the Australian New Zealand Clinical Trials 
registry as ACTRN12612000579897. 
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7.3  Manuscript 
BACKGROUND 
Patients with head and neck cancer are at high risk of malnutrition and dysphagia. Evidence-
based guidelines are available to provide optimal nutrition care to this patient group 
throughout the treatment trajectory (Brown et al., 2013a). There is good evidence to support 
the role of dietetic counselling to improve nutrition outcomes in patients with head and neck 
cancer receiving radiotherapy (Garg et al., 2010). Enteral tube feeding via a gastrostomy or 
nasogastric tube is often required in response to dysphagia, odynophagia or other side 
effects of treatment that lead to dehydration and/or weight-loss during or after cancer 
treatment. A recent systematic review concluded that the optimal method of tube feeding 
remains unclear (Nugent, Lewis, & O'Sullivan, 2010b), although this was based on only one 
eligible randomised controlled trial (RCT) comparing the use of nasogastric tubes and 
gastrostomy tubes placed when required during treatment (Corry et al., 2008). Since then a 
new RCT has been published (Sadasivan et al., 2012) which supports the use of 
gastrostomy over nasogastric tubes, however the actual timing of the tube placement in 
relation to the treatment is unclear. Two further RCTs have compared proactive to reactive 
enteral feeding approaches, and while less weight loss is seen with the proactive approach, 
the differences are not statistically significant (Salas et al., 2009; Silander et al., 2012)  
There are benefits and disadvantages to both types of enteral feeding and their timing 
(Koyfman & Adelstein, 2012). Prophylactic placement of a gastrostomy, in anticipation of its 
use during and after treatment, is common practice. Consideration must be given to the risks 
associated with the procedure of gastrostomy placement (Grant et al., 2009) and there is 
increasing concern that gastrostomy placement leads to prolonged tube dependency and 
long-term dysphagia (Corry et al., 2008; Langmore, Krisciunas, Miloro, Evans, & Cheng, 
2012; Mekhail et al., 2001). Although one additional study comparing two different centre’s 
approaches with reactive gastrostomy placement versus proactive gastrostomy placement 
found a higher rate of gastrostomy dependency in the proactive placement group at three 
months there was no difference at six or 12 months (Olson et al., 2013). The risks of 
gastrostomy placement are often outweighed by the number of benefits that have been 
demonstrated with a prophylactic gastrostomy tube with, earlier commencement of nutrition 
support (Scolapio et al., 2001), reduced weight loss (Beaver et al., 2001; Tyldesley et al., 
1996), improved quality of life (Fietkau, Iro, Sailer, & Sauer, 1991; Salas et al., 2009; Senft 
et al., 1993), and reduced admissions and healthcare costs (Hughes et al., 2013; Lee et al., 
1998; Piquet et al., 2002). 
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Of note the majority of these studies have been undertaken in patients receiving 
radiotherapy alone. As concurrent chemoradiotherapy is the generally accepted non-
surgical standard of care for many of these patients, the additional toxicities associated with 
this dual modality treatment place the patient at greater nutritional risk. More recent studies 
are showing that despite prophylactic gastrostomy placement significant weight loss still 
occurs (Li et al., 2009; Rutter et al., 2011; Silander et al., 2012), placing the patient at risk 
of the consequences of malnutrition.  
One large study of patients receiving chemoradiotherapy which compared reactive (n=279) 
and proactive (n=166) gastrostomy placement reported no difference in weight loss 
outcomes between the two groups but the proportion of patients with weight loss >10% at 
the end of treatment was 37-42%, and by 12 months post-treatment is was 42-53% (Olson 
et al., 2013). A separate study utilising a reactive feeding approach with nasogastric tubes 
also reported a mean weight loss of 10.4% during treatment, with a weight loss of >10% 
affecting over half of their patients (54%) (Clavel et al., 2011).  
Similar to the literature, our current clinical practice guidelines with prophylactic gastrostomy 
tubes (Brown et al., 2013b), whilst effective in reducing unplanned hospital admissions and 
length of stay (Hughes et al., 2013), did not appear to be effective in achieving positive 
nutrition outcomes (Brown et al., 2014a). We have hypothesised from clinical observation 
that this may be due to: poor tolerance to nutrition support during treatment due to the side 
effects; difficulties adhering to nutrition recommendations secondary to other barriers such 
as time, finance or fatigue; increased nutritional requirements during treatment; and/or 
reluctance of patients to engage with utilising the tube for nutrition support. Therefore it was 
hypothesised as to whether earlier nutrition intervention can improve these patient’s 
nutritional outcomes. 
The majority of studies published in the literature utilising prophylactic gastrostomy tubes 
generally commence nutrition support when clinically indicated in response to deterioration 
in swallowing or nutritional status (Nugent et al., 2010a; Raykher et al., 2009; Scolapio et 
al., 2001). Some studies have reported on commencement of enteral feeds prior to 
treatment (Beer et al., 2005; Marcy et al., 2000; Nguyen et al., 2006; Wiggenraad et al., 
2007) however these study designs are quite different to our proposal, with their patients 
often having a poor nutritional status or dysphagia at baseline therefore requiring immediate 
or therapeutic nutrition support, in comparison to our target population being primarily well-
nourished with minimal dysphagia.  
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Whilst this innovative pre-treatment nutrition intervention strategy of prophylactic feeding 
may not address all our concerns or barriers experienced with current practice with 
gastrostomy feeding, the intervention is intended to particularly aid the psychological 
aspects. Anecdotally in practice, we have seen that patients who have a gastrostomy placed 
for surgery and then require nutrition support again during radiotherapy, appear to be better 
adapted to the tube, than patients who have had the tube placed for definitive 
chemoradiotherapy. This observation was supported by recent studies in the literature 
where Salas et al. (2009) reported a negative physical effect of the gastrostomy just after 
the beginning of treatment, but also a positive mental effect over time as patients became 
used to the tube (Salas et al., 2009). Merrick& Farrell (2012) also recently explored patient 
experiences with a gastrostomy tube through a qualitative study design, and three themes 
were found (Merrick & Farrell, 2012). The majority of patients demonstrated “constructive 
cognitive appraisal” whereby they positively adapted to the tube and accepted tube feeding. 
However some patients were described as displaying “cognitive affective dissonance”, 
whereby although they experienced no physical concerns with the tube, there was a 
negative mental reaction to the tube. Smaller numbers of patients were found to have 
“emotion focused appraisal” so while accepting the necessity of the tube, there was a lot of 
anxiety and fear. Therefore part of the rationale for this current study design is to also assist 
patients with adapting to their tube by commencement of earlier tube feeding, so that when 
tube feeding becomes absolutely necessary during treatment, there is less anxiety and it 
becomes easier to adapt to and manage. 
This study aims to compare the outcomes of early prophylactic tube feeding compared to 
commencement of feeding during treatment, as per current standard practice, in patients 
undergoing prophylactic gastrostomy prior to treatment for head and neck cancer. The 
research will directly inform future clinical practice and will provide more evidence on the 
role of pre-treatment nutrition support in this patient population. 
 METHODS/DESIGN 
Study design and setting 
This study is a single centre randomised controlled trial. Recruitment will be from patients 
attending the Combined Head and Neck Clinic at the Royal Brisbane and Women’s Hospital, 
a tertiary hospital for cancer care services in Queensland, Australia.  
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The study has been approved by the Royal Brisbane and Women’s Hospital Human 
Research Ethics Committee on 19th July 2012 (HREC/12/QRBW/162) and The University of 
Queensland Medical Research Ethics Committee on 8th August 2012 (2012000890). 
Participants and recruitment 
Patients will be eligible for the study if they are identified as high risk patients and referred 
for a prophylactic gastrostomy as per the Royal Brisbane and Women’s Hospital Swallowing 
and Nutrition Management Guidelines for Patients with Head and Neck Cancer (Brown et 
al., 2013b). A patient would be deemed high risk at the multidisciplinary combined head and 
neck clinic if they meet the following criteria: oral cavity or oropharyngeal cancer receiving 
bilateral chemoradiotherapy; nasopharyngeal or hypopharyngeal cancer receiving 
chemoradiotherapy; or an unknown primary tumour receiving chemoradiotherapy; or if they 
have severe malnutrition. The final decision of tube placement is made by the treating team. 
Patients will be excluded if they: are under the age of eighteen; are pregnant; have cognitive 
impairment, an intellectual disability or a mental illness; or are receiving non-curative intent 
treatment.  
Patients meeting these criteria will be identified by a member of the treating team (radiation 
oncologist, medical oncologist or surgeon) who will discuss the study and provide a copy of 
the Patient Information and Consent Form if they are interested. The research dietitian 
(author TB) will be notified of these patients and a follow-up telephone call will be made to 
provide full details of the study and to answer any patient questions. If the patient wishes to 
enrol the research dietitian will assess the patient when they attend for their gastrostomy 
procedure to complete eligibility criteria. A full nutritional assessment will be undertaken 
using the Patient Generated Subjective Global Assessment (PG-SGA) tool (Bauer et al., 
2002). This is a validated tool recommended to assess nutritional status in patients with 
cancer (Isenring et al., 2013), and encompasses assessment of weight history, dietary 
intake, nutrition impact symptoms, function/activity, and physical assessment of muscle/fat 
stores. The tool provides a subjective global assessment (SGA) rating of well-nourished 
(SGA A), moderate malnutrition (SGA B) or severe malnutrition (SGA C). A numerical score 
is also generated indicating the level of nutritional risk. A score >9 indicates a referral to the 
dietitian for management. Patients will be excluded if they are found to have either: severe 
malnutrition or moderate malnutrition with significant dysphagia requiring a liquid or puree 
texture modified diet. Remaining eligible patients will provide written consent and baseline 
data will be collected. 
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Interventions 
All eligible patients who consent for the study will be allocated randomly to either the 
intervention or control group (usual care). All patients will receive education from the dietitian 
and nursing staff on the care of their gastrostomy tube pre-treatment and will receive joint 
dietetic and speech pathology review on a weekly basis during treatment.  
In the hospital’s usual care, patients will commence enteral nutrition via their prophylactic 
gastrostomy when required during treatment following assessment by the clinical dietitian. 
Indicators for commencing enteral nutrition are: oral intake less than 60% of estimated 
energy requirements (based on 125-145kJ/kg) for a period of or anticipated to be, greater 
than 10 days; or the patient is unable to maintain weight; or the patient requires significant 
texture modification of diet; or the patient has increased or uncontrolled nutrition impact 
symptoms. The regimen will be determined by the clinical dietitian to suit the patients’ 
individual requirements and adapted as required during treatment. All patients are 
encouraged to maintain oral intake as much as possible during treatment and as long as it 
remains safe to do so as advised by the speech pathologist.  
The intervention group will commence prophylactic nutritional support via their gastrostomy 
at the time of tube placement (pre-treatment) in addition to their current oral intake. The 
supplementary enteral nutrition will consist of a 200ml bolus feed (1.5kcal/ml polymeric 
formula) to be administered twice a day between meal times, and will continue until 
completion of treatment. The enteral nutrition products for this intervention will be provided 
to the patient by the Department of Nutrition and Dietetics. Adherence will be monitored by 
the patient completing a self-reporting diary and verified by the clinical dietitian. If during 
treatment the patient displays any of the clinical indicators described above in usual care, 
the enteral feeding regimen will be increased by the clinical dietitian to suit the patients’ 
individual requirements.  
All patients will be referred to their local dietitian service on completion of treatment for 
ongoing care as required. The research dietitian will provide monthly telephone review with 
all patients to determine ongoing use of the gastrostomy tube for a maximum of six months 
post-treatment.
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Objectives 
The aim of this study in patients undergoing prophylactic gastrostomy prior to treatment for 
head and neck cancer is to compare the nutritional, clinical and patient outcomes following 
an early prophylactic tube feeding approach versus our standard care of commencing tube 
feeding via the prophylactic gastrostomy as required. It is anticipated that the intervention 
group will have improved nutritional outcomes, which in turn is expected to improve patient 
outcomes, such as quality of life, and clinical outcomes, due to the earlier commencement 
of nutritional support. The null hypothesis is that there is no difference in the outcomes 
between the two groups. 
Outcomes 
The primary endpoint is percentage weight change from baseline (pre-treatment) to three 
months post-treatment. Secondary endpoints will also be measured at baseline and three 
months post completion of treatment and include: nutritional status using the Patient-
Generated Subjective Global Assessment tool (PG-SGA), body composition using 
Bioelectrical Impedance Analysis (BIA), and quality of life using the European Organisation 
for Research and Treatment of Cancer (EORTC) tools. The questionnaires to be used 
include the quality of life of cancer patients (EORTC QLQ-C30) and the module for head 
and neck (EORTC QLQ-H&N35). Additional qualitative data will be collected through the 
patient diary to assess adherence to the intervention. If patients are unable to meet the 
recommended goal intake, the reason why will be recorded by the patient e.g. nausea, lack 
of time, too tired etc. Tertiary endpoints will include: tolerance to chemotherapy and 
radiotherapy (dose received, changes to treatment, interruptions); unplanned hospital 
admissions; gastrostomy complications; and treatment response. Follow-up to assess 
gastrostomy use (duration and degree of tube use post-treatment) will occur monthly for six 
months post-treatment or until tube is removed. If the tube is still in-situ at six months, then 
follow-up would also occur at 12 months post-treatment to assess long-term gastrostomy 
dependency. Survival will also be measured at one year and five years.  
The primary and secondary outcomes have been set at three months to ensure maximum 
follow-up and prevent attrition from the study. As the centre is a major tertiary hospital in 
Queensland which covers an area of 715 309 square miles, many patients do not receive 
ongoing follow-up at the tertiary centre, but at regional cancer centres or local health 
services.  
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In addition the aim of this study is to see whether an early nutrition intervention can minimise 
weight loss in the acute period of treatment. Other studies have shown the nadir of weight 
loss occurs around this time point (Brown et al., 2014a; Paccagnella et al., 2010), and 
looking at weight outcomes beyond this time point can be impacted upon by so many other 
variables such as the effect of recurrent disease or a change in the nutrition management 
goals from weight maintenance during treatment to achieving a healthy weight through 
lifestyle and dietary changes as recommended for cancer survivorship. Therefore the aim of 
this study was to investigate the effect of an early nutrition intervention on minimising this 
nadir of weight loss.  
To enhance the quality of the measurements and to reduce any inter-rater variability in 
assessment the data will be collected by the designated research dietitian. The research 
dietitian is responsible for recruitment and data collection only, and is not providing any 
dietetic patient care. 
Adverse Events 
A data monitoring committee will meet quarterly to review and collate serious adverse 
events. Any serious adverse events resulting from the study intervention will be reported to 
the RBWH Human Research and Ethical Committee as per standard procedures, and would 
be appropriately managed by the medical team to minimise or eliminate the effect of the 
adverse event on the patient. 
Intervention Team Roles 
The study intervention team consists of: one research dietitian (author TB) who is 
responsible for the recruitment and outcome assessments at baseline and follow-up, and a 
second research dietitian (author MB) who is responsible for the randomisation process. 
The dietetic care is provided by two different treating clinicians (not blinded): one is allocated 
to the care of the standard arm; the second is allocated to the care of the intervention arm. 
This is to prevent any cross contamination between the cares given in each arm of the study. 
The multidisciplinary treatment team is also notified of the randomisation outcome so that 
there is reinforcement of the nutrition protocol from all professions involved in the patient 
care. The research dietitians are not involved in the clinical care of the patient. The research 
dietitian responsible for recruitment and outcome assessment is blinded to the 
randomisation sequence but not to the randomisation outcome, as they also provide support 
and encouragement to the intervention group to maximise adherence to the protocol. 
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Sample size 
The primary outcome in this study is a continuous response variable (% weight loss) from 
independent control and intervention patients, which have been randomised in a ratio 1:1. 
In a previous study we have found high risk patients recommended for a prophylactic 
gastrostomy (i.e. the target population for this RCT) to experience a mean 9% weight loss 
at three months post-treatment with standard deviation 9.4 (Brown et al., 2014a). The aim 
of this intervention is to reduce this weight loss; however there are no other studies which 
have investigated the impact of prophylactic enteral tube feeding on which we can draw an 
anticipated response for this study for the sample size calculation. Ideally the goal for the 
intervention group is a mean weight loss of <5% as this is not deemed to be clinically 
significant, and thus a positive nutrition outcome. Therefore to detect a 5% true difference 
in % weight loss between the intervention and control groups, 56 patients in each group will 
be required to be able to reject the null hypothesis that the population means of the 
intervention and control groups are equal with probability (power) 0.8. The Type I error 
probability associated with this test of this null hypothesis is 0.05. Given that mortality during 
treatment is low and good follow-up at three months is expected, as patients are returning 
to the hospital for their treatment scans and appointment with the oncologist, an attrition rate 
of 10% is used. Therefore the total sample required is 123 patients (62 patients in each 
group).  
There is a study to consider, of patients receiving chemoradiotherapy, in which an early pre-
treatment nutrition intervention of dietary counselling with or without oral supplements or 
tube feeding was compared to patients without a pre-treatment nutrition assessment and 
intervention. They found a mean weight loss at three months post-treatment of 9.75% + 5.75 
in their standard care group compared to a mean weight loss of 2.77% + 7.93 (Paccagnella 
et al., 2010).  
The sample size was calculated based on this demonstrated difference of 7% and examples 
of multiple sample sizes based on varying assumptions are illustrated in Table 7-1. 
Therefore sample size could be reduced to 39 patients per arm, with an attrition rate of 10%, 
which then results in total sample size of 86 (43 patients in each group), at a power of 90%. 
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Table 7-1: Examples of sample sizes with varying assumptions (Type I Error 0.05) 
Power 
Number of patients required in each arm 
 
SD = 9.4  
(Brown et al., 2014a) 
SD = 5.34 
 (Paccagnella et al., 2010) 
 
5% difference* 
 
7% difference** 5% difference 7% difference** 
80% 
 
56 29 19 10 
90% 
 
75 39 25 13 
Abbreviations: *Difference to reach clinically significant target weight loss of <5% (as studies have shown 
weight loss of 9.3-9.75% (Brown et al., 2014a; Paccagnella et al., 2010). ** Difference seen with pre-treatment 
dietary counselling intervention (Paccagnella et al., 2010) 
 
Both of these sample sizes are deemed feasible from historical data at our institute. Each 
year approximately 500-550 patients attend the Combined Head and Neck Clinic at our 
institution. In a sample year (2010-11) 270 patients went on to have curative treatment with 
a standard referral to the dietitian. Of these; 106 patients were planned for adjuvant or 
definitive concurrent chemoradiotherapy with 88 categorised as high risk. The majority of 
these proceeded with a prophylactic gastrostomy as per the guideline recommendation 
(n=86), and nil were considered high risk due to severe malnutrition. Based on 86 eligible 
patients per year, factors such as patients not giving consent (20%) and other factors such 
as scheduling difficulties (5%) were considered, resulting in an estimated 64-65 patients per 
year (or approximately five patients per month). Therefore recruitment is anticipated to be 
achievable in two years from a single centre. 
Randomisation 
The research dietitian (author TB) will inform the clinical treating dietitian of newly recruited 
patients following consent and baseline data collection. The clinical dietitian will provide 
patient details to an independent member of the research team (author MB) for 
randomisation. The random allocation sequence is generated by computer and stratified 
according to baseline nutritional status (well-nourished versus moderate or suspected 
malnutrition). 
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Additional stratification based on tumour site or treatment was not undertaken, as the high 
risk category of the guidelines used to determine prophylactic gastrostomy placement has 
been based on these factors. As the guidelines have been found to be highly specific at 
predicting the requirement for a gastrostomy (Brown et al., 2013b) it was not deemed 
necessary that additional stratification was required. It is not possible for this study to be 
double-blinded; however the allocation sequence is concealed to the participants, their 
health care providers, and the research dietitian responsible for recruitment, as it is 
undertaken by an independent member of the research team not involved in patient care or 
data collection.  
Statistical methods 
To determine whether there are any differences between the two groups at baseline - 
participant characteristics will be summarised using mean and standard deviation for 
continuous variables and analysed using student t-tests, and categorical variables will be 
summarised using frequencies and percentages and analysed using chi-squared tests of 
association. If the data is not normally distributed and found to be skewed, then the data can 
be transformed using log transformation before applying the appropriate parametric test. If 
this is not successful, then alternative non parametric tests can be applied, such as the 
Wilcoxon-Mann-Whitney test for continuous variables.  
Analysis will be undertaken on an intention-to-treat basis. To determine the effect of the 
nutrition intervention group versus the control group (the independent categorical variable) 
on the primary outcome of % weight loss (the dependent continuous variable), analysis of 
variance (ANOVA) will be used. For the secondary outcomes, % fat free mass, PG-SGA 
score and quality of life score, the change over time from baseline to three months will be 
analysed between groups using the repeated measures ANOVA. Univariate analysis will be 
used to determine the association of any other independent variables on the outcome 
measures. Any statistically significant associations found will then be used to add each 
variable into a normal regression model to enable adjusting for any confounding effects. The 
regression model will also enable adjusting for any important clinical differences found 
between the intervention and control group at baseline. All tests will assume normal 
distribution; otherwise alternative non parametric tests will be applied for non-normal 
distributed data. Statistical significance will be set at p<0.05. For any results that are not 
statistically significant, any relevant clinically significant results will be reported.  
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Table 7-2: Comparison of key studies which report on timing of commencement of enteral feeding during treatment 
Citation Study population N Type and timing of 
tube placement  
Commencement of 
feeds (no. days after 
start of treatment) 
Outcomes 
Nugent 2010a  
 
HNC with radical 
chemoradiotherapy 
requiring tube 
feeding 
50 Prophylactic PEG 
(before start of 
treatment) n=21 
 
Late PEG (during 
treatment) n=11 
 
NG tube n=18 
 
Range: 1-33 days 
 
 
 
Range: 14-30 days 
 
 
Range: 10-34 days 
Mean weight loss: -4.6% 
 
 
 
Mean weight loss: -8.7% 
 
 
Mean weight loss: -8.5% 
Raykher 2009 
 
HNC with definitive 
or adjuvant 
chemoradiotherapy 
or radiotherapy 
requiring PEG 
163 Prophylactic PEG 
(before start of 
treatment) n=161 
 
Late PEG (during 
treatment) n=2 
 
Mean 21 days o PEG used by n=160 (98%) due to 
severe dysphagia (mean duration of 
use 251 + 317 days) 
o Treatment interruptions in 7% 
o Strictures requiring dilatation in 12% 
o BMI optimised in obese/overweight 
patients through individual regimens 
Scolapio 2001 
 
HNC with definitive 
or adjuvant 
radiotherapy 
requiring PEG 
54 Prophylactic PEG 
(before start of 
treatment) n=41 
 
Late PEG (during 
treatment) n=13 
 
Mean 10 days 
 
 
 
Mean 23 days 
Mean wt loss 2.7kg 
Nil nutrition-related admissions 
 
 
Mean wt loss 4.5kg 
Nutrition-related admissions n=4 
Abbreviations: HNC=head and neck cancer; PEG=gastrostomy; NG=nasogastric; BMI=body mass index. 
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Table 7-3: Comparison of key studies which commence enteral feeding via a prophylactic gastrostomy immediately 
Citation Study 
population 
(N) 
Study design Nutrition 
characteristics 
at baseline 
Timing of PEG tube 
placement 
Commencement 
of PEG feeds 
Oral 
intake 
Outcomes 
Marcy 2000 
 
Stage IV 
HNC treated 
with CRT and 
prophylactic 
PEG (n=50) 
Retrospective 
case series 
34% had BMI 
<20kg/m2 
Within 5 days before 
treatment (n=38) or 
within 5 days after 
treatment started 
(n=12) 
All patients 
started 48 hours 
post insertion 
 
Tube feeds were 
increased over 4 
days to provide 
goal of 2000 
kcal/day 
Unknown  Mean weight 
increase of 2.5kg 
by 3 weeks 
Beer 2005 
 
HNC with 
radical 
radiotherapy 
or CRT and 
PEG tube 
feeding 
(n=151) 
Retrospective 
comparative 
cohort 
Group A – 49% 
malnourished 
 
Group B – 47% 
malnourished 
Group A (n=78, 52%) 
early PEG: before or 
within 2 weeks of 
radiotherapy.  
 
Group B (n=73, 48%) 
delayed PEG: after 2 
weeks of 
radiotherapy. 
All patients 
started 12 hours 
post insertion 
 
Tube feeds were 
increased over 3 
days to provide 
individual goal 
Clear 
fluids 
only 
Mean weight loss 
1.03 kg Group A 
vs. 4.0 kg Group B 
(P=0.004) 
 
Radiotherapy 
interruptions (>3 
days) 10% Group 
A vs. 25% Group B 
(P=0.02) 
Wiggenraad 
2007 
 
Stage III and 
IV HNC 
treated with 
CRT and 
prophylactic 
PEG (n=50) 
Retrospective 
case series 
48% on puree 
or liquid diet 
 
78% had weight 
loss  
Mostly 1-2 weeks 
before treatment 
commenced  
(N=3 had placed >3 
weeks prior) 
26% commenced 
prior to treatment 
(tube feeding 
initiated if 
reduced food 
intake or weight 
loss) 
Unknown  Mean loss of 
weight during 
treatment 2.8% 
 
 
Abbreviations: HNC=head and neck cancer; CRT=chemoradiotherapy; PEG=gastrostomy; BMI=body mass index. 
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DISCUSSION 
This study will evaluate the effectiveness of prophylactic nutrition support via a gastrostomy 
compared to current standard practices of commencing nutrition support in a reactive way 
during treatment. To our knowledge this is the first study to trial this approach of prophylactic 
nutrition support in a formal research setting. Of those studies that report specific details on 
the actual timing of the commencement of nutrition support, all commence a number of days 
after the commencement of treatment: 1-33 days (Nugent et al., 2010a), 21 days (Raykher 
et al., 2009) and 10 days (Scolapio et al., 2001). See Table 7-2.  
The studies which have reported on the early commencement of tube feeding have quite a 
different study design and intent to our protocol (Table 7.3). Nguyen et al. (2006) stated 
criteria in their study for the initiation of enteral feeds prior to treatment being; poor oral 
intake prior to treatment, or aspiration on pre-treatment Modified Barium Swallow 
assessment (Nguyen et al., 2006). However the authors did not describe the number of 
patients in their study that met these criteria. Wiggenraad et al. (2007) reported 26% of their 
patients commenced enteral feeds prior to treatment (Wiggenraad et al., 2007), however 
this was likely in response to poor swallowing or nutritional status, with 48% of patients 
already requiring a puree or liquid diet and 78% of patients with weight loss prior to 
treatment. It was also found that when there was dysphagia at baseline, tube feeding was 
commenced earlier (day 2) compared to when there was no dysphagia at baseline (day 17).  
There have been two other studies which have looked at initiating tube feeding immediately 
following prophylactic placement (Beer et al., 2005; Marcy et al., 2000). Both of these studies 
also had a significant proportion of patients who were nutritionally compromised at baseline 
and therefore the characteristics of the patients commencing early nutrition support are likely 
to be quite different to the patient characteristics we are anticipating studying. Both also 
appear to provide the majority of nutrition via the gastrostomy tube, with minimal oral intake. 
This is a very different approach to our proposed intervention where we are providing 
supplementary nutrition via the tube and advocate patients maintain/continue with oral 
intake for as long as possible to minimise the risk of long-term dysphagia and prolonged 
rehabilitation post-treatment (Rosenthal, Lewin, & Eisbruch, 2006).  
Salas et al. (2009) reports on a randomised controlled trial on the quality of life in patients 
with a systematic gastrostomy (n=21) versus no systematic gastrostomy (n=18) (Salas et 
al., 2009). In the control group 13 patients later receive an insertion of a gastrostomy and 
the other five patients remained on oral intake alone.  
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There are no details in the methodology on the nutrition interventions provided to either 
group and the results do not include information on the actual timing of gastrostomy 
placement or the timing for the commencement of feeding. Therefore it is difficult to ascertain 
whether prophylactic nutrition support was utilized or whether it was prophylactic 
(systematic) tube placement. 
Some of the anticipated problems with this current study protocol will be patient adherence 
to recommendations. Capuano et al. (2008) have shown that patients who adhere to dietary 
recommendations have improved outcomes compared to those that do not adhere 
(Capuano et al., 2008). Therefore patients have been asked to keep a record of the number 
of feeds they have each day so that adherence can be considered as a confounding variable. 
Patients have also been asked to record any reasons why they have not had the 
recommended amount. This may be due to feeling full or bloating, or from side effects of 
treatment such as nausea, or from practical issues such as not having enough time in the 
day due to treatment schedules/appointments, being fatigued or financial difficulties to 
purchase the recommended feeds. This additional information from the study will provide 
evidence for the feasibility of implementing the early intervention into clinical practice, and 
will also assist in identifying factors that patients experience during treatment so that 
alternative strategies can be found. 
With the advent of evolving techniques using intensity-modulated radiotherapy and helical 
Tomotherapy, the dose to surrounding tissues (pharyngeal constrictor muscles) and salivary 
glands can be spared due to steeper dose gradient outside target volumes, and as a 
consequence there are less reports of long-term dysphagia and xerostomia (Kam et al., 
2007; Nutting et al., 2011; Pow et al., 2006). Therefore it is hypothesized that patients may 
be less likely to require feeding tubes. The guidelines for prophylactic gastrostomy at our 
institution were previously validated in a patient cohort receiving standard 3D conformal 
radiotherapy (Brown et al., 2013b) and so additional research is also planned to 
retrospectively re-validate these guidelines in patients now receiving helical Tomotherapy to 
see whether the requirement for a feeding tube has changed.  
However it should be noted there are a range of other reasons why patients may have an 
inadequate oral intake other than dysphagia and xerostomia. Therefore these patients are 
still susceptible to weight loss and malnutrition, and the adverse consequences. So despite 
the reduction of some side effects in this population with evolving treatments, nutrition 
support can still be indicated for other reasons.  
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Patients in this study protocol are being asked to record the main reason they are using the 
gastrostomy for nutrition support e.g. pain on swallowing (odynophagia), difficulty 
swallowing (dysphagia), painful ulcers (mucositis), difficulty chewing/dry mouth 
(xerostomia), taste changes (dysgeusia), nausea/vomiting or general poor appetite. These 
nutrition impact symptoms can all lead to a decline in nutritional status and weight loss, both 
of which have been associated with poor quality of life (Langius et al., 2013a; Ravasco, 
Monteiro-Grillo, & Camilo, 2003). 
In conclusion the results from this study will aim to address the questions regarding the 
optimal nutrition interventions required to manage patients with head and neck cancer and 
will also assist in our understanding of the impact of the new treatment regimens. Together 
this will inform future clinical practice for the nutritional management of this patient 
population to achieve positive outcomes. 
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7.4 Chapter summary 
This chapter has outlined the methodology for the proposed RCT to investigate the impact 
of an early nutrition intervention versus standard care in patients who receive a proPEG 
prior to treatment. Current standard care practice commences use of the gastrostomy tube 
when it is clinically indicated during treatment and this has resulted in clinically significant 
weight loss as previously reported. The proposed early intervention will commence patients 
using their gastrostomy immediately following placement to supplement their usual meal 
intake, and will then increase the volume of feeding as it becomes clinically necessary during 
treatment. This is the first study to investigate such an approach. The primary outcome is 
weight loss, but a number of other nutritional, patient and clinical outcome measures have 
also been included as secondary outcomes.
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8.1 Chapter overview 
This chapter summarises the results from the RCT described in the previous chapter. 
Relevant information for this trial is available in the appendices including: ethical approvals 
(Appendix D, Appendix E, and Appendix F); nutrition and quality of life (QOL) outcome 
assessment tools (Appendix G, Appendix H); and data collection tools (Appendix I). The 
findings in this chapter have been published as three manuscripts as outlined below. 
The main results from the trial, including the nutrition, patient and clinical outcomes, are 
presented in section 0 as a manuscript published in the British Journal of Cancer (Journal 
Impact Factor 5.569; Ranked 28/213; Oncology category; Quartile 1). Section 8.2.1 and 
8.2.2 are presented in their accepted format prior to publication. The results have been 
presented at two international conferences: 18th Australia and New Zealand Head and Neck 
Cancer Society ASM, Auckland, New Zealand, 2016 (Appendix C – 11.3.9) and the 10th 
International Head and Neck Cancer Quality of Life Conference, Liverpool, UK, 2016 
(Appendix C – 11.3.10). 
Date submitted: 13/12/2016 
Date accepted: 24/04/2017 
Citation: Brown, T., Banks, M., Hughes, B., Kenny, L., Lin, C., Bauer, J. (2017). 
Randomised controlled trial of early prophylactic feeding vs standard care in patients with 
head and neck cancer. Br J Cancer, 117(1), 15-24. doi:10.1038/bjc.2017.138 
The longer term results from the trial in relation to gastrostomy outcomes are presented in 
section 8.3 as a manuscript published in Oral Oncology (Journal Impact Factor 4.286; 
Ranked 52/213; Oncology category; Quartile 1). Section 8.3.1 and 8.3.2 are presented in 
their accepted format prior to publication. The results have been presented at the following 
international conference: 10th International Head and Neck Cancer Quality of Life 
Conference, Liverpool, UK, 2016 (Appendix C– 11.3.11). 
Date submitted: 08/05/2017 
Date accepted: 24/06/2017 
Citation: Brown, T., Banks, M., Hughes, B., Kenny, L., Lin, C., Bauer, J. (2017). Impact of 
prophylactic feeding on long term dependency outcomes in patients with head and neck 
cancer. Oral Oncology, 72, 17-25. doi:10.1016/j.oraloncology.2017.06.025. 
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The results on patient adherence and barriers to tube feeding are presented in section 8.4 
as a manuscript published in Oral Oncology (Journal Impact Factor 4.286; Ranked 52/213; 
Oncology category; Quartile 1). Section 8.4.1 and 8.4.2 are presented in their accepted 
format prior to publication. The results have been presented at the following conference: 
Clinical Oncological Society of Australia 43rd Annual Scientific Meeting, Gold Coast, 2016 
(Appendix C – 11.3.12).  
Date submitted: 28/02/2017 
Date accepted: 16/07/2017 
Citation: Brown, T., Banks, M., Hughes, B., Kenny, L., Lin, C., Bauer, J. (2017). Tube 
feeding during treatment for head and neck cancer - adherence and patient reported 
barriers. Oral Oncology, 72, 140-149. doi:10.1016/j.oraloncology.2017.07.017 
Finally section 8.5 provides an overall summary of the findings from this trial.
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8.2 RCT: Nutritional, patient and clinical outcomes 
8.2.1 Abstract 
Background: Weight loss remains significant in patients with head and neck cancer, despite 
prophylactic gastrostomy and intensive dietary counseling. The aim of this study was to 
improve outcomes utilising an early nutrition intervention. 
Methods: Patients with head and neck cancer at a tertiary hospital in Australia referred for 
prophylactic gastrostomy prior to curative intent treatment were eligible for this single centre 
randomised controlled trial. Exclusions included severe malnutrition or dysphagia. Patients 
were assigned following computer-generated randomisation sequence with allocation 
concealment to either intervention or standard care. The intervention group commenced 
supplementary tube feeding immediately following tube placement. Primary outcome 
measure was percentage weight loss at three months post treatment. 
Results: Recruitment completed June 2015 with 70 patients randomised to standard care 
(66 complete cases) and 61 to intervention (56 complete cases). Following intention-to-treat 
analysis, linear regression found no effect of the intervention on weight loss (10.9% + 6.6 
standard care vs 10.8% + 5.6 intervention, p=0.930) and this remained non-significant on 
multivariable analysis (p=0.624). No other differences were found for quality of life or clinical 
outcomes. No serious adverse events were reported. 
Conclusion: The early intervention did not improve outcomes but poor adherence to nutrition 
recommendations impacted on potential outcomes. 
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8.2.2 Manuscript 
INTRODUCTION 
Treatments for head and neck cancer (HNSCC) including surgery, radiotherapy and 
chemotherapy have a number of side effects which can impact on nutritional intake (Talwar 
& Findlay, 2012), with multi-modality therapy having higher toxicity (Moroney et al., 2017). 
As a consequence many patients experience significant weight loss and develop 
malnutrition during the course of treatment (Hebuterne et al., 2014). This is associated with 
a number of detrimental outcomes including reduced physical functioning, quality of life, and 
immune function, and increased treatment interruptions, toxicities, hospital admissions, and 
mortality (Gorenc, Kozjek, & Strojan, 2015). Critical weight loss of 5% or more during 
treatment has been associated with worse survival outcomes (Langius et al., 2013a) 
demonstrating the importance of optimal nutrition to minimise weight loss. Improvements in 
nutritional status have also been linked to improved aspects of quality of life (Isenring et al., 
2004, Ravasco et al., 2004).  
A number of systematic reviews have recommended the importance of dietary counselling 
to improve nutritional and patient outcomes (Langius et al., 2013c, Garg et al., 2010), 
however the role of tube feeding remains unclear due to a lack of well-designed clinical trials 
to inform optimal tube type and timing of placement (Nugent et al., 2013, Wang et al., 2014a, 
Orphanidou et al., 2011). A recent meta-analyses comparing outcomes with nasogastric 
tubes and either prophylactic or reactive gastrostomy tubes, found the prophylactic tubes 
resulted in a reduction in treatment interruptions and nutrition related hospital admissions, 
but had no superiority in managing nutritional status (Zhang et al., 2016). Either way, 
clinically significant weight loss of greater than 10% occurs with either the prophylactic or 
reactive approach (Silander et al., 2012, Chang et al., 2009, Rutter et al., 2011, Clavel et 
al., 2011, Olson et al., 2013).  
Of those studies that report specific details on the actual timing of the commencement of 
nutrition support through the prophylactic gastrostomy, the majority are after the 
commencement of treatment when it becomes clinically indicated in response to 
deterioration in swallowing or nutritional status (Nugent et al., 2010a, Raykher et al., 2009, 
Scolapio et al., 2001). Hence it is not surprising that there are similar nutrition outcomes with 
reactive tube use; as although the prophylactic tube is in situ and ready for access, the 
initiation and indication for nutrition support is reactive in both groups. 
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Some studies have reported the commencement of enteral feeds prior to treatment (Nguyen 
et al., 2006, Wiggenraad et al., 2007, Marcy et al., 2000, Beer et al., 2005) but these patients 
had poor nutritional status or dysphagia at baseline and therefore nutrition support was 
clinically indicated immediately.  
This is the first study to our knowledge to trial an early prophylactic tube feeding intervention 
prior to treatment in a target population who are primarily well-nourished with minimal 
dysphagia. This group may be considered to have low motivation to use their tube as there 
is no current obvious problem with eating, but despite good baseline nutritional and 
swallowing status, these patient have still been shown to have high rates of tube feeding 
and weight loss during treatment (Brown et al., 2015). The validation of the protocol used at 
our institute to identify patients for prophylactic gastrostomy also supports this finding 
(Brown et al., 2016b). The criteria used in this protocol are primarily based on tumour site 
and treatment, and so the majority of patients selected are those receiving 
chemoradiotherapy for unresectable tumours or as organ-preserving treatment. By 
increasing nutritional intake through prophylactic supplementary tube feeding it was 
assumed this would assist in reducing weight loss. The additional rational for this 
interventional approach was based on the psychological impact of gastrostomy tube 
placement, including anxiety and fear associated with tube use (Salas et al., 2009, Merrick 
& Farrell, 2012). Therefore this period of early tube feeding could assist patients to adapt to 
the tube more easily. 
The aim of this study is to compare nutritional, clinical and patient outcomes following an 
early tube feeding approach via the prophylactic gastrostomy versus standard care of 
commencing tube feeding via the prophylactic gastrostomy when clinically indicated. The 
null hypothesis being no difference in the outcomes between the two groups. It is anticipated 
that the intervention group will have improved nutritional outcomes, according to an 
established nutrition framework, which in turn is expected to improve patient outcomes, such 
as quality of life, and other clinical outcomes (Splett, 1996). 
MATERIALS AND METHODS 
This was a single centre randomised controlled trial conducted in Queensland, Australia. 
The full protocol is published (Brown et al., 2014b). The study design was a parallel group 
study using equal randomisation (1:1). No changes occurred to the study design or outcome 
measures following commencement.
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Participants and Study Setting 
Patients with HNSCC were eligible for the study if referred for a prophylactic gastrostomy 
prior to treatment. A local protocol was used by the multidisciplinary clinic to identify high 
nutrition risk patients suitable for prophylactic gastrostomy (Brown et al., 2016b), however 
the final decision of tube placement was made by the treating team. Excluded patients 
included; age < 18; pregnant; cognitively impaired or with an intellectual disability or mental 
illness; planned for non-curative intent treatment; or if diagnosed as severely or moderately 
malnourished with significant dysphagia requiring a liquid or puree texture modified diet.  
The study was approved by the Royal Brisbane and Women’s Hospital Human Research 
Ethics Committee on 19th July 2012 (HREC/12/QRBW/162) and The University of 
Queensland Medical Research Ethics Committee on 8th August 2012 (2012000890). All 
patients provided written informed consent to participate. This trial has been registered in 
the Australian New Zealand Clinical Trials registry as ACTRN12612000579897. Available 
at http://www.anzctr.org.au.  
Patients were recruited from the Royal Brisbane and Women’s Hospital from September 
2012 to June 2015. This is a major tertiary/quaternary hospital providing specialist cancer 
care services to patients throughout Queensland, Australia. All patients see the dietitian and 
speech pathologist as part of routine care, with access to other allied health services as 
required. 
Dependent on the patient’s home address and local health service district location, follow 
up care post treatment may continue at the tertiary centre or be transferred to a regional 
cancer centre. Level of allied health services and thus access to follow up care at each 
regional centre may vary, particularly for patients from rural or remote areas. 
Interventions 
All patients received education on the care of their feeding tube during their overnight 
elective admission for gastrostomy placement. Prior to discharge patients were randomly 
allocated to either the standard care or intervention arm and booked into the joint dietitian 
and speech pathology clinic for weekly review during treatment.
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In the standard care arm, patients were commenced on enteral nutrition via their 
prophylactic gastrostomy by the dietitian when indicated. Indicators included: oral intake less 
than 60% of estimated energy requirements (based on 125-145kJ/kg) for a period of, or 
anticipated to be, greater than 10 days; the patient was unable to maintain weight; the patient 
required significant texture modification of diet; or the patient had increased or uncontrolled 
nutrition impact symptoms. The regimen was determined by the clinical dietitian to suit the 
patients’ individual requirements and adapted as required during treatment.  
For patients in the intervention group, this meant initiation of enteral nutrition via their 
prophylactic gastrostomy immediately following tube placement prior to commencement of 
treatment. The prophylactic enteral nutrition was in addition to their current oral intake and 
consisted of 2x 200ml bolus feeds (1.5kcal/ml polymeric formula with fibre) per day. Patients 
were provided with weekly supplies and were given guidance and suggestions on how to 
incorporate the enteral feeding into their daily routine (e.g. behavioural strategies and 
reminders; appropriate timings for administration, such as between meals). This enteral 
nutrition recommendation was continued until completion of treatment, and was increased 
as necessary during treatment if the patient had any of the clinical indicators for starting 
enteral nutrition as described in standard care. If patients required an increase in enteral 
nutrition they were converted to a home enteral nutrition prescription and were required to 
pay a co-payment for the product as per standard care. If patients described enteral feed 
intolerance, an alternative non-fibre formula was trialled. 
To monitor adherence, patients in both arms were asked to maintain a self-reporting diary 
of their daily prescribed enteral nutrition intake, and any barriers to this prescription. These 
were verified by the clinical dietitian on weekly review. Overall adherence was defined as 
achieving >75% of prescribed enteral nutrition intake (Hubbard, Elia, Holdoway, & Stratton, 
2012). All patients were encouraged to maintain oral intake as much as possible during 
treatment and as long as it remained safe to do so as per the speech pathologist. On 
completion of treatment all patients were referred to their local dietitian service for ongoing 
care as required. 
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Outcomes 
The primary endpoint was percentage weight change with additional nutrition outcomes 
including body composition (fat mass and fat free mass) and nutritional status. Weight and 
body fat percentage were measured on digital Bioelectrical Impedance Analysis (BIA) scales 
(Tanita Body Composition Monitor BC-582, Manufacturer Tanita Corporation, Japan) at 
recruitment (baseline) and three months post treatment. Patients were asked to remove 
shoes, socks and outer clothing and to empty their pockets. Nutritional status was assessed 
by the Patient-Generated Subjective Global Assessment tool (PGSGA) (Bauer et al., 2002), 
a validated tool recommended to assess nutritional status in patients with cancer (Isenring 
et al., 2013).  
The secondary endpoint was quality of life, which was assessed using the European 
Organisation for Research and Treatment of Cancer (EORTC) tools (Aaronson et al., 1993). 
The questionnaires included the quality of life of cancer patients (EORTC QLQ-C30) and 
the module for head and neck (EORTC QLQ-H&N35). The raw data was transformed into 
scores ranging from 0-100, following established procedures (Fayers et al., 2001). A higher 
score for global quality of life and functioning scales was indicative of higher quality of life 
and function. A higher score for symptom scales was indicative of a higher level of symptom 
burden. Guidelines for interpretation of longitudinal changes in quality of life scores for 
EORTC QLQ-C30 were used to determine clinical impact (Cocks et al., 2012) and these 
were graded as either an improvement or deterioration, with trivial, small, medium or large 
clinical effect. 
Tertiary endpoints included tolerance to chemotherapy and radiotherapy, rate of unplanned 
hospital admissions and gastrostomy complications. Dose of chemotherapy and 
radiotherapy received were recorded. Delays to radiotherapy were recorded as days beyond 
expected finish date and a prolonged treatment time was defined as those greater than 
seven days. Completion of planned chemotherapy was defined as either completion of three 
cycles of high dose cisplatin, seven cycles of weekly cisplatin or eight cycles of cetuximab. 
Completion of target dose was defined as >200mg/m2 cisplatin or > six cycles of cetuximab. 
Reasons for changes to chemotherapy were coded as toxicities (gastrointestinal, 
haematological, renal, or other). 
Unplanned hospital admissions and length of stay were prospectively recorded during 
treatment and classified as either a medical admission, or management of gastrostomy 
complications or management of nutrition impact symptoms. 
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Gastrostomy complications were recorded during the first three months post insertion. Major 
complications were defined as those requiring hospital admission. Minor complications were 
defined as site infections or other stoma issues such as hypergranulation, excoriation, 
erythema, pressure injury or leakage. Monthly follow up was completed via the telephone to 
assess gastrostomy use and date of removal for up to six months post treatment. If the tube 
was still in-situ at six months, then follow up was repeated at 12 months. Day of gastrostomy 
removal was recorded in relation to the day of treatment completion. 
Treatment response was assessed via the three month post treatment PET/CT scan and 
defined as either complete metabolic response, or persistent disease requiring salvage 
surgery or persistent disease requiring palliative care. Survival outcomes were assessed at 
12 months post treatment and time (in months) to disease relapse and/or death were 
recorded. 
To enhance the quality of the measurements and to reduce any inter-rater variability in 
assessment the data was collected by the designated research dietitian. If patients failed to 
attend their follow up appointment, quality of life data were obtained by telephone interview 
and/or completion of postal surveys, and weight and PGSGA data were obtained following 
face to face assessment by the local dietitian. 
Sample Size 
The primary outcome for the study was a continuous response variable of percentage weight 
loss. The aim was to reduce the absolute amount of percentage weight loss by 5% in the 
intervention group compared to the percentage weight loss seen in the standard care group. 
A sample size of 123 patients was required to detect a 5% difference in percentage weight 
loss between the intervention and control groups, with a two sided 5% significance level, 
power of 80% and an attrition factor of 10%. Recruitment continued until sample size was 
attained. 
Randomisation 
Patients were stratified according to baseline nutritional status (well nourished (PGSGA A) 
versus moderate/suspected malnutrition (PGSGA B)), and then randomly assigned to one 
of two groups (with an allocation ratio 1:1) following simple randomisation procedures. The 
randomisation sequence was computer generated using MS Excel. This allocation 
sequence was concealed to the researcher enrolling participants but the participants, 
healthcare team or outcome assessor were not able to be blinded to the allocation.
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Statistical Methods 
Baseline participant characteristics were summarised using mean and standard deviation 
for continuous variables and frequency and percentage for categorical variables. 
Differences between groups were assessed using Chi-squared tests for categorical 
variables (or Fishers Exact test if assumptions could not be met due to small expected cell 
counts) and two sample t –tests for continuous variables (or two sample Wilcoxon tests if 
assumptions could not be met for normally distributed data and homogeneity of variance). 
Normal distribution was formally assessed using Shapiro-Wilk test and variance assessed 
using Levene’s test. Analysis was performed on an intention to treat basis. To determine the 
effect of the nutrition intervention group versus the control group (the independent 
categorical variable) on the primary outcome of % weight loss (the dependent continuous 
variable), analysis of variance (ANOVA) was used. For the secondary outcomes (% fat free 
mass, % fat mass, PGSGA score and quality of life scores), the mean change over time 
from baseline to three months was also analysed between groups using ANOVA. Bivariate 
analysis determined the association of any other independent variables on the outcome 
measures. Any variables with statistically significant associations (p<0.1) were entered into 
a linear regression model (or logistic regression for any binary outcome variables). Any 
variables with baseline differences between groups were also added into the model as 
covariates to adjust for any confounding effects. Final variable selection for each 
multivariable model used Akaike’s Information Criteria (AIC) with a backward stepwise 
algorithm. The final models reported were those with the smallest objective AIC. Time to 
event outcomes (gastrostomy removal, disease relapse, death) were analysed using the 
Kaplan Meier method with the log rank test. Statistical significance was set at p<0.05. Data 
were analysed using R Commander Version 2.1-7 and R version 3.1.3 (2015-03-09) (R 
Foundation for Statistical Computing, Vienna, Austria). For any results that were not 
statistically significant, any relevant clinically significant results were reported. 
RESULTS 
Eligible patients (n=174) were invited to participate in the study between September 2012 
to June 2015 with 131 patients recruited and randomised (Figure 8-1). The final 12 month 
outcomes were completed in August 2016 and all patients were analysed on an intention-
to-treat basis. Patient, clinical and treatment characteristics and their baseline nutrition 
measures are summarised in Table 8-1 and baseline quality of life measures are available 
in Supplementary Table 1 (Table 8-4).
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Figure 8-1: CONSORT Flow Diagram 
Abbreviations: PEG=gastrostomy.
Assessed for eligibility 
(n=383) 
Not meeting criteria (n=209) 
- PEG not placed (n=133) 
- Palliative intent (n=10) 
- Severe malnutrition (n=41) 
- Physician decision (n=5) 
- Treatment elsewhere (n=10) 
- Declined any treatment (n=4) 
- Changed plan/diagnosis (n=6) 
Intention to Treat Analysis (n=61)  
Complete cases at 3 months (n=57) 
Lost to follow-up (n=2) 
- Died during treatment (n=1) 
- Died before 12 month follow up (n=1) 
 
Discontinued intervention (n=1) 
- Withdrawn, patient choice (n=1) 
 
Non-adherent to intervention (n=26) 
 
Allocated to intervention (n=61) 
 Received allocated intervention (n=58) 
 Did not receive allocated intervention (n=3) 
- Withdrawn, no longer eligible (n=2) 
- PEG placed 1 day pre-op (n=1) 
Lost to follow-up (n=3) 
- Died before 3 month follow up (n=2) 
- Died before 5 month follow up (n=1) 
 
Discontinued intervention (n=1) 
- Withdrawn as PEG removed (n=1) 
 
Allocated to standard care (n=70) 
 Received allocated intervention (n=67) 
 Did not receive allocated intervention (n=3)  
- Withdrawn, no longer eligible (n=2) 
- Patient initiated early feeding (n=1) 
Intention to Treat Analysis (n=70)  
Complete cases at 3 months (n=65) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=131) 
Enrolment 
Eligible (n=174) 
 Excluded (n=43) 
- Declined to participate (n=19) 
- Scheduling issues (n=21) 
- Competing trial (n=2) 
- Previously enrolled (n=1) 
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Table 8-1: Summary of patients enrolled in the trial and comparison of baseline 
characteristics between standard care and intervention groups 
Variable 
Total                
(n=131) 
Standard Care 
(n=70) 
Intervention 
(n=61) 
P value 
Age 
Years (mean + sd) 60.5 + 10.1 60.0 + 10.9 61.1 + 9.1 0.558 
Sex 
Male 115 (88) 59 (84) 56 (92) 
0.19 
Female   16 (12) 11 (16) 5 (8) 
Smoking history 
Non smoker  26 (20) 14 (20) 12 (20) 
0.147 Former  81 (62) 39 (56) 42 (69) 
Current  24 (18) 17 (24)   7 (11) 
Tumour Site 
Oral cavity   14 (11)   7 (10)   7 (11) 0.885 
Oropharynx 101 (77) 56 (80) 45 (74)  
Nasopharynx     4 (3)   2 (3)   2 (3)  
Hypopharynx     8 (6)   3 (4)   5 (8)  
Larynx     2 (1)   1 (1)   1 (2)  
UKP     1 (1)   0 (0)   1 (2)  
Other     1 (1)   1 (1)   0 (0)   
T Stage 
T0   1 (1) 0 (0) 1 (2) 0.111 
T1   8  (6) 4 (5) 4 (7)  
T2 44 (34) 20 (29) 24 (39)  
T3 37 (28) 26 (37) 11 (18)  
T4 41 (31) 20 (29) 21 (34)   
N Stage 
N0 12 (9)   7 (10)   5 (8) 0.629 
N1 13 (10)   8 (11)   5 (8)  
N2a   4 (3)   1 (1)   3 (5)  
N2b 55 (42) 30 (43) 25 (41)  
N2c 42 (32) 20 (29) 22 (36)  
N3   5 (4)   4 (6)   1 (2)   
p16 status 
Positive   85 (69) 43 (65) 42 (72) 0.385 
Negative   39 (31) 23 (35) 16 (28)   
Treatment  
ChemoRT 123 (94) 67 (96) 56 (92) 0.472 
Other 8 (6) 3 (4) 5 (8)   
Chemotherapy 
HD cisplatin 68 (58) 36 (56) 32 (60) 0.382 
Weekly cisplatin 25 (21) 12 (19) 13 (25)  
Cetuximab 24 (21) 16 (25) 8 (15)   
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Weight Loss 6mths 
Nil 51 (39) 22 (31) 29 (48) 0.266 
<5% 43 (33) 27 (39) 16 (26)  
5-10% 22 (17) 12 (17) 10 (16)  
>=10% 15 (11)   9 (13)   6 (10)   
Nutritional status 
PG-SGA A 99 (76) 50 (71) 49 (80) 0.237 
PG-SGA B 32 (24) 20 (29) 12 (20)  
PG-SGA C   0 (0)   0 (0)   0 (0)   
Diet 
Full 87 (66) 47 (67) 40 (66) 0.579 
Soft 35 (27) 20 (29) 15 (25)  
Minced   8 (6)   3 (4)   5 (8)  
Puree   1 (1)   0 (0)   1 (1)   
Anthropometry 
Weight (kg) 82.6 + 18.7 79.7 + 18.7 85.8 + 18.4 0.063 
Fat free mass (kg) 59.2 + 10.4 57.6 + 10.5 60.9 + 10.1 0.073 
BMI (kg/m2) 27.2 + 5.5 26.4 + 5.7 28.1 + 5.2 0.078 
Nutrition Risk 
PG-SGA score  
(median, range) 
6 (1-21) 6 (1-21) 5 (1-20) 0.052 
Abbreviations: UKP=Unknown primary; ChemoRT=Chemoradiotherapy; HD=High Dose; PG-SGA=Patient 
Generated Subjective Global Assessment; BMI=Body Mass Index. 
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In the standard care group two patients received surgery alone and one patient had 
radiotherapy alone. There were five patients in the intervention group who had post-
operative radiotherapy. All other patients in the study received definitive or adjuvant 
chemoradiotherapy (94%), of which five also had neoadjuvant chemotherapy. Radiotherapy 
was delivered by helical intensity modulated radiotherapy for 98% of patients, with definitive 
doses at >66Gy (n=111) and adjuvant doses at 60-66Gy (n=12). Most patients had their 
gastrostomy placed via endoscopy (93%) versus radiologically (7%), a median of five days 
prior to treatment in each group (p=0.277). 
Nutrition Outcomes 
There were no significant differences for weight loss, body composition or nutritional status 
once adjusted for any differences at baseline or any other confounding variables in 
multivariable models (Table 8-2). The only predictors of weight loss in the multivariate model 
were baseline BMI and P16 status; with every 10 unit increase in BMI there was 
approximately 4% more weight loss, and patients with p16 negative disease had 
approximately 4% less weight loss than those with p16 positive disease. No variables were 
identified to predict loss of fat free mass loss. Predictors of other nutritional outcomes (fat 
mass and PGSGA) from multivariable models are summarised in Supplementary Table 2 
(Table 8-5).  
Quality of Life Outcomes 
There were no statistical differences in any of the domains of quality of life or functional 
scales after adjusting for any baseline differences. See Supplementary Table 3 (Table 8-6). 
Multivariable models were created for global quality of life, functioning scales and selected 
symptoms scales for which the intervention may have impacted on (e.g. fatigue, appetite, 
gastrointestinal symptoms, dysphagia and social eating), however no significant effects of 
the intervention were found following adjustment for other confounding variables. See 
Supplementary Table 4 (Table 8-7). On review of the clinical impact of quality of life (EORTC 
QLQ-C30) the majority of domains showed some degree of deterioration over time 
(particularly loss of appetite, role functioning and fatigue) but comparisons between groups 
was limited due to baseline differences. The only exception was social functioning which 
was similar at baseline, but clinical differences were seen with a medium deterioration in the 
intervention group and no change in the standard group. See Supplementary Table 5 (Table 
8-8).
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Table 8-2: Summary of unadjusted and adjusted linear regression analysis for the effect of the early nutrition intervention on 
nutrition outcomes in patients with head and neck cancer compared to standard care 
Outcome Variable 
Comparison of Outcomes 
Between Groups 
Summary of Regression Analysis  
(Ref: Standard Care) 
Standard 
Care 
Intervention Unadjusted 
Adjusted for 
baseline 
differences 
Adjusted in full multivariable model 
Mean + sd β P value β P value β SE 95% CI P value 
Weight (% change)  -10.9 + 6.6  -10.8 + 5.6 0.1 0.93 1.01 0.326 0.48 0.98 -1.46 2.43 0.624 
Fat Free Mass (% change)  - 4.2 + 4.9  -6.3 + 5.4 -2.06 0.036* -1.51 0.104 -1.22 0.92 -3.03 0.6 0.187 
Fat Mass (% change)  -28.5 + 16.7  -22.7 + 15.2 5.85 0.056 NA NA 1.72 2.64 -3.52 6.96 0.515 
PG-SGA score (change) 3.2 + 6.0 3.7 + 5.3 0.45 0.665 -0.52 0.534 -0.28 0.86 -1.98 1.42 0.743 
SGA nutritional status  
(% decline) 
31% 26% 
OR 
0.79 
0.551 NA NA 
OR 
0.78 
1.55 0.33 1.83 0.569 
Abbreviations: PG-SGA=Patient Generated Subjective Global Assessment; SGA=Subjective Global Assessment.
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Radiotherapy tolerance 
The proportion of patients completing planned radiotherapy treatment was 100% in standard 
care (n=65/65) and 95% in the intervention group (n=55/58) (p=0.102). Two patients in the 
intervention failed to attend scheduled treatment (one patient completed 62/70Gy and one 
patient completed 66/70Gy) and one further patient died during treatment from liver failure 
due to complications of chemotherapy. There was no difference in rates of treatment re-
planning (22% standard care vs 19% intervention, p=0.723) or delays to radiotherapy 
treatment (n=9 standard care vs n=7 intervention, p=0.381). Three patients in the 
intervention and one patient in standard care had a prolonged treatment time which were 
due to: admission for myocardial infarction; admission to a regional hospital for neutropenia 
and infection; admission to manage severe mucositis and secretions; and identification of a 
new node requiring re-scanning and planning. 
Chemotherapy tolerance 
Although only approximately half of patients completed their planned chemotherapy 
prescription (59% standard care vs 51% intervention, p=0.361), almost all completed the 
target dose of chemotherapy (95% standard care vs 98% intervention, p=0.407). Overall 
there was no statistical difference in the changes to the planned chemotherapy (45% 
standard care vs 53% intervention, p=0.418). The toxicity reasons for deviations from the 
prescribed chemotherapy plan were similar in each group: haematological (42%), renal 
(27%), gastrointestinal (5%) and other (22%).  
Unplanned Admissions 
Unplanned admissions affected approximately half of all patients in each group (47% 
standard care vs 57% intervention, p =0.270) with no statistical differences for reasons for 
admissions or associated length of stay (Table 8-3). Nutrition-related admissions accounted 
for 47% of all admission events in the standard care group (n=20/43) and 53% in the 
intervention group (n=20/38).
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Table 8-3: Summary of the effect of the early nutrition intervention on unplanned 
admissions and LOS in patients with head and neck cancer 
 Standard Care Intervention P value 
Total number of patients with an 
unplanned admission 
31 33 0.27 
Reason for unplanned admission n (%)   
Clinical 
 
15 (48) 12 (36) 0.33 
Nutrition 
 
20 (65) 20 (61) 0.747 
G tube 
 
8 (26) 6 (18) 0.461 
LOS per unplanned admission Median (range)   
Clinical 
 
3 (1-23) 6 (1-36)  0.182 
Nutrition 
 
4 (1-24)  5 (2-25) 0.981 
G tube 
 
3 (1-22) 1 (1-2) 0.154 
Abbreviations: LOS=Length of Stay; G tube=Gastrostomy tube.
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Gastrostomy Outcomes 
There was no gastrostomy placement associated mortality. Major tube complications were 
similar in each group (12% standard care vs 10% intervention, p=0.775). Pain management 
accounted for 45% of all major complications (n=9/20). Minor tube complications affected 
40% of patients in both groups (p=0.995), and events included: site infections requiring oral 
antibiotics (n=27), other site/stoma complications (n=29). Fifty percent of all patients had 
commenced clinically indicated tube feeding by week three. Tube use was high at the end 
of treatment with no differences between groups (88% standard care and 86% intervention, 
p=0.776). The mean day of tube removal from completion of treatment was 104.7 +/- 54.0 
days in the standard care group vs 115.5 +/- 62.5 days in the intervention group (p=0.333).  
Survival and Disease outcomes 
The outcomes on PET at three months post treatment were no different between groups 
(p=0.661). A complete response was seen in 78% of patients in standard care (n=49) and 
81% in the intervention (n=42). Salvage surgery for persistent disease was carried out for 
six patients in each group, and palliative care was required for eight patients in standard 
care and four patients in the intervention. At 12 months there were no differences in disease 
free survival or overall survival, with 19 cases of disease relapse in the standard care group 
and 10 cases in the intervention group (p=0.135) (Figure 8-2a) and six and five deaths in 
the standard care and intervention group respectively (p=0.946) (Figure 8-2b). 
Additional analysis 
Adherence to the intervention was defined as consuming >75% of the prescribed enteral 
feeding and unfortunately this was only achieved by 51% of patients. Due to this poor 
adherence, a per-protocol analysis was also performed to compare those patients who 
adhered to the intervention (n=29) to standard care (n=57) but no significant differences 
were found for any outcomes. When adherence to the therapeutic phase of feeding was 
compared (i.e. when tube feeding became clinically indicated in each group) the intervention 
group had a higher adherence (58% vs 38%, p=0.037). Adherent patients (n=49) had less 
weight loss than non-adherent patients (n=55) (-10.3% vs -12.6%, p=0.038). 
Weight outcomes at the end of treatment were reviewed using routine clinical data. Weight 
loss was -6.7% +/- 5.3 in standard care versus -6.1% +/- 4.5 in the intervention group on an 
intention-to-treat basis (p=0.466) and -5.6% +/- 4.6 in the adherent intervention group on a 
per-protocol basis (p=0.299).
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Figure 8-2: Kaplan Meier curves to compare disease free survival (a) and overall 
survival (b) at twelve months post-treatment between standard care and intervention 
groups 
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DISCUSSION 
This randomised controlled trial investigating an early tube feeding intervention was primarily 
conducted in a well-nourished group of patients with HNSCC who had a prophylactic 
gastrostomy placed prior to treatment without any significant dysphagia. The results from 
the intention-to-treat analysis found no impact on weight loss outcomes at three months post 
treatment, with both groups losing approximately 10% of their body weight. Consequently 
there were no statistical differences in any of the other secondary outcomes in regards to 
nutritional status, body composition, quality of life or other clinical outcomes.  
The overall body composition results are very similar to a recent report (although they 
measured outcomes at one month post treatment), with an absolute percentage fat mass 
loss of 3.9% and a FFM loss of 2.4kg, versus our measures of 4.3% and 3.3kg (de Carvalho 
et al., 2015). One study has reported lean mass accounts for 62% of weight loss mass 
(Jager-Wittenaar et al., 2011b), however this present study found the reverse with fat mass 
accounting for 67% of weight loss. The preservation of fat free mass with nutrition 
intervention has been reported in other studies (Isenring, Capra, Bauer, & Davies, 2003). 
Further research is required on changes in body composition during and post treatment to 
understand any long term implications. Meanwhile routine monitoring of body composition 
is suggested as this provides more information than body weight alone. 
This is the first study to report on outcomes following an early prophylactic tube feeding 
intervention. There has been one other study which has described an early nutrition 
intervention of dietary counseling pre-chemoradiotherapy compared to a historical control 
group, which found statistically significantly less weight loss, fewer breaks in radiotherapy 
and less unplanned admissions (Paccagnella et al., 2010). However their early nutrition 
intervention was essentially equivalent to our control group. A similar style of study has 
recently been undertaken in patients with lung cancer (Kiss et al., 2016). Our current study 
design initiates supplementary prophylactic tube feeding prior to commencement of 
treatment and so could be described as an even more intensive early intervention. The only 
other study to our knowledge which has looked at early nutrition interventions in patients 
with HNSCC is a secondary analysis in patients undergoing definitive radiotherapy as part 
of a larger prospective RCT (n=1073) (Rabinovitch et al., 2006). Their results showed that 
although patients who received nutrition support prior to treatment had benefits in terms of 
less weight loss and less grade three or four mucositis, they ultimately had poorer overall 
survival (Rabinovitch et al., 2006). 
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Their patients who received pre-treatment nutrition support had more advanced stage 
tumours, lower performance status, more weight loss in last six months and more grade 
three and four dysphagia at baseline, and the detrimental impact of malnutrition at diagnosis 
on overall survival is well known (Datema, Ferrier, & Baatenburg de Jong, 2011). The 
methodological limitations of these exploratory findings are acknowledged by the authors 
and they recommend that RCT’s are required to explore how nutrition support in the 
malnourished patient may negatively impact upon treatment outcomes (Rabinovitch, 
Berkey, Raben, & Cooper, 2007), however there have been no further studies in this field. 
Other factors also need to be taken into consideration in interpretation of these findings such 
as evolving treatment and disease, with patients now primarily receiving chemoradiotherapy 
(compared to radiotherapy alone) and a higher incidence of human papilloma virus (HPV) 
associated tumours (Hocking et al., 2011). The profile of patients selected for our study was 
also quite different as the eligibility criteria focused on well-nourished patients with minimal 
dysphagia. Given critical weight loss during treatment is also an independent prognostic 
indicator of worse disease-specific and overall survival rates (Langius et al., 2013a) and 
even subtle weight loss of 2.4% is related to decreased survival (Martin et al., 2015), these 
studies highlight the importance of including mortality as an outcome for any nutrition 
intervention studies. Our one year survival outcomes to date have not demonstrated any 
differences with respect to the timing of nutrition intervention, although this was not the 
primary outcome and sample size may be a limiting factor to draw any firm conclusions. 
Further survival analysis is planned at five years post treatment. 
One of the potential reasons for the negative findings from this trial was the poor adherence 
to the prescribed nutrition intervention (51%) which was much lower than expected. A study 
in hospitalised patients found 87% of prescribed tube feedings were met, however this was 
in a group of patients that were entirely dependent on enteral nutrition (van den Broek, 
Rasmussen-Conrad, Naber, & Wanten, 2009). A systematic review on adherence to 
prescribed oral nutrition supplements, which is perhaps more akin to the supplementary 
bolus feeds used in this study, found a mean adherence of 79% (Hubbard et al., 2012). The 
prescribed daily tube feeds for the intervention were provided to the patients at no extra cost 
to facilitate adherence, as it has been shown that provision of complimentary nutritional 
supplements can improve outcomes (Lee et al., 2008b), but this did not appear to help in 
this case. 
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Key barriers patients encountered to tube feeding recommendations were nausea and early 
satiety, as well as a perception that the extra tube feeding was not required as patients felt 
they were eating normally. Further qualitative research is recommended to investigate these 
barriers in depth, as they are potentially modifiable and can be addressed. Improving 
adherence to dietary recommendations has been shown to result in improved outcomes 
both within this study and others (Capuano et al., 2008, Hopanci Bicakli et al., 2017). The 
characteristics of this patient population also suggest that adherence may be particularly 
challenging given the high rate of mental health problems, substance use and social issues 
which increases psychologic distress and depression (Kugaya et al., 2000, DiMatteo, 
Lepper, & Croghan, 2000). Adherence to other aspects of clinical management, such as 
adherence to radiotherapy protocols by the clinician, has also been shown to influence 
patient outcomes (Peters et al., 2010). 
The main limitation of this study is that, despite a motivated patient cohort, poor adherence 
to the intervention impacted on the power of the study which may also explain why no 
significant differences were found on the post-hoc per-protocol analysis. Steps were taken 
through the study by the research dietitian to improve adherence such as; increased 
communication to the multidisciplinary team and more regular contact with the intervention 
patients. The clinician staff did change over the course of the study period which may have 
led to variations in clinical practice, however this is reflective of the pragmatic nature of 
nutrition care delivery in healthcare settings, and was minimised as much as possible, 
particularly for the intervention care arm. Whilst attrition from the study was generally very 
low, geographical location of patients did inhibit some follow up care for the study, 
particularly for physical measurement of BIA.  
Our study identified P16 status as a strong confounding variable associated with a number 
of outcomes which was adjusted for in the multivariate models, however, given the impact 
of HPV status on survival outcomes (Ang et al., 2010) it is increasingly being suggested that 
clinical trials should stratify for smoking, staging and HPV (P16) status. Differences in quality 
of life related to tube feeding may also not have been addressed with the tools used, 
however they are the most widely accepted tools used in this population (Ojo et al., 2012). 
Future studies could consider additional tools specifically related to tube feeding, such as 
the QOL-EF (Stevens et al., 2011). Finally swallowing outcomes were not measured using 
a validated assessment tool in this study, but there was no impact of long term gastrostomy 
dependency as a surrogate measure of dysphagia. 
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This interventional approach is not only restricted to hospitals which utilise prophylactic 
gastrostomy placement. Although designed as a tube feeding intervention, it could still be 
used by sites who prefer the reactive approach to nutrition management during treatment, 
as the supplements could be prescribed orally, and this is actually what some of our patients 
preferred to do. They were still included in the study as their nutritional intake was still being 
supplemented whether it was by the oral or enteral route. Only 11% of eligible patients 
(19/174) declined to participate which demonstrated a high acceptability of the trial, although 
this did not translate into adherence.  
The use of prophylactic gastrostomy tubes remained high in this cohort of pre-defined high 
nutritional risk patients, with 87% of all study patients using their tube at the end of treatment, 
which confirms appropriate decision-making regarding tube placement. Although the early 
nutrition intervention did not minimise weight loss or improve other associated outcomes, 
this study has highlighted the significant barriers that patients encounter. Given the finding 
that patients who followed the early nutrition intervention had higher levels of adherence to 
nutrition recommendations later on in treatment, which did reduce weight loss, it is planned 
to introduce this approach into practice.   
In conclusion this research demonstrates the high complexity of managing patients with 
head and neck cancer, as desired outcomes have not been attained even with intensive 
intervention and support. Whilst this novel early nutrition intervention can be considered to 
assist adherence, it is but one of many potential strategies. A multi-component intervention 
by the multidisciplinary team is recommended to adequately address and overcome patient 
barriers to healthcare recommendations before further improvements in nutrition outcomes 
are realised.
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Table 8-4: Supplementary Table 1 - Comparison of baseline quality of life in patients 
with head and neck cancer in the early nutrition intervention and standard care 
groups 
Variable 
 
 
Baseline Quality of Life (QOL) scores 
 
Standard Care (n=70) 
 
 
Intervention (n=61) 
 
Wilcoxon Two 
Sample Test 
 
 
 
Mean +/- sd 
 
Mean +/- sd 
 
p value 
Median (range) 
 
Median (range) 
 
EORTC-QLQ C30 
 
Global Health Status/QOL  
65.2 + 22.8 73.9 + 20.0 
0.025* 
67 (0-100) 83 (17-100) 
Physical functioning  
86.7 + 17.9 93.6 + 9.0 
0.085 
93 (20-100) 100 (60-100) 
Role functioning  
79.1 + 27.3 89.1 + 21.5 
0.011* 
92 (0-100) 100 (0-100) 
Emotional functioning  
73.3 + 18.9 78.7 + 19.0 
0.071 
75 (8-100) 83 (17-100) 
Cognitive functioning  
80.9 + 21.3 87.6 + 14.6 
0.089 
83 (0-100) 83 (50-100) 
Social functioning  
77.4 + 26.9 83.3 + 22.8 
0.257 
83 (0-100) 100 (0-100) 
Fatigue  
28.9 + 23.6 17.2 + 17.0 
0.004* 
22 (0-89) 22 (0-67) 
Nausea and vomiting  
5.0 + 10.4 3.3 + 9.0 
0.301 
0 (0-33) 0 (0-50) 
Pain  
30.7 + 30.1 18.4 + 24.3 
0.017* 
25 (0-100) 17 (0-100) 
Dyspnoea  
11.1 + 20.3 10.4 + 17.8 
0.94 
0 (0-67) 0 (0-67) 
Insomnia  
36.2 + 30.4 24.6 + 26.5 
0.024* 
33 (0-100) 33 (0-100) 
Appetite loss  
21.4 + 30.1 9.3 + 18.4 
0.017* 
0 (0-100) 0 (0-100) 
Constipation  
12.4 + 22.1 11.2 + 21.2 
0.763 
0 (0-100) 0 (0-100) 
Diarrhoea  
7.1 + 14.9 2.2 + 8.3 
0.026* 
0 (0-67) 0 (0-33) 
Financial difficulties  
27.4 + 36.1 21.9 + 30.4 
0.498 
0 (0-100) 0 (0-100) 
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Variable 
 
 
Baseline Quality of Life (QOL) scores 
 
Standard Care (n=70) 
 
 
Intervention (n=61) 
 
Wilcoxon Two 
Sample Test 
 
 
 
Mean +/- sd 
 
Mean +/- sd 
 
p value 
Median (range) 
 
Median (range) 
 
EORTC-QLQ H&N35    
Pain  
31.1 + 27.5 19.9 + 19.8 
0.017* 
25 (0-100) 17 (0-67) 
Swallowing  
13.6 + 18.1 11.8 + 16.4 
0.708 
4 (0-67) 0 (0-58) 
Senses Problems  
12.6 + 21.1 8.2 + 13.8 
0.324 
0 (0-100) 0 (0-50) 
Speech Problems  
19.2 + 19.2 13.5 + 18.5 
0.035* 
11 (0-78) 11 (0-78) 
Social eating  
16.2 + 18.9 11.8 + 17.7 
0.147 
8 (0-67) 0 (0-92) 
Social contact  
8.00 + 13.4 5.1 + 10.4 
0.098 
0 (0-60) 0 (0-40) 
Less sexuality  
15.7 + 27.5 22.8 + 33.6 
0.278 
0 (0-100) 0 (0-100) 
Teeth  
14.3 + 28.1 14.2 + 23.9 
0.618 
0 (0-100) 0 (0-100) 
Opening mouth  
23.3 + 31.8 12.6 + 28.0 
0.006* 
0 (0-100) 0 (0-100) 
Dry mouth  
26.7 + 26.4 19.1 + 26.8 
0.048* 
33 (0-100) 0 (0-100) 
Sticky saliva  
21.4 + 27.8 19.1 + 26.9 
0.61 
0 (0-100) 0 (0-100) 
Coughing  
25.2 + 26.3 19.7 + 25.4 
0.171 
33 (0-100) 0 (0-100) 
Felt ill  
11.9 + 19.7 9.6 + 17.9 
0.494 
0 (0-67) 0 (0-67) 
Pain killer  
70.0+ 46.2 47.5 + 50.4 
0.009* 
100 (0-100) 0 (0-100) 
Nutritional supplements 
21.4 + 41.3 18.0 + 38.8 
0.631 
0 (0-100) 0 (0-100) 
Feeding tube  
0 + 0 0 + 0 
NA 
0 (0-0) 0 (0-0) 
Weight loss  
30.0 + 46.2 26.2 + 44.4 
0.636 
0 (0-100) 0 (0-100) 
Weight gain  
25.7 + 44.0 26.2 + 44.4 
0.949 
0 (0-100) 0 (0-100) 
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Table 8-5: Supplementary Table 2 - Summary of multivariable models for effects on nutrition outcomes in patients with head and 
neck cancer 
Linear Regression Unadjusted Adjusted 
Variable 
 
β SE 95% CI P value β SE 95% CI P value 
Model for % weight loss  (F(4,104)=14.3, p<0.001, R2 = 0.354) 
 
Neoadjuvant chemo (Reference: no) 
- Yes 
 
-5.21 
 
2.71 
 
-10.58 
 
0.15 
 
0.057 
 
-3.00 
 
2.41 
 
-7.77 
 
1.78 
 
0.216 
 
Age 
 
0.14 
 
0.05 
 
0.03 
 
0.25 
 
0.011* 
 
0.10 
 
0.05 
 
0.00 
 
0.19 
 
0.056 
p16 (Reference: positive) 
- Negative 
 
6.04 
 
1.17 
 
3.72 
 
8.35 
 
<0.001* 
 
4.36 
 
1.11 
 
2.15 
 
6.56 
 
<0.001* 
 
Baseline BMI 
 
-0.55 
 
0.09 
 
-0.73 
 
-0.37 
 
<0.001* 
 
-0.43 
 
0.09 
 
-0.61 
 
-0.24 
 
<0.001* 
Model for % FFM loss (F(4,103)=7.7, p<0.001, R2 = 0.230) 
 
 
Age 
 
0.09 
 
0.05 
 
0.00 
 
0.18 
 
0.061 
 
0.05 
 
0.05 
 
-0.04 
 
0.14 
 
0.264 
Gender (Reference: male) 
- Female 
 
2.91 
 
1.58 
 
-0.21 
 
6.04 
 
0.067 
 
0.74 
 
1.86 
 
-2.95 
 
4.44 
 
0.690 
p16 (Reference: positive) 
- Negative 
 
3.19 
 
1.09 
 
1.03 
 
5.35 
 
0.004* 
 
1.90 
 
1.06 
 
-0.21 
 
4.01 
 
0.077 
 
Baseline FFM 
 
-0.19 
 
0.04 
 
-0.28 
 
-0.11 
 
<0.001* 
 
-0.18 
 
0.06 
 
-0.29 
 
-0.07 
 
0.002* 
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Model for % FM loss (F(9,92)=5.78, p<0.001, R2 = 0.361) – only significant variables shown 
Age  
0.26 
 
0.15 
 
-0.03 
 
0.55 
 
0.077 
 
0.26 
 
0.13 
 
0.00 
 
0.51 
 
0.048* 
Current Smoking (Reference: none) 
- High >20/day 
 
-18.4 
 
6.13 
 
-30.55 
 
-6.27 
 
0.003* 
 
-13.06 
 
5.46 
 
-23.91 
 
-2.22 
 
0.019* 
p16 (Reference: positive) 
- Negative 
 
9.93 
 
3.35 
 
3.29 
 
16.56 
 
0.004* 
 
9.06 
 
3.11 
 
2.89 
 
15.23 
 
0.004* 
Social support (Reference: Yes) 
- No 
 
-10.4 
 
3.46 
 
-17.24 
 
-3.54 
 
0.003* 
 
-11.37 
 
3.07 
 
-17.46 
 
-5.27 
 
<0.001* 
Model for change in PG-SGA score (F(4,110)=18.6, p<0.001, R2 = 0.403)  
Usual residence (Reference: City) 
- Regional 
- Remote 
 
-2.58 
-3.81 
 
1.06 
1.70 
 
-4.68 
-7.18 
 
-0.47 
-0.44 
 
0.017* 
0.027* 
 
-0.89 
-1.89 
 
0.90 
1.45 
 
-2.67 
-4.76 
 
0.89 
0.98 
 
0.323 
0.194 
p16 (Reference: positive) 
- Negative 
 
-4.69 
 
1.09 
 
-6.84 
 
-2.54 
 
<0.001* 
 
-2.36 
 
0.99 
 
-4.32 
 
-0.41 
 
0.018* 
Baseline PG-SGA -0.66 0.08 -0.82 -0.50 <0.001* -0.57 0.09 -0.75 -0.39 <0.001* 
Logistic Regression Unadjusted Adjusted 
Variable OR SE 95% CI P value OR SE 95% CI P value 
Model for change in nutritional status (SGA)   
Gastrostomy tube (Reference: PEG) 
- RIG 
 
3.42 
 
2.02 
 
0.85 
 
14.62 
 
0.081 
 
6.85 
 
2.62 
 
1.13 
 
59.0 
 
0.046* 
p16 (Reference: positive) 
- Negative 
 
0.24 
 
1.79 
 
0.07 
 
0.68 
 
0.014* 
 
0.21 
 
1.84 
 
0.06 
 
0.63 
 
0.011* 
Abbreviations: BMI=Body mass index; FFM=Fat free Mass; FM=Fat mass; PG-SGA=Patient generated subjective global assessment; SGA=Subjective global 
assessment; PEG=percutaneous endoscopic gastrostomy; RIG=radiological inserted gastrostomy.
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Table 8-6: Supplementary Table 3 - Comparison of change in quality of life scores 
over treatment in patients with head and neck cancer for the early nutrition 
intervention and standard care groups 
Variable 
Change in QOL scores Linear Regression model 
Standard 
Care (n=70) 
Intervention 
(n=61) 
Unadjusted 
(ANOVA) 
Adjusted for 
baseline 
differences 
(ANCOVA) 
Mean (sd) Mean (sd) β p value β p value 
EORTC-QLQC30 
Global Health 
Status/QOL  
 -2.9 + 22.7  -6.2 + 20.3 -3.28 0.405 0.8 0.818 
Physical functioning   -5.5 + 14.1  -9.4 + 16.8 -3.93 0.164 -1.77 0.505 
Role functioning   -4.7 + 31.6  -14 + 30.7 -9.35 0.102 -3.66 0.435 
Emotional functioning  2.5 + 18.9 2.3 + 21.5 -0.13 0.971 2.14 0.526 
Cognitive functioning   -5.7 + 23.6  -6.9 + 19.6 -1.14 0.775 -34.92 0.061 
Social functioning   -2.1 + 27.1  -12.1 + 31.7 -10.05 0.063 NA NA 
Fatigue  8.4 + 23.2 17.0 + 22.4 8.63 0.040* 2.77 0.46 
Nausea and vomiting  1.6 + 15.1 4.7 + 18.3 3.12 0.307 NA NA 
Pain   -8.3 + 29.7  -0.7 + 30.8 7.61 0.17 1.6 0.731 
Dyspnoea  3.7 + 25.5 0.6 + 22.2 -3.12 0.479 NA NA 
Insomnia   -2.6 + 34.8 0.0 + 37.3 2.61 0.691 -6.1 0.288 
Appetite loss  19.8 + 34.5 18.7 + 28.2 -1.08 0.852 -6 0.282 
Constipation   -0.5 + 21 2.6 + 22.2 3.15 0.425 NA NA 
Diarrhoea  0.0 + 20.6 1.8 + 11.6 0 0.571 -3.87 0.131 
Financial difficulties  1.8 + 31.7 4.1 + 35.7 2.27 0.712 NA NA 
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Variable 
Change in QOL scores Linear Regression model 
Standard Care 
(n=70) 
Intervention 
(n=61) 
Unadjusted 
(ANOVA) 
Adjusted for 
baseline 
differences 
(ANCOVA) 
Mean (sd) Mean (sd) β p value β p value 
EORTC-QLQ H&N35 
Pain   -5.1 + 27.6  -2.7 + 26.3 2.37 0.631 -4.93 0.202 
Swallowing  6.2 + 22.5 8.8 + 28.1 2.66 0.564 NA NA 
Senses Problems  21.6 + 27.2 19.6 + 22.7 -2.03 0.659 NA NA 
Speech Problems  3.1 + 20.6 8.2 + 25.2 5.06 0.228 8.47 0.082 
Social eating  13.7 + 27.0 18.8 + 31.2 5.12 0.335 NA NA 
Social contact  1.2 + 15.8 6.1 + 16.5 4.93 0.096 3.6 0.187 
Less sexuality  13.0 + 39.0 9.1 + 38.6 -3.88 0.589 NA NA 
Teeth  1.0 + 30.8 6.1 + 38.7 5.1 0.421 NA NA 
Opening mouth   -1.6 + 31.1 4.1 + 29.6 5.65 0.309 -0.38 0.939 
Dry mouth  41.1 + 38.4 55.6 + 32.9 14.42 0.030* 8.95 0.094 
Sticky saliva  32.3 + 39.8 35.1 + 44.7 2.79 0.717 NA NA 
Coughing  0.0 + 31.4 4.7 + 23.9 4.68 0.363 NA NA 
Felt ill   -0.5 + 19.2  -0.3 + 21.9 0.23 0.952 NA NA 
Pain killer   -29.7 + 60.9  -14 + 51.5 15.65 0.132 -0.04 0.997 
Nutritional 
supplements 
31.3 + 61.4 31.6 + 60.2 0.33 0.976 NA NA 
Feeding tube  26.6 + 44.5 36.8 + 48.7 10.28 0.227 NA NA 
Weight loss   -4.7 + 60.2 10.5 + 67.3 15.21 0.192 NA NA 
Weight gain  10.9 + 62.0 7.0 + 67.8 -3.92 0.74 NA NA 
Abbreviations: QOL=Quality of Life; ANOVA=analysis of variance; ANCOVA=analysis of co-variance; 
EORTC=European Organisation for Research and Treatment of Cancer; QLQC30=QOL of Cancer Patients; 
QLQ H&N35=QOL module for Head and Neck Cancer.
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Table 8-7: Supplementary Table 4 - Summary of multivariable linear regression models for selected Quality of Life outcome 
measures from the EORTC QLQ-C30 and EORTC H&N35 questionnaires in patients with head and neck cancer 
 Unadjusted Adjusted 
Variable β SE 95% CI P value β SE 95% CI P value 
Model for Global QOL (F(6,108)=10.1, p<0.001, R2 =0.360 ) 
Baseline FFM -0.51 0.19 -0.89 -0.14 0.008* -0.17 0.18 -0.53 0.18 0.333 
Weight loss history 6mths (Reference: 
nil) 
- <5% 
- >5% 
- >10% 
 
 
-5.91 
-6.01 
20.59 
 
 
4.34 
5.41 
6.56 
 
 
-14.51 
-16.72 
7.59 
 
 
2.69 
4.70 
33.59 
 
 
0.176 
0.268 
0.002* 
 
 
-6.26 
-12.11 
8.45 
 
 
3.76 
5.13 
6.39 
 
 
-13.71 
-22.29 
-4.21 
 
 
1.19 
-1.93 
21.12 
 
 
0.099 
0.020* 
0.189 
p16 (Reference: positive) 
- Negative 
 
 
13.54 
 
 
4.18 
 
 
5.25 
 
 
21.83 
 
 
0.002* 
 
 
8.79 
 
 
3.80 
 
 
1.26 
 
 
16.32 
 
 
0.022* 
Baseline global QOL -0.56 0.09 -0.73 -0.39 <0.001* -0.47 0.09 -0.64 -0.30 <0.001* 
Model for Physical Functioning (F(4,116)=7.6, p<0.001, R2 =0.209 ) 
Current ETOH (Reference: nil) 
- low 
- high 
- very high 
 
3.17 
-0.97 
-9.41 
 
3.27 
4.59 
4.16 
 
-3.29 
-10.05 
-17.64 
 
9.64 
8.11 
-1.18 
 
0.333 
0.833 
0.025* 
 
3.05 
-0.36 
-7.30 
 
3.04 
4.27 
3.90 
 
-2.97 
-8.82 
-15.02 
 
9.07 
8.09 
0.42 
 
0.318 
0.932 
0.064 
Baseline physical function -0.49 0.10 -0.69 -0.28 <0.001* -0.45 0.10 -0.65 -0.25 <0.001* 
Model for Role Functioning (F(5,103)=13.8, p<0.001, R2 =0.401 ) 
Baseline SGA (Reference: A – well 
nourished) 
- B (malnourished) 
 
 
 
14.81 
 
 
 
7.06 
 
 
 
0.83 
 
 
 
28.79 
 
 
 
0.038* 
 
 
 
-0.21 
 
 
 
6.41 
 
 
 
-12.92 
 
 
 
12.50 
 
 
 
0.974 
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Synchronous Primary (Reference: No) 
- Yes 
 
 
24.81 
 
 
12.07 
 
 
0.92 
 
 
48.70 
 
 
0.042* 
 
 
12.20 
 
 
10.66 
 
 
-8.95 
 
 
33.34 
 
 
0.255 
Neoadjuvant chemotherapy (Reference: 
No) 
- Yes 
 
 
 
30.34 
 
 
 
12.81 
 
 
 
2.97 
 
 
 
57.71 
 
 
 
0.030* 
 
 
 
14.51 
 
 
 
11.62 
 
 
 
-8.54 
 
 
 
37.56 
 
 
 
0.215 
p16 (Reference: positive) 
- Negative 
 
 
19.88 
 
 
3.28 
 
 
7.74 
 
 
32.02 
 
 
0.002* 
 
 
10.53 
 
 
5.69 
 
 
-0.75 
 
 
21.82 
 
 
0.067 
Baseline role function -0.80 0.10 -1.00 -0.61 <0.001* -0.73 0.12 -0.97 -0.50 <0.001* 
Model for Emotional Functioning (F(2,112)=15.4, p<0.001, R2 =0.215 ) 
p16 (Reference: positive) 
- Negative 
 
 
8.44 
 
 
4.16 
 
 
0.19 
 
 
16.68 
 
 
0.045* 
 
 
7.61 
 
 
3.77 
 
 
0.13 
 
 
15.08 
 
 
0.046* 
Baseline emotional function -0.46 0.09 -0.64 -0.28 <0.001* -0.47 0.09 -0.65 -0.28 <0.001* 
Model for Cognitive Functioning (F(4,110)=8.1, p<0.001, R2 =0.229 ) 
p16 (Reference: positive) 
- Negative 
 
 
8.94 
 
 
4.47 
 
 
0.09 
 
 
17.80 
 
 
0.048* 
 
 
5.00 
 
 
4.14 
 
 
-3.20 
 
 
13.20 
 
 
0.230 
Current Smoking (Reference: None) 
- Low 
- High 
 
 
14.51 
8.27 
 
 
6.54 
7.87 
 
 
1.56 
-7.31 
 
 
27.46 
23.84 
 
 
0.028* 
0.295 
 
 
3.75 
1.73 
 
 
6.35 
7.79 
 
 
-8.83 
-13.71 
 
 
16.32 
17.16 
 
 
0.556 
0.825 
Baseline cognitive function -0.54 0.10 -0.73 -0.34 <0.001* -0.52 0.11 -0.74 -0.31 <0.001* 
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Model for Social Functioning (F(1,113)=9.7, p=0.002, R2 =0.079) 
p16 (Reference: positive) 
- Negative 
 
 
18.05 
 
 
5.80 
 
 
6.55 
 
 
29.54 
 
 
0.002* 
 
 
18.05 
 
 
5.80 
 
 
6.55 
 
 
29.54 
 
 
0.002* 
Model for Fatigue (F(6,108)=9.7, p<0.001, R2 =0.349) 
Baseline SGA (Reference: A – well 
nourished) 
- B (malnourished) 
 
 
 
-9.51 
 
 
 
5.22 
 
 
 
-19.85 
 
 
 
0.83 
 
 
 
0.071 
 
 
 
-1.18 
 
 
 
4.79 
 
 
 
-10.67 
 
 
 
8.31 
 
 
 
0.806 
Current ETOH (Reference: Nil) 
- Low 
- High 
- Very high 
 
 
-10.01 
-8.81 
3.61 
 
 
4.93 
6.93 
6.28 
 
 
-19.78 
-22.53 
-8.82 
 
 
-0.24 
4.91 
16.04 
 
 
0.045* 
0.206 
0.567 
 
 
-8.50 
-6.26 
5.72 
 
 
4.33 
5.85 
5.41 
 
 
-17.08 
-17.85 
-5.01 
 
 
0.08 
5.33 
16.45 
 
 
0.052 
0.287 
0.293 
p16 (Reference: positive) 
- Negative 
 
 
-11.94 
 
 
4.56 
 
 
-20.96 
 
 
-2.91 
 
 
0.010* 
 
 
-9.33 
 
 
3.99 
 
 
-17.23 
 
 
-1.43 
 
 
0.021* 
Baseline fatigue -0.59 0.09 -0.77 -0.42 <0.001* -0.52 0.09 -0.70 -0.34 <0.001* 
Model for Nausea and Vomiting (F(3,117)=2.9, p=0.038, R2 =0.069) 
Current ETOH (Reference: Nil) 
- Low 
- High 
- Very high 
 
 
2.53 
2.68 
12.94 
 
 
3.54 
4.97 
4.50 
 
 
-4.47 
-7.16 
4.03 
 
 
9.53 
12.51 
21.85 
 
 
0.476 
0.591 
0.005* 
 
 
2.53 
2.68 
12.94 
 
 
3.54 
4.97 
4.50 
 
 
-4.47 
-7.16 
4.03 
 
 
9.53 
12.51 
21.85 
 
 
0.476 
0.591 
0.005* 
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Model for Appetite (F(3,117)=5.7, p=0.001, R2 =0.134) 
p16 (Reference: positive) 
- Negative 
 
 
-15.90 
 
 
6.35 
 
 
-28.48 
 
 
-3.31 
 
 
0.014* 
 
 
-10.01 
 
 
6.43 
 
 
-22.76 
 
 
2.74 
 
 
0.122 
Overall Stage (Reference: II/III) 
- IV 
 
 
17.41 
 
 
8.35 
 
 
0.88 
 
 
33.94 
 
 
0.039* 
 
 
14.60 
 
 
8.27 
 
 
-1.79 
 
 
30.98 
 
 
0.080 
Baseline SGA (Reference: A – well 
nourished) 
- B (malnourished) 
 
 
 
-22.32 
 
 
 
6.93 
 
 
 
-36.03 
 
 
 
-8.60 
 
 
 
0.002* 
 
 
 
-20.11 
 
 
 
7.17 
 
 
 
-34.33 
 
 
 
-5.90 
 
 
 
0.006* 
Model for Constipation (F(5,113)=3.9 p=0.003, R2 =0.146) 
RT technique (Reference: Tomotherapy) 
- Other 
 
 
21.77 
 
 
12.59 
 
 
-3.17 
 
 
46.71 
 
 
0.087 
 
 
17.98 
 
 
12.38 
 
 
-6.54 
 
 
42.51 
 
 
0.149 
Weight loss history 6mth (Reference: Nil) 
- <5% 
- >5% 
- >10% 
 
 
8.18 
0.68 
-11.81 
 
 
4.48 
5.57 
6.77 
 
 
-0.69 
-10.35 
-25.21 
 
 
17.04 
11.72 
1.59 
 
 
0.070 
0.903 
0.084 
 
 
7.38 
2.32 
-12.70 
 
 
4.43 
5.80 
6.64 
 
 
-1.39 
-9.16 
-25.87 
 
 
16.14 
13.80 
0.46 
 
 
0.098 
0.690 
0.058 
Synchronous Primary (Reference: No) 
- Yes 
 
 
-21.22 
 
 
8.19 
 
 
-37.45 
 
 
-5.00 
 
 
0.011* 
 
 
-21.62 
 
 
8.36 
 
 
-38.18 
 
 
-5.06 
 
 
0.011* 
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Model for Diarrhoea (F(10,108)=8.4 p<0.001, R2 =0.439) 
N stage (Reference: N0) 
- N1 
- N2a 
- N2b 
- N2c 
- N3 
 
 
-3.03 
3.03 
2.37 
10.52 
-13.62 
 
 
6.95 
9.51 
5.42 
5.55 
9.51 
 
 
-16.79 
-15.81 
-8.36 
-0.46 
-32.46 
 
 
10.73 
21.87 
13.10 
21.51 
5.22 
 
 
0.664 
0.751 
0.662 
0.060 
0.155 
 
 
-7.96 
-10.48 
-8.20 
-0.92 
-15.00 
 
 
6.93 
8.74 
5.96 
5.96 
8.79 
 
 
-21.70 
-27.81 
-20.01 
-12.74 
-32.42 
 
 
5.78 
6.84 
3.60 
10.90 
2.42 
 
 
0.254 
0.233 
0.171 
0.878 
0.091 
RT technique (Reference: Tomotherapy) 
- Other 
 
 
-23.64 
 
 
9.77 
 
 
-42.99 
 
 
-4.28 
 
 
0.017* 
 
 
-12.95 
 
 
10.41 
 
 
-33.59 
 
 
7.69 
 
 
0.216 
Treatment (Reference: Surgery) 
- RT 
- PORT 
- CRT 
- POCRT 
 
 
-33.3 
-6.66 
2.86 
-16.66 
 
 
19.70 
13.45 
11.48 
12.71 
 
 
-72.31 
-33.31 
-19.88 
-41.84 
 
 
5.71 
19.99 
25.59 
8.52 
 
 
0.094 
0.622 
0.804 
0.193 
 
 
NA 
6.23 
11.56 
6.85 
 
 
NA 
16.03 
14.44 
14.76 
 
 
NA 
-25.55 
-17.06 
-22.40 
 
 
NA 
38.01 
40.18 
36.11 
 
 
NA 
0.698 
0.425 
0.643 
Baseline diarrhoea -0.84 0.10 -1.05 -0.64 <0.001* -0.73 0.12 -0.97 -0.49 <0.001* 
Model for Swallowing (F(5,109)=6.1 p<0.001, R2 =0.218) 
Current Smoking (Reference: None) 
- Low 
- High 
 
 
-11.68 
16.46 
 
 
7.56 
9.10 
 
 
-26.65 
-1.56 
 
 
3.30 
34.47 
 
 
0.125 
0.073 
 
 
-2.39 
21.30 
 
 
7.27 
8.94 
 
 
-16.79 
3.58 
 
 
12.00 
39.00 
 
 
0.742 
0.019* 
Guideline Risk rating (Reference: High) 
- Low 
 
 
14.47 
 
 
8.67 
 
 
-2.69 
 
 
31.63 
 
 
0.098 
 
 
23.20 
 
 
9.17 
 
 
5.01 
 
 
41.38 
 
 
0.013* 
Baseline FM 0.58 0.21 0.17 1.00 0.006* 0.47 0.21 0.05 0.90 0.029* 
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p16 (Reference: positive) 
- Negative 
 
 
-18.13 
 
 
4.88 
 
 
-27.79 
 
 
-8.46 
 
 
<0.001* 
 
 
-18.11 
 
 
4.93 
 
 
-27.89 
 
 
-8.33 
 
 
<0.001* 
Model for Social Eating (F(2,112)=9.2 p<0.001, R2 =0.141) 
Baseline SGA (Reference: A – well 
nourished) 
- B (malnourished) 
 
 
 
-18.55 
 
 
 
6.43 
 
 
 
-31.27 
 
 
 
-5.82 
 
 
 
0.005* 
 
 
 
-14.87 
 
 
 
6.43 
 
 
 
-27.60 
 
 
 
-2.14 
 
 
 
0.022* 
p16 (Reference: positive) 
- Negative 
 
 
-19.82 
 
 
5.60 
 
 
-30.92 
 
 
-8.73 
 
 
<0.001* 
 
 
-17.50 
 
 
5.59 
 
 
-28.56 
 
 
-6.43 
 
 
0.002* 
Model for Mouth Opening (F(5,115)=11.8 p<0.001, R2 =0.340) 
Baseline Diet (Reference: General) 
- Soft 
- Minced 
- Puree 
 
 
-14.62 
-22.69 
-6.02 
 
 
6.28 
12.61 
30.00 
 
 
-27.06 
-47.66 
-65.45 
 
 
-2.19 
2.28 
53.40 
 
 
0.022* 
0.075 
0.841 
 
 
-6.77 
-14.60 
30.46 
 
 
5.54 
10.88 
26.59 
 
 
-17.74 
-36.16 
-22.22 
 
 
4.20 
6.95 
83.13 
 
 
0.224 
0.182 
0.254 
Days G Tube inserted pre treatment -1.23 0.32 -1.85 -0.61 <0.001* -0.91 0.29 -1.48 -0.34 0.002* 
Baseline Mouth opening -0.51 0.08 -0.67 -0.35 <0.001* -0.45 0.09 -0.62 -0.28 <0.001* 
Abbreviations: QOL=quality of life; FFM=Fat free mass; ETOH=alcohol; SGA=subjective global assessment; RT=radiotherapy; PORT=post-operative radiotherapy; 
CRT=chemoradiotherapy; POCRT=post-operative chemoradiotherapy; FM=fat mass; G tube=gastrostomy.
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Table 8-8: Supplementary Table 5 - The clinical importance of change in quality of life scores from baseline to three months post 
treatment in patients with head and neck cancer – comparison between standard care group (prophylactic gastrostomy used as 
clinically indicated) and intervention group (early prophylactic gastrostomy use to supplement oral intake) 
 Score 
change 
Direction of 
change 
Size of clinical 
effect 
Score change Direction of 
change 
Size of clinical 
effect 
Differences 
between 
groups 
Global Health Status/QOL -2.9 + 22.7 Deterioration Trivial -6.2 + 20.3 Deterioration Small  Yes 
Physical functioning  -5.5 + 14.1 Deterioration Small  -9.4 + 16.8 Deterioration Small  No 
Role functioning -4.7 + 31.6 Deterioration Trivial -14.0 + 30.7 Deterioration Small/Medium  Yes* 
Emotional functioning  2.5 + 18.9 Improvement Trivial 2.3 + 21.5 Improvement Trivial No 
Cognitive functioning  -5.7 + 23.6 Deterioration Small  -6.9 + 19.6 Deterioration Small  No 
Social functioning  -2.1 + 27.1 Deterioration Trivial -12.1 + 31.7 Deterioration Medium  Yes* 
        
Fatigue  8.4 + 23.2 Deterioration Small  17.0 + 22.4 Deterioration Large  Yes* 
Nausea and vomiting  1.6 + 15.1 Deterioration Trivial 4.7 + 18.3 Deterioration Trivial No 
Pain -8.3 + 29.7 Improvement Small  -0.7 + 30.8 Improvement Trivial Yes 
Dyspnoea 3.7 + 25.5 Deterioration Trivial 0.6 + 22.2 Deterioration Trivial No 
Insomnia  -2.6 + 34.8 Improvement Trivial 0.0 + 37.3 Neutral Trivial No 
Appetite loss  19.8 + 34.5 Deterioration Medium  18.7 + 28.2 Deterioration Medium  No 
Constipation -0.5 + 21.0 Improvement Trivial 2.6 + 22.2 Deterioration Trivial No 
Diarrhoea  0.0 + 20.6 Neutral Trivial 1.8 + 11.6 Deterioration Trivial No 
Financial difficulties  1.8 + 31.7 Deterioration Trivial 4.1 + 35.7 Deterioration Small  Yes 
Abbreviations: EORTC=European Organisation for Research and Treatment of Cancer; QLQC30=QOL of Cancer Patients; QOL=Quality of Life. Methodology: 
Interpretation of clinical effect following Guidelines for interpretation of longitudinal QOL differences (Cocks et al., 2012). *difference between groups over two levels 
of clinical effect (i.e. trivial to medium or small to large). 
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8.3 RCT: Gastrostomy outcomes 
8.3.1 Abstract 
Objectives: Prophylactic gastrostomy tube (PGT) is frequently used in patients with head 
and neck cancer (HNSCC). There are concerns this leads to tube dependency but this 
phenomena is not well defined. This study aimed to determine whether early feeding via 
PGT impacted on longer term tube feeding outcomes. 
Materials and Methods: Patients with HNSCC with PGT were observed monthly post-
treatment regarding tube use and time to removal up to twelve months. Patients were from 
a randomised controlled trial comparing an early feeding intervention via the PGT (n=57) 
versus usual care which commenced feeding when clinically indicated (n=67).  
Results: Patient characteristics; male (88%), mean age 60+10.1 years, oropharyngeal 
tumours (76%), receiving chemoradiotherapy (82%). Tubes were used by 87% (108/124) 
on completion of treatment and 66% (83/124) one month post. No differences in tube use 
between groups at any time point or tube removal rates over 12 months (p=0.181). In 
patients free of disease (n=99), the intervention had higher tube use at 4 months (p=0.003) 
and slower removal rates (p=0.047). Overall ten patients had their tube in-situ at 12 months 
(8%) but five were awaiting removal (4% true dependency rate). Of the five patients 
legitimately using the tube, only one (<1%) was from severe dysphagia post definitive 
chemoradiotherapy.  
Conclusion: PGT use is high in the acute phase post-treatment. Encouraging early use may 
prolong time to tube removal but it does not increase long term dependency rates beyond 
four months post treatment. Monitoring tube use is important to prevent over-estimation of 
dependency rates. 
. 
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8.3.2 Manuscript 
INTRODUCTION  
Prophylactic gastrostomy tube (PGT) placement is a common method of nutrition support in 
patients with mucosal head and neck cancer (HNSCC), however there are concerns this 
leads to dysphagia and long term tube dependency (Chen et al., 2010; Corry et al., 2008; 
Langmore et al., 2012; Mekhail et al., 2001). Some studies have reported nil impact on 
swallowing function (Crombie et al., 2015; Silander et al., 2010), and the most recent 
systematic review on this topic remains inconclusive (Shaw et al., 2015). As there is no 
agreed definition of the term gastrostomy dependency, its use can therefore be 
misunderstood (Talwar & Findlay, 2012). Although many investigators are now reporting 
rates of gastrostomy retention it is unclear if patients are legitimately so because of 
dysphagia, other nutrition impact symptoms or poor nutritional status, or if patients elect to 
continue gastrostomy use despite no physical barriers to oral nutrition.  
Several studies document the predictive factors for long term tube feeding, or gastrostomy 
dependency, such as tumour sites (Caudell et al., 2010; Ishiki et al., 2012), tumour stage 
(Akst et al., 2004; Avery et al., 2008; Gokhale et al., 2010; Kornguth et al., 2005; Lawson et 
al., 2009), treatment modality (Avery et al., 2008; Kornguth et al., 2005; Lango et al., 2010), 
radiotherapy treatment fields and dose (Caudell et al., 2010; Gokhale et al., 2010; Li et al., 
2009; Sanguineti et al., 2011), smoking (Li et al., 2009), age (Kornguth et al., 2005; Lango 
et al., 2010; Lawson et al., 2009), and pre-treatment weight loss or low body mass index 
(BMI) (Lango et al., 2010; McRackan et al., 2008). These types of clinical factors are often 
considered for the prediction of patients who may benefit from PGT placement (Brown et 
al., 2013b; Jack et al., 2012; Wood, 2005), as they are anticipated to require a feeding tube 
for longer than four weeks and thus a gastrostomy is the most suitable long term feeding 
device (Arends et al., 2006). It is therefore little surprise that these characteristics are also 
associated with prolonged use.  
However prolonged feeding tube use can also be influenced by psychosocial factors 
(Magnuson et al., 2013) as well as ongoing nutrition impact symptoms which continue to 
effect the patient’s nutritional status and intake (Bressan et al., 2016). Many studies which 
report on gastrostomy dependency outcomes fail to report adequate information on the 
patient’s nutritional status (Hatoum et al., 2009; Sanguineti et al., 2013) which may be the 
key reason for prolonged tube feeding. 
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Another limitation of historical studies is the lack of information on the level of allied health 
input they have received both during and post-treatment for swallowing and nutritional 
rehabilitation. Maintenance of oral intake during treatment has been shown to reduce the 
duration of feeding tube use (Ames et al., 2011). The role of the dietitian has been identified 
as important in assisting patients wean from their feeding tube (Mayre-Chilton et al., 2011) 
and the prophylactic swallowing exercises prescribed by the speech pathologist are also 
important to maintain or improve long term swallow outcomes (Duarte, Chhetri, Liu, Erman, 
& Wang, 2013; Hutcheson et al., 2013).  
Likewise there is also insufficient detail on the criteria used for decision making regarding 
gastrostomy removal. Whilst some guidelines advocate a multidisciplinary team decision 
(Brown et al., 2013b), there is still minimal information in the literature on when it is 
appropriate to remove a gastrostomy. One study addressed predictors of gastrostomy 
removal and reported patients with localised HNSCC and those under 65 years old were 
independent predictors, however this was in a mixed population of HNSCC, other 
malignancies and neurological indications (Naik, Abraham, Roche, & Concato, 2005). 
Further limitations of this study were that oral intake resumption was used as the reason for 
gastrostomy removal however there was no additional information on the adequacy of the 
oral intake or the patients’ nutritional status at the time of removal. The lack of evidence in 
this area means that evidence based guidelines (Head & Neck Guideline Steering 
Committee, 2011; Talwar et al., 2016) are unable to provide clear recommendations to guide 
clinical practice on gastrostomy removal indications and report the patient should be able to 
maintain their nutritional status with safe swallowing prior to tube removal (Head & Neck 
Guideline Steering Committee, 2011). 
A recent randomised controlled trial comparing an early feeding intervention versus standard 
care in patients with HNSCC and a PGT prior to treatment has been completed to determine 
the effectiveness of this early intervention on minimising weight loss (Brown et al., 2014b) 
with the main outcomes reported elsewhere (Brown et al., 2017a). This current study is a 
planned secondary analysis from this trial to determine whether this early feeding 
intervention had any impact on longer term tube feeding outcomes. In addition, patterns of 
tube use post treatment and their role in providing nutrition support will be described. 
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PATIENTS AND METHODS 
Participants and Study Setting 
Adult patients with HNSCC were recruited from a tertiary hospital in Queensland, Australia 
from September 2012 to June 2015 if referred for a PGT prior to treatment based on a 
validated protocol (Brown et al., 2016b). Patients identified as high risk from this protocol 
and recommended a PGT typically received definitive or adjuvant chemoradiotherapy. Other 
patients may be considered for a PGT based on a consultant decision. 
Radiotherapy was delivered using helical-intensity modulated radiotherapy at a standard 
2Gy per fraction, five fractions per week, to a total maximal dose of 60-66Gy for adjuvant 
treatment (to the surgical bed) and 70Gy (to the gross disease) for definitive treatment. 
Elective nodal irradiation was delivered to bilateral neck using the same technique. Cervical 
lymph node levels at risk of harbouring subclinical disease were electively irradiated 
simultaneously to a total dose of 52-54Gy in 33-35 fractions delivered at 5 fractions per 
week. Concurrent chemotherapy was prescribed at the discretion of the medical oncologist 
and usually consisted of high dose cisplatin, weekly cisplatin or cetuximab.  
Patients were excluded from the study if: planned for non-curative intent treatment; or were 
severely malnourished; or were moderately malnourished with significant dysphagia 
requiring a liquid or puree texture modified diet.  
The study was approved by the Royal Brisbane and Women’s Hospital Human and The 
University of Queensland Medical Research Ethics Committees. All patients provided written 
informed consent to participate. This trial is listed in the Australian New Zealand Clinical 
Trials registry (ACTRN12612000579897) and the protocol is published for further 
information (Brown et al., 2014b). 
Randomisation 
Patients were stratified according to baseline nutritional status and randomly assigned to 
either the intervention or standard care (allocation ratio 1:1). Simple randomisation 
procedures were followed with a computer-generated randomisation sequence concealed 
to the researcher enrolling participants. 
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Interventions 
All patients were seen by the dietitian during overnight admission for PGT placement and 
then reviewed weekly by the dietitian and speech pathologist in a joint clinic as part of routine 
care. All patients were encouraged to maintain some level of oral intake during treatment as 
long as it remained safe to do so. 
Patients in the standard care group were commenced on enteral nutrition following 
assessment by the dietitian during treatment. Patients in the intervention group were 
commenced on supplemental enteral nutrition immediately following PGT placement prior 
to commencement of treatment in addition to their current oral intake. The prophylactic 
enteral nutrition consisted of 2x 200ml bolus feeds (1.5kcal/ml polymeric formula with fibre) 
per day and was continued until completion of treatment, increasing as necessary during 
treatment. Indicators for commencing or increasing enteral nutrition in both groups followed 
local protocol recommendations (Brown et al., 2016b).  
On completion of treatment all patients were referred to their local health service district 
dietitian and speech pathology service either at the tertiary centre itself or a regional cancer 
centre in Queensland, Australia. The research dietitian maintained monthly telephone 
contact with the patient to determine degree of tube use for up to six months post-treatment 
or until the tube was removed. If the tube was still in situ at six months, then follow up was 
repeated at 12 months post-treatment. 
Outcomes 
The primary outcome for this sub-study was the day of tube removal in relation to the day of 
completion of treatment. The null hypothesis being no difference in time to tube removal 
between the two groups. The use of the tube at each month was assessed as either: tube 
removed; tube in situ but not using; tube in situ and using for either 25% or 50% or 75% of 
nutrition requirements (supplementary nutrition); or tube in situ and using for 100% of 
nutrition requirements (with either oral intake as tolerated or nil by mouth due to aspiration 
risk). Diet texture, classified as either full, soft, minced, puree, or liquids, was recorded at 
baseline and at three months post treatment. Gastrostomy complications were recorded 
prospectively as part of routine care for the first three months the tube was in-situ. Major 
complications were defined as any complication necessitating hospital admission for 
management, including prolonged admissions post insertion. Minor complications were 
defined as stoma issues including site infections managed with oral antibiotics. 
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Statistical Methods 
Baseline participant characteristics for continuous variables were summarised using means 
and standard deviations and differences between groups assessed with two sample t–tests 
or Wilcoxon tests. For categorical variables at baseline and tube outcomes, frequency and 
percentages were calculated and group difference assessed using Chi-squared or Fishers 
Exact tests. Normal distribution was assessed using Shapiro-Wilk test and variance 
assessed using Levene’s test. Time to tube removal was analysed using the Kaplan Meier 
method and the log rank test. Statistical significance was set at p<0.05. Data were analysed 
using R Commander Version 2.1-7 and R version 3.1.3 (2015-03-09).  
RESULTS 
Participant Flow 
Overall 131 patients were randomised (61 intervention and 70 standard care). Seven 
patients were excluded and there were four deaths from persistent disease in the follow up 
phase (all died with their tube in-situ). There was one protocol deviation in each group. All 
patients that completed treatment were analysed on an intention-to-treat basis (n=124) and 
subsequent analysis was performed following exclusion of patients with persistent disease 
at three months (n=99) (Figure 8-3). 
Patient Characteristics  
There were no differences in patient, clinical and treatment characteristics between groups 
at baseline (Table 8-9). Patients were predominantly male, median age 60 years, with 
oropharyngeal tumours, and non-metastatic stage IV disease. The majority of patients 
received definitive or adjuvant chemoradiotherapy (n=116), five of whom had neoadjuvant 
chemotherapy, and the remaining patients received surgery alone (n=2), radiotherapy alone 
(n=1), and post-operative radiotherapy (n=5). There was a higher proportion of current 
smokers in the standard care group although this did not reach statistical significance (24% 
vs 9%, p=0.072)
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Assessed for eligibility (n=383) 
Excluded (n=252) 
   Not meeting criteria (n=209) 
   Eligible but failed to recruit (n=43) 
 
Lost to follow-up (n=2) 
- Withdrawn, patient choice (n=1) 
- Died during treatment (n=1) 
 
 
 
Lost to follow-up (n=1) 
- Died before 12 month review (n=1) 
 
 
 
Allocated to intervention (n=61) 
 Received allocated intervention (n=58) 
 Did not receive allocated intervention (n=3) 
- Withdrawn, no longer eligible (n=2) 
- PEG placed 1 day pre-op (n=1) 
Lost to follow-up (n=3) 
- Died before 3 month review (n=2) 
- Died before 5 month review (n=1) 
 
 
Allocated to standard care (n=70) 
 Received allocated intervention (n=67) 
 Did not receive allocated intervention (n=3)  
- Withdrawn, no longer eligible (n=2) 
- Patient initiated early feeding (n=1) 
Lost to follow-up (n=1) 
- Withdrawn as PEG removed (n=1) 
 
 
Allocation 
Analysis 
Follow-Up 
Randomised (n=131) 
Enrolment 
Complete cases at end of treatment (n=57) 
 
Complete cases at end of treatment (n=67) 
 
 
End of Intervention 
Figure 8-3: CONSORT Diagram of Patient Flow 
Abbreviations: PEG=gastrostomy tube.
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Table 8-9: Summary of patient characteristics at baseline with comparison of 
standard care group and intervention group  
Variable  Standard Care 
(n=67) 
Intervention 
(n=57) 
P value 
Age (years) 
 
Mean + sd 
Median (range) 
59.6 + 10.7 
59 (36-83) 
61.1 + 9.4 
60 (40-83) 
0.424 
Gender Male 58, 87% 52, 91% 0.414 
Female 9, 13% 5, 9% 
Smoking history Non smoker 14, 21% 12, 21% 0.072 
Former 37, 55% 40, 70% 
Current 16, 24%   5, 9% 
Tumour Site Oral cavity   6, 9%   7, 12% 0.899 
 Oropharynx 54, 81% 43, 75%  
 Nasopharynx   2, 3%   2, 4%  
 Hypopharynx   3, 5%   4, 7%  
 Larynx   1, 1%   0, 0%  
 Unknown Primary   0, 0%   1, 2%  
 Other   1, 1%   0, 0%  
T Stage T0 0, 0% 1, 2% 0.175 
 T1 4, 6% 4, 7%  
 T2 20, 30% 23, 40%  
 T3 25, 37% 11, 19%  
 T4 18, 27% 18, 32%  
N Stage N0   7, 10%   4,   7% 0.561 
 N1   7, 10%   4,   7%  
 N2a   1,   2%   3,   5%  
 N2b 29, 43% 24, 42%  
 N2c 19, 28% 21, 37%  
 N3   4,   6%   1,   2%  
Overall Stage II 1, 1% 0, 0% 0.409 
 III 10, 15% 5, 9%  
 IV 56, 84% 52, 91%  
P16 status Positive 43, 68% 41, 76% 0.358 
 Negative 20, 32% 13, 24%  
Treatment a Chemoradiotherapy 59, 88%  49, 86% 0.468 
 Adj chemoradiotherapy 5, 8%  3, 5%   
 Radiotherapy 1,  1% 0, 0%   
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 Adj radiotherapy 0, 0%  5, 9%   
 Definitive surgery 2, 3%  0, 0%   
Chemotherapy High dose cisplatin 36, 56% 31, 60% 0.395 
 Low dose cisplatin 12, 19% 13, 25%  
 Cetuximab 16, 25% 8, 15%  
Weight loss history Nil 21, 31% 28, 49% 0.193 
(in last 6 months) <5% 26, 39% 16, 28%  
 5-10% 11, 16% 9, 16%  
 >=10%   9, 13%   4, 7%  
Nutritional status Well-nourished  49, 73% 48, 84% 0.136 
 Malnourished 18, 27% 9, 16%  
Diet Full 46, 69% 38, 67% 0.778 
 Soft 18, 27% 14, 25%  
 Minced   3,   4%   4,   7%  
 Puree   0,   0%   1,   1%  
 
a For statistical analysis compared chemo based treatments (high risk) vs non-chemo based treatments (non-
high risk). Risk rating as per validated protocol for prophylactic gastrostomy selection (Brown et al., 2016b). 
 
Gastrostomy Tube Insertion and Complications  
Most patients had their PGT placed via endoscopy (93%) versus radiologically (7%), with 
no difference in method of placement between groups (p=0.505). The tubes were placed a 
median of five days prior to treatment in each group (p=0.334). There was no mortality 
associated with placement. There was no difference in major complications (10% standard 
care vs 11% intervention, p=0.989), or minor complications (40% standard care vs 40% 
intervention, p=0.995) between groups. The major complications included: peritonitis (n=3); 
IV antibiotics for site infection (n=1); blood transfusion for bleeding (n=1); failed endoscopic 
placement (n=2); and prolonged admission for pain management post insertion (n=7). Site 
infections accounted for approximately half of the minor complications (n=27/50).
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Gastrostomy Tube Use 
On assessment of the whole cohort, the PGT was used for full nutrition by 72% of patients 
(89/124) on completion of treatment, with 15% (19/124) using the tube for supplementary 
nutrition (Table 8-10). There were eight patients in standard care who did not use their PGT 
at all during treatment and eight patients in the intervention group that did not increase their 
feeds above the prescribed intervention amount (13%). Half of these had a less than 
desirable outcome of >10% weight loss or malnutrition. Five of these patients used their 
tube post-treatment and three were clearly non-adherent with recommendations to use.  
Patterns of PGT use and removal over time for each group can be seen in Figure 8-4. At 
one month post-treatment approximately two thirds of patients were still using their tube, 
and a third were requiring the tube for full nutrition. At two months tube use was 
predominantly for supplementary nutrition (27%) versus full enteral feeding (15%), and by 
three months this dropped slightly to 22%. By four months, just over half of the tubes had 
been removed (57%). There was no statistical difference between groups at any time point 
(Table 8-10). At four months, there was a trend to higher rates of supplementary feeding in 
the intervention group (21% vs 6%, p=0.052) (Table 8-10). The pattern of tube use was 
similar when only patients free of disease at three months post treatment were considered, 
although the differences observed at four months were significant (p=0.003). See 
Supplementary Table 1 (Table 8-13). 
Diet Texture Outcomes 
Just over half the patients in each group had returned to a full diet texture at three months 
post-treatment and there were no differences in diet texture between groups (p=0.727) 
(Table 8-11). 
Gastrostomy Tube Removal 
Median time (range) to tube removal was no different in each group: standard care group 
100 days (28-276) versus intervention group 110 days (21-280) (p=0.339). The Kaplan 
Meier curve shows that there was no statistical difference in the rate of removal over the 12 
month follow up period (p=0.181) (Figure 8-5). However the rate of removal was slower in 
the intervention arm when patients with persistent disease were excluded (p=0.047). See 
Supplementary Figure 1 (Figure 8-6). 
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Table 8-10: Comparison of gastrostomy use and tube outcomes for twelve months 
post-treatment between standard care and intervention group 
Months post 
treatment 
Tube use or 
Outcome 
Standard Care 
(n=67) 
Intervention 
(n=57) 
Total 
(n=124) 
Fishers 
Exact 
  N (%) N (%) N (%) P value 
0 Nil 8 (12) 8 (14) 16 (13) 0.737 
(N=124) Supplementary 9 (13) 10 (18) 19 (15) 
 Full 50 (75) 39 (68) 89 (72) 
1 Nil 22 (33) 15 (26) 37 (30) 0.857 
(N=124) Supplementary 22 (33) 22 (39) 44 (35) 
 Full 21 (31) 18 (32) 39 (31) 
 Removed 2 (3) 2 (4) 4 (3) 
2 Nil 27 (40) 18 (32) 45 (36) 0.710 
(N=124) Supplementary 18 (27) 16 (28) 34 (27) 
 Full 8 (12) 10 (18 ) 18 (15) 
 Removed 14 (12) 13 (23) 27 (22) 
3 Nil 26 (39) 21 (37) 47 (38) 0.477 
(N=124) Supplementary 11 (16) 16 (28) 27 (22) 
 Full 6 (9) 3 (9) 9 (7) 
 Removed 22 (33) 17 (30) 39 (31) 
 Died tube in situ 2 (3) 0 (0) 2 (2) 
4 Nil 18 (28) 10 (18) 28 (23) 0.052 
(N=122) Supplementary 4 (6) 12 (21) 16 (13) 
 Full 3 (5) 5 (9) 8 (7) 
 Removed 40 (62) 30 (53) 70 (57) 
5 Nil 8 (12) 9 (16) 17 (14) 0.331 
(N=122) Supplementary 2 (3) 5 (9) 7 (6) 
 Full 2 (3) 4 (7) 6 (5) 
 Removed 52 (80) 39 (68) 91 (74) 
 Died tube in situ 1 (2) 0 (0) 1 (1) 
6 Nil 6 (9) 7 (12) 13 (11) 0.239 
(N=121) Supplementary 1 (2) 5 (9) 6 (5) 
 Full 2 (3) 3 (5) 5 (4) 
 Removed 55 (86) 42 (74) 97 (80) 
12 Nil 3 (4) 2 (3) 5 (4) 0.526 
(N=121) Supplementary 0 (0) 2 (3) 2 (2) 
 Full 1 (2) 2 (3) 3 (2) 
 Removed 60 (94) 50 (88) 110 (91) 
 Died tube in situ 0 (0) 1 (2) 1 (1) 
Abbreviations: *Statistically significant (p<0.05)
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Table 8-11: Comparison of diet texture outcomes at three months post treatment 
between standard care and intervention group 
Diet Texture at 3 months post treatment Standard Care 
(n=64)a 
Intervention 
(n=57) 
P value 
Full 33, 51% 30, 53% 
0.727 
Soft 21, 33% 14, 25% 
Minced 4, 6% 4, 7% 
Puree 3, 5% 4, 7% 
Liquid 3, 5% 3, 5% 
NBM 0, 0% 2, 3% 
Abbreviations: *Statistically significant (p<0.05), a n=2 died before 3 month follow up and n=1 missing data 
(patient too unwell to attend follow up appointment) 
 
Gastrostomy Outcomes at 12 months 
At 12 months there were ten patients overall with tubes in-situ giving an apparent 
gastrostomy dependency rate of 8%; however only five were using the tube, giving a true 
gastrostomy dependency rate of 4% (Table 8-10). Of those not using the tube; two were 
waiting appointments for removal and three were delayed decision-making due to suspected 
recurrent disease. Patients still using the tube at 12 months were all legitimate cases (Table 
8-12). When patients with persistent disease in the 12 month follow up period were excluded 
there were only three patients overall using the tube at one year post-treatment. Two of 
these were due to post-operative functional dysphagia and one was due to severe 
dysphagia following definitive chemoradiotherapy.   
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Figure 8-4: Patterns of gastrostomy use over twelve month’s post-treatment with comparison between standard care and 
intervention group 
Abbreviations: Std=standard care group; Int=intervention group.
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Table 8-12: Characteristics of patients who are still tube dependent at twelve months post-treatment 
Patient Diagnosis PET response at 
3 months 
Clinical outcome 
at 12 months 
Diet textures before and during 
treatment 
Diet outcomes 
at 12 months 
Tube use at 12 
months 
1 T1N2b oropharynx  
SCC P16+ 
Chemoradiotherapy 
 
Full response Disease free Dysphagia diagnosed from week 2 of 
treatment, placed NBM from end of 
treatment to 6 months post treatment 
Recommended 
to remain NBM, 
but eating and 
drinking as 
tolerated 
Supplementary 
(75%) 
2 T4N2b oropharynx  
SCC P16+ 
Chemoradiotherapy 
Persistent 
disease 
Disease free 
following salvage 
surgery 
Dysphagia diagnosed from week 6 of 
treatment, thick fluids only at end of 
treatment, and NBM between 4-6 
months post treatment 
Liquids/puree as 
tolerated 
Full 
3 T4N0 oropharynx 
Adenoid cystic 
carcinoma 
Adjuvant radiotherapy 
 
N/A as primary 
resection 
Disease free NBM from surgery to 6 months post 
treatment 
Commenced 
thick fluids only 
Full 
4 T4N2b oropharynx 
SCC P16- 
Chemoradiotherapy 
 
Persistent 
disease 
Palliative with 
lung metastases  
Dysphagia pre-treatment – requiring 
soft diet. Modified texture diet as 
tolerated throughout treatment – with 
full tube use at end of treatment 
Liquids/puree as 
tolerated 
Full 
5 T2N1 oral cavity 
SCC 
Adjuvant 
chemoradiotherapy 
N/A as primary 
resection 
Disease free Dysphagia post op – requiring puree 
diet. Modified texture diet as tolerated 
throughout treatment  – with full tube 
use at end of treatment 
Puree Supplementary 
(25%) 
Abbreviations: PEG=gastrostomy tube; SCC=squamous cell carcinoma; NBM=nil by mouth.
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Figure 8-5: Kaplan Meier curves to compare the rate of gastrostomy tube removal 
over twelve months post-treatment between standard care and intervention group 
DISCUSSION 
This study reports on PGT use in the post-treatment period in a group of patients with 
advanced HNSCC predominantly receiving chemoradiotherapy. This study demonstrated 
that tube use remains important in the immediate acute phase post-treatment despite the 
predominate use of helical-IMRT in this trial. The majority of patients then recover relatively 
quickly prior to their three month outcome assessment with the oncologist and there is a low 
incidence of long term tube dependency at 12 months. The early intervention which 
encouraged early PGT use to supplement oral intake may have prolonged time to tube 
removal in this heterogeneous study cohort but it did not increase long term dependency 
rates beyond four months post treatment. 
On completion of treatment, 87% of patients utilised their tube, with the majority entirely 
dependent for their full nutritional needs. This is higher than previous reports in the literature 
at 75% (Akst et al., 2004), but may be attributable to the increasing incidence of human 
papillomavirus (HPV) related tumours (Hocking et al., 2011). These p16 positive tumours 
(as a marker for HPV status) appear to have increased acute toxicities compared to p16 
negative tumours (Becker-Schiebe et al., 2015), and thus the need for nutrition support is 
likely to be higher. A recent study has confirmed that p16 status can be used as a predictor 
of PGT requirement (Brown et al., 2017b).
Chapter 8 Early nutrition intervention pre-treatment: Results 
   
 196 
Overall usage is still high at one month post-treatment at 66% and then drops to 29% at 
three months. This compares favourably to other studies with rates of 66% of patients 
requiring a feeding tube at three months (Akst et al., 2004) and 62-65% at six months in a 
study where patients received accelerated or hyper fractionated chemoradiotherapy 
(Hatoum et al., 2009). This improvement is potentially attributed to advanced radiotherapy 
techniques such as helical-IMRT which further minimise doses to organs at risk and thus 
reduce long term toxicities such as xerostomia and dysphagia (Lee et al., 2008a; Sheng et 
al., 2006), thus allowing patients to recover more quickly.  
When cumulative tube use is considered both during and post-treatment, this highlights that 
the majority of patients do require nutrition support via a feeding tube for greater than four 
weeks and therefore selection of a gastrostomy over a nasogastric tube is appropriate based 
on this outcome (Arends et al., 2006). Given the ultimate reason for placing a PGT is to 
ensure provision of adequate nutrition and to minimise the negative sequelae of malnutrition, 
longer term use should not be negatively viewed. 
Malnutrition is common post-treatment (Jager-Wittenaar, et al., 2011a; Silander et al., 2012; 
van den Berg et al., 2008), and poor nutrition indicators such as low BMI and pre-treatment 
weight loss have also been associated with gastrostomy dependence (McRackan et al., 
2008; Wopken et al., 2014b). This suggests that gastrostomy use can be appropriate to 
assist improving long term nutritional status. It is acknowledged there were 16 patients that 
did not use their PGT by the end of treatment, however some patients went on to use their 
PGT post-treatment, whilst others were non-adherent to recommendations and would have 
benefited from using the PGT based on their poorer nutritional outcomes. 
The median removal time following completion of treatment was 110 days (range 21-280) 
for the whole cohort. This is similar to another study where the median duration of tube 
feeding after completion of treatment was 110 days, although the range was much wider 
from 0-592 days (Silander et al., 2010), and more favourable than a study that reported a 
median duration of tube use at 192 days in a group of patients receiving chemoradiotherapy 
with IMRT (Li et al., 2009). However it is difficult to compare results across other studies due 
to variations in how authors define the time period of tube use/duration. Limitations of 
several studies which report on gastrostomy dependency have not considered appropriate 
nutritional outcome data including degree of tube use, or the intensity and frequency of 
dietary counselling (Talwar & Findlay, 2012). 
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This study has illustrated that using the presence of a gastrostomy as a measure of 
gastrostomy dependency is not an accurate indicator due to potential non-use of the tube, 
and thus leads to over-estimation of dependency rates. For future study designs it is 
recommended that gastrostomy use is recorded to determine whether patients are truly 
dependent on their tube or not.  
Dysphagia is a major long term toxicity in many patients, even in those without enteral 
feeding tubes (Oozeer et al., 2011; Sethugavalar et al., 2016). There are concerns in the 
literature that gastrostomy insertion can lead to dysphagia and tube dependency (Chen et 
al., 2010; Corry et al., 2008; Langmore et al., 2012; Mekhail et al., 2001), although other 
studies have shown no detrimental impact on swallowing function (Crombie et al., 2015; 
Silander et al., 2010) and the body of literature remains inconclusive from a recent 
systematic review (Shaw et al., 2015). Whilst the data from this current study suggests there 
may have been more tendency for the intervention group to use the tube for supplementary 
feeding for longer, with an increased use at four months post-treatment, there were no other 
statistical differences at any other time point. Overall encouraging early use of the PGT 
before treatment and before nutrition impact symptoms develop did not result in an increase 
in long term dependency, with the only differences observed at four months. Post-hoc 
analysis in patients free of disease indicated that the intervention group may have had 
slower rates of removal; however this was largely attributed to patients who underwent 
primary surgical resection of their tumour which increases the risk of dysphagia.  
A limitation of this study was that swallowing outcome measures were not included. However 
both groups had similar outcomes in terms of diet texture tolerance at three months post-
treatment, with half of all patients in each group resuming full diet texture.  At this time point, 
31% of patients had their tube removed and 38% were no longer using it. This is similar to 
a previous study which reported that half of all patients had resumed a full diet by the time 
of PGT removal (Crombie et al., 2015). Whilst PGT placement has been reported to show 
improvements in quality of life during the acute treatment phase (Salas et al., 2009; Silander 
et al., 2012), the presence of a long term feeding tube has the greatest negative impact on 
quality of life (Terrell et al., 2004), particularly in the domains of interference with family life, 
relationships, social activities and hobbies (Rogers et al., 2007). It has also been associated 
with clinical depression (Chen et al., 2013). One study also reported that two thirds of 
patients were longing to have the tube removed (Roberge et al., 2000) and similar comments 
were seen in a qualitative study (Merrick & Farrell, 2012). 
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This current study has shown that as patients recover post-treatment many have tubes in-
situ which are no longer being used and thus has the potential to impact on quality of life, 
mental health and their recovery from their cancer experience. As there are no general 
guidelines as to when gastrostomy removal should occur when the tube is no longer 
required, many clinicians opt to wait for the outcome of the post-treatment scans to ensure 
no further treatment or salvage surgery is required for persistent disease. One study has 
reported that the relative risk of feeding tube dependence at 18 and 24 months was 4.74 
and 7.66 respectively in patients who have undergone a post-treatment neck dissection 
(Lango et al., 2010). This risk needs to be outweighed with the potential benefit of tube 
removal on the patient’s quality of life, and should be discussed with the individual patient 
to inform decision making. 
CONCLUSION 
PGT use continues to play a significant role in the nutritional management of patients with 
HNSCC in the acute phase post-treatment and long term dependence rates are low. 
Encouraging early use of the PGT may prolong time to tube removal but it does not increase 
long term dependency rates beyond four months post treatment.  However prolonged 
gastrostomy use is a complex multifaceted phenomena and consideration must be given to 
the patient’s nutritional status to assist understanding of the reasons for long term tube use 
as it may be appropriate. 
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Table 8-13: Supplementary Table 1 - Comparison of gastrostomy use and tube 
outcomes for twelve months post-treatment between standard care and intervention 
groups in patients clear of disease at three months 
Months post 
treatment 
Tube use or 
Outcome 
Standard Care 
(n=52) 
Intervention 
(n=47) 
Total 
(n=99) 
P value 
0 Nil 5 (10) 7 (15) 12 (12) 0.477 
 Supplementary 6 (11) 8 (17) 14 (14) 
 Full 41 (79) 32 (68) 73 (74) 
1 Nil 18 (34) 13 (28) 31 (31) 0.919 
 Supplementary 15 (29) 15 (32) 30 (30) 
 Full 17 (33) 17 (36) 34 (34) 
 Removed 2 (4) 2 (4) 4 (4) 
2 Nil 22 (42) 15 (32) 37 (37) 0.305 
 Supplementary 16 (31) 12 (26) 28 (28) 
 Full 4 (8) 9 (19 ) 13 (13) 
 Removed 10 (19) 11 (23) 21 (21) 
3 Nil 21 (40) 15 (32) 36 (36) 0.581 
 Supplementary 11 (21) 15 (32) 26 (26) 
 Full 2 (4) 3 (6) 5 (5) 
 Removed 18 (35) 14 (30) 32 (32) 
4 Nil 14 (27) 5 (11) 19 (19) 0.003* 
 Supplementary 4 (8) 12 (26) 16 (16) 
 Full 0 (0) 4 (8) 4 (4) 
 Removed 34 (65) 26 (55) 60 (61) 
5 Nil 5 (10) 7 (15) 12 (12) 0.082 
 Supplementary 2 (4) 5 (11) 7 (7) 
 Full 0 (0) 3 (6) 3 (3) 
 Removed 45 (86) 32 (68) 77 (78) 
6 Nil 3 (6) 5 (11) 8 (8) 0.166 
 Supplementary 1 (2) 5 (11) 6 (6) 
 Full 1 (2) 2 (4) 3 (3) 
 Removed 47 (90) 35 (74) 82 (83) 
12 Nil 1 (2) 2 (4) 3 (3) 0.244 
 Supplementary 0 (0) 2 (4) 2 (2) 
 Full 0 (0) 1 (2) 1 (1) 
 Removed 51 (98) 42 (89) 93 (94) 
*Statistically significant (p<0.05) 
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Figure 8-6: Supplementary Figure 1 - Kaplan Meier curves to compare the rate of 
gastrostomy tube removal over twelve months post-treatment between standard care 
and intervention group in patients clear of disease at three months 
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8.4 RCT: Patient adherence and barriers 
8.4.1 Abstract 
Objectives: The main aim was to investigate the incidence of patient adherence to nutritional 
tube feeding recommendations in patients with head and neck cancer and to determine 
patient barriers to meeting tube feeding prescription.  
Materials and Methods: This was an observational study from a randomised controlled trial 
in patients with head and neck cancer deemed at high nutritional risk with prophylactic 
gastrostomy (n=125). Patients were randomised to receive early tube feeding prior to 
treatment (intervention group) or standard care. All patients in the intervention and standard 
care groups then commenced clinical tube feeding as required during treatment. Patients 
maintained a daily record of gastrostomy intake, main nutrition impact symptom 
necessitating gastrostomy use, and reasons for not meeting nutrition prescription. 
Adherence was defined as meeting ≥75% of total prescribed intake.  
Results: Patients were predominantly male (89%), median age 60, with oropharyngeal 
tumours (78%), stage IV disease (87%) treated with chemoradiotherapy (87%). Primary 
reasons for gastrostomy use were poor appetite/dysgeusia (week 2-3) and 
odynophagia/mucositis (week 4-7). Early tube feeding adherence was 51%. Clinical tube 
feeding adherence was significantly higher in the intervention group (58% vs 38%, p=0.037). 
Key barriers to both phases of tube feeding were; nausea, early satiety and treatment factors 
(related to hospital healthcare processes). 
Conclusions: Early tube feeding can improve patient adherence to clinically indicated tube 
feeding during treatment. Low adherence overall is a likely explanation for clinically 
significant weight loss despite intensive nutrition interventions. Optimising symptom 
management and strategies to overcome other barriers are key to improving adherence.
 Chapter 8 Early nutrition intervention pre-treatment: Results  
 202 
8.4.2 Manuscript 
INTRODUCTION 
Treatment fidelity is important to assess in intervention research trials as it refers to the 
extent to which interventions are delivered as intended according to the study protocol 
(Gearing et al., 2011). It is particularly important for intervention research trials which 
encompass behavioural change, so that the efficacy of the intervention can be considered 
in the correct context and inappropriate rejection of potentially effective interventions can be 
minimised (Beck et al., 2015). Treatment fidelity has been described as having at least four 
core components including: study design and protocol to outline how the intervention should 
be organised and delivered; training and supervision of those delivering the intervention to 
ensure consistency; monitoring of intervention delivery to determine whether the 
intervention was delivered as intended; and monitoring of intervention receipt to determine 
whether the intervention was received and understood (Bellg et al., 2004; Gearing et al., 
2011). A recent systematic review identified that monitoring of intervention delivery is 
currently the most widely reported component in the literature, with monitoring of intervention 
receipt having the least focus (Gearing et al., 2011). Assessment of intervention receipt can 
include considerations to patient comprehension, engagement and adherence to the 
intervention (Beck et al., 2015). 
Patient adherence alone is a complex area of treatment fidelity affecting many aspects of 
healthcare. A number of studies have investigated patient adherence in different aspects of 
generic multidisciplinary cancer care and their impact on clinical outcomes such as; oral 
chemotherapy (Greer et al., 2016; Muluneh et al., 2016), analgesics (Oldenmenger, Sillevis 
Smitt, de Raaf, & van der Rijt, 2016; Meghani & Knafl, 2016), and anti-emetic medication 
(Vidall et al., 2015). Patient characteristics have been shown to influence adherence to 
clinical practice guidelines in the critical care setting (Cahill, Suurdt, Ouellette-Kuntz, & 
Heyland, 2010). It has been reported that patients with head and neck squamous cell 
carcinoma (HNSCC) have a high rate of mental health problems, substance use and social 
issues which increases psychologic distress and depression (Kugaya et al., 2000), which in 
this population, can predict malnutrition outcomes (Britton et al., 2012). Depression has also 
been shown to reduce adherence to medical treatment recommendations (DiMatteo et al., 
2000) and so the characteristics of this patient population suggests that adherence may be 
particularly challenging. Indeed a recent systematic review on swallowing preservation 
exercises reported low adherence rates in all trials reporting on this outcome (n=4) (Perry, 
Lee, Cotton, & Kennedy, 2016).  
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Adherence to dietary advice in patients with HNSCC has rarely been studied. One study 
defined adherence as patient acceptance of dietary counselling or tube feeding as part of 
their nutrition program, and found non-adherence resulted in more weight loss (Capuano et 
al., 2008). However this did not account for adherence to the dietary advice actually 
provided. This has been addressed more recently, where a study defined adherence to 
dietary counselling as consuming ≥75% of recommended energy and protein intake, and 
this confirmed favourable outcomes on body composition parameters with adherence 
(Hopanci Bicakli et al., 2017). 
Nutrition support and intervention is considered an integral component of HNSCC 
management and includes regular nutrition screening and assessment, dietary counselling 
and tube feeding interventions, including consideration to prophylactic gastrostomy 
placement (Talwar et al., 2016). However despite these intensive recommended nutrition 
interventions, significant weight loss still occurs (Brown et al., 2014a; Silander et al., 2010). 
A randomised controlled trial (RCT) was initiated to further intensify nutrition intervention 
through commencement of an early supplementary tube feeding phase via the prophylactic 
gastrostomy before there were any clinical indicators for tube feeding during treatment 
(Brown et al., 2014b). It was hypothesised that this “early tube feeding phase” would reduce 
fear and anxiety associated with the tube (Merrick & Farrell, 2012), assist patients to adapt 
to using the tube for when it was required during the “clinical tube feeding phase” to meet 
nutritional requirements (Salas et al., 2009), and thus result in less weight loss. There was 
no difference in the primary outcome of weight loss or secondary outcomes including quality 
of life, nutritional status, body composition, clinical outcomes and survival (Brown et al., 
2017a). 
The primary aim of this sub study from the RCT described above was to report on patient 
adherence to nutritional tube feeding recommendations, as a measure of one component of 
treatment fidelity, and to determine if there were any differences in adherence following the 
early tube feeding intervention versus standard care. The second aim was to determine any 
patient barriers to meeting the prescribed level of tube feeding, during both the early and 
clinical phases of tube feeding. Once the clinical phase of tube feeding had commenced the 
final aim was to explore reasons why patients felt they needed the tube for nutrition support, 
to gain a greater understanding of their experience and perspective. 
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PATIENTS AND METHODS 
Participants and Study Setting 
Patients with HNSCC were recruited from the Royal Brisbane and Women’s Hospital 
(RBWH), a tertiary/quaternary hospital in Queensland, Australia from September 2012 to 
June 2015. They were included if referred for a prophylactic gastrostomy prior to treatment 
based on a validated protocol (Brown et al., 2016b). Patients were randomly assigned using 
a computer generated concealed allocation sequence to either the early intervention or 
standard care (1:1). 
The full trial protocol has been published and describes the full eligibility criteria, 
randomisation procedures, primary outcome measures and sample size calculation in more 
detail (Brown et al., 2014b). The study had ethical approval by the RBWH Human Research 
Ethics Committee and The University of Queensland Medical Research Ethics Committee. 
All patients provided written informed consent to participate. 
Interventions 
Patients were reviewed weekly by the dietitian, speech pathologist, radiation oncologist and 
medical oncologist, and had access to nursing support and other allied health services as 
required. Radiotherapy was delivered using helical-intensity modulated radiotherapy at 
doses of 2Gy per day to a total 60-70Gy. Chemotherapy was prescribed at the discretion of 
the medical oncologist. 
Patients in the intervention group had supplemental tube feeding commenced immediately 
following gastrostomy placement (prior to treatment/surgery) in addition to their current oral 
intake. The prescription consisted of two bolus feeds (1.5kcal/ml polymeric formula with 
fibre) per day (total 400ml) which continued as a minimum until completion of treatment. 
This was defined as the “early tube feeding phase” and was only prescribed in the 
intervention arm. Weekly supplies were provided to the patient and they were all encouraged 
to maintain oral intake as much as possible. Once treatment commenced, patients were 
assessed weekly by the dietitian and in response to clinical criteria, were commenced on 
tube feeding (standard care) or had tube feeding increased (intervention). Indicators for 
commencing or increasing enteral nutrition in both groups were stated in the local protocol 
(Brown et al., 2016b) and included factors such as reduced oral intake, weight loss and/or 
uncontrolled symptoms. This was defined as the “clinical tube feeding phase” and was 
possible in both groups. 
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When this phase commenced the patient was given a script requiring co-payment to obtain 
supplies through pharmacy or home delivery. The regimen was determined by the dietitian 
to suit the patients’ individual requirements and adjusted weekly as required. If tolerance 
was a concern, alternative feed formulas and delivery methods were negotiated and trialled.  
On commencement of either phase of tube feeding all patients were provided with weekly 
diary log books. Patients were asked to record the main reason necessitating gastrostomy 
use each week, which may have been for the study intervention itself. A checklist of nutrition 
impact symptoms was provided and included free text space for any other reasons. Patients 
were asked to complete this step to determine the underlying cause of the triggers for the 
recommendation to commence clinical tube feeding (i.e. the resultant weight loss or poor 
oral intake). This patient reported information would also prevent any bias from clinician 
interpretation of the reasons. Secondly patients were asked to maintain a daily record of 
gastrostomy intake with any reasons for not meeting nutrition prescription if applicable (free 
text space). The dietitian collected the diaries from the patients at each weekly review and 
if incomplete assisted with completion as able with information obtained from 
interview/assessment. 
Outcomes 
Daily percentage adherence to tube feeding was calculated from patient diaries based on 
prescribed versus actual recorded intake and mean adherence for the duration of tube 
feeding was calculated as the primary outcome. So that all diaries were complete, 
retrospective chart audits were undertaken if required to obtain any missing data from the 
documented weekly dietitian assessments which were based on patient reported intake 
data. Daily and overall adherence was then classified as a binary variable (adherent vs non-
adherent) which was defined as ≥75% of prescribed intake. 
Days that patients were non-adherent based on this definition were identified from patient 
diaries and any stated barriers were extracted. If patients recorded multiple barriers for any 
one day, all were included. If no barriers were stated on non-adherent days this was also 
recorded to calculate adherence to diary completion. Due to the qualitative and individual 
nature of this outcome, any missing data was accepted as missing and not statistically 
imputed. Barriers were then classified according to: nutrition impact symptoms as per the 
Patient-Generated Subjective Global Assessment (PG-SGA) (Ottery, 2005); other physical 
symptoms; patient factors and environmental factors. The rationale for these classifications 
and examples of entries from patient diaries are shown in Table 8-14.  
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The date the dietitian recommended initiating the clinical tube feeding phase was recorded 
and classified as week of treatment according to fractions of radiotherapy received (5# per 
week). Reasons for gastrostomy tube use each week were collated from patient diaries. 
Weight was measured in kilograms using digital scales at baseline, end of radiotherapy 
treatment and at three months post radiotherapy, and percentage weight loss was 
calculated. 
Statistical Methods 
Baseline participant characteristics and outcomes between groups (where relevant) were 
summarised using mean and standard deviation for continuous variables and frequency and 
percentage for categorical variables. Differences between groups were assessed using Chi-
squared or Fishers Exact tests for categorical variables and two sample t–tests for 
continuous variables. The Shapiro-Wilk test was used to test normality and Levene’s test 
was used to assess variance. Adherence and barriers to feeding were assessed as either 
the early tube feeding phase (intervention group only) or the clinical tube feeding phase 
(both groups) and outcomes reported using descriptive statistics. Statistical significance was 
set at p<0.05. Data were analysed using Excel 2013 and R Commander Version 2.1-7 and 
R version 3.1.3 (2015-03-09). 
RESULTS 
Patient Characteristics 
One hundred and thirty one patients entered the RCT. The flow through the study is 
illustrated in Figure 8-7. Of the eligible patients, 58 were in the intervention and 67 were in 
the standard care group. The early tube feeding phase was completed by 57/58 patients in 
the intervention group. The clinical tube feeding phase was completed by 50/58 eligible 
patients in the intervention group and 58/65 eligible patients in standard care. Two patients 
were excluded in standard care as they received surgery alone. The patient demographic 
and clinical characteristics are shown in Table 8-15. Patients were predominantly male 
(89%), median age 60 (range 36-83), with oropharyngeal tumours (78%), stage IV disease 
(87%) treated with chemoradiotherapy (87%), with no statistically significant differences 
between groups. Clinically there was a higher proportion of patients with advanced T stage 
in the standard care group and a higher mean BMI in the intervention group. 
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Table 8-14: Classification of patient reported barriers to tube feeding during 
definitive/adjuvant (chemo) radiotherapy for head and neck cancer 
Category Individual barriers 
 
Examples from diaries 
Nutrition 
Impact 
Symptoms 
No problems eating Eating normally 
Still eating and drinking orally 
Not needing PEG 
Constipation 
 
Constipated since chemo 
Problems with constipation 
Diarrhoea 
 
Had loose bowel 
Pump reduced due to diarrhoea 
Feel full quickly 
 
Too full and unable to eat other meals 
Bloated feeling – too full 
Nausea 
 
Have felt nauseous for a few days 
I feel like I want to throw up every meal 
No appetite 
 
Appetite down 
Not hungry 
Pain 
 
Too much pain 
Using Endone for pain and headaches 
Smells Bother me 
 
Smells make me feel ill 
Smell sensitivity 
Vomiting 
 
Had two feeds but threw one up 
Vomiting after PEG feed 
Other physical 
symptoms 
Reflux 
 
Bad reflux in the evening couldn’t eat 
Hiccups all day 
Fatigue 
 
Too fatigued 
Very tired, asleep by 6pm 
Malaise 
 
Felt unwell 
Not well 
Patient factors Psychosocial 
(e.g. mood, motivation, support) 
Not bothered 
Feeling very low – no get up and go 
Wife not there to encourage 
Script 
(e.g. ordering, delivery, supply) 
Not ordered script due to finances 
Haven’t got script yet 
Ran out of supply 
Time 
(e.g. lack of time) 
Not enough time 
Out all day 
Home late 
Other alternatives 
(e.g. choosing other food/drink) 
Tried Weetabix and Sustagen 
Ate fruit 
2L water 
Environmental 
factors 
Treatment 
(e.g. appointments, admissions) 
On drip at hospital for 2hours 
Stopped doing feeds when admitted 
Interrupted by chemo & rad treatment 
Medical  
(e.g. tube/feeding complications) 
Nil by tube for endoscopy 
Advised no feeds until review by doctor 
Having trouble with tube 
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Figure 8-7: Patient Flow through Study Phases 
Abbreviations: PEG=gastrostomy; Pre-op=pre-operatively; Pre-RT=pre- radiotherapy.
Total patients recruited and randomised (N=131) 
Intervention Group (N=61) 
Total patients analysed in the Clinical Tube Feeding Phase (N=108) 
-  
Standard Care group (N=70) 
Early Tube 
Feeding Phase 
N=57 
Eligible for Clinical Tube Feeding  
N=58 
Eligible for Clinical Tube Feeding 
N=65 
Pre-treatment PEG Placement (N=125) 
 
PEG Pre-op 
N=4 
 
PEG Pre-RT 
N=54 
 
PEG Pre-RT 
N=65 
 
PEG Pre-op 
N=2 
 
No Early Tube 
Feeding Phase 
N=1 
Withdrawn (n=3) Withdrawn (n=3) 
 
Never used tube (n=8) Never used tube (n=7) 
Surgery 
alone 
(n=2) 
Intervention Group (N=58) Standard Care group (N=67) 
Completed Clinical  
Tube Feeding Phase (N=50) 
Note: N=1 incomplete (died week 3) and 
N=8 completed week 6 
Completed Clinical  
Tube Feeding Phase (N=58) 
Note: N=1 completed week 6 
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Table 8-15: Summary of demographic and clinical characteristics of patients with 
head and neck cancer (n=125) 
Variable Total 
(n=125) 
Standard 
(n=67) 
Intervention 
(n=58) 
p value 
Age (years) Mean + sd 60.3 + 10.1 59.6 + 10.7 61.0 + 9.3 0.439 
BMI (kg/m2) Mean + sd 27.4 + 5.5 26.5 + 5.7 28.4 + 5.2 0.063 
  N (%)  
Gender Male 111 (89) 58 (87) 53 (91) 0.395 
Female 14 (11) 9 (13) 5 (9) 
Tumour Site Oral cavity 13 (10) 6 (9) 7 (12) 0.770 
 Oropharynx 97 (78) 54 (81) 43 (74) 
 Nasopharynx 4 (3) 2 (3) 2 (3) 
 Hypopharynx 8 (6) 3 (5) 5 (9) 
 Other 3 (3) 2 (2) 1 (2) 
T Stage T0 1 (1) 0 (0) 1 (2) 0.153 
 T1 8 (6) 4 (6) 4 (7) 
 T2 44 (35) 20 (30) 24 (41) 
 T3 36 (29) 25 (37) 11 (19) 
 T4 36 (29) 18 (27) 18 (31) 
N Stage N0 11 (9) 7 (10) 4 (7) 0.567 
 N1 11 (9) 7 (10) 4 (7) 
 N2a 4 (3) 1 (2) 3 (5) 
 N2b 54 (43) 29 (43) 25 (43) 
 N2c 40 (32) 19 (28) 21 (36) 
 N3 5 (4) 4 (6) 1 (2) 
Overall Stage II-III 16 (13) 11 (16) 5 (9) 0.344 
 IV 109 (87) 56 (84) 53 (91) 
p16 status Positive 84 (71) 43 (68) 41 (75) 0.452 
(n=118) Negative 34 (29) 20 (32) 14 (25) 
Treatment Surgery +/- RT 8 (7) 3 (4) 5 (9) 0.617 
  CRT 109 (87) 59 (88) 50 (86) 
 Adj CRT 8 (6) 5 (8) 3 (5) 
Abbreviations: BMI=body mass index; RT=radiotherapy; CRT=chemoradiotherapy. 
 
Weight Outcomes 
Both groups experienced similar levels of weight loss during radiotherapy (6.7+5.3% 
standard care vs 6.1+4.5% intervention, p=0.471, 95% CI [-2.4, 1.1]) as well as up to three 
months post treatment (10.9+6.7% standard care vs 10.8+5.6% intervention, p=0.930, 95% 
CI [-2.3, 2.1]). 
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Adherence to tube feeding 
Overall mean adherence to the early tube feeding phase was 67.9+29.6%. Adherence to 
the early tube feeding phase improved over time, and was consistently above 70% from 
week 3 onwards (Figure 8-8), although the number of patients in this phase decreased over 
time as patients progressed to the clinical tube feeding phase (Table 8-16).  
Overall mean adherence to clinical tube feeding was higher in the intervention group at 
77.4+18.7% compared to 69.0+20.2% in the standard care group (p=0.028, 95% CI [0.9, 
15.9]). Adherence to the clinical tube feeding phase in the intervention group was 
consistently high throughout treatment at approximately 70% or more, but only reached this 
level after week four of treatment in standard care (Figure 8-8). This illustrates a period of 
adaptation is required following commencement of tube feeding irrespective of whether it 
was prophylactic or clinically indicated. 
 
Figure 8-8: Mean adherence to tube feeding recommendations over time for patients 
with head and neck cancer receiving definitive/adjuvant (chemo) radiotherapy 
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Table 8-16: Timing of commencement and reason for clinical tube feeding in patients with head and neck cancer receiving 
definitive/adjuvant (chemo) radiotherapy 
Week of 
Treatment 
Number of patients commencing 
clinical tube feeding 
Accumulative 
use of tube 
Patient reason for clinical tube feeding 
 Standard 
(n=60) 
Intervention 
(n=50) 
Total  
(n=110) 
Total 
(n=125) 
 Standard 
(n=60) 
Intervention 
(n=50) 
Total  
(n=110) 
n n (%) n n (%) 
Week 0 3 4 7 7 (6) Odynophagia 
Nausea 
Appetite/taste 
Dysphagia 
0 
0 
1a 
2 
0 
0 
0 
4 
0 (0) 
0 (0) 
1 (14) 
6 (86) 
Week 1 3 1 4 9 (7) b Odynophagia 
Nausea 
Appetite/taste 
Dysphagia 
1 
1 
1 
1 
0 
0 
1 
4 
1 (11) 
1 (11) 
2 (22) 
5 (56) 
Week 2 16 9 25 34 (28) Odynophagia 
Nausea 
Appetite/taste 
Dysphagia 
2 
5 
11 
2 
0 
3 
7 
4 
2 (6) 
8 (23) 
18 (53) 
6 (18) 
Week 3 12 16 28 62 (50) Odynophagia 
Nausea 
Appetite/taste 
Dysphagia 
13 
2 
15 
2 
7 
3 
13 
7 
20 (32) 
5 (8) 
28 (45) 
9 (15) 
Week 4 15 12 27 88 (72) c Odynophagia 
Nausea 
Appetite/taste 
Dysphagia 
22 
3 
16 
6 
12 
7 
14 
8 
34 (39) 
10 (11) 
30 (34) 
14 (16) 
Week 5 6 4 10 98 (80) Odynophagia 
Nausea 
Appetite/taste 
Dysphagia 
25 
7 
16 
5 
17 
6 
14 
8 
42 (43) 
13 (13) 
30 (31) 
13 (13) 
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Week of 
Treatment 
Number of patients commencing 
clinical tube feeding 
Accumulative 
use of tube 
Patient reason for clinical tube feeding 
 Standard 
(n=60) 
Intervention 
(n=50) 
Total  
(n=110) 
Total 
(n=125) 
 Standard 
(n=60) 
Intervention 
(n=50) 
Total  
(n=110) 
n n (%) n n (%) 
Week 6 4 3 7 105 (86) Odynophagia 
Nausea 
Appetite/taste 
Dysphagia 
30 
5 
15 
7 
24 
6 
8 
10 
54 (51) 
11 (10) 
23 (22) 
17 (16) 
Week 7 1 1 2 98 (87) d Odynophagia 
Nausea 
Appetite/taste 
Dysphagia 
35 
4 
11 
6 
26 
4 
5 
7 
61 (62) 
8 (8) 
16 (16) 
13 (13) 
Abbreviations: a Patient request to start pre radiotherapy. b Patients discontinued as had surgery alone (n=2). c Patient discontinued as died during treatment (n=1). 
d Patients discontinued as completed treatment in week 6 (n=9).
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Classification of overall tube feeding adherence in the early and clinical phases between 
groups is shown in Figure 8-9. The proportion of patients classified as adherent to the early 
phase was 51% (n=29). Adherent patients were older (64.4+7.9yr vs 57.8+9.7yr, p=0.006, 
95% CI [2.0, 11.4]) but no other differences in patient characteristics/demographics were 
seen. The proportion of patients classified as adherent to the clinical phase was higher in 
the intervention group at 58% compared to 38% in standard care (p=0.037). There were no 
differences in patient characteristics/demographics between the adherent and non-adherent 
patients for this phase. The group differences for clinical tube feeding were more evident at 
higher adherence rates, with more patients in the intervention achieving ≥75% adherence, 
and more patients in standard care achieving 50-75% adherence. If patients were adherent 
to the clinical phase, they had less weight loss at three months post treatment (-10.3+5.7% 
vs -12.6+5.7%, p=0.038, 95% CI [0.1, 4.6]). 
Figure 8-9: Comparison of overall adherence to tube feeding recommendations 
during the early and clinical phases in patients with head and neck cancer receiving 
definitive/adjuvant (chemo) radiotherapy
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Figure 8-10: Summary of the main barriers to tube feeding recommendations during 
the early and clinical phases in patients with head and neck cancer receiving 
definitive/adjuvant (chemo) radiotherapy 
Barriers to tube feeding 
The most common reasons for non-adherence to the early tube feeding phase included; 
feels full quickly (19%), nausea (18%), no problems eating (12%), treatment factors (8%), 
reflux (7%) and time available to administer feeds (6%) (Figure 8-10). The number of 
reported barriers decreased over time (especially in week 6 and 7) as patients progressed 
to the clinical tube feeding phase. Overall the most common reasons for non-adherence to 
the clinical tube feeding phase were; nausea (18%), feels full quickly (16%), vomiting (8%), 
treatment factors (7%), fatigue (6%), other alternatives (6%) and no problems eating (6%) 
(Figure 8-10). The number of reported barriers was very low in week 0 and 1, as most 
patients progressed to the clinical tube feeding phase from week 2 onwards.  
Mean adherence to diary completion for recording barriers was 52.5+35.4% overall, with no 
differences between groups (49.3+33.4% intervention vs 55.7+37.4% standard care, 
p=0.333, 95% CI [-6.6, 19.4]). When the groups were compared in the clinical phase, 
common key barriers were; nausea, vomiting, feels full quickly and treatment factors. Only 
minor differences were observed; with patients in standard care more frequently reporting 
no problems eating, fatigue and psychosocial reasons, whereas patients in the intervention 
stated using other alternatives more often. 
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Commencement of Clinical Tube Feeding 
There was no difference in the time to commencement of clinical tube feeding between the 
groups (p=0.825) with the majority (74%) commencing between weeks 2-4. Patients using 
the tube prior to treatment were due to post-operative dysphagia (n=6) or poor appetite (n=1, 
standard care). Loss of appetite/taste were primary reasons for tube use in weeks 2-3 and 
odynophagia became the most predominant factor from week 4-7.  The timing and reasons 
for commencing this phase are summarised in Table 8-16. 
DISCUSSION 
This study has investigated the reasons for initiation of tube feeding and the adherence and 
barriers to tube feeding prescriptions both before and during treatment in a group of patients 
with HNSCC who had a prophylactic gastrostomy placed prior to treatment. The findings 
provide a unique insight into understanding tube use and barriers to tube feeding 
prescriptions from a patient perspective. 
Adherence to the early tube feeding phase for this trial was only 51%, which was lower than 
expected given other nutrition intervention trials with oral supplements report much higher 
adherence rates of 79% (Hubbard et al., 2012). However the intervention group did have 
significantly higher adherence rates to subsequent clinical tube feeding compared to 
standard care (58% vs 38%, p=0.037), and this in itself led to less weight loss. This 
confirmed our secondary hypothesis that by promoting and encouraging early use of the 
tube, this allowed patients to develop a habit of accessing the gastrostomy on a daily basis, 
thus promoting behavioural change resulting in better adaptation to the tube and feeding 
management in the later stages of treatment.  
Three common barriers were identified across all phases/groups and included nausea, feels 
full quickly and treatment factors. Nutrition impact symptoms such as nausea and feels full 
quickly, have been reported as highly prevalent in a large HNSCC cohort (n=635) prior to 
treatment at 14% and 28% respectively (Farhangfar et al., 2014), however as they excluded 
patients being tube fed it is unclear how these findings compare to this current study. 
Vomiting also became a more important factor in the clinical phase, highlighting that 
optimising symptom management is a key area to address. 
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Treatment barriers included healthcare system processes interfering with their ability to 
administer tube feedings e.g. time spent for appointments or treatment, and the hospital 
admission, transfer and discharge processes. Clinician knowledge and healthcare systems 
have been identified previously as key themes in barriers and enablers to nutrition care in 
HNSCC (Martin, de van der Schueren, Blauwhoff-Buskermolen, Baracos, & Gramlich, 
2016). Another study on the impact of tube feeding upon daily life found that that finding “a 
place to feed” and “negative attitudes of others towards feeding” were challenges 
experienced (Brotherton et al., 2006), which may influence how patients cope in the hospital 
(and their social) environment. This will be important to investigate further to understand 
how the environment can be improved to better support patients’ needs. 
Another key barrier in the early phase of tube feeding, although it was also one of the main 
barriers in the standard care group during the clinical tube feeding phase, was the patient 
perception that they had “no problems eating” and thus did not see the need for tube feeding. 
Choosing “other alternatives” tended to occur more in the clinical phase of tube feeding and 
was more frequently reported in the intervention group. Although some of these alternatives 
appeared to be reasonable high protein/energy options (e.g. cheese, chicken, smoothies, 
custard), portion sizes were not determined to assess overall nutritional adequacy, and there 
was also a high number that reported nutritionally inadequate alternatives such as fruit, tea, 
coffee and water. 
Both of these barriers highlight that there may be a gap in patient knowledge and 
underestimation of their nutritional needs, which are increased during treatment (Arends et 
al., 2017). It may also reflect conflicting goals of weight management between the patient 
and clinician. The patient desire for weight loss has been observed anecdotally in clinical 
practice and confirmed in some qualitative studies which have reported patients found 
perceived benefits of weight loss; "I lost weight when I was on my PEG…a little benefit” 
(Mayre-Chilton et al., 2011) and “I haven’t been able to eat, and have lost between 10 and 
12kg. I’m pleased with my weight reduction” (Ehrsson et al., 2015). This observation may 
also be a reflection of the changing demographic of HNSCC patients with a greater 
proportion of over-weight patients with p16 positive disease rather than the classical 
underweight/malnourished patient with p16 negative disease (Albergotti et al., 2016). In the 
current study the mean (SD) BMI was 27.4 + 5.5 kg/m2. 
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This current study identified the loss of appetite/dysgeusia as important factors necessitating 
tube use in the earlier stages of treatment, but also highlighted their importance in the final 
weeks of treatment accounting for 16-22% of cases. Traditionally requirement for 
gastrostomy in patients with HNSCC has been associated with dysphagia (Lango et al., 
2016) or odynophagia from mucositis (Trotti et al., 2003), as these symptoms present as the 
physical inability to eat or drink. A review of the influence of nutrition impact symptoms on 
nutritional status, weight loss, and oral intake found most studies report on dysphagia and 
xerostomia (Bressan et al., 2016), with loss of appetite shown to have the greatest reduction 
on oral intake (Farhangfar et al., 2014). This study has demonstrated that patients perceive 
loss of appetite/dysgeusia as severe enough to necessitate feeding tube use, which 
supports recommendations that lack of appetite should be used as a clinical indicator for 
initiation of nutrition support in cancer care (Arends et al., 2006). 
The limitation to this current study is the poor adherence to diary completion for reporting 
barriers to tube feeding recommendations (49-56%), despite prompting by the dietitian at 
weekly appointments, which means that only half the days in which patients were non-
adherent are accounted for. This in itself may be a reflection of the overall impact of 
treatment on even motivated patients. It was not recorded how often patients required 
prompting by the dietitian at weekly reviews but even this strategy did not fully assist diary 
completion, highlighting inadequate appointment time may also have been a barrier. It also 
creates bias in patient reported symptoms from those that were adherent. For example if 
one patient suffered from reflux and diligently recorded this reason daily, this may have 
overestimated the true frequency of this barrier within the population. 
The accuracy and reliability of the patient diaries to calculate tube feeding adherence rates 
is also a limitation, as if incomplete, data had to be estimated from recall or obtained 
retrospectively from charts. Future studies should consider how adherence could be more 
accurately recorded. Dedicated research assistant time to allow for daily contact with the 
patient is one option or smartphone app technology could be considered as this has been 
successful at improving self-monitoring in weight loss trials (Carter, Burley, Nykjaer, & Cade, 
2013; Wharton, Johnston, Cunningham, & Sterner, 2014) and so perhaps may be effective 
at self-monitoring intake. Other studies have also reviewed service delivery models (Wall, 
Ward, Cartmill, Hill, & Porceddu, 2016), and utilised a novel telepractice application (Wall, 
Ward, Cartmill, Hill, & Porceddu, 2017) to improve adherence to prophylactic swallowing 
exercises which could also be methods to apply to improving dietary adherence. 
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Finally, as the focus was on adherence to tube feeding, other sources of dietary intake and 
adherence to dietary advice were not assessed.  
The strength of this study is that it is the first to investigate and identify reasons for patient 
non-adherence to tube feeding prescriptions in this population which will help to inform future 
research and models of care. It is acknowledged that other outcomes which may have 
impacted on motivation and adherence, such as psychosocial distress and depression were 
not assessed in this study, and these would also be useful to consider for future studies in 
this field. Further qualitative research is suggested to develop an in-depth understanding of 
the physical, practical and psychological barriers patients face to inform the design of 
appropriate multidisciplinary models of care, ideally with a focus on patient and carer 
empowerment and ownership of care.  
The role of psychosocial care appears paramount to improving outcomes, with one study 
already showing the benefits of a psychological intervention on nutrition outcomes and 
mortality (Britton et al., 2016). The impact of a dietitian-delivered health behaviour 
intervention is currently underway based on motivational interviewing and cognitive 
behavioural therapy (Britton et al., 2015) and has considered treatment fidelity across all key 
components (Beck et al., 2015). Other potential models include using social cognitive theory 
to improving dietary adherence (Cases, Fruge, & Daniel, 2015), following beneficial 
application on exercise adherence post treatment (Rogers et al., 2015). Current apps 
targeting areas of behaviour change however are not based on behavioural theories which 
is a potential limitation to their application in this context and thus require further research 
and development (DiFilippo, Huang, Andrade, & Chapman-Novakofski, 2015). 
CONCLUSION 
The observed low adherence to tube feeding recommendations overall is a likely explanation 
for clinically significant weight loss in patients with HNSCC during chemoradiotherapy. 
Whilst several barriers have been identified to tube feeding recommendations in this study, 
the early tube feeding approach is one strategy which has been shown to improve patient 
adherence to clinically indicated tube feeding during treatment. The implications of this in 
clinical practice is that routine encouragement of early tube feeding should be considered 
purely for behavioural purposes to improve adherence. Optimising symptom management 
will also be key; with nausea, vomiting and early satiety identified as primary barriers for 
patients. 
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As adherence was found to be lower in the earlier stages of treatment, this presents 
opportunities for increased dietetic and psychological interventions prior to treatment to 
improve patient understanding of nutritional needs and develop additional behavioural 
change strategies to overcome any environmental and psychosocial barriers. A 
collaborative multidisciplinary approach to addressing these factors will ultimately improve 
adherence to dietary recommendations, resulting in less clinically significant weight loss and 
thus improving other associated clinical outcomes. 
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8.5 Chapter summary 
The results from the RCT did not show any benefit of the early nutrition intervention in 
relation to the planned outcomes. There were no significant differences in nutritional 
outcomes (weight, body composition, and nutritional status), QOL outcomes, or clinical 
outcomes (radiotherapy tolerance, chemotherapy tolerance, unplanned admissions, 
gastrostomy complications, and overall disease and survival outcomes). The early 
intervention did not show an increased dependency on the gastrostomy tube with most tubes 
removed between 3-4 months post treatment, with only five patients remaining dependent 
on their tubes at 12 months (4%). 
The main explanation for the negative outcomes from the trial were likely due to the poor 
adherence to the intervention component of the trial, with only 29/57 patients (51%) adhering 
to the protocol.  However one of the benefits that this study found was the intervention group 
had better adherence to tube feeding during the treatment phase compared to the standard 
care group (58% vs 38%, p=0.037). Sub analysis between adherent patients (n=49) and 
non-adherent patients (n=55) found the adherent group had less weight loss (-10.3% vs -
12.6%, p=0.038). However the adherence rates are still low in general which implies 
nutritional requirements are frequently not being met, offering a hypothesis as to why 
patients continue to lose such a large amount of weight, despite what appears to be very 
intensive dietetic input with prophylactic gastrostomy (proPEG) tube placement prior to 
treatment. A number of potential barriers to tube feeding recommendations have been 
identified that warrant further investigation. 
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9.1 Chapter overview 
This chapter summarises the results of the research in this thesis in relation to the aims and 
hypotheses, and discusses the strengths and limitations of the studies. The significance of 
the thesis and how the original research contributes to the field of dietetics are summarised, 
including implications for clinical practice and application of the results to the theoretical 
model. Finally opportunities for future research are identified, followed by concluding 
remarks.
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9.2 Discussion of results in relation to aims and hypothesis 
Study 1 (Chapter 4) 
This study aimed to compare the outcomes of weight change and the requirement for tube 
feeding across two types of radiotherapy treatment – 3D conformal and helical-IMRT.  
H0 - There would be no difference in weight loss or tube feeding outcomes between the two 
treatment groups (helical-IMRT and 3D radiotherapy) 
H1 - The helical-IMRT group would experience less weight loss and need for tube feeding 
due to the more targeted nature of treatment which would reduce toxicities and nutrition-
impact symptoms 
The sample size (n=187) was sufficient to detect a 2.3% difference in weight loss between 
the two groups with 80% power and a Type I error 0.05. No differences in nutritional outcome 
measures were seen between the two groups. Median weight loss during radiotherapy was 
7.3% (-20.1% to 22.9%) in the 3D group and 7.2% (-19.1% to 8.5%) in the helical-IMRT 
group (p=0.573). Incidence of severe weight loss (>10%) was 27% in the 3D group and 28% 
in the helical-IMRT group (p=0.843). Requirement for proPEG was 86% in the 3D group and 
92% in the helical-IMRT group (p=0.213). The alternative hypothesis was refuted and the 
null hypothesis retained. 
Study 2 (Chapter 5 Section 0) 
This study aimed to validate the updated Royal Brisbane and Women’s Hospital (RBWH) 
protocol to identify patients for proPEG insertion in a new cohort of patients (n=270) following 
the introduction of helical-IMRT.  
H0 - There would be no difference in protocol specificity between the two cohorts following 
the introduction of helical-IMRT  
H1 - The specificity of the protocol would reduce as it was anticipated there would be a 
reduced need for tube feeding with helical-IMRT 
The results indicated an improvement in all validity measures compared to the original 
validation study (Brown et al., 2013b). The sensitivity improved from 54% to 72% and the 
specificity improved from 93% to 96%. The positive predictive value improved from 82% to 
92% and the negative predictive value improved from 77% to 82%. The alternative 
hypothesis was refuted and the null hypothesis retained. The protocol remains valid for use. 
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Study 3 (Chapter 5 Section 5.3) 
This was a hypothesis generating study to determine if any other variables, not previously 
considered, could be used to improve the predictive ability of the RBWH protocol to identify 
patients for proPEG. Four variables were investigated in a cohort of 269 patients. 
1-H0 – Systemic therapy agent or regimen does not improve the protocol’s ability to identify 
patients for proPEG 
1-H1 – Systemic therapy agent or regimen does improve the protocol’s ability to identify 
patients for proPEG 
Since the protocol was originally developed, the choice of systemic therapy agents has 
increased. The newly approved monoclonal antibody (Cetuximab) had different toxicity 
profiles (Bonner et al., 2006), which were expected to influence nutrition impact symptoms 
and thus the need for tube feeding. The results from the study found the choice of systemic 
therapy agent or regimen was not associated with meeting the criteria for proPEG, and so 
the null hypothesis was retained. 
2-H0 – MST score does not improve the protocol’s ability to identify patients for proPEG 
2-H1 – MST score does improve the protocol’s ability to identify patients for proPEG 
The second factor investigated was the Malnutrition Screening Tool (MST) which detects 
patients at risk of malnutrition based on two questions related to weight loss and appetite 
(Ferguson, Capra, Bauer, & Banks, 1999b). It is routinely completed to identify those who 
would benefit from dietetic intervention before treatment, but is not currently used in the 
protocol definitions. A score of two or more identifies patients at risk of malnutrition and this 
score was found to identify additional patients for proPEG in the low risk group. The 
alternative hypothesis was accepted. 
3-H0 – Nutritional biochemical markers (CRP/albumin) do not improve the protocol’s ability 
to identify patients for proPEG 
3-H1 – Nutritional biochemical markers (CRP/albumin) do improve the protocol’s ability to 
identify patients for proPEG 
The third factor investigated was the role of albumin and C-reactive protein (CRP), as these 
biochemical markers are associated with the pre-cachectic state (Couch et al., 2014).  
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It was anticipated that abnormal albumin or CRP levels may be able to predict patients who 
are likely to lose weight/develop cachexia and thus an increased need for tube feeding. The 
current method of nutrition screening using the MST relies on weight loss to have already 
occurred, and thus these biochemical markers may be able to help identify patients earlier. 
Unfortunately CRP was not routinely measured in our clinic and only available in six patients 
(out of 269), therefore this could not be explored. Albumin data were more readily available, 
although still limited to 72% of the cohort. The results from this study showed that albumin 
was not associated with the criteria for proPEG and the null hypothesis was retained.  
4-H0 – p16 status does not improve the protocol’s ability to identify patients for proPEG 
4-H1 – p16 status does improve the protocol’s ability to identify patients for proPEG  
The final factor investigated was p16 status (an immunohistological marker for human 
papillomavirus-related tumours), which has become increasingly important to clinicians due 
to influences on treatment recommendations (Rischin et al., 2015). Routine testing of p16 
status was not completed during the data collection period and was limited to 61% of the 
cohort. Despite these sample size limitations, a p16-positive status was found to identify 
additional patients for proPEG in the low risk group. The alternative hypothesis was 
accepted.  
Study 4 (Chapter 6)  
This study was commenced following observation of increasing clinician non-adherence to 
the RBWH protocol for proPEG in routine annual audits. During the time period of the 
previous three studies (2010-2011) the clinician adherence to the protocol was high at 89%, 
but this dropped to 53% during 2012-2014 (Appendix C – 11.3.7). This was attributed to the 
evolving changes in treatments described in preceding studies, despite a lack of supporting 
evidence to change practice. The aim of this study was to compare the outcomes of high 
risk patients who received a proPEG (protocol adherence) (n=69) to those that did not 
receive a proPEG and were managed reactively (protocol non-adherence) (n=61).  
H0 – There would be no difference in weight loss or unplanned admissions between high 
risk patients managed with a proPEG and those managed reactively 
H1 – Patients who were managed with a proPEG would have less weight loss and less 
unplanned admissions 
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The results found that patients with a proPEG had 2% less weight loss (7% vs 9%, p=0.04). 
Overall unplanned admissions rates were no different between groups (50% vs 50%, 
p=0.803) but the proPEG group had fewer unplanned admissions for nutrition-related 
reasons (65% vs 91%, p=0.008). Therefore the alternative hypothesis was accepted.  
Study 5 (Chapter 8) 
Study 5 (Chapter 8) 
Although the previous study demonstrated proPEG was beneficial compared to reactive 
management, the overall nutrition outcomes were still poor. Mean weight loss was still 
deemed critical and at a level associated with reduced survival (Langius et al., 2013b). The 
final study in this thesis aimed to minimise this weight loss through an early tube feeding 
intervention in high risk patients with HNC who had a proPEG placed pre-treatment. 
H0 – There would be no difference in weight loss (or other secondary outcomes) between 
the intervention group (early tube feeding) and the standard care group (clinical tube feeding 
when indicated) 
H1 – There would be less weight loss (and thus improvements in other secondary outcomes) 
between the intervention group (early tube feeding) and the standard care group (clinical 
tube feeding when indicated) 
By minimising weight loss, it was hypothesised that this would translate into other benefits 
with: reduced loss of lean body mass; improved nutritional status; improved QOL; less 
unplanned admissions; improved tolerance to radiotherapy and chemotherapy treatment 
(with higher completion rates of target/planned doses); which may then improve treatment 
response and survival outcomes. The sample size (n=131) was adequate to detect a 5% 
difference in weight loss with 80% power and two-sided 5% significance. There was no effect 
of the early intervention on the primary outcome of percentage weight loss (10.8% vs 10.9% 
p=0.930). On multivariable analysis the intervention group had 0.5% less weight loss but 
this remained non-significant (p=0.624). The alternative hypothesis was refuted and the null 
hypothesis retained.
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9.3 Strengths and limitations 
Study 1 (Chapter 4) 
The major strength of this study, investigating weight loss and tube feeding requirement 
following helical-IMRT, is the primary focus on nutrition outcome measures in the largest 
cohort size to date (n=53). Other studies have only: reported nutrition outcomes as 
secondary measures; had smaller sample size (11 to 31 patients) for weight loss (Capelle 
et al., 2012; Chao et al., 2000; Duma et al., 2012; You et al., 2012); and only five to 17 
patients for tube feeding (Chao et al., 2000; Loo et al., 2011). As the change to helical-IMRT 
at the hospital was a gradual process, this enabled a comparison of patients receiving the 
two different treatments (helical-IMRT vs 3D conformal) over a concurrent period of time. 
The advantage of this study design over a historical cohort comparison is less confounding 
variables or changes in practice which may have also affected outcomes. The adherence 
with the protocol for proPEG selection was also high at this time (84%), which minimised 
any selection bias issues and meant comparable patient groups (defined as high or low 
nutrition risk) were managed in a similar manner.  
Study 2 and 3 (Chapter 5) 
The limitations of Study 2 to validate the protocol for proPEG selection (Chapter 5) included 
a smaller sample size (n=270) compared to the original validation study (n=501) (Brown et 
al., 2013b), as the data were collected over one year rather two years. It was also a single 
site study, which reduces generalisation to other centres. Retaining the methodology from 
the original validation study was important to enable a direct comparison of outcomes, 
however, it was recognised this also provided some drawbacks. The definition for 
determining proPEG requirement did not consider duration of gastrostomy use, as if used 
for less than four weeks and nutritional status was not compromised, then a nasogastric 
tube would suffice. Whilst the gradual transition to helical–IMRT was an advantage in the 
previous study, this did present some limitations for this study. Only 60% of the high risk 
patients actually received helical-IMRT (53/88), which translated to only 33% of the whole 
cohort who received radiotherapy as part of their treatment (75/230). Ideally repeating the 
study with all high risk patients receiving helical-IMRT would more accurately determine the 
true requirement of proPEG. The disadvantages of all of the retrospective study designs 
(Chapter 4 and Chapter 5) were limitations of missing data, as a number of cases needed 
to be excluded due to no access to medical charts, or variables of interest were not routinely 
collected or recorded. 
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Study 4 (Chapter 6)  
The strength of comparative Study 4 between proactive and reactive nutrition support, based 
on adherence and non-adherence to the protocol for proPEG selection, was the prospective 
concurrent study design (level III-2 evidence). The statistical analysis was thorough to 
account for the differences between groups and this was the first study to control for any 
selection bias in the decision-making processes by including the treating Consultant as a 
co-variate in the multivariable models. Despite prospective data collection, it was difficult to 
distinguish whether non-adherence to the protocol was attributed to either the Consultant or 
the patient. This is an important consideration as a patient-led decision may be based on 
attitudes or motivation towards the role of nutrition in treatment and thus influence outcomes. 
Weight was only measured until the end of radiotherapy. Routine assessment post-
treatment, particularly for patients from rural or regional areas, is difficult to implement as 
part of standard practice. Therefore the true extent of weight loss may not have been 
captured as the nadir has been reported to occur up to six months post-treatment (Ehrsson 
et al., 2012). A surrogate measure was the collection of unplanned admission data for one 
month post-treatment, as unplanned admissions are usually attributed to weight loss, 
dehydration or other treatment toxicities. However, it was recognised admissions in 
local/regional areas when patients returned home may have been missed.  
Study 5 (0 and Chapter 8) 
The strength of Study 5 was the RCT study design (level II evidence), which included: robust 
design and implementation; attainment of target sample size; intention-to-treat analysis; 
statistical adjustments for any baseline differences; and full disclosure of outcomes. The 
target sample size (n=123) was exceeded (n=131), which provided 80% power at a two-
sided 5% significance level, to detect a 5% difference in weight loss between groups.  
Although treatment fidelity was not formally assessed, a number of components were 
considered to strengthen the study (Beck et al., 2015). In regards to the first component of 
fidelity (study design), the intervention was based on theory from the literature review 
regarding the behaviours associated with feeding tubes (Merrick & Farrell, 2012; Salas et 
al., 2009) and the role of pre-treatment nutrition interventions in other cancer patients (Kiss 
et al., 2016). The study ensured minimising contamination between treatment arms by 
designating different dietitians to each arm of the trial.  
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For the second component of fidelity (training providers), steps were taken to ensure the 
dietitian providing the intervention was appropriately skilled and experienced, and a checklist 
was provided to standardise education and information given to the patient. Steps were also 
taken to minimise workload rotations whilst the study was in place so that the intervention 
was delivered as consistently as possible. The research dietitian completed all outcome 
measures to ensure standard assessment.  
In the third component of fidelity (delivery of treatment), weekly discussions were held 
between the research dietitian and the intervention dietitian to ensure the intervention was 
being provided as planned. Communication was also developed with the multidisciplinary 
team (MDT) to provide additional support in promoting the intervention and communicating 
any problems with the delivery. Finally, the fourth component of fidelity (receipt of treatment) 
was monitored via patient self-reported diaries to record adherence to the intervention, 
however this methodology could have been strengthened through pilot testing of the diaries 
prior to implementation to ensure that patients knew how to define their symptoms. 
The main limitation of the RCT was the unexpected poor patient adherence to the early 
feeding intervention. Some other difficulties were encountered in relation to the recruitment, 
randomisation process and outcome measurements. Some patients were recruited who 
were technically low risk but had a proPEG as per Consultant decision (n=10). Four were 
due to late changes to treatment plans (e.g. cancellation of chemotherapy or change to 
unilateral field treatment) and the other six had primary surgery and required their tube for 
functional postoperative dysphagia rather than to manage side effects of CRT, and thus 
created a more heterogeneous sample. 
In retrospect, the stratification procedure should also have included p16 status, as HPV-
related tumours have been recognised as a distinct clinical entity (Mallen-St Clair et al., 
2016), and should be controlled for from the onset. An independent outcome assessor 
blinded to the randomisation allocation would have been useful to strengthen the study, but 
was not deemed practical within resources available. 
An extension of nutrition and QOL outcome measurements at the end of treatment or one 
to two weeks post-treatment would also have strengthened the study. Three months post-
treatment was selected to minimise attrition, however by this point most patients were 
recovering and so any group differences may have been more evident earlier. 
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Additional outcome measures such as the Performance Status Scale (List, Ritter-Sterr, & 
Lansky, 1990) or the MD Anderson Dysphagia Inventory (Chen et al., 2001) for swallowing 
function and the Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983) for 
psychosocial distress, would have also enhanced the study.  
Some body composition outcomes were missing due to patients not returning to the tertiary 
centre for follow-up, and so additional body composition equipment at regional cancer 
centres would have been useful. Otherwise, efforts were made to ensure all other data 
collection was complete by contacting patients by telephone/mail or liaising with the local 
dietitian, and so overall attrition and missing data were of minimal concern. 
Finally the quality of life tools selected for this study, although widely used and validated, do 
not adequately address QOL issues arising from tube feeding. The QLQ-H&N35 has 
recently been reviewed and updated to the QLQ-H&N43, however the only question relating 
to feeding tubes has been removed, and no new questions have been added on this topic 
(Singer et al., 2015). Future studies should consider additional QOL tools specifically related 
to enteral feeding, such as the QOL-EF (Stevens et al., 2011), although this has rarely been 
used in clinical practice with only six citations to date, and only one of which is for a clinical 
trial (Bernstein et al., 2015).
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9.4 Significance of the thesis 
9.4.1 Contribution to the field  
The research in this thesis has made a significant contribution to the field of nutrition and 
cancer care with five manuscripts (Chapters 4-7) accepted for publication in high impact 
international journals (Journal of the Academy of Nutrition and Dietetics, Head and Neck, 
European Journal of Clinical Nutrition, and BMC Nursing), with a further three submitted and 
under review.  
The work of the candidate has been widely recognised with invitations to present at one 
international conference (World Congress of Larynx Cancer, 2015) and two national 
conferences (Australian and New Zealand Head and Neck Cancer Society, 2013 and the 
Advanced Symposium for Health Professionals working in Head and Neck Cancer, 2016). 
The candidate was also invited to present at a Patient Reported Research Forum as part of 
the 10th International Head and Neck Cancer Quality of Life Conference, 2016. The 
candidate has also presented peer reviewed abstracts at a number of national and 
international conferences, as well as locally within the Metro North Health Service District 
and Queensland Health.  
The thesis comprises a number of areas of original research to contribute to and advance 
the knowledge of nutrition management of patients with HNC. Dietitians working in this field 
currently refer to “Evidence-based practice guidelines for the nutritional management of 
patients receiving radiation therapy and/or chemotherapy” (Isenring et al., 2013) and 
internationally endorsed “Evidence-based practice guidelines for the nutritional 
management of adult patients with head and neck cancer” (Head & Neck Guideline Steering 
Committee, 2011) which are maintained through an online wiki format to ensure they remain 
current (Brown et al., 2013a). The publications arising from this thesis will enable ongoing 
updates to be made and will gain international exposure through the link of these guidelines 
to “Practice-based Evidence in Nutrition” – a global resource for nutrition recognised in 
Canada, United Kingdom, South Africa, Australia, New Zealand and Spain. Evaluation of 
the online guidelines demonstrated even broader international exposure with access 
recorded in 33 countries following their initial launch in 2011 (Brown et al., 2013a).  
The next section maps the research from this thesis to the nutrition care model and this is 
followed by a discussion of the results in the context of the current literature and how they 
can inform clinical practice recommendations within the guidelines (Head & Neck Guideline 
Steering Committee, 2011). 
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9.4.2 Nutrition care model in the context of head and neck cancer 
In summary, the results from this study can be used to update the nutrition care model in 
relation to the care of patients with HNC (Figure 9-1). Appropriate access to necessary care 
relies on routine referral processes for all patients and identification of high risk patients to 
implement proPEG insertion. Both of which are dependent on patient and clinician 
adherence. Additional components of quality nutrition care have been added to include 
strategies to help overcome barriers to nutrition care and improve adherence to nutrition 
care recommendations. This should then achieve improved nutrient intake, and allow the 
cascade of events to continue resulting in improved clinical, cost and patient outcomes.  
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Figure 9-1: Updated Theoretical Model of the Nutrition Care Model in the context of head and neck cancer  
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9.4.3 Recommendations for clinical practice 
Appropriate Access to Nutrition Care  
The first phase of this thesis (Study 1-3 in Chapter 4 and Chapter 5) explored if current 
procedures for appropriate access to nutrition care remain valid in the context of evolving 
treatments/disease. Study 1 identified that weight loss and requirement for tube feeding are 
no different in patients receiving helical-IMRT (n=53) compared to patients previously 
treated with 3D conformal radiotherapy (n=134). This is the first study to report detailed 
nutrition outcomes in patients receiving helical-IMRT in the largest cohort to date. Other 
studies have reported varying degrees of weight loss, with minimal details on tube feeding 
if at all, but sample sizes are small and nutrition was not the primary focus (Capelle et al., 
2012; Chao et al., 2000; Duma et al., 2012; You et al., 2012). No previous studies have 
investigated the requirement for tube feeding with helical-IMRT treatment and so Study 2 is 
the first to confirm that the current protocol used at the RBWH to identify patients for proPEG 
remains valid in the era of helical-IMRT treatment.  
Study 3 reviewed the protocol for proPEG insertion in the context of other evolving aspects 
of disease and treatment. The chemotherapy agent was not found to be predictive of 
proPEG requirement, supporting other studies in the literature in which regardless of 
chemotherapy agent, the impact on weight loss and tube feeding is similar (Wopken et al., 
2014b; Ye et al., 2013). The role of pre-cachectic nutrition markers such as albumin, 
although potentially useful at predicting development of cachexia and associated weight loss 
and survival (Couch et al., 2007; Gupta & Lis, 2010), was not found to be useful in predicting 
proPEG need. The established MST for identifying patients at risk of malnutrition (Ferguson 
et al., 1999a) was for the first time found to be associated with predicting proPEG in the low 
risk group of patients. As the MST identifies patients with baseline weight loss this supports 
other studies which have identified baseline weight loss to be predictive of proPEG (Beaver 
et al., 2001; Gardine et al., 1988; Mangar et al., 2006; Mays et al., 2014; Orphanidou et al., 
2011). Finally a positive p16 status was also found to be predictive of proPEG in the low risk 
group of patients. This is a novel finding with no other studies previously investigating the 
role of p16 status on nutrition-related outcomes. It is possibly explained by patients with p16-
positive status having higher levels of acute and long-term toxicity (Hanasoge et al., 2016).  
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Clinical Questions 
Q. What are the impacts of new developing treatment regimens on nutritional status and 
outcomes? 
The current recommendation (Grade C) for IMRT states “Patients should be managed in the 
same way as for conventional radiotherapy” (Head & Neck Guideline Steering Committee, 
2011). The results from this thesis provide level III-2 evidence to support this 
recommendation in relation to treatment with helical-IMRT.  
The current recommendation (Grade C) for targeted therapy treatments states “Patients 
should be managed in the same way as for conventional CRT” (Head & Neck Guideline 
Steering Committee, 2011). The results from this thesis provide additional level IV evidence 
to support this recommendation.  
Q. Which patients should be identified for prophylactic enteral feeding? 
The current recommendation (Grade C) states that “Prophylactic enteral feeding should be 
considered to improve nutritional status, cost and patient outcomes, for patients with T4 or 
hypopharyngeal tumours undergoing concurrent CRT. Other patient groups should be 
considered by the MDT on an individual basis dependent on other clinical factors” (Head & 
Neck Guideline Steering Committee, 2011). The RBWH protocol referred to in this thesis is 
not included as part of the recommendation as it is level IV evidence. However, it is the only 
validated protocol published and its use is increasing at other centres across Australia (e.g. 
Gold Coast, Darwin) as well as receiving seven citations from the UK, Spain, Netherlands, 
Korea and Morocco demonstrating international impact (Source: Scopus 13/02/2017) .  
The results from this thesis provide further level IV evidence that the protocol remains a valid 
method of identifying patients for proPEG in the era of helical-IMRT, and so can continue to 
be used as a tool to aid decision-making in other centres. The information from the updated 
literature review in this thesis also suggests this recommendation should be reviewed. There 
is now a clearer distinction and difference between predictors of tube requirement for 
treatment and predictors of prolonged tube dependence, particularly with tumours of the 
hypopharynx (Bhayani et al., 2013a). 
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Quality Nutrition Care and Outcomes – during treatment 
The second phase of the thesis (Study 4 in Chapter 6) explored different methods of nutrition 
implementation during treatment in the nutrition intervention phase of the quality nutrition 
care process. Proactive nutrition care (adherence to proPEG protocol) versus reactive 
nutrition care (non-adherence to proPEG protocol) was compared in relation to nutrition-
related and cost-related outcomes.  
The benefit of the proactive approach seen in this study with reduced weight loss and 
reduced unplanned admissions has been supported in other studies (Lewis et al., 2014; 
Romesser et al., 2012), although disputed by others (Olson et al., 2013). The most recent 
systematic review suggests the proPEG approach is preferred (Zhang et al., 2016), although 
it is acknowledged further high level evidence is required to fully validate this 
recommendation. The research in this chapter also confirms barriers to achieving 
appropriate access to quality nutrition care can arise from both clinician adherence to 
protocols (Lacey & Pritchett, 2003) and patient adherence to recommendations (Capuano 
et al., 2008).  
Clinical Questions 
Q. What are the effective methods of implementation to ensure positive outcomes? 
The current recommendation (Grade B) states that “Prophylactic tube feeding compared to 
reactive tube feeding demonstrates improves nutrition outcomes (weight loss), quality of life 
and clinical outcomes (reduced hospital admissions, length of stay and treatment 
interruptions) during the treatment phase” (Head & Neck Guideline Steering Committee, 
2011). The results from this thesis provide additional level III-2 evidence to support this 
recommendation.  
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Quality Nutrition Care and Outcomes – pre- treatment 
The final phase of the thesis (Study 5 in Chapter 7 and Chapter 8) explored a new pre-
treatment nutrition intervention as part of the quality nutrition care process and monitored 
how this impacted on nutritional, clinical, cost and patient outcomes. All components of 
nutrition intervention were considered. Both groups had the same method of implementation 
with proPEG and weekly dietetic counselling scheduled during treatment. The nutrition 
prescription was altered in the intervention group with an early tube feeding phase consisting 
of two bolus feeds per day to supplement oral intake. Both groups had the same overarching 
goal as per current evidence-based guidelines, although the aim of the intervention was to 
minimise weight loss further. 
As this was the first study in this field, there were no studies with which to compare results. 
There was no difference in weight loss between groups, and as such there was no cascade 
of events to then influence the other clinical, cost and patient outcomes. However, patient 
adherence to the intervention was poor due to a range of nutrition impact symptoms 
including; nausea and early satiety, which are known to be prevalent pre-treatment 
(Farhangfar et al., 2014). Another common barrier was that patients frequently reported “no 
problems with eating” which implied they didn’t perceive the need for tube feeding and/or 
their oral intake was adequate. Improving patient education may be one strategy that could 
assist in overcoming this barrier. Patient factors have been identified in the literature as 
affecting the nutrition care process and outcomes and these include motivation, lifestyle, 
disease acuity and socioeconomic status (Splett & Myers, 2001) as well as depression 
(Britton et al., 2012). Therefore this highlights a role for improving or increasing 
psychological supports and interventions. 
Likewise the skills of the healthcare professional delivering the nutrition care process can 
also influence outcomes, such as the skills of communication and collaboration (Lacey & 
Pritchett, 2003), which are essential for symptom management in conjunction with the MDT. 
The healthcare professional’s expertise in behavioural change has also been recognised 
(Splett & Myers, 2001). A psychological intervention incorporating motivational interviewing 
and cognitive behavioural therapy has been shown to improve nutrition outcomes (Britton et 
al., 2016) and the role of a dietitian-led similar psychological intervention is currently being 
studied (Britton et al., 2015). The results of this may well provide guidance on future models 
of care by allied health professionals and highlights the potential importance of training 
dietitians to deliver psychological-based interventions to facilitate behaviour change. 
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The other key finding from this study was that the early tube feeding phase did improve 
adherence to the clinical tube feeding phase later in treatment when indicated. This early 
approach appeared to have a psychological benefit in helping patients adjust to their feeding 
tube which has been reported in other qualitative studies (Merrick & Farrell, 2012; Salas et 
al., 2009). 
Clinical Questions 
A new question for quality nutrition care in the pre-treatment phase is proposed. Following 
identification of patients for prophylactic enteral tube placement, it is suggested to add: 
Q. When should tube feeding through the prophylactic tube commence? 
The results from this thesis provide level II evidence that commencement of early tube 
feeding immediately following placement improves adherence to clinical tube feeding later 
in treatment. Routine encouragement of early supplementary feeding is recommended to 
enhance behavioural change to facilitate adaptation to the tube and improve overall 
adherence. 
Q. What is the impact of patient adherence with dietary advice to their outcomes? 
The current recommendation (Grade B) states “the role of the MDT is essential to ensure 
management of treatment side effects and other psychosocial factors to enable patients to 
follow dietary advice” (Head & Neck Guideline Steering Committee, 2011). The results from 
this thesis provide level IV evidence on the types of barriers patient encounter with tube 
feeding recommendations, including nutrition impact symptoms, psychosocial factors and 
environmental factors, and thus provides ongoing support for this recommendation to help 
address these barriers and improve adherence. 
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9.5 Recommendations for future research 
Opportunities for research on appropriate access to care and quality nutrition care 
The first opportunity is ongoing improvements of the protocol for proPEG selection. Chapter 
5 identified a number of other variables that are worthy of further investigation such as p16 
status, MST score at baseline, smoking status, T stage and a review of the tumour sites. 
The literature also suggests other parameters could include; baseline dysphagia, poor 
performance status, older age, and higher TNM stage (Lango et al., 2016; Ottosson et al., 
2013). Consideration needs be given to the surgical population, as there is increasing 
evidence that patients undergoing certain surgical procedures may also warrant proPEG 
(Jack et al., 2012; Mays et al., 2014). Revalidation of the protocol in a patient cohort with a 
larger proportion of patients receiving helical-IMRT is currently underway, and will address 
previous limitations by accounting for duration of gastrostomy use. Finally, new research to 
demonstrate the external validity of the protocol in other centres would help enhance 
generalisability and applicability in a broader clinical setting. Translational research could 
also investigate similar protocol development in other relevant patient populations such as 
oesophageal cancer and motor neurone disease. 
The optimal method of tube feeding remains unknown and although results are pending 
from the RCT comparing proactive and reactive approaches in the UK (Paleri et al., 2016), 
nutrition was not considered a primary outcome. High level evidence may well be difficult to 
obtain, as patients often do not want to be randomised in tube feeding trials (Corry et al., 
2008). The research from Chapter 6 has already been expanded to compare nutrition 
outcomes across hospital sites using proPEG versus reactive management. This will provide 
additional level III-2 evidence with less bias, as tube placement will be according to protocol 
rather than physician discretion as per a previous study (Olson et al., 2013). 
The main barrier from the RCT in Chapter 8 was poor adherence to the intervention. A 
qualitative study is recommended to further investigate the patient barriers to tube feeding 
in more detail. This type of research has only been completed in mixed patient populations 
with long-term feeding tubes (Jaafar et al., 2016) and so the findings are not applicable to 
patients with HNC during an acute period of treatment when the tube is deemed temporary. 
This information could be used to inform and evaluate new models of care delivered by the 
MDT. This area of research could also be applied to other patient groups requiring temporary 
enteral feeding to determine if adherence and barriers to tube feeding was exclusive to the 
HNC population. 
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Opportunities for research in causes and management of nutrition impact symptoms  
The research from this thesis in Chapter 8 identified nausea and early satiety to be the key 
barriers to tube feeding, with loss of appetite and dysgeusia common reasons for initiating 
tube feeding in the earlier weeks of treatment. These nutrition impact symptoms have not 
been as widely studied as other common symptoms such as dysphagia and xerostomia 
(Bressan et al., 2016) and thus provide various opportunities for further research as 
described below. 
The high prevalence of poor appetite prior to treatment (Farhangfar et al., 2014) suggests 
cachexia is already present. Appetite pathways are affected by the complex interaction of 
inflammatory cytokines and hormones associated with cancer cachexia (Couch et al., 2015). 
Fish oils and omega-3 fatty acids have been widely studied in other cancer populations (de 
Aguiar Pastore Silva, Emilia de Souza Fabre, & Waitzberg, 2015). This intervention 
proposes to counteract this inflammatory state (Talvas et al., 2015), but has only recently 
been studied in HNC. Two RCTs (level II, one neutral, one positive quality) compared an 
omega-3 fatty acid enhanced enteral feed (with or without arginine/nucleotides) versus a 
standard enteral feed, resulting in improvements to nutritional status (Fietkau et al., 2013) 
and functional outcome measures (Vasson et al., 2014). However, both studies were 
predominantly in malnourished patients at baseline and in mixed populations of HNC and 
oesophageal cancer. It is questionable whether the findings would translate into well-
nourished HNC patients and so a trial in this population is recommended. Likewise, it is 
unknown if cachexia pathways are similar in HPV-related tumours due to different metabolic 
features (Couch et al., 2015), and this presents further areas to research.  
Another potential area to investigate is the role of the cephalic phase response, which occurs 
as a result of the thought of food, including sensory stimuli such as sight, smell and taste, 
triggering the parasympathetic nervous system to produce digestive enzymes (Power & 
Schulkin, 2008). Therefore the loss of appetite related to cachexia and the loss of appetite 
associated with taste changes will also reduce the natural cephalic phase response. 
Additionally when patients are tube fed they completely bypass this sensory phase (Stratton 
& Elia, 1999). This reduces the cephalic phase response and a decrease in gastric emptying 
results (Morey, Shafat, & Clegg, 2016) which has the potential to affect satiety, and may 
explain this symptom particularly in the later stages of treatment.  
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A comparison of the modes of enteral feeding delivery (pump versus bolus) could be 
undertaken to determine tolerance. A slower feed delivery system via a pump may help to 
minimise nutrition impact symptoms such as nausea and early satiety. It may also help 
patients who reported lack of time as a factor in administering feeds, as the pump could be 
connected and left to run overnight. 
Finally dysgeusia is an area of limited research in HNC despite being highly prevalent. The 
incidence of grade two dysgeusia in patients receiving CRT has been reported at 94% at 
the end of treatment and approximately 20% at 12 weeks post-treatment (Moroney et al., 
2017). Some research has been completed in the chemotherapy setting, in patients with 
breast cancer (Boltong et al., 2014) and colorectal cancer (Boltong, Keast, & Aranda, 2012). 
These studies demonstrate the negative impact taste dysfunction has on dietary intake and 
nutritional outcomes, although symptoms were transient and had resolved by eight weeks 
post-treatment. In comparison radiotherapy-induced dysgeusia can take months to years to 
fully resolve (Maes et al., 2002; Sandow, Hejrat-Yazdi, & Heft, 2006). Research to 
investigate patient experiences and consequences of taste changes resulting from HNC 
treatment is required. 
Opportunities for research across the continuum of care  
The research from this thesis in Chapter 8 was one of the first studies to investigate a pre-
treatment nutrition intervention. Poor patient adherence to the intervention was potentially 
due to a lack of understanding of increased nutritional needs. A trial of earlier dietary 
counselling may be beneficial to develop patient engagement and self-management, as this 
has been successful in a pilot study in lung cancer (Kiss et al., 2016).  
While historical studies provided evidence to support weekly dietetic review (Isenring et al., 
2004; Ravasco et al., 2005a), they were compared to nil dietetic intervention and thus it is 
difficult to ascertain whether less frequent intervention would have still been beneficial. They 
were also undertaken in cohorts receiving radiotherapy alone and as standard treatment is 
now concurrent CRT, with some patients having triple modality treatment, increased toxicity 
during treatment is seen compared to radiotherapy alone (Moroney et al., 2017). More 
intensive dietetic care may be required and a study comparing twice weekly reviews versus 
weekly could be completed. 
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Likewise, this historical evidence for fortnightly review post-treatment may no longer be 
sufficient. Moroney et al. (2017) reported continual improvement of toxicities post-treatment, 
however, the first measurement was at two weeks and so it is unknown what occurs during 
that initial acute period post-treatment. It has been identified as a time when patients feel 
most vulnerable as they are “entering the unknown”, with the post-treatment period 
described as “probably the worst part” in a recent qualitative study (Nund et al., 2014). Thus 
a more intensive review period in the first two weeks post-treatment could be trialled. 
Finally, further research is required into the appropriate time to transition into the provision 
of nutrition advice for survivorship. To reduce the risk of secondary cancers developing or 
other chronic health diseases, it is strongly recommended that cancer survivors strive to 
maintain an optimal weight and maintain a healthy lifestyle (Arends et al., 2017). Given 
patients are recovering more quickly from treatment side effects due to advances in 
technology (Beadle et al., 2017) and the increasing incidence of HPV-related tumours is 
resulting in younger patients with improved survival outcomes (Mallen-St Clair et al., 2016), 
the transition into survivorship is becoming increasingly important to address. However, 
when designing education programs, long-term toxicities, which either persist post-
treatment (e.g. xerostomia) or potentially develop over time (e.g. trismus, fibrosis, and 
dysphagia) still need to be taken into consideration for this population (Kraaijenga et al., 
2015). 
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9.6 Conclusions 
The findings from this thesis have contributed to the body of knowledge of the nutritional 
management of patients with HNC across several aspects of the nutrition care process. The 
thesis includes original research on the nutritional outcomes of patients receiving helical-
IMRT and refutes claims that advancing treatment techniques reduces nutrition impact 
symptoms and weight loss. The research has added to the literature supporting the benefits 
of proPEG over reactive tube feeding, with less weight loss and unplanned admissions. The 
updated protocol for proPEG selection has been validated in a contemporary patient cohort 
with a high positive predictive value thus minimising unnecessary tube placement. There 
are opportunities to improve the protocol classification further in a subset of low risk patients. 
The thesis also contains results from an early tube feeding intervention, which is the first 
study of its kind in this patient population. There was no improvement in nutritional, quality 
of life or clinical outcomes, however adherence to the intervention was poor, which limited 
the power of the study. It was identified that patient barriers to tube feeding were a significant 
issue, even when tube feeding was clinically indicated. This was a novel finding to perhaps 
explain why patients continue to lose weight, despite intensive nutrition interventions. The 
early tube feeding approach significantly improved patient adherence to clinically indicated 
tube feeding later in treatment. Routine encouragement of early tube feeding could therefore 
be a method purely to facilitate behavioural change, and allow the patient to adapt to and 
become accustomed with the tube. 
In summary, the research demonstrates the high complexity of patient management within 
a health service environment. Patients currently receive significant input from the dietitian 
and healthcare team but even this does not achieve desired outcomes. The additional 
nutrition intervention of commencing early tube feeding to prevent weight loss was not 
effective to achieve this on its own. The research has highlighted the many intricacies of 
patient care including barriers to healthcare recommendations. The role of the MDT is 
imperative for the design and implementation of multi-component interventions to overcome 
these barriers before improvements in nutrition outcomes can be seen. 
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11.1 Appendix A: Summary of studies on prophylactic tube feeding 
Citation Level & 
Quality 
Study design Interventions & 
Outcomes 
Results Comments/Limitations 
Prophylactic tube versus Oral Intake 
Daly 1984 II Ø Prospective RCT, 
USA 
 
N=35 
 
Stage III/IV HNC 
with RT 
Intensive NGT feeding 
(n=22) vs Oral diet + 
dietetic counselling 
(n=18) 
 
Outcomes: 
Energy & Protein Intake 
Wt 
Albumin 
Treatment response 
Survival 
 
NGT had: 
 higher mean energy intake 
during RT 
 higher mean protein intake 
during RT 
 lower mean weight loss for all 
sites except NPC 
 
No significant differences for: 
 albumin  
 weight loss in NPC patients 
 survival/treatment response 
 
Lack of clarity for the randomisation 
method 
 
Inadequate statistical reporting & protocol 
violations in each arm 
 
Intervention group had greater duration of 
toxicity, despite same RT field/dose 
 
Radiotherapy alone 
Hearne 1985 II Ø 
 
 
Prospective RCT, 
USA 
 
N=31 
  
Stage III/IV HNC 
with RT 
 
 
Intensive NGT feeding 
(n=18) vs Oral diet + 
dietetic counselling 
(n=13)  
 
Outcomes: 
Energy & Protein Intake 
Wt 
Albumin 
Toxicities 
Treatment response 
Survival 
 
NGT had: 
 higher mean energy intake 
 higher mean protein intake 
 less wt loss for oropharyngeal 
and recurrent nasopharyngeal 
 
No significant differences for: 
 Toxicities 
 Albumin 
 weight loss in NPC patients 
 
 
Patients were stratified according to 
tumour site, previous treatments and 
surgery and so similar at baseline 
 
Good explanation of randomisation, drop 
outs and changes to protocol (2 refused 
NGT and 2 had late NGT in oral group) 
 
Intention to treat analysis used 
 
Lack of significance levels 
 
Blinding not possible 
 
Zogbaum 2004 III-2 + 
 
 
 
Comparative 
cohort, USA 
 
N=34 
 
HNC with RT +/- 
chemo +/- surgery 
ProPEG (n=17) vs Oral 
diet (n=17) 
 
Outcomes: 
Wt and BMI 
Missed treatment days 
 
ProPEG had: 
 stable BMI compared to reduced 
BMI in oral intake 
 less missed treatment days  
 
 
Additional 4 patient excluded from 
intervention arm (n=21)  
 
Small study numbers 
 
Indications and decision making for tube 
feeding were not clear  
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Anwander 2004 III-2 Ø Prospective 
comparative 
cohort, Germany 
 
N=30 
 
Oropharynx with 
pre-op CRT 
 
ProPEG  (n=15) vs Oral 
diet and post-op NGT 
(n=15) 
 
Outcomes: 
Wt & Anthropometry 
(TSF, MAC) 
 
Oral diet had: 
 Decrease TSF  
 
No significant differences for: 
 weight 
 MAC 
 
Control group due to PEG refusal, which 
was more common in men 
 
Unusual treatment with pre-op CRT 
 
Both groups had post-op tube feeding 
(PEG vs NGT in control) 
Mercuri 2009 III-2 - Comparative 
cohort, Australia 
 
N=20 
 
HNC with RT (3D) 
PEG (N=10) vs Oral diet 
(n=10) 
 
Outcomes: 
Wt 
RT set up variations 
 
PEG had: 
 less weight loss during RT  
 reduction in set-up variation in 
the superior-inferior and anterior-
posterior planes  
 
PEG placed according to local guidelines: 
1) dysphagia pre-RT 
2) >10% wt loss pre-RT 
3) CRT 
4) Bilateral neck RT 
 
Small study, with no Dietitian or nutrition 
assessment parameters  
 
Fietkau 1991 III-2 - Prospective 
comparative 
cohort, Germany 
 
N=212 
 
HNC with RT + 
chemo or surgery 
 
ProPEG (n=47) vs oral 
diet (n=134) 
 
Outcomes: 
Wt & Anthropometry 
(MAMC, TSF) 
 
ProPEG had: 
 wt gain 2kg during RT (compared 
to wt loss of 3kg in oral group) 
 less wt loss post RT 
 increase TSF 
 
No significant differences for: 
 MAMC 
 
 
Excluded n=31 who had late PEG 
 
Wide range of treatment regimens with 
low numbers of patients having CRT 
(n=13) which is more relevant to current 
practice 
 
Nil PEG complications observed 
 
Senft 1993 III-2 – 
 
Prospective 
comparative 
cohort, Germany 
 
N=212  
 
HNC with RT + 
chemo or surgery 
 
ProPEG (n=28) vs oral 
diet (n=81) 
 
Outcomes: 
QOL  
ProPEG had: 
 maintained QOL during RT 
(whereas oral group dropped) 
 higher QOL at 6/52 
 
Probable bias due to poor response rate 
to QOL questionnaire (only 60%) 
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Prophylactic tube versus Reactive tube 
Prestwich 2014  III-2 + Retrospective 
comparative 
cohort, UK 
 
N=56 
 
Oropharynx with 
CRT/POCRT (3D) 
ProPEG (n=43) vs 
NGT (n=13) 
 
Outcomes: 
Swallow (MDADI) >2yr 
post treatment 
 
Median follow up 36mth 
 
ProPEG had: 
 Longer tube use (161d vs 53d) 
but NS (p=0.68) 
 
No significant differences for: 
 MDADI 
Tube placement at discretion of clinician 
or patient preference with diet/speech 
input as required 
 
Good response rate 89% (n=63 eligible) 
 
BMI higher in NGT group at baseline and 
higher Cisplatin use in proPEG group 
 
Kramer  2014  III-2 + Retrospective 
comparative 
cohort, USA 
 
N=86 
 
HNC with CRT 
/POCRT (IMRT) 
 
ProPEG (n=56) vs 
Reactive PEG (n=30) 
 
Outcomes: 
Wt 
Tube duration 
Survival 
 
ProPEG had: 
 longer duration in situ (227 vs 
139d, p<0.01) 
 
No significant differences for: 
 wt loss at 2,6,12mths 
 survival when adjusted for HPV 
and TNM stage 
Tube placement at discretion of clinician 
or patient preference 
 
Full MDT support 
 
Unclear if measured time tube in place or 
being used. Had to be on oral for 1 month 
with stable wt before tube removed 
 
Ward  2016 III-2 Ø Retrospective 
comparative 
cohort, USA 
 
N=78 
 
HNC with CRT 
(3D/IMRT)  
 
5 years post 
treatment with no 
disease relapse 
NGT (n=36) vs reactive 
PEG (n=17) vs proPEG 
(n=25) 
 
Outcomes:  
Severe late dysphagia 
 
SLD = stricture, 
aspiration pneumonia, 
or 2nd feeding tube after 
3mths post treatment or 
tube fed at 1 year 
 
ProPEG had: 
 Higher 5yr cumulative SLD than 
NGT (61% vs 31%, p=0.016) 
 
PEG use associated with SLD (HR 
3.195) on multivariate analysis 
Long study period (1996-2012) led to 
variations in treatment practices, tube 
selection practices and group differences 
(IMRT and smoking) – mostly accounted 
for in multivariate but tube selection bias.  
 
Excluded oropharyngeal HPV+ due to 
potential treatment de-intensification 
 
Patients only seen by speech as required 
when developed dysphagia 
 
Morton 2009 III-2  Ø Retrospective 
comparative 
cohort, New 
Zealand 
 
N=36 
 
HNC with CRT 
ProPEG (n=30) vs 
Reactive PEG (n=6) 
 
Outcomes: 
Swallow (PSS) 
QOL 
Wt 
Diet 
ProPEG had: 
 less wt loss at 12mth (p=0.049) 
 
No significant differences for: 
 diet texture at end of treatment or 
12mth 
 PSS 
 QOL 
All patients offered proPEG, so reactive 
group is patients who declined 
 
ProPEG was placed before or in first 
month of treatment 
 
Outcomes at 12-18mths post diagnosis 
 
Small sample size 
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Beer 2005 III-2 Ø Retrospective 
comparative 
cohort, 
Switzerland 
 
N=151 
 
HNC with 
RT/CRT 
ProPEG (n=78) vs 
reactive PEG (n=73) 
 
Outcomes: 
Wt/BMI 
Malnutrition 
RT delays 
 
ProPEG had: 
 Less wt loss ( 1.03kg vs 3.58kg) 
 Decreased malnutrition at end 
RT (31% vs 60%) 
 Less RT delays (10% vs 25%) 
 
 
Malnutrition not defined 
 
Significantly higher smoking and alcohol 
intake in proPEG group 
 
Planned for PEG on the basis of unable 
to meet energy needs by oral intake so 
full enteral feeding with oral clear fluids if 
tolerated 
 
Scolapio 2001 III-2 Ø Retrospective 
comparative 
cohort, USA 
 
N=54 
 
HNC with RT +/- 
surgery +/- chemo 
 
 
ProPEG (n=41) vs 
reactive PEG (n=13) 
 
Outcomes: 
Wt 
RT delays 
Unplanned admissions 
ProPEG had: 
 Earlier commencement of nutrition 
support (day 10 vs day 23)  
 Less wt loss (2.7kg vs 4.5kg) 
 Less admissions for dehydration 
(0 vs 4) 
 
Other results: 
 Median duration of tube use 165d  
 90% of patients lost wt (mean wt 
loss 3.4kg) despite goal intakes of 
25-30kcal/kg, and attributed to 
bloating/nausea/tube malfunction 
 
Selection bias in those selected for PEG 
placement: no clearly defined criteria 
 
Groups were not similar at baseline, no 
randomization and poor statistics 
 
95% of pts used the proPEG and tubes 
removed when consuming >50% orally 
 
Commenced nutrition support 24hr post 
placement to goal, but unclear if oral 
intake allowed 
 
Magne 2001 III-2 Ø 
 
 
Retrospective 
comparative 
cohort, France 
 
N=90  
 
Stage IV 
oropharynx or 
hypopharynx with 
CRT (bd) 
ProPEG (n=50) vs NGT 
(n=40) 
 
Outcomes: 
Complications 
Duration of feeding 
QOL 
BMI/Wt 
ProPEG had: 
 Better weight gain (+2.5kg vs 
+0.7kg) but no difference in BMI 
at week 1,3,6 
 No major tube complications 
 Less aspiration pneumonia (n=6 
vs n=21) 
 Less mechanical failure (n=5 vs 
n=32) 
 Longer duration of use (605d vs 
89d) 
 Better cosmesis and more 
mobility 
 Improved global QOL (67% vs 
27%) 
 
Commenced nutrition support 48hr post 
tube placement to goal 8400kJ/d + clear 
fluids/additional oral diet (oral intake not 
accounted) 
 
Groups similar at baseline with equal 
treatment regimens 
 
No statistics for complications 
 
Limited QOL results presented – only 
completed in 33 survivors (n=15 NG, 
n=18 PEG) 
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Prophylactic tube versus Reactive care (i.e. oral intake with tube feeding as required) 
Salas 2009 II + RCT, multicentre, 
France 
 
N= 39 
 
HNC with CRT 
 
,  
ProPEG (n=21) vs 
Reactive Care (n=18)  
 
Reactive: PEG (n= 13)  
Oral (n=5) 
  
Outcomes: 
BMI 
QOL 
ProPEG had: 
 Higher QOL at 6/12 
 
No significant differences for: 
 BMI at end of RT or 6/12 
 
Other results: 
 Higher BMI & lower KPS score at 
baseline were significantly related 
to higher QOL at 6/12 
 
Reactive care: PEG placed when 
indicated (dysphagia/ severe 
odynophagia, dehydration, wt loss 
>15%). Unclear what/when nutrition 
support was given in ProPEG group 
 
Median PEG use was 1.5mths post-RT 
but effect reported at 6mths 
 
Inclusion criteria: BMI>20, wt loss<10% 
previous 6/12, KPS>70 
 
Silander 2013 II Ø RCT, Sweden 
 
N=127 
 
HNC with 
CRT/PORT 
ProPEG (n=62) vs 
Reactive care (n=65)  
 
Outcomes: 
Energy/protein intakes 
Wt 
Dysphagia (EORTC35 
QOL single item) 
No significant differences for: 
 Energy and protein intakes or their 
source (oral, ONS, EN, PN) 
 Wt loss 
 Dysphagia (eating difficulty) 
 
Other results: 
 Energy and protein intakes did not 
meet requirements until after 6mths 
 Wt loss was 7% at 3mth, peaked at 
11-12% at 6mths, then stabilised or 
improved 
 EN and difficulty with eating was 
highest at 2-3mths 
 
Intakes measured with 3d food record 
(compliance 88%) with 7 non complaint 
patients excluded from original study 
 
Reactive care had oral or tube feeding as 
required – unable to determine exact 
tubes received due to extra exclusions 
 
PN use was low in both groups but exact 
use unknown and indications unclear 
 
No information on speech pathology input 
 
Malnutrition defined: >10% wt loss 6mth 
 
Silander 2012 II Ø RCT, Sweden 
 
N=134 
 
HNC with 
CRT/PORT 
ProPEG (n=64) vs 
Reactive care (n=70)  
 
Reactive: Tube (n=51) 
Oral (n=19) 
 
Outcomes: 
Wt/BMI  
Admissions 
QOL 
Survival 
Tube use & dependency 
Dysphagia 
ProPEG had: 
 Better QOL at 6mth (10 domains) 
 Less patients unable to swallow at 
1yr (2% vs 9% p=0.047) 
 Less patients with >10% wt loss at 
2mth (6% vs 19% p=0.059) 
 Longer tube use (177d vs 122d 
p<0.001) but started 23d earlier  
 
No significant differences for: 
 Survival, RT delays, Admissions 
 Mean wt loss at 6mth,1 or 2yr 
Reactive care had oral or tube feeding as 
required (overall 6 had PEG – but some 
may have converted from NGT as many 
placed months post treatment) 
 
No information on speech pathology input 
 
Malnutrition defined: >10% wt loss 6mth 
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Quon 2015  III-2 + Comparative 
cohort, Canada 
 
N=178 
 
HNC with 
RT/CRT 
(3D/IMRT) 
ProPEG (n=92) vs 
Reactive care (n=86) 
 
Reactive: Tube (n=24) 
Oral (n=62) 
 
Outcomes: 
Swallow (RBHOMS, 
PSS, ESAS) 
No significant differences for: 
 Swallow outcome 
 Tube dependency 
Tube placement at discretion of 
oncologist and practices changed after 
IMRT commenced 
 
Reactive care had tubes usually placed 
for wt loss 5-10% and were usually PEG 
(96%) vs NGT (4%) 
 
No baseline differences between tube 
groups, but the oral group had lower T-
stage/overall stage, less CRT, less 
baseline dysphagia/wt loss 
 
Lack of information on MDT care 
 
Williams 2012  III-2 + 
 
Retrospective 
comparative 
cohort, UK 
 
 
N=104 
 
Oropharynx  
with CRT/POCRT 
(3D) 
 
ProPEG (n=71) vs 
Reactive care (n=21) vs 
Therapeutic PEG (n=12) 
 
Outcomes:  
Time to start feeds 
LOS  
Unplanned admission 
Wt 
Diet  
Tube dependence 
Survival 
 
ProPEG vs reactive NGT had: 
 Earlier commencement (24d vs 
41d, p<0.001) 
 Less unplanned admission days 
(6 vs 14, p<0.01) 
 Longer tube duration (181d vs 
64d, p<0.01) 
 
No significant differences for: 
 Wt loss (end RT or 6mths) 
 Diet texture 
 RT delays 
 Survival 
 
Other results: 
 Tube duration associated with 
proPEG and T stage 
 
Significant baseline differences: 
-Therapeutic PEG had lower wt/BMI, 
more modified diet, higher T stage and 
more surgery 
-ProPEG group had higher dose RT  
  
Tube selection bias at discretion of 
clinician and patient choice 
 
Regular MDT care during/post treatment 
 
Therapeutic PEG started feeds 
immediately post placement 
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Romesser 2012  III-2 + Retrospective 
comparative 
cohort, USA 
  
N=400 
 
Oropharynx with 
CRT (IMRT) 
ProPEG (n=325) vs 
Reactive care (n=75) 
 
Reactive: PEG (n=29) 
Oral (n=46) 
 
Outcomes: 
Wt 
Albumin 
Toxicities 
Admissions 
RT delays 
Survival 
 
ProPEG had: 
 Less wt loss at 3mth (12% vs 
14.3%, p=0.05)  
 Less admissions (p=0.026) 
 Less rehydration (p=0.004) 
Shorter time to tube removal 
(3.4mths vs 5.1mths p=0.004) 
 
No significant difference for: 
 Albumin, toxicities, RT delays or 
survival 
 
Other results: 
 Predictors of prolonged PEG 
were older age, female, T3/T4 
 
Large sample but long study period of 11 
years may have influenced treatment and 
service provision with lack of information 
on diet/speech roles/input 
 
Intention-to-treat analysis completed 
 
All patients offered proPEG so reactive 
group is from patients who declined 
 
Differences at baseline: age, follow up 
time, tumour site, chemo type 
 
Only 7/325 did not use proPEG 
 
 
Bahl 2004 III-2 + Retrospective 
comparative 
cohort, Canada 
 
N=75 
 
NPC with CRT + 
adjuvant chemo  
ProPEG (n=23) vs 
Reactive care (n=52) 
 
Reactive: Tube (n=17) 
Oral (n=35) 
 
Outcomes: 
Compliance to CRT 
Toxicity 
Weight change 
Feeding tube use 
ProPEG had: 
 Slowest decline to nadir wt (186d 
vs. 117d and 129d) 
 Greatest recovery of baseline wt 
by 1yr (94% vs 87% and 92%) 
 Longer duration of tube use 
(145d vs 116d) 
 
Other results: 
CRT compliance associated with: 
 Higher baseline wt and proPEG  
CRT non-compliance associated: 
 lower baseline wt, female, non-
Asian, Stage III  
 
Main aim of paper was compliance to 
CRT regimen  
 
Type of feeding tubes used reactively 
and prophylactically (ProPEG) unclear - 
described as feeding tube only. 
Confounding factors regarding tube 
insertion decision was acknowledged 
 
No criteria for feeding tube placement but 
weight loss, stomatitis, and pharyngeal 
dysfunction were cited as most common 
 
No details regarding dietetic intervention 
 
Pramyothin 2016  III-2 Ø Prospective 
comparative 
cohort, Thailand 
 
N=95 
 
HNC with CRT 
 
ProPEG (n=25) vs 
Reactive care (n=70) 
 
Reactive: NGT (n=16) 
Oral (n=54) 
 
Outcomes: 
Treatment Delays 
Wt 
QOL 
ProPEG had: 
 Less wt loss (5% vs 8%, p=0.05) 
 Less with >10% wt loss (4% vs 
24%, p=0.03) 
 
No significant differences for: 
 QOL 
 Treatment delays 
Patient selection of study group led to 
baseline differences with more women in 
ProPEG group and better performance 
status in reactive care. Overall high 
proportion of cohort with NPC and mean 
age younger which may affect 
generalisability 
 
Only 16/53 patients consented to NGT 
when met reactive tube feeding criteria 
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Yamazaki 2016  III-2 Ø Retrospective 
comparative 
cohort, Japan 
 
N=27 
 
HNC with CRT 
(Cetuximab and 
IMRT) 
 
 
ProPEG (n=15) vs 
Reactive care (n=12)  
 
Outcomes: 
Toxicity 
Treatment delays 
Admissions 
Survival 
Wt 
 
 
ProPEG had: 
 Less leukopenia (7% vs 68%, 
p=0.002) 
 Less Grade 3 mucositis (47% vs 
83%, p=0.058) 
 Less RT delays (5 vs 0)  
 Less with >10% wt loss (27% vs 
75%, p=0.013) 
 Better overall survival (93% vs 
73%, p=0.055) 
 
No significant differences for: 
 Unplanned admissions (8 vs 9) 
 Progression-free survival (33% 
vs 33%, p=0.934) 
 
Small sample size 
 
Decision process regarding ProPEG 
placement unclear – became mandatory 
but unclear when 
 
Unplanned admissions in proPEG group 
mainly for worsening nutrition (due to 
non-use of PEG) 
 
Unknown if anyone had NGT placed in 
reactive care 
 
Sethugavalar 2016  III-2 Ø Comparative 
cohort matched 
pair analysis, UK 
 
N=52 
 
Oropharynx with 
CRT (IMRT) 
ProPEG (n=26) vs 
Reactive care (n=26)  
 
Reactive: NGT (n=17) 
Oral (n=9) 
 
Outcomes 
Swallow (MDADI) at 
>2years post treatment 
 
ProPEG had: 
 Worse total swallow scores (59.4 
vs 68.1, p=0.04) 
 Worse global, emotional and 
functional swallow scores 
 
No significant differences for: 
 Physical swallow scores 
Tube selection bias as per Consultant or 
patient decision 
 
No measures of: nutritional status at 
baseline or post; adherence to 
diet/speech appointments; whether 
prophylactic swallow exercises used 
 
Lewis 2014 III-2 Ø Retrospective 
comparative 
cohort, USA 
 
N=109 
 
HNC with CRT 
ProPEG (n=25) vs 
Reactive care (n=84) 
 
Reactive: Tube (n=34) 
vs Oral (n=50) 
 
Outcomes: 
Wt loss 
Admissions/DEM 
Completion chemo 
Tube dependency 
ProPEG had: 
 Less wt loss at 12mth (2% vs 
10% reactive, 15% oral, p<0.001) 
 Less DEM visits (p<0.001) 
 Less admissions (p<0.001) 
 Completed more chemo cycles 
(p<0.001) 
 
No significant differences for: 
 Mean duration of tube use (319d 
vs 277d, p=0.492) 
 Tube use at 12mth 
 
Type of feeding tubes used reactively 
and prophylactically (ProPEG) unclear - 
described as feeding tube only 
 
Tube placement on case by case basis 
 
Race differences between groups - 
ProPEG group had lower BMI and more 
wt loss at baseline (adjusted in analysis) 
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Baschnagel 2014  III-2 Ø Retrospective 
comparative 
cohort, USA 
 
N=193 
 
HNC with CRT 
(IMRT) 
 
ProPEG (n=139) vs 
Reactive care (n=54) 
 
Reactive: PEG (n=22) 
Oral (n=32) 
 
Outcomes: 
Admissions & Costs 
Tube dependence 
Complications/Toxicities 
 
ProPEG had: 
 Less strictures and aspiration 
 Less admissions 
 Reduced costs 
 
No significant differences for: 
 Tube dependence at 1 or 2yr 
 
 
Tube placement at discretion of clinician 
or patient preference 
 
Placed proPEG in outpatients 
 
No baseline difference between groups 
(Tumour site and N stage different in 
those without tube) 
 
Olson 2013 III-2 Ø Comparative 
cohort, USA 
 
N=445 
 
HNC with CRT 
(3D/IMRT) 
 
 
ProPEG centre (n=166) 
 88% had PEG 
Reactive centre (n=279) 
 31% had PEG 
 
Outcomes: 
Wt (end RT and 1yr) 
Tube complication  
Late toxicity  
Tube dependency  
 
ProPEG centre had: 
 Higher tube dependence at 3mth 
 
No significant differences for: 
 Wt 
 Admissions 
 Complications 
 Survival 
 Late toxicity 
 Tube dependence at 6 or 12mths 
 
Several differences between centres; 
site, stage, chemo type, baseline wt. No 
mention of speech pathology input 
 
Secondary analysis removed NPC and 
Cetuximab – did not change results 
 
Reports higher rate of complications 
when whole cohort compared, but when 
you only compare patients with PEG 
there is no difference 
 
Peerawong 2012 III-2 Ø 
 
Retrospective 
comparative 
cohort, Thailand 
 
N=219  
 
NPC with CRT 
(3D)  
 
ProPEG (n=77) vs 
Reactive care (n=142) 
 
Outcomes: 
Wt 
Toxicities 
Treatment completion 
ProPEG had: 
 Less wt loss 
 Less severe wt loss (>10%) at 
3rd, 4th and 5th cycle of chemo 
 Less hypokalaemia (p=0.002) 
 
No significant differences for: 
 Haematological toxicities 
 Completion of CRT 
Excluded patients with altered 
fractionation and IMRT 
 
ProPEG group had better ECOG but 
more co-morbidity at baseline 
 
Unclear what decision criteria used for 
proPEG placement and not clear if any 
patient in reactive care needed tube 
 
Langmore 2012 III-2 Ø 
 
Retrospective 
comparative 
cohort, USA 
  
N=59  
 
HNC with 
RT/CRT-3D/IMRT 
ProPEG (n=27) vs 
Reactive care (n=32) 
 
Reactive: PEG (n=6) 
Oral (n=26) 
 
Outcomes: 
Wt & Diet at 3, 6, 12mth 
No difference in wt loss, but reactive 
group had better diet (p=0.002) 
 
No difference in wt loss, but 
partial/oral diet at end of RT had 
better diet vs NBM groups (p<0.001) 
 
 
Author noted limitations: retrospective 
study design; did not include formal 
swallow studies, standardized diet score, 
or QOL scale.  
 
No comparison of differences between 
groups at baseline 
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Oozeer 2011  III-2 Ø 
 
Retrospective 
case control, UK  
 
N=44 
 
HNC with CRT 
>2years post 
treatment 
 
ProPEG (n=16) vs 
Reactive care (n=15) 
 
Outcomes: 
Swallow (MDADI score) 
ProPEG had: 
 Worse swallow with lower 
MDADI score in all domains 
(emotional, functional, physical, 
and global) P=0.001 
 
Groups poorly matched re: time since 
treatment (ProPEG assessed on average 
7 month later). Tube selection bias as per 
patient or clinician preference 
 
Lack of swallowing and nutritional status 
at baseline. No swallow exercise given. 
Unclear if proPEG maintained oral intake 
 
Small sample size and drop out n=13 
 
Rutter 2011   III-2 Ø Retrospective 
comparative 
cohort, USA 
 
n=111  
 
HNC with CRT 
(3D/IMRT) 
 
 
 
ProPEG (n=59) vs 
Reactive care (n=52) 
 
Reactive: PEG (n=31) 
Oral (n=21) 
 
Outcomes: 
Wt 
Admissions 
Complications 
Tube dependency 
 
 
Any PEG (vs Oral) had: 
 2.6% less wt loss during CRT 
(p=0.064), at 6 weeks post 
(p=0.02), and 3 months post 
(p=0.008) 
 No difference in wt loss at 6 
months post or admissions 
 
ProPEG (vs reactive PEG) had: 
 Less wt loss at 6 weeks 
(p=0.003) and 6 months post 
(p=0.011) 
 Decreased LOS (p=0.012) 
 Lower risk of nutrition admissions 
(p =0.01) 
 No difference in survival, tube 
dependence, or complications 
 
Varied treatment protocols 
 
Good MDT input but no information on 
speech pathology until post treatment 
 
Study investigated timing of PEG 
placement (only 59% were pre-treatment 
and true proPEG). Greatest effects seen 
if placed before week 3. 
 
All patients offered proPEG prior to 
treatment 
 
Disease control was the only predictor of 
tube dependence.  
 
McLaughlin 2010 III-2 Ø Retrospective 
comparative 
cohort, USA 
 
N=91 
 
HNC with 
CRT/POCRT 
 
 
 
ProPEG (n=15) vs 
Reactive care (n=76) 
 
Reactive: PEG (n=21) 
Oral (n=55) 
 
0utcomes: 
Duration tube  
Complications 
 
ProPEG had: 
 Longer tube duration (12mth vs 
5mth) 
 
No significant differences for: 
 Tube complications (n=2 in each 
group) 
 
Other results: 
 Tube duration associated: T3-4 
 
 
ProPEG offered if wt loss >10%, 
progressive dysphagia, aspiration risk, 
poor nutritional status, therefore likely 
reason for longer use 
 
Reactive PEG not initiated until 10-15% 
wt loss or dysphagia or aspiration 
 
No information on nutritional status or 
dietitian interventions. Tube dependency 
used as surrogate measure of dysphagia. 
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Chen 2010 III-2 Ø 
 
 
Retrospective 
comparative 
cohort, USA 
 
N=120  
 
HNC with CRT 
(3D/IMRT) 
 
 
ProPEG (n=70) vs 
Reactive care (n=50) 
 
Reactive: PEG (n= 16) 
Oral (n=34) 
 
Outcomes:   
Wt 
Admissions 
Tube dependence 
Survival 
RT delays 
Dysphagia 
Strictures 
ProPEG had: 
 Less wt loss during CRT (-8% vs 
-14%) 
 Less IV fluids (17% vs. 54%) 
 More dysphagia at 3mths (46% 
vs 27%) and 6mths (34% vs 5%) 
 More tube dependence at 6mths 
(41% vs 8%) and 12mths (21% 
vs 0%) 
 More strictures (30% vs 6%) 
 
No significant differences for: 
 RT delays 
 Admissions 
 Survival 
 Wt loss at 3 and 6mths 
 
ProPEG at the discretion of physician 
 
Patients with proPEG were encouraged 
to feed by mouth for as long as possible 
 
Decisions to initiate tube feeds were 
based on individual patient and toxicities 
 
Dysphagia assessed using validated tool 
 
Nugent 2010a III-2 Ø 
 
Retrospective 
comparative 
cohort, UK 
 
N=196 
 
HNC with 
RT/CRT 
 
 
 
ProPEG (n=27) vs 
Reactive care (n=169) 
 
Reactive: PEG (n=17), 
NGT (n=35), Oral 
(n=117) 
 
Outcomes: 
Wt 
RT delays 
ProPEG had: 
 Less wt loss compared to each 
reactive care group across all 
treatments (RT, CRT, induction) 
but not statistically significant 
 
Other results: 
 oropharyngeal cancer associated 
with wt loss 
 pre-treatment wt loss and dual 
modality treatments associated 
with tube feeding 
 
Consultant decision on type of tube 
 
Included only patients who were seen by 
dietitian within 1st week of treatment.  
 
Tube feeding commenced when oral 
intake <60% and/or wt loss >5% 
 
No statistical results presented 
 
 
Chang 2009 III-2 Ø Retrospective 
cohort, New 
Zealand 
 
N=71 
 
HNC with RT + 
surgery or chemo 
ProPEG (n=7) vs 
Reactive care (n=64) 
 
Reactive: NGT (n=28) 
Oral (n=36) 
 
Outcomes: 
 Wt 
 Admissions  
 RT delays 
ProPEG had: 
 Less wt loss (P=0.016) 
  
No significant differences for: 
 Admissions 
 RT delays 
 
Selection bias as no criteria for proPEG 
so group had more stage III/IV, CRT and 
6mth wt loss (controlled for in analysis) 
 
Criteria for reactive NGT if inadequate 
oral intake or significant wt loss (5%) 
 
Commenced PEG feeding when required 
- threshold seemed lower than for NGT 
 
  303 
Allen 2007 III-2 Ø Comparative 
cohort, USA 
 
N=46 
 
HNC with CRT 
(3D) – hyper 
fractionated 
 
ProPEG (n=22) vs 
Reactive care (n=24) 
 
Reactive: PEG (n= 14) 
Oral (n=10) 
 
Outcomes: Wt 
ProPEG had: 
 Less wt loss (-3.8% vs -7.9%, 
p=0.08) 
 
 
Clear criteria for proPEG (pharynx in the 
high-dose treatment volumes) but 20/42 
patients refused or unable to schedule 
(14/20 ended up with reactive PEG) 
 
Late referral to speech - Patients with 
dysphagia >3mths post therapy 
 
 
Mangar 2006 III-2 Ø Retrospective 
comparative 
cohort, UK 
 
N=160 
 
HNC with RT  
 
 
ProTube (n=30) vs 
Reactive care (n=130) 
 
ProTube:  
PEG n=6 NGT n=24 
Reactive:  
Tube n=20 Oral n=110 
 
Outcomes: Wt 
 
ProTube had: 
 Less wt loss than reactive tube 
 
Other results: 
 Any tube feeding (n=50) 
associated with: stage III/IV, 
smoking >20/d, poor 
performance status 
Comparison of tube timing not primary 
outcome 
 
No criteria for proactive tube placement, 
but all had 5-10% wt loss 
 
 
Beaver 2001 III-2 Ø 
 
Retrospective  
comparative 
cohort, USA 
 
N=249 
 
HNC with 
RT/PORT +/-
chemo 
 
 
ProTube (n=33) vs 
Reactive care (n=192) 
 
Reactive: Tube (n=72) 
Oral (n=120) 
 
Outcomes: 
Wt 
Admissions 
DEM visits 
ProTube had: 
 Less severe wt loss (14% vs 
reactive 60% oral 25%, p<0.05) 
 Less admissions and DEM visits  
 
Other results: 
 Need for tube associated with 
T3-T4, oral, oropharynx, pre-
treatment severe wt loss, PORT 
 No need for tube associated with 
T1-T2, nasopharynx, RT alone 
Comparison of tube not primary outcome 
 
Long study period (11 years) which may 
influence practice/treatment delivery with 
tube selection dependent on clinician 
 
Data in tables/text not consistent and 24 
patients not accounted for 
 
Severe wt loss defined as >10% 6mth, 
>5% 1mth, 2% 1wk, >7% of BMI 6mth 
 
Lee 1998 III-2 Ø 
 
Retrospective 
comparative 
cohort, USA 
 
N=88 
 
HNC with RT +/- 
chemo/surgery 
 
ProPEG (n=36) vs 
Reactive care (n=52) 
 
Reactive: PEG (n= 16) 
Oral (n=36) 
 
Outcomes: 
 Wt 
 Admissions 
 RT delays 
ProPEG had: 
 Less nutrition-related admissions 
(13% vs. 34%) 
 Less wt loss (3.1kg vs. 7kg) 
 Less wt loss >5% (n=15 vs n=37) 
 
No significant differences for: 
 RT delays 
 All-cause admissions 
 Survival or local control 
Selection criteria for proPEG dependent 
on clinician (generally expected toxicity) 
 
No randomization, groups not similar at 
baseline 
 
Incomplete data on pre-treatment wt loss 
 
70% of hospitalizations overall were due 
to malnutrition or dehydration 
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Tyldesley 1996 III-2 Ø 
 
 
Retrospective 
comparative 
cohort, Canada 
 
N=64 
 
HNC with RT 
 
ProPEG (n = 12) vs 
Reactive care (n=52) 
 
Reactive: PEG (n=22) 
NGT (n=1) Oral (n=29) 
 
Outcomes: 
Wt 
Admission/LOS 
RT delays 
ProPEG had: 
 Less wt loss during RT (3% vs 
6%) 
 Shorter LOS (4.9d vs 19d) 
 Longer duration tube in situ (20.9 
weeks vs 13.8 weeks) 
 No RT delays 
 
Any PEG had: 
 Less wt loss 4-6wk (3-5% vs 9%) 
 Less wt loss 3mth (3-4% vs 12%) 
 
Selection criteria for proPEG dependent 
on clinician – factors considered included 
tumour size, RT volume, age, medical 
status, nutritional status   
 
PEG group matched to no PEG control 
group using age, sex, RT volume & dose 
 
N=3 in PEG group were palliative intent 
 
Small study, lacking power 
 
Pezner 1987 III-2 Ø Comparative 
cohort, Canada 
 
N=89 
 
HNC with RT 
ProTube (n=17) vs 
Reactive care (n=72) 
 
ProTube:  
NGT n=4, cervical 
oesophagostomy n=4, 
gastrostomy n=9 
Reactive:  
NGT n=3, gastrostomy 
n=6, Oral n=63 
 
Outcomes: Wt 
ProTube had: 
 Less wt loss during RT (4.8% vs 
9.4% and 7.1%) 
 Less pts with >10% wt loss (6% 
vs 44% and 24%) 
 
Other results: 
 Well-nourished patients tended 
to lose more weight than those 
malnourished at baseline, 
however not statistically 
significant due to small numbers 
 
Old study using data and older RT 
technology >30 years ago  
 
Tube selection bias based on clinician 
and patient acceptance 
 
Does not appear to be prophylactic tube 
placement but early tube feeding - more 
likely ProTube if malnourished at 
baseline 
 
 
Hughes 2013 III-3 + 
 
Retrospective 
comparative 
cohort, Australia 
 
N=165 
 
 
HNC with 
CRT/POCRT (3D) 
Pre 2005 (n=77) 
-ProPEG n=5 (6%) 
-Reactive n=18 
-Oral n=54 
 
Post 2007 (n=88) 
-ProPEG n=39 (44%) 
-Reactive n=4 
-Oral n=45 
 
Outcomes: 
Admissions 
LOS 
30d mortality 
 
Post guidelines (proPEG): 
 Less admissions (p<0.001) 
 Less unplanned admissions 
(p<0.001) 
 Shorter LOS (p<0.001) 
 
No significant differences for: 
 Mortality 
 
Other results: 
 Associations with admission - 
male and reactive tube 
 
Study evaluating impact of proPEG 
guidelines in pre and post phase 
 
Cohorts differences for tumour site and 
chemo regimen 
 
Nutritional outcomes and PEG 
complications only collected for 2007  
cohort 
 
 
  305 
Piquet 2002 III-3 + Retrospective 
comparative 
cohort, 
Switzerland 
 
N=90 
 
Oropharynx with 
RT 
 
Early intervention (n=45) 
-ProPEG n=33 (74%)  
-NGT n=6 
-Oral n=6 
 
Historical control (n=45) 
-ProPEG n=5 (11%) 
-NGT n=12 
-Oral n=28 
 
Outcomes: 
Wt 
Admissions 
 
Post early intervention (proPEG): 
 Less wt loss (3.5kg vs 6.1kg 
p<0.01) 
 Less hospital admission for 
dehydration (0% vs 8% p<0.01) 
  
 
Study evaluating impact of early nutrition 
intervention (including proPEG) in pre 
and post phase 
 
Clear PEG insertion criteria: wt loss 
>10%, BMI< 20, age >70 
 
Those without proPEG received 
counseling and ONS, but nutrition 
interventions in historical group less clear 
 
Groups matched so similar for age and 
TNM staging 
 
Assumed QOL is better for PEG patients 
(not measured) 
 
Assenat 2011  III-3 Ø 
 
Retrospective 
comparative 
cohort, France  
 
N=139 
 
HNC with CRT 
(3D) 
 
ProPEG (n=61) vs 
Reactive care (n=78) 
 
Reactive: PN (n=45), 
oral (n=33) 
 
Outcomes:  
Wt 
RT delays 
Admissions/LOS 
Survival 
 
ProPEG had: 
 Less wt loss (1kg vs 5kg, 
p<0.0001) 
 Less RT delays (38% vs 59%, 
p=0.01) 
 Shorter RT delays (100d vs 
236d, p=0.03) 
 
No significant differences for: 
 Survival 
Tube selection based on time period of 
study 
 
ProPEG had worse baseline nutrition 
status and more hyper-fractionated RT 
 
Inappropriate measures of nutritional 
status (NRI, albumin and/or wt loss)  
 
Indications for PN not clear 
 
 
Abbreviations: BMI=body mass index; CRT=chemoradiotherapy; DEM=Department of Emergency Medicine; EN=enteral nutrition; ESAS=Edmonton Symptom 
Assessment System; HPV=human papilloma virus; HNC=head and neck cancer; IMRT=intensity-modulated radiotherapy; KPS=Karnofsky performance scale; 
LOS=length of stay; MAC=mid-arm circumference; MAMC=mid-arm muscle circumference; MDADI=MD Anderson Dysphagia Inventory; MDT=multidisciplinary team; 
NGT=nasogastric tube; NPC=nasopharynx; NRI=nutritional risk index; ONS=oral nutrition supplements; PEG=gastrostomy tube; PN=parenteral nutrition; 
POCRT=post-operative chemoradiotherapy; PORT=post-operative radiotherapy; proPEG=prophylactic gastrostomy; ProTube=prophylactic feeding tube; 
PSS=performance status scale; QOL=quality of life; RCT=randomised controlled trial; RBHOMS =Royal Brisbane Hospital Outcome Measure for Swallowing; 
RT=radiotherapy; TNM=tumour, nodal, metastases staging; TSF=triceps skinfold; Wt=weight.
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11.2 Appendix B: Summary of studies on reactive tube feeding 
Citation Level & 
Quality  
Study design Interventions and 
Outcomes 
Results Comments/Limitations 
Comparison of reactive feeding tubes (PEG vs NGT) 
Corry 2008 II Ø RCT, Australia 
 
N=33 
 
HNC with RT/CRT  
 
PEG (n=15) vs NGT 
(n=18) 
 
Outcomes: 
Performance status 
Wt 
Anthropometry (MAC, 
TSF) 
QOL 
Dysphagia 
Treatment response 
 
 
 
PEG had: 
 less wt loss 6/52 (p<0.001) 
 less tube dislodgement 
(p=0.0001) but more pain at 1/52 
(p=0.03) 
 less body image concern 
(p=0.05) 
 more tube convenience at 1/52 
(p=0.02) 
 less interference with social 
activities (p=0.04) 
 longer duration of use in those 
with no evidence of disease 
(n=26) (p=0.0004) 
 higher costs 
 
No significant differences for: 
 Performance status or QOL  
 Treatment response 
 Wt or dysphagia at 6mth 
 Complication rates 
 
Slow recruitment as 37% refused to be 
randomised and study closed early.  
 
Did not use intention-to-treat analysis: 9 
excluded as did not receive tube to which 
they were randomised 
 
Feeding tubes placed when intake <50% 
and/or >5 kg wt loss from start of 
treatment 
 
Cost analysis excluded admission costs 
 
 
Sadasivan 2012 II - RCT, India 
 
N=100 
 
HNC with PORT or 
CRT/POCRT 
 
PEG (n=50) vs NGT 
(n=50) 
 
Outcomes: 
Wt 
Anthropometry (MAC) 
Haemoglobin 
Albumin 
Complications 
Patient satisfaction 
 
PEG had: 
 Less wt loss 6wk (3% vs 11% 
p<0.001) and better haemoglobin 
and MAC 
 Less infections (4% vs 64% 
p<0.001) 
 Less dislodgements (0% vs 36% 
p<0.001) 
 Better QOL (p<0.01) 
 
No significant differences for: 
 Albumin 
PEG group had lower baseline wt and 
more surgery 
 
No report of pre-treatment wt loss or 
dysphagia 
 
Tube placement timing unclear 
 
Did not use intention-to-treat analysis: 6 
NGT excluded as opted for PEG at 6 
weeks 
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Sobani 2011 III-2 Ø 
 
Retrospective 
cohort, 
Pakistan 
 
N=32  
 
Oral cavity with 
surgery ± RT  
 
 
PEG (n=16) vs NGT 
(n=16)  
 
Outcomes:  
Wt 
Psychosocial 
acceptance 
Tube complications 
 
PEG had: 
 Less wt loss (1.3 vs 5.4kg, 
p=0.025)  
 Longer mean tube use (6mths vs 
15d) 
 Less complications 
 Better patient acceptance (100% 
recommend vs 0%) 
 Higher patient rating of tube as 
good/excellent (7 vs 1) 
 
Tube selection based on patient 
preference 
 
Timing of tube placement, duration of 
follow-up and outcome time-points 
unclear 
 
No discussion of limitations - small 
sample size with limited statistical 
analysis 
 
Corry 2009 III-2 Ø Prospective 
comparative cohort, 
Australia 
 
N=105 
 
HNC with RT/CRT 
 
81% CRT 
(including 
Tirapazamine) 
 
 
PEG (n=32) 
(Randomised n=22) vs 
NGT (n=73) 
(Randomised n=20) 
 
Outcomes: 
Wt 
Anthropometry (MAC) 
Complications 
Patient satisfaction 
Cost 
Mucositis 
Performance status 
Dysphagia  
Treatment response  
 
PEG had: 
 Less wt loss 6/52 (p<0.001) 
 Less severe wt loss >10% 6/52 
(p=0.05) 
 Higher infections (p=0.001) 
 Longer duration of use (p<0.001) 
 Less tube dislodgements 
(p<0.001) 
 More pain but less body image 
concerns 
 Less severe wt loss 6mth (13% 
vs 35%, p=0.09) 
 
No significant differences for: 
 Performance status or QOL 
 Treatment response 
 Grade 3 dysphagia at 6mth  
 
Continued observation from study after 
RCT ceased early enabling patients to 
choose tube type 
 
Feeding tubes usually placed ~wk5 when 
intake <50% and/or >5 kg wt loss from 
start of treatment 
 
Did not discuss tube complications 
beyond 6mths when NGT used up to 
396d 
 
Higher incidence Grade 3 dysphagia 
could explain higher chest infections in 
PEG group 
 
Toxicity scale uses tube feeding as 
measure of dysphagia  
 
Mekhail 2001 III-2 Ø 
 
 
Retrospective 
comparative cohort, 
USA 
 
n=91 
 
HNC with RT/CRT  
PEG (n=62) vs NGT 
(n=29) 
 
Outcomes: 
Dysphagia 
Tube duration 
Dilatations 
PEG had: 
 More dysphagia at 3 and 6 
months (p=0.015)  
 Longer feeding duration (28  vs 8 
weeks, p<0.001) 
 More dilatations (p=0.022) 
 
No significant differences for: 
 dysphagia at 12 months 
Tube selection bias as based on clinician 
or patient preference with PEG more 
likely if malnourished or expected longer 
feeding 
 
Unclear if NGT patients are more 
motivated with rehab due to tube 
discomfort & appearance 
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Lees 1997 III-2 - 
 
 
Prospective 
comparative cohort, 
UK 
 
N=100 
 
HNC with RT  
 
PEG (n=32) vs NGT 
(n=68) 
 
Outcomes: 
Wt 
Tube use and duration 
QOL 
Survival 
 
PEG had: 
 More bolus feeds than pump 
 Longer duration (28 vs 21d) 
 Better QOL 
 
No significant differences for: 
 Wt 
 Survival 
Included radical and palliative treatment 
 
Tube selection criteria: PEG if enteral 
feeding >21d and does not interrupt RT  
 
QOL assessment did not use validated 
tool and limited reporting and statistics 
 
Reactive feeding tube vs oral intake 
Sanguinetti 2013 III-2 Ø 
 
 
Retrospective 
comparative cohort,  
USA 
 
N=59  
 
Oropharynx with 
RT (IMRT)  
 
 
Reactive PEG (n=22) 
vs Oral (n=37) 
 
Outcomes: 
Toxicity 
Admissions 
Wt 
 
 
Reactive PEG had: 
 More mucositis (0.032) 
 More dysphagia (p<0.001) 
 More admissions (p=0.001) 
 More wt loss (p=0.031) 
 
Other results: 
 Reduced need for PEG if <50-
60cm3 of oral mucosa has <9.5-
10 Gy/week  
 
Main aim was to determine predictive 
factors for PEG 
 
Tube placement as per physician based 
on criteria: >10% wt loss during RT, 
protracted symptoms and inadequate 
pain control 
 
 
 
Clavel  2011 III-2 Ø Retrospective 
comparative cohort, 
Canada 
 
N=253 
 
HNC with CRT 
Reactive NGT (n=126) 
vs Oral (n=127) 
 
2% were prophylactic  
 
Outcomes:  
Wt 
Tube use and duration 
Admissions 
Survival 
No significant differences for: 
 Wt (data not shown) 
 3yr survival (83.7% vs 82.0%) 
 
Other results: 
 Overall mean weight loss 10.4% 
 Median NGT duration 40d 
 Nutrition admissions 15% of total 
 
 
NGT placement criteria: wt loss >5-10%, 
uncontrolled odynophagia and/or risk of 
aspiration. No criteria for prophylactic 
placement 
 
Good MDT care and follow up 
 
Baseline characteristics similar in groups 
 
>50% of patients had wt loss >10% 
 
Ahmed 2005 III-2 Ø 
 
Retrospective 
comparative cohort, 
USA 
 
N=477 
 
HNC with CRT 
Any PEG (n=220) vs 
Oral (n=257) 
 
Outcomes:  
Wt 
Mucositis 
Nausea 
No significant differences for: 
 Wt/ nausea/ mucositis 
 
Other results: 
 PEG associated with T4, oral, 
oropharynx, hypopharynx 
 No need for PEG associated with 
T2, larynx & paranasal sinus 
Combined proPEG (n=52) and reactive 
PEG (n=129) 
 
Tube placement as per clinician decision 
 
No baseline nutritional status/dysphagia 
information 
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Goda 2015  III-2 - Retrospective 
comparative cohort, 
Japan 
 
N=44 
 
HNC with CRT  
Reactive PEG 
“adherent” (n=13) vs 
Oral “non-adherent” 
(n=20) 
 
Additional 11 patients 
in oral group who did 
not meet criteria for 
tube insertion 
 
Outcomes: 
Total serum protein 
RT delays 
Reactive PEG had 
 Less RT delays (0% vs 50%) 
 
No significant differences for: 
 Total serum protein 
 
 
 
 
PEG placed if Grade 3 mucositis and 
inadequate oral intake (<1/3 usual) but 
exact timing of PEG placement unknown 
 
High refusal of tube feeding (NGT or 
PEG) when indicated (20/31) 
 
Role of MDT input unknown 
 
Inappropriate measure of nutritional 
status and wt loss outcomes not known 
 
High proportion of hypopharynx/larynx 
 
 
Abbreviations: CRT=chemoradiotherapy; HNC=head and neck cancer; IMRT=intensity-modulated radiotherapy; MAC=mid-arm circumference; 
MDT=multidisciplinary team; NGT=nasogastric tube; PEG=gastrostomy tube; POCRT=post-operative chemoradiotherapy; PORT=post-operative radiotherapy; 
proPEG=prophylactic gastrostomy; QOL=quality of life; RCT=randomised controlled trial; RT=radiotherapy; TNM=tumour, nodal, metastases staging; TSF=triceps 
skinfold; Wt=weight.
 Chapter 11 Appendices 
 310 
11.3 Appendix C: Peer-reviewed conference abstracts/posters
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11.3.1 Enteral Feeding & Nutritional Management in Head and Neck Cancer: Current 
Best Practice 
Australian & New Zealand Head & Neck Cancer Society ASM, Melbourne, Australia. July 2013 
(oral) 
Teresa Brown1, 2 
1Royal Brisbane & Women’s Hospital, 2Centre of Dietetics Research (C-DIET-R), The University of 
Queensland 
The prevalence of malnutrition, weight loss and dysphagia is common in patients in with 
head and neck cancer. Several studies have demonstrated beneficial effects of dietary 
counselling during radiotherapy treatments, with improvements in weight, nutritional status 
and quality of life. Many patients also require nutrition support through enteral tube feeding, 
however the evidence remains unclear as to the optimal form of tube feeding. Prophylactic 
gastrostomy has been recommended in some patient groups due to the beneficial effects 
on maintaining nutritional status or weight as well as other benefits such as improved quality 
of life and reduced hospital admissions. However, many of these studies were undertaken 
in patients receiving radiotherapy alone, and now as chemoradiotherapy treatments become 
standard of care; the same results for nutrition outcomes in more recent trials are not seen. 
On overview of the current evidence in this area will be presented. At the Royal Brisbane 
and Women’s Hospital, we are using validated guidelines to predict which patients may 
require prophylactic gastrostomy, and despite this proactive intervention, we have found that 
high risk patients can still lose 6-7% of body weight during treatment and up to 9-10% by 
three months post treatment. Weight loss and malnutrition can impact on the patients’ quality 
of life, functional ability and other clinical outcomes. This presentation will also discuss 
current research underway to investigate novel approaches of nutrition intervention through 
prophylactic nutrition support and to determine whether early tube feeding improves nutrition 
outcomes. 
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11.3.2 Nutrition outcomes in patients with mucosal squamous cell carcinoma of the 
head and neck (HNSCC): Tomotherapy compared to 3D conformal radiotherapy 
European Congress of Head & Neck Oncology, Liverpool, UK, April 2014 (oral) 
Teresa Brown1,2,  Merrilyn Banks2, Brett Hughes3, Charles Lin3, Lizbeth Kenny3, Judith Bauer1 
1Centre for Dietetics Research (C-DIET-R), University of Queensland, 2Department of Nutrition & Dietetics, 
Royal Brisbane & Women’s Hospital, 3Cancer Care Services, Royal Brisbane & Women’s Hospital. 
Background: Patients with HNSCC have a high incidence of malnutrition and frequently 
require enteral tube feeding. Since 2007 our institution has used validated local hospital 
guidelines for the insertion of prophylactic gastrostomy feeding tubes. Tomotherapy 
treatment was introduced in 2010; therefore this study investigated whether associated 
reduced treatment toxicity impacted weight loss and tube feeding requirements. 
Methods: Patients with HNSCC attending a major tertiary hospital in 2010 – 2011 were 
included in the study. Patients assessed as high nutrition risk requiring a prophylactic 
gastrostomy were compared according to treatment received; Tomotherapy (n=53) versus 
3D conformal radiotherapy (n=34). Data on clinical factors, weight change from baseline to 
completion of treatment, and utilisation of tube feeding were collected. Severe weight loss 
defined as >10%. 
Results: The Tomotherapy cohort had higher proportions of patients with definitive 
chemoradiotherapy (p=0.043) and more advanced N stage (p=0.003). Nutrition outcomes 
were not significantly different between the two groups: prophylactic gastrostomy insertion 
(Tomotherapy: 87% versus conformal: 76%, p=0.473); mean percentage weight loss 
(Tomotherapy: 6.3% + 5.6 versus conformal: 8.6% + 5.8, p=0.07); incidence of severe 
weight loss (Tomotherapy: 28% versus conformal: 35%, p=0.492). Two patients in each 
group required later placement of a feeding tube. Five patients did not use their prophylactic 
tube (n=3, Tomotherapy; n=2, conformal) with one patient in each group non-adherent to 
recommendations to use their tube resulting in >10% weight loss.  
Conclusion: The clinical significance of mean weight loss and high incidences of tube 
feeding and severe weight loss in both groups warrants no change to current practice 
regarding prophylactic gastrostomy insertion. While statistical significance of results is 
limited by inadequate sample size, a possible trend for less weight loss was noted in patients 
receiving Tomotherapy. Further research with adequate sample size and strategies to 
improve nutrition outcomes and adherence to recommendations are required.
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11.3.3 Do advancing radiotherapy techniques impact on our nutrition management 
of patients with head and neck cancer?  
Dietitians Association of Australia 31st National Conference, Brisbane, Australia. May 2014 (oral) 
Teresa Brown1,2, Merrilyn Banks2, Brett Hughes3, Charles Lin3, Lizbeth Kenny3, Judith Bauer1 
1Centre for Dietetics Research (C-DIET-R), University of Queensland, 2Department of Nutrition and Dietetics, 
Royal Brisbane and Women’s Hospital, 3Cancer Care Services, Royal Brisbane and Women’s Hospital 
Patients with head and neck cancer have a high incidence of malnutrition and frequently 
require enteral tube feeding. Since 2007 our institution has used validated local hospital 
guidelines for the insertion of prophylactic gastrostomy feeding tubes. Tomotherapy (an 
advanced radiotherapy technique) was introduced in 2010; therefore this study investigated 
whether associated reduced treatment toxicity from Tomotherapy impacted nutrition 
outcomes. Patients with head and neck cancer assessed as high nutritional risk with 
recommendation for prophylactic gastrostomy were included in the study from 2010-2011. 
Retrospective data were collected on clinical factors, weight change from baseline to 
completion of treatment, incidence of severe weight loss (>10%) and tube feeding. 
Outcomes were compared according to treatment; Tomotherapy (n=53) versus 3D 
conformal radiotherapy (n=34). The Tomotherapy cohort had higher proportions of patients 
with definitive chemoradiotherapy (p=0.043) and more advanced N stage (p=0.003). 
Nutrition outcomes were not significantly different between the two groups: prophylactic 
gastrostomy insertion (Tomotherapy: 87% versus conformal: 76%, p=0.473); mean 
percentage weight loss (Tomotherapy: 6.3% + 5.6 versus conformal: 8.6% + 5.8, p=0.07); 
severe weight loss incidence (Tomotherapy: 28% versus conformal: 35%, p=0.492). Both 
groups had mean weight loss >5% and high incidences of tube feeding and severe weight 
loss, which are clinically significant results supporting no change to current nutrition 
management for Tomotherapy. While statistical significance of results is limited by 
inadequate sample size, a possible trend for less weight loss was noted in patients receiving 
Tomotherapy. Further research is required with strategies to improve nutrition outcomes and 
adherence to recommendations.
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11.3.4 A retrospective validation of the criteria for proactive gastrostomy tube 
insertion in patients with head and neck cancer in the era of Tomotherapy 
Australian & New Zealand Head & Neck Cancer Society ASM, Melbourne, Australia. July 2013 
(oral) 
Vanessa Getliffe1, Teresa Brown1,2,  Merrilyn Banks2, Brett Hughes3, Charles Lin4, Lizbeth Kenny4, Judy 
Bauer1 
1School of Human Movement Studies, University of Queensland, 2Department of Nutrition and Dietetics, 
Royal Brisbane and Women’s Hospital, 3Department of Medical Oncology, Royal Brisbane and Women’s 
Hospital, 4Cancer Care Services, Royal Brisbane and Women’s Hospital. 
Aim. The “Swallowing and Nutrition Guidelines for Patients with Head and Neck Cancer” 
were developed in response to the high risk of malnutrition and dysphagia that patients 
experience as a result of cancer treatment. The purpose of this study was to retrospectively 
re-validate the guidelines’ assessment criteria in the era of Tomotherapy and compare these 
results to a previous two year cohort where the treatment modality was standard 3D 
conformal radiotherapy. 
Methods. Patients (n=271) attending a Combined Head and Neck Clinic at a major tertiary 
hospital in 2010 - 2011 were assessed using the guidelines, with high-risk category patients 
recommended for proactive gastrostomy. Data were collected on clinical factors, nutrition 
outcome measures, type and duration of enteral tube feeding, and guideline adherence. 
Sensitivity, specificity, and positive predictive value were calculated. These results were 
compared to a previous validation cohort from 2007 - 2008 (n=502).  
Results. The only significant difference between the two cohorts was the number of patients 
receiving Tomotherapy (P=<0.001). Proactive gastrostomy tubes were inserted in 87 of 271 
patients (32%). Overall guideline adherence was 91% (vs. previous cohort results of 87%). 
High risk category adherence was 81% (compared to 75%). Validation outcomes were 
sensitivity 75% (compared to 54%), and specificity 90% (compared to 93%). 
Conclusion. The results of this study confirm the Head and Neck Guideline’s criteria and 
categories remain valid in the era of Tomotherapy to aid risk assessment and to guide early 
decision making for the suitability and timing of tube feeding in patients with head and neck 
cancer.
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11.3.5 Investigation of p16 status, chemotherapy regimen and other nutrition 
markers for predicating gastrostomy in patients with head and neck cancer 
Multinational Association of Supportive Care in Cancer, Adelaide, Australia. June 2016 (poster) 
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11.3.6 Validation of a protocol to predict proactive gastrostomy tube placement in 
patients with head and neck cancer receiving helical-IMRT 
Australia & New Zealand Head & Neck Cancer Society, Auckland, New Zealand. Oct 2016 (poster) 
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11.3.7 Outcomes following proactive vs reactive nutrition support in patients 
undergoing chemoradiotherapy 
World Congress of Larynx Cancer, Cairns, Australia July 2015 (oral) 
Teresa Brown1,2, Merrilyn Banks2, Brett Hughes3, Charles Lin3, Lizbeth Kenny3, Judith Bauer1 
1Centre for Dietetics Research (C-DIET-R), University of Queensland, 2Department of Nutrition and Dietetics, 
Royal Brisbane and Women’s Hospital, 3Cancer Care Services, Royal Brisbane and Women’s Hospital 
Purpose: The optimal method of tube feeding for patient with head and neck cancer remains 
unclear. Our institution uses validated local hospital guidelines for the insertion of 
prophylactic gastrostomy feeding tubes. The aim of this study was to investigate the 
outcomes of patients following non adherence to these recommendations.  
Methodology: Patients assessed as high nutrition risk according to local guidelines were 
included from August 2012 – July 2014. Patients were grouped according to adherence to 
guideline recommendation for gastrostomy placement. Clinical outcomes were: weight 
change from diagnosis to the end of radiotherapy; use of feeding tubes; and admissions for 
up to one month post treatment.  
Results: Over two years there were 130 high nutrition risk patients with the following 
characteristics - 88% male, median 59 years old, 77% oropharyngeal tumours, 91% stage 
IV disease, and 88% chemoradiotherapy treatment. Group 1 received a gastrostomy (n=69). 
Group 2 were managed reactively (n=61), with 26 patients (43%) requiring a feeding tube 
or with weight loss >=10%. Mean weight loss during treatment was 7.0% (gastrostomy 
group) versus 8.4% (reactive group) (p=0.114), which was significant when adjusting for T 
stage, tumour site, and age (p=0.048). Unplanned admissions accounted for 75% of total 
length of stay in the gastrostomy group and 82% in the reactive group (p=0.029). 
Conclusion: Nutritional and clinical outcomes were improved in the group receiving 
gastrostomy when adjusting for clinical differences between the groups. Some selection bias 
was evident in patients without a gastrostomy and further investigation of this group could 
help to assist to improve the guidelines for gastrostomy selection.
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11.3.8 Optimising nutrition outcomes for patients with head and neck cancer 
through innovative pre-treatment intervention strategies 
Clinical Oncological Society of Australia, Brisbane, Australia. Nov 2012 (oral) 
Teresa Brown1, 2 
1Royal Brisbane & Women’s Hospital, 2Centre of Dietetics Research (C-DIET-R), The University of 
Queensland 
There is high level evidence to support the role of the dietitian in the multidisciplinary team 
for the management of patients with head and neck cancer. Several studies have 
demonstrated the beneficial effects of dietary counselling during radiotherapy treatments, 
with improvements in weight, nutritional status and quality of life (Garg et al., 2010). Many 
patients also require nutrition support through tube feeding, however the evidence remains 
unclear as to the optimal form of tube feeding (Nugent et al 2010b). Prophylactic 
gastrostomy has been recommended in some patient groups due to the beneficial effects 
on maintaining nutritional status or weight (Tyldesley et al 1996, Lee et al 1998), as well as 
other benefits such as improved quality of life (Senft et al 1993) and reduced hospital 
admissions (Piquet et al 2002, Lee et al 1998). Many of these studies were undertaken in 
patients receiving radiotherapy alone, and now as chemoradiotherapy treatments become 
standard of care, the same results for nutrition outcomes in more recent trials are not seen 
(Silander et al 2010). At the Royal Brisbane and Women’s Hospital, we are using validated 
guidelines to predict which patients may require prophylactic gastrostomy, and despite this 
proactive intervention, we have found that high risk patients can still lose 6-7% of body 
weight during treatment and up to 9-10% by three months post treatment. Weight loss and 
malnutrition can impact on the patients’ quality of life, functional ability and other clinical 
outcomes. Therefore the aim of this research is to investigate novel approaches of nutrition 
intervention through prophylactic nutrition support and to determine whether early tube 
feeding improves nutrition outcomes. 
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11.3.9 Early feeding via a prophylactic gastrostomy – Preliminary findings from a 
RCT in high risk HNSCC patients undergoing chemoradiotherapy 
Australia & New Zealand Head & Neck Cancer Society, Auckland, New Zealand. Oct 2016 (poster) 
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11.3.10 Does early feeding via a prophylactic gastrostomy improve quality of 
life in patients with HNSCC? 
10th International Quality of Life in Head & Neck Cancer Conference, Liverpool, UK. Nov 2016 
(oral) 
Teresa Brown1,2, Merrilyn Banks2, Brett Hughes3,4, Charles Lin3,4, Lizbeth Kenny3,4, Judith Bauer1  
1Centre for Dietetics Research (C-DIET-R), University of Queensland, 2Department of Nutrition and Dietetics, 
RBWH, 3Cancer Care Services, RBWH, 4School of Medicine, University of Queensland 
Background: Patients with HNSCC are at high risk of malnutrition and weight loss which is 
associated with reduced quality of life. Enteral tube feeding is often required, however even 
with prophylactic gastrostomy placement significant weight loss still occurs. The aim of this 
study was to improve nutrition outcomes utilising an early feeding approach via the 
prophylactic gastrostomy and thus improve quality of life. 
Patients and Methods: Patients with HNSCC were eligible if identified for prophylactic 
gastrostomy prior to treatment and randomly allocated to the intervention (n=61) or usual 
care (n=70). The intervention recommended gastrostomy feeding immediately post 
placement to supplement oral intake. Usual care commenced gastrostomy feeding when 
clinically indicated. Key outcome measures were percentage weight loss and quality of life 
(EORTC-QLQ30, HN35) at three months post treatment. 
Results: Patients were predominantly male (88%), mean age 60+10.1, with oropharyngeal 
tumours (76%), receiving chemoradiotherapy (82%). Adherence to the early intervention 
was poor (51%). There were no significant baseline differences for demographics, clinical 
or nutritional status variables, but a reduced quality of life in the usual care group. Weight 
loss outcomes were no different in each group (10.9% usual vs 10.8% intervention, 
p=0.930). Following adjustment of baseline differences in quality of life no statistical 
differences were observed for functional or symptom scales. The intervention group had a 
clinically important decline in social functioning (p=0.065). Both groups had clinically 
important deteriorations in; fatigue, appetite, senses, dry mouth, sticky saliva and social 
eating. 
Clinical Implications: Symptoms impacting on quality of life persist post treatment and 
highlight the role of allied health support. There were no improvements in nutrition or quality 
of life measures following the early feeding approach. Poor adherence was explained by 
several clinical, environmental and psychosocial barriers which can be addressed to 
improve clinical practice, patient adherence and future outcomes.
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11.3.11 Prophylactic gastrostomy use in patients with HNSCC post treatment – 
is there really a problem? 
10th International Quality of Life in Head & Neck Cancer Conference, Liverpool, UK. Nov 2016 
(poster) 
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11.3.12 Understanding initiation of nutrition support in patients with HNSCC 
and adherence to recommendations – a patient perspective 
Clinical Oncology Society of Australia ASM, Gold Coast, Australia. Nov 2016 (poster) 
 Chapter 11 Appendices 
 323 
11.4 Appendix D: RBWH Human Research Ethics Committee Approval
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11.5 Appendix E: UQ Medical Research Ethics Committee Approval
 Chapter 11 Appendices 
 327 
11.6 Appendix F: Patient Information and Consent Form
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11.7 Appendix G: Nutrition Assessment Tool – PG-SGA
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11.8 Appendix H: Quality of Life Assessment Tools – EORTC 
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11.9 Appendix I Patient PEG Diary – example page 
 
 
